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THE RESEARCHER 
 
Following completion of a BSc in Life Sciences with The Open University, I 
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Hospitals Bristol in January 2008. This position allowed me to formally combine 
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England in February 2012 which ignited my interest in clinical research and 
allowed me to form a strong academic connection with the university. In 
February 2013 I was awarded an NIHR/CSO Healthcare Scientist Doctoral 
Research Fellowship. This funded me to undertake research at 60% whole time 
equivalent (WTE) over a period of five years commencing from April 2013. 
During this period I continued to work clinically as a CVS at 40% WTE. I am a 
Health and Care Professions Council registered Clinical Scientist (CS18759) 
having undertaken the Academy of Healthcare Science Scientist Training 
Program Equivalence process in 2014. I was a member of the SVT Education 
Committee for 3 years and represented the SVT on the Venous Forum Council 
(2012-2015).  
 
I am highly motivated to continue to combine clinical practice and research in 
my career and to contribute to the continual improvement of services and 
patient care in the field of physiological measurements to enable my 
professional group to work more effectively and efficiently. I have a particular 
interest in venous disease and the diagnosis and management of deep vein 
thrombosis. 
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ABSTRACT 
 
Objective  
To examine the natural history and response to treatment of deep vein 
thrombosis (DVT) and assess associations between baseline or follow-up 
characteristics and longer term outcomes. 
Methods  
A literature review and survey of clinical vascular scientists were undertaken to 
inform a prospective observational study.  171 consecutive participants with a 
first episode of acute DVT were followed-up at defined intervals for up to two 
years. Ultrasound was used to examine changes in thrombus and venous 
function. A medical history and presenting symptoms were recorded for each 
patient at baseline and each research visit. Post thrombotic syndrome (PTS) 
was assessed using the Villalta score. Possible predictors of outcome after DVT 
were analysed using multivariate logistic regression.  
Results  
In 34% of cases DVT remained unresolved when prescribed anticoagulation 
treatment ceased and in 27% it remained unresolved at two years post 
diagnosis. Recurrent DVT during follow-up was detected in 15%, new venous 
incompetence developed in 28% and PTS developed in 30%. Following 
adjustment for confounding, distal DVT and cases with lower thrombus burden 
were significantly more likely to resolve. The development of venous 
incompetence was associated with proximal DVT and treatment with heparin 
and warfarin rather than Rivaroxaban. Women were more likely to develop PTS 
than men. PTS was also associated with being overweight, residual DVT, not 
using compression stockings, superficial venous incompetence and deep 
venous incompetence when combined with superficial incompetence. No 
significant associations were found between PTS and treatment duration, 
smoking, hypertension, provocation status, pre-existing incompetence, 
superficial thrombophlebitis, symptoms duration, thrombus evolution pattern, or 
recurrence. 
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Conclusions 
This study has provided data that could inform future patient education 
and lifestyle advice.  It has also provided preliminary data to inform risk 
stratification for PTS and individually tailored treatment for DVT. 
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DUS - Duplex Ultrasound 
DVT - Deep Vein Thrombosis 
EMBASE - Excerpta Medica Database  
FREC – Faculty Research Ethics Committee 
GCP – Good Clinical Practice 
GP - General Practitioner  
H0 - Null Hypothesis  
HR - Hazard Ratio 
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HRT - Hormone Replacement Therapy 
IBD – Inflammatory Bowel Disease 
ICAM - Intercellular Adhesion Molecule 
IL-6 – Interleukin-6  
INR - International Normalised Ratio 
LMWH - Low Molecular Weight Heparin 
LREC – Local Research Ethics Committee 
MCP – Monocyte chemoattractant protein 
MEDLINE - Medical Literature Analysis and Retrieval System Online  
MEGA Study - Multiple Environmental and Genetic Assessment Study 
MEMO - Medical Equipment Management Organisation  
MeSH - Medical Sub-headings  
MI - Myocardial Infarction 
mmHg – millimetres of mercury 
MRV – Magnetic Resonance Venography 
N (n) - Number  
NICE - National Institute for Health and Care Excellence  
NHS - National Health Service  
NPV - Negative Predictive Value 
OPTIMEV - Optimisation de l'interrogatoire dans l'évaluation du risque de 
maladie thromboembolique veineuse  
OR - Odds Ratio 
PCDT - Pharmaco-mechanical Catheter Directed Thrombolysis 
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PE - Pulmonary Embolism 
PRISMA - Preferred Reporting Items for SLRs and Meta-Analyses  
PTS - Post Thrombotic Syndrome 
QA – quality assurance 
R & I - Research and Innovation  
RCT - Randomised Controlled Trial  
REC - Regional Ethics Committee  
RIETE - Registro Informatizado de Enfermedad TromboEmbólica 
RR - Risk Ratio 
RVO - Residual Vein Obstruction 
SD - Standard Deviation  
SLR - Systematic Literature Review  
SVT – Society for Vascular Technology 
UHBristol - University Hospitals Bristol NHS Foundation Trust  
UK – United Kingdom 
UWE - University of the West of England  
VCAM – Vascular Cell Adhesion Molecule 
VKA – Vitamin K Antagonist 
VOR – Venous Outflow Resistance 
VSU – Vascular Science Unit 
VTE - Venous thromboembolism 
WTE - Whole Time Equivalent 
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GLOSSARY 
 
B-mode ultrasound – that in which the position of a spot on the display 
corresponds to the time elapsed and therefore the position of the echogenic 
surface and the brightness of the spot to the strength of the echo, movement of 
the transducer produces a sweep of the ultrasound beam and a tomographic 
scan of a cross section of the body. 
Catheter directed thrombolysis - a percutaneous procedure used to dissolve 
thrombus by administering a lytic directly into the clot through a catheter.  
Chronic venous insufficiency – a condition that occurs when the venous wall 
and/or valves in the leg veins are not working effectively, which makes it difficult 
for blood to return to the heart from the legs. This condition causes blood to 
“pool” or collect in these veins, and this pooling is called stasis. 
Coagulation cascade - a series of steps beginning with activation of the 
pathways of coagulation leading to the formation of the fibrin clot. 
D-dimer - a fibrin split product measurement of which detects the presence of 
an abnormally high level of cross-linked fibrin degradation products which 
indicate that there has been significant thrombus formation and breakdown 
somewhere in the body. 
Deep vein thrombosis (DVT) – a blood clot within a deep vein. 
Deep venous system – the deep venous system in the leg includes the iliac, 
femoral, popliteal and deep femoral veins. Deep veins are almost always beside 
an artery with the same name and collectively they carry the vast majority of the 
blood back to the lungs. 
Direct oral anticoagulants – a new class of oral anticoagulants which have 
predictable pharmacokinetic properties when they are administered at a fixed 
dosing and limited interactions with food. 
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Distal DVT – DVT in the veins of the calf which does not extend into the 
popliteal vein. 
Doppler ultrasound – radiological measurement to measure the presence, 
direction and speed of blood flow in which measurement and a visual record are 
made of the shift in frequency of an ultrasonic pulse proportional to the blood 
flow velocity.  
Duplex ultrasound – employing two modalities of diagnostic ultrasound e.g. B-
mode and colour or B-mode and Doppler. 
Echogenicity - the ability to bounce an echo, e.g. return the signal in 
ultrasound examinations. Echogenicity is higher when the surface bouncing the 
sound echo reflects increased sound waves. 
Endogenous lysis – breaking down of thrombus as part of the body’s natural 
processes. 
Endothelium - cells that line the interior surface of blood vessels and lymphatic 
vessels, forming an interface between circulating blood or lymph in the lumen 
and the rest of the vessel wall. 
False negative – a result that appears negative when it should not, for 
example, if an ultrasound examination for DVT returns a negative result but the 
person actually does have a DVT. 
False positive – a test result which wrongly indicates that a particular condition 
is present, for example, if an ultrasound examination for DVT returns 
a positive result but the person actually does not have a DVT. 
Heart failure – a condition in which the heart is unable to pump blood around 
the body to its maximum potential. It usually occurs because the heart has 
become too weak or stiff. 
Hypercoagulability - an abnormality of blood coagulation that increases the 
risk of thrombosis.  
Ileo-femoral DVT – DVT that extends into the iliac and femoral veins. 
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International Normalised Ratio – a measure of how long it takes blood to clot. 
Low shear stress – low frictional force generated by blood flow. 
Mechanical thrombectomy – the interventional procedure of removing a 
thrombus from a blood vessel using a mechanical device. 
Medical Sub-headings - categories used in the Medline database 
Negative predicative value – the probability that subjects with 
a negative screening test truly do not have the disease.  
Peri-vascular area - situated or occurring around a blood vessel. 
Phlegmasia cerulea dolens - severe form of deep venous thrombosis which 
results from extensive thrombotic occlusion of the major and the collateral veins 
of an extremity, characterised by sudden severe pain, swelling, cyanosis 
and oedema of the affected limb.  
Post thrombotic syndrome – medical condition that may occur as a long-term 
complication of deep vein thrombosis characterised by symptoms that may 
include persistent or intermittent leg pain, cramp, heaviness, itching, tingling, 
parasthesia or tiredness which are typically worsened by walking or standing for 
long periods and tend to improve through rest and elevation. 
Provoked DVT – DVT that occurs in the presence of an antecedent major 
clinical risk factor for DVT. 
Proximal DVT – DVT that involves the popliteal vein or any  proximal vein (in 
relation to the heart). 
Pulmonary embolism – a blockage of an artery in the lungs by a substance 
that has moved from elsewhere in the body through the bloodstream, usually 
resulting from a blood clot in the leg that travels to the lung. 
Puerperium – the period of about six weeks after childbirth during which the 
mother's reproductive organs return to their original non-pregnant condition. 
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Recurrent ipsilateral DVT - new thrombus on compression ultrasound at a site 
in the same leg which was previously free from thrombus, which had been 
completely recanalised or the proximal extension of a thrombus from the 
previous measurement. 
Residual vein obstruction - the persistent presence of thrombus as measured 
by compression Doppler ultrasonography at the site of the original DVT after 
some period of time. 
Rivaroxaban – type of oral anticoagulant and part of the group of direct oral 
anticoagulants (DOACs) which acts as a direct inhibitor of activated factor X 
(factor Xa) in the coagulation cascade. 
Rutosides - a group of compounds derived from horse chestnut and used as a 
traditional herbal remedy for treating oedema.  
Sensitivity – the ability of a test to correctly identify those with the disease (true 
positive rate). 
Specificity - the ability of the test to correctly identify those without the disease 
(true negative rate). 
Superficial thrombophlebitis - a thrombosis and inflammation of the 
superficial veins which presents as a painful induration with erythema.   
Superficial venous system – the superficial venous system in the legs 
includes the long saphenous vein and the short saphenous vein. It transports 
the blood from the subcutaneous tissues to the deep veins.  
Ultrasound - radiologic technique in which deep structures of the body are 
visualised by recording the reflections (echoes) of ultrasonic waves directed into 
the tissues. 
Unprovoked DVT - DVT that occurs in the absence of an antecedent major 
clinical risk factor for DVT. 
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Valve leaflets - consist of thin collagen half-moon–shaped folds covered by 
endothelium, which spring from the wall of the vein very close to each other to 
prevent venous reflux in the presence of gravitational effect.  
Venography - radiography of a vein after injection of a radiopaque fluid. 
Venous incompetence/venous reflux – the detection of back flow through the 
valves of the veins demonstrating the non-functioning of the one-way valve 
system. 
Venous stasis – the process in which blood “pools” or collects in veins as a 
result of chronic venous insufficiency and this pooling is called stasis. 
Venous stenting – placement of a venous stent in a deep vein following a 
recanalisation procedure (usually catheter directed thrombolysis) with the 
purpose of helping the vein to remain open and patent. 
Venous thromboembolism – a condition where a blood clot forms in a vein, 
most commonly in a leg vein but includes also pulmonary embolism. 
Villalta Score - a disease score specific for PTS. PTS is considered present if 
the Villalta score is ≥5. A score of 5-9 signifies mild disease, 10-14 moderate 
disease, and ≥15 severe disease. 
Virchow’s Triad - describes the three broad categories of factors that are 
thought to contribute to thrombosis. It is named after the eminent German 
physician Rudolf Virchow (1821-1902). 
Vitamin K anatagonist – group of anticoagulants (including warfarin) which 
exhibit their anticoagulant effect by inhibition of vitamin K epoxide reductase. 
Wells Score – scoring system that objectifies the risk of DVT based on clinical 
findings. 
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CHAPTER 1: BACKGROUND 
 
1.0 Introduction 
The purpose of this chapter is to provide the background to the research idea, 
the subsequent research and the overall thesis. The chapter addresses the 
following topics: 
 
 The clinical presentation of Deep Vein Thrombosis (DVT) and how it is 
diagnosed and managed. 
 An overview of the epidemiology of DVT including the current evidence 
for risk factors associated with DVT. 
 A summary of the existing evidence regarding the natural history of DVT 
in terms of resolution and recurrence. 
 The clinical presentation of post-thrombotic syndrome (PTS) and an 
overview of existing evidence regarding the underlying pathophysiology 
of this condition. 
 An overview of the diagnostic methods used for PTS and the 
management of this condition. 
 A brief introduction to the origin of the research idea and the role of the 
PhD student. 
 The aims and objectives of the study and the structure of this thesis. 
 
  
1.1 Overview of the clinical problem 
Venous thromboembolism (VTE) is a common clinical condition that comprises 
DVT and Pulmonary Embolism (PE) and causes significant morbidity and 
mortality. VTE is the third most common cause of vascular death after 
myocardial infarction (MI) and cerebrovascular insult (Goldhaber & 
Bounameaux, 2012). A DVT is a blood clot or thrombus in one or more of the 
deep veins of the body. It most commonly affects the deep veins of the lower 
limbs and abdomen although, whilst less common, it can also manifest in the 
upper limb. It is known to have a number of well-recognised, potentially life-
threatening complications including PE, where part or all of the thrombus 
embolises and prevents blood flow to the lungs. DVT may also lead to chronic 
long-term sequelae which are grouped under the umbrella term of PTS (Baxter 
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& Goss, 2011). This research and thesis focus only on lower limb DVT rather 
than upper limb DVT. The majority of cases of upper limb DVT seen in the 
researcher’s clinical practice (and therefore the potential study cohort) are 
oncology patients with a peripherally inserted central catheter in situ for drug 
delivery. Patients with active cancer were excluded from the study (discussed 
later in Section 4.2.3) and spontaneous upper limb thrombosis is a rare 
presentation. For these reasons, the focus of this study is lower limb DVT alone. 
1.2 Clinical presentation of DVT 
Patients with a query DVT will typically present with acute, generally unilateral 
lower limb swelling and pain. This may be accompanied by erythema, distended 
superficial veins and occasionally warmth (Streiff et al, 2016). Pain associated 
with DVT is frequently described as a cramp or ache in the calf or thigh. There 
are many differential diagnoses for acute pain and swelling of the lower 
extremity other than DVT and an alternative diagnosis is established in 
approximately 50% of ambulatory patients presenting with suspected DVT 
(Blattler et al, 2004). However, as the consequences of not treating a DVT can 
be potentially fatal, ambulatory patients are often treated with therapeutic 
anticoagulation until DVT is excluded. 
1.3 Diagnosis and Management 
1.3.1 Diagnosis 
Presentation with clinical symptoms and signs of suspected DVT warrants 
urgent assessment for diagnosis and initiation of anticoagulation therapy to 
prevent PE. The prevalence of DVT in those investigated for having the disease 
is estimated at one in four (Wells et al, 1995). This results in most centres 
employing the diagnostic strategy of safely ruling out a DVT by rapid, non-
invasive and cost-effective methods which combine clinical history, physical 
examination, laboratory studies and non-invasive imaging (Tick et al, 2002). 
1.3.2 Clinical assessment 
The two levels Wells score is a clinical probability assessment tool to aid 
stratification of patients into categories of ‘likely’ or ‘unlikely’ to have a DVT  
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(Wells et al, 2003, National Institute for Health and Care Excellence, 2012a). 
Assessment of the pre-test probability can be affected by many differential 
diagnoses which raises concerns over the reliability of pre-test probability 
assessments when undertaken by less experienced clinicians. Evidence shows, 
however, that the test can be accurately applied by medical staff with varied 
duration of training and experience (Kelly & Hunt, 2003) and simplified models 
have been validated in emergency care settings (Dryjski et al, 2001). 
1.3.3 Laboratory studies 
D-dimer (a fibrin split product) measurement has become commonplace in 
recent years as part of the diagnostic pathway for DVT. This simple blood test 
detects the presence of an abnormally high level of cross-linked fibrin 
degradation products, which indicate that there has been significant thrombus 
formation and breakdown somewhere in the body. The test does not identify the 
cause or location of the thrombus formation and D-dimer levels may be 
elevated, not only due to a VTE, but also as a result of recent surgery, trauma, 
infection, liver or kidney disease, cancers and in pregnancy (Pulivarthi & 
Gurram, 2014) which limits its usefulness in certain patient groups (Kyrle & 
Eichinger, 2005). The test has a high sensitivity and a high negative predictive 
value (NPV) and is therefore considered a fast and cost-effective test for ruling 
out acute DVT (Kelly & Hunt, 2003). The evidence does not support the use of 
D-dimer testing alone in the diagnosis of DVT (Heim et al, 2004) but a negative 
D-dimer in combination with a low clinical probability score has been shown to 
safely exclude acute DVT (Wells et al, 2003; Stein et al, 2004).  
1.3.4 Imaging techniques 
Venography, an x-ray image of the veins following injection of a radiopaque 
substance, is still considered by some to be the gold standard test for DVT 
diagnosis but the test relies on the variable and complex anatomy of the venous 
system, lacks physiological information, is costly and invasive, carries a risk for 
contrast reaction and toxicity and ironically a risk of thrombosis itself (Flanigan 
et al, 1978; Hull et al, 1981).  
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Ultrasound is now the main diagnostic modality for the diagnosis of DVT (Tenna 
et al, 2012) and has been used in the researcher’s hospital Trust in this capacity 
for over 20 years. It is non-invasive and aids in differential diagnosis. Ultrasound 
imaging is able to investigate anatomy and provide a physiological/functional 
assessment. When compared to venography its advantages are that it is 
portable, more cost effective, time efficient, widely available and has 
comparable sensitivity/specificity (Gaitini, 2006).  
 
Two strategies can be employed in diagnosing lower limb DVT using the 
ultrasound compression technique: 
 
1. Serial proximal vein compression ultrasound. The proximal veins 
(common femoral, femoral, profunda and popliteal veins) are assessed 
for thrombosis. This scan will be repeated within 1-2 weeks if the first is 
negative. Distal thrombi (calf veins) that extend into the proximal veins 
within 2 weeks would be associated with a greater risk of an adverse 
clinical event so anticoagulation therapy would be warranted.  
 
2. Complete assessment of the proximal and distal lower limb veins using 
compression ultrasound. 
 
Both these diagnostic approaches are widely accepted as safe and effective 
(Palareti et al, 2008; Johnson et al, 2010). Compared with venography, the 
sensitivity and specificity for the ultrasound compression technique for 
diagnosing proximal DVT in symptomatic patients is over 97% and 98%, 
respectively. Ultrasonography is less accurate in diagnosing distal DVT with the 
sensitivity and specificity reduced to 71% and 94% respectively for calf vein 
thrombosis (Goodacre et al, 2005). The reduced sensitivity carries a risk for 
false-negative results, whereas the reduced specificity could lead to over-
treatment. However, combining Doppler signals with ultrasound images to 
determine characteristics of blood flow in the form of Duplex ultrasound has 
improved the accuracy of detecting isolated calf DVT (Tenna et al, 2012). 
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A review by Righini et al (2006) and two randomised studies in symptomatic 
patients (Bernardi et al, 2008; Gibson et al, 2009) compared the results of the 
two diagnostic strategies: serial proximal ultrasound or single whole-leg vein 
examination, with only the latter being able to diagnose and treat calf DVT. 
They consistently found that the three month thromboembolic risk did not differ 
in the two diagnostic approaches, indicating that diagnosing and treating distal 
DVT is not indispensable. This is discussed further in Section 1.3.6. 
 
Current clinical guidelines recommend proximal vein ultrasound assessment 
within 4 hours of presentation of suspected DVT or within 24 hours of a 
parenteral dose of anticoagulation (National Institute of Health and Care 
Excellence, 2012). If the ultrasound scan is negative and a DVT is clinically 
suspected (two level Wells score ≥2) and the D-dimer test is positive, a repeat 
ultrasound scan of the proximal veins should be offered 6-8 days later (National 
Institute of Health and Care Excellence, 2012). Essentially, the guideline does 
not support ultrasound assessment of distal (calf) veins. In the absence of calf 
DVT progression after serial ultrasound scans, the calf DVT is thought to be 
clinically irrelevant and anticoagulation may be withheld (Horner et al, 2012).  
 
1.3.5 Management of DVT 
DVT is generally treated with anticoagulation therapy, which, until recent years, 
comprised the administration of subcutaneous low molecular weight heparin 
(LMWH) until a target International Normalised Ratio (INR) of approximately 2.5 
was reached. This was then followed by the vitamin k antagonist Warfarin to 
maintain the INR in the therapeutic range of 2-3. More commonly, in the last few 
years, direct oral anticoagulants (DOACs) including the Factor X inhibitors or 
Xbans such as Rivaroxaban are prescribed in the treatment of DVT. Continued 
treatment with oral anticoagulants will prevent most episodes of DVT extension 
or recurrence, however, the optimum duration of anticoagulant therapy is 
uncertain (Baglin, 2007). The balance between the increased risks of bleeding 
from anticoagulation therapy and the risk of DVT recurrence/extension is not 
easily predicted on an individual basis (Baglin, 2007). As a result patients are 
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usually treated for a finite period of 3-6 months (British Committee for Standards 
in Haematology Guidelines, 1998; Buller et al, 2004; Baglin et al, 2006).  
 
Guidelines issued by the American College of Chest Physicians recommend 
that the duration of anti-coagulation therapy should be determined by weighing 
the risks and benefits of oral anticoagulation (Kearon et al, 2008). The National 
Institute for Health and Care Excellence (NICE) clinical guideline for the 
management of thromboembolic diseases (2012a) emphasises that treatment 
with anticoagulation medication exposes patients to side effects and is 
expensive (cost of drug and district nursing time). It is therefore considered 
important not to anti-coagulate patients unnecessarily. Since the initiation of this 
research study and the publication of the NICE clinical guidance (2012a), 
DOACs have become much less expensive altering the economic arguments 
against longer term anticoagulation. The NICE (2012a) guidelines stated that 
the two main issues to be addressed regarding treatment are: how long 
treatment needs to be given and whether it is possible to define a group of 
patients who should continue anticoagulation therapy indefinitely which 
supports the need to develop a more tailored approach to anticoagulation 
treatment for lower limb DVT.  
 
A review by Comerota (2012) also addresses the issue of tailored 
anticoagulation in a manuscript that examines the future of DVT and PTS in 
2020. This review concluded that the long-term management of DVT will focus 
on establishing appropriate anticoagulation treatment duration for the individual 
patient. Certain patient groups may benefit from longer term anticoagulation and 
these may include those with certain risk factor profiles or those with residual 
thrombus present on completion of an initial course of anticoagulation.  There is 
however currently no standard for ordering an ultrasound at the end of 
anticoagulation treatment periods to determine the degree of thrombus 
resolution or the presence of residual thrombus (Needleman et al, 2018) and 
there is currently no evidence to support this strategy.  
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1.3.6 Proximal DVT versus calf DVT 
DVT is usually classified as being proximal in the event of popliteal vein 
involvement and distal when the thrombus is isolated to the calf veins and does 
not extend proximally into the popliteal vein. The use of anticoagulation therapy 
for proximal DVT is well established and justified by evidence (Kearon, 2003). 
Much controversy rests amongst professionals on the clinical significance of 
isolated calf vein DVT. Calf DVT is clinically accepted to present less risk of 
propagation and PE than proximal vein DVT although consensus on 
management is lacking (Parisi et al, 2009; Rosfors et al, 2010). Despite being 
lower risk there still remains a risk with calf DVT of extension into the proximal 
vein, PE, death, recurrence and PTS (Masuda et al, 2012). Anticoagulation of 
all calf DVT however, remains controversial due to the risk of adverse effects 
with anticoagulation that include major bleeding, death, treatment burden and 
cost. As such, reported management strategies are variable across the 
professional community. Epidemiological studies suggest that 50% of 
diagnosed lower limb DVT in ambulatory patients occur in the calf, highlighting 
the need to develop standardised management strategies (Oger, 2000; Ouriel 
et al, 2000; Galanaud et al, 2009).  
 
It is widely accepted that most symptomatic DVTs start in the calf and extend 
into the proximal veins with a concomitant increase in the risk of subsequent PE 
(Nicolaides et al, 1971; Moser & LeMoine, 1981; Cogo et al, 1993). This infers 
that calf DVT presents a risk upon progression into the proximal veins which is 
only a minority of isolated calf thrombi in untreated patients (Masuda & Kistner, 
2010). There exists, however, a theoretical risk that a proportion of untreated 
calf thrombi are of danger to some patients. From research, proximal vein 
propagation has been reported as high as 15% in untreated patients but can be 
as low as 2% in low risk groups (Ferrara et al, 2006). Complication rates for calf 
DVT, defined as proximal vein propagation or symptomatic PE, are variably 
reported between 3 and 29% (Lagerstedt et al, 1985b; Oishi et al, 1994; Lohr et 
al, 1995; Schwarz et al, 2001; Macdonald et al, 2003; Righini et al, 2006; 
Palareti et al, 2010; Schwarz et al, 2010). This implies not all calf DVT present a 
risk of propagation and embolisation. Anticoagulation may therefore not be 
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warranted in the majority of patients with calf DVT; however, identification of 
volatile thrombi remains an important research question, yet to be answered.  
 
Anticoagulation for calf DVT using the same management strategy as a 
proximal DVT is however recommended by some under the following conditions 
(Kearon et al, 2012): 
  
 if multiple calf veins are involved 
 a positive D-dimer (>500ng/mL) 
 proxmitiy to proximal veins (<5cm) 
 active cancer 
 previous history of VTE 
 inpatient status 
 if the thrombus has distended the vein >7mm in diameter  
 
In a meta-analysis undertaken by De Martino et al (2012), studies using 
ultrasound and venography to assess calf thrombus propagation were analysed 
(Lagerstedt et al, 1985a; Solis et al, 1992; Pellegrini et al, 1993; Lohr et al, 
1995; Masuda et al, 1998; Sachdev et al, 2006). As expected, thrombus 
propagation was less amongst patients treated with anticoagulation compared 
to controls (Odds Ratio (OR), 0.29; 95% Confidence Interval (CI), 0.14-0.62). 
How this relates to risk reduction for PE however has yet to be established as 
the meta-analysis demonstrated limited differences in the rates of PE. A 
comprehensive compilation of case series suggested about 10% of distal DVTs 
propagate to the proximal veins (Righini et al, 2006). This implies that 90% do 
not propagate and thus indirectly present little risk, if any, of PE.  
 
Some centres treat all incidences of DVT, including calf vein thrombosis, with 
anti-coagulation therapy whilst others only treat proximal vein thrombosis. 
Current evidence suggests the majority of isolated calf DVT cases do not 
present a clinical risk of proximal vein propagation or PE (Masuda et al, 2012; 
Horner et al, 2014) and a recent randomised, double-blind, placebo-controlled 
study found that anticoagulation therapy was not superior to placebo in reducing 
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the risk of proximal extension or venous thromboembolic events in low-risk 
outpatients with symptomatic calf DVT, but did increase the risk of bleeding 
(Righini et al, 2016). Serial ultrasound scans within 8 days can identify thrombi 
that are likely to propagate proximally and trigger the initiation of treatment. 
When multiple calf veins are involved in distal DVT, anticoagulation appears to 
be warranted in order to prevent venous thromboembolism, however, 
consensus on treatment intensity and duration are lacking (Masuda et al, 2012). 
 
At the time of this research, University Hospitals Bristol NHS Foundation Trust 
(UHBristol), where the main study was undertaken, treated all episodes of DVT 
(unless contraindicated) regardless of their location or extent. UHBristol has 
since changed its management strategy to treat only those patients with 
isolated calf vein thrombosis that are considered high risk for propagation. This 
decision was taken by the lead Haematologist for the Trust and was unrelated 
to this research project. All other cases receive a rescan at 7 days post 
diagnosis to assess for propagation. If the clot has extended to the proximal 
veins the patient is anticoagulated, however, if the clot has not propagated to 
the proximal veins the patient is discharged without further follow-up.  
 
1.3.7 Endovascular treatment of DVT  
In recent years, more aggressive endovenous treatments for DVT such as 
catheter directed thrombolysis (CDT), mechanical clot retrieval techniques and 
venous stenting procedures are being used in some patients with proximal DVT 
that meet specific criteria. Historically, systemic thrombolysis, which refers to 
the administration of a fibrinolytic drug through an intravenous line placed distal 
to the target vessel(s), was investigated for the treatment of acute DVT. Its use 
was assessed in clinical trials which demonstrated that although effective in 
removing partial clot, major bleeding was increased by 3-4 times that in 
anticoagulation alone (Goldhaber et al, 1984).  
 
This led to the development of catheter directed methods which permit a more 
targeted venous thrombus removal with reduced fibrinolytic drug dose and 
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hence a lower risk of major bleeding. CDT refers to direct intra-thrombus 
administration of fibrinolytic drugs via a catheter or device guided into the 
thrombus using medical imaging (Vedantham et al, 2006). Theoretically, intra-
thrombus delivery provides the ability to achieve a high concentration of the 
fibrinolytic drug locally within the thrombus whilst avoiding bypass of the drug 
around the occluded segment. The addition of mechanical thrombus disruption 
with some delivery systems may also enhance the breakdown of the thrombus. 
This improved efficacy reduces thrombolytic drug dose and hence the bleeding 
risk as well as reducing treatment time and length of stay (Vedantham et al, 
2016). 
 
Ultrasound is used to guide venous access using a micro-puncture system 
whilst venography is used to map the extent of the thrombus. Mechanical 
thrombectomy techniques are employed to remove residual thrombus whilst 
balloon angioplasty (sometimes with stent placement to retain patency), is used 
to treat venous stenosis (Vedantham et al, 2014). Venography is widely used to 
re-assess the results of CDT and report outcomes.  
 
Treating DVT with thrombolytic therapy is undertaken with the following three 
goals: to reduce the thrombus burden, restore venous patency and reduce 
venous congestion. If successful, this can result in important therapeutic 
outcomes in certain patients. These can include preserving life, limb and/or 
organs. It is especially important in patients with extensive iliofemoral DVT 
which can cause acute circulatory compromise (e.g. phlegmasia cerulea 
dolens) or those with a progressive inferior vena cava thrombosis which can 
cause visceral organ compromise and an elevated risk of PE (Patel et al, 1998). 
Thrombolytic therapy may also play a role in providing relief for highly 
symptomatic patients who exhibit DVT extension or worsening symptoms of 
pain and swelling despite initial traditional anticoagulation therapy. It may also 
be used with a view to preventing the development of PTS caused by residual 
obstruction or valvular incompetence (Elsharawy & Elzayat 2002; Haig et al, 
2013).  
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The CaVenT study (catheter-directed thrombolysis for deep vein thrombosis) 
was a rigorously conducted multi-centre, single country randomised controlled 
trial of 189 patients with proximal DVT who underwent drug only CDT with 
anticoagulation. The study demonstrated 26% relative reduction in the risk of 
developing PTS within 2 years in patients that underwent CDT with 
anticoagulation compared to anticoagulation alone (Enden et al, 2012). The 
degree of residual thrombus post CDT was correlated with venous patency (the 
complete absence of residual occlusion) at 2 years (p=0.04) and venous 
patency at 6 months and 2 years correlated with a negative diagnosis of PTS 
(p=0.001) (Haig et al, 2013). Major bleeding occurred in 3.2% of patients 
undergoing CDT but the study reported no intracranial bleeds or deaths (Enden 
et al, 2012). 
 
There is a lack of published evidence relating to the efficacy of mechanical 
thrombectomy devices without the use of thrombolytic agents. However, the few 
published studies have demonstrated poor therapeutic outcomes with aspirating 
devices not removing sufficient thrombus (Kasirajan et al, 2001; Vedantham et 
al, 2002) and an increased risk of PE with non-aspirating devices (Uflaker, 
1997; Delomez et al, 2001). New devices are emerging but there are currently a 
lack of published data regarding their efficacy (Vedantham et al, 2016).  
Pharmamechanical CDT incorporates both thrombolytic drugs and mechanical 
devices. Observational studies have shown promising results in terms of safety 
and efficacy for this technique. These results are comparable to drug only CDT 
whilst demonstrating the clear health and cost benefits of 40-50% drug dose 
reduction and treatment time, reduced hospital stays and intensive care usage 
(Bush et al, 2004; Vedantham et al, 2004; Kim et al, 2006; Lin et al, 2006). As a 
result clinical practice has largely evolved towards the use of this type of device 
and ongoing research is likely to report further on the safety and efficacy of this 
method in the near future (Vedantham et al, 2013).  
 
These endovenous techniques are however invasive, expensive and require 
careful risk stratification to ensure that they are directed only to those patients at 
greatest risk of short or long term complications from their DVTor its treatment. 
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This will help to ensure that individuals benefit from this aggressive intervention 
but are also low risk for procedural complications (Vedantham et al, 2016). 
Clinicians are currently faced with difficult decisions regarding appropriate 
individualised treatment to mitigate both short and long-term risks. An important 
factor when considering endovascular thrombolytic intervention for acute DVT is 
the projected risk of bleeding. Generally speaking, a low threshold should be 
applied to exclude patients with any bleeding concerns, especially but not 
limited to, individuals with a history of recent active bleeding, recent major 
surgery or other invasive procedure, lesions that may bleed in critical areas 
such as the central nervous system, recent trauma, cardio pulmonary 
resuscitation or pregnancy except in cases where urgent intervention is required 
to save life, organ or limb (Vedantham et al, 2016).  
 
The clinical severity of the DVT is another consideration that informs any 
decision to escalate treatment. In addition to urgent thrombolysis to preserve 
life, limb and/or organs, non-urgent thrombolysis may be considered when initial 
standard anticoagulation has failed to achieve therapeutic outcomes either 
through the progression of the DVT or an increase in the severity of the 
symptoms which renders a patient unable to tolerate increased pain and 
swelling or that are limiting physical activity (Vedantham et al, 2016). Again a 
low threshold is generally applied to exclude patients with bleeding risks and 
caution must be exercised to inform patients of the risks, benefits and 
alternative approaches to such intervention for symptom reduction (Vedantham 
et al, 2016). 
 
The anatomic extent of the DVT is also considered in any decision to proceed 
with thrombolytic therapy and at present it is not considered for patients in 
whom the DVT does not extend as proximally as the common femoral vein 
(Mewissen et al, 1999). Patients with acute iliofemoral DVT are at much greater 
risk of developing recurrent DVT or PTS and are generally considered the most 
appropriate candidates for thrombolytic therapy (Douketis et al, 2001; Delis et 
al, 2004; Jaff et al, 2011). Evidence indicates that endovenous techniques are 
most effective in the treatment of non-organised thrombus which promotes early 
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intervention and thrombolytic therapy is generally discouraged in those patients 
with symptoms duration of more than 4 weeks (Mewissen et al, 1999).  
 
The challenge for clinicians is that decisions regarding the use of thrombolytic 
therapy in the treatment of acute DVT need to be made in the early stages of 
presentation and must be highly individualised to patient circumstances 
(Vedantham et al, 2016). Of course not every patient that has a first episode of 
DVT will go on to develop a recurrence or PTS but there is a lack of robust 
research evidence to indicate which patients will, making early identification and 
selection of candidates for long term anticoagulation or endovenous intervention 
difficult. 
 
1.4 Epidemiology of DVT  
1.4.1 Prevalence of DVT 
Epidemiological data for DVT come from large cohort studies which reflect 
symptomatic rather than asymptomatic disease. A systematic literature review 
found the incidence of a first episode of DVT in the general population was 0.5 
per 1000 person-years (Fowkes et al, 2003). The frequency of DVT increases 
with age: 1.8 per 1000 person years aged 65-69 and 3.1 per 1000 person years 
aged 85-89 (Kniffin et al, 1994) and the risk of DVT is slightly higher in men 
than in women (Anderson et al, 1991; Cushman et al, 2004). 
 
The short term mortality rate for a VTE involving the pulmonary vascular tract is 
quoted as 17% (Goldhaber et al, 1999) and somewhere between 7 and 15% for 
lower limb DVT (Prandoni et al, 1998). Longer term observational studies have 
demonstrated decreasing survival over the eight years post diagnosis with a 
first episode of symptomatic DVT (Prandoni et al, 1996). 
 
Annual incidence rates for DVT have remained fairly consistent in men over the 
last 30 years with slight fluctuation in females probably related to the increased 
risk from pregnancy and the use of oral contraception and hormone 
replacement therapy (HRT) (Silverstein, 1998; Sakuma et al, 2009). Despite 
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increased public and healthcare awareness, vigilance against hospital acquired 
DVT, established guidelines and widespread implementation of 
thromboprophylaxis, there has been no observed drop in incidence rates and 
DVT remains a prominent issue on the healthcare agenda (NICE, 2010). 
 
1.4.2 Risk factors 
Risk factors for VTE and DVT are numerous and varied. A DVT can either occur 
spontaneously or as a result of trauma or surgery (Kyrle & Eichinger, 2005). 
The risk of developing VTE after major general surgery (defined as requiring 
general anaesthetic of ≥30 mins) is well documented in the literature (Clagett & 
Reisch, 1988), however, lower limb orthopaedic surgery carries a particularly 
high risk of DVT (Anderson & Spencer, 2003). Without prophylactic 
anticoagulation, approximately 50% of patients undergoing total hip or knee 
replacement surgery develop VTE, although only approximately 5% of those will 
be symptomatic (Bergqvist, 1983; Stulberg et al, 1984; Collins et al, 1988). 
Traumatic hip, pelvic, femur and tibial fractures are also associated with high 
risk of developing VTE. The VTE risk following cast immobilisation in those with 
tibial fractures was demonstrated as 45% in one early seminal study although 
only one third of those were symptomatic (Hjelstedt & Bergvall, 1968). 
 
There are several coagulation abnormalities, usually hereditary, that are 
associated with increased risk for DVT. These include Factor V Leiden, Factor II 
G20210A, natural inhibitor deficiencies such as anti-thrombin deficiency, protein 
C deficiency and protein S deficiency, lupus anticoagulant, plasminogen 
deficiency and mild hyperhomocysteinaemia (Kyrle and Eichinger, 2005). High 
clotting factor levels (factors VIII, IX and XI) as well as increased levels of 
plasma pro-coagulant proteins such as fibrinogen and pro-thrombin are 
established risk factors (Wolberg et al, 2012).  
 
Oral contraceptive use and hormone replacement therapy (HRT) are associated 
with an increased risk for DVT in women. The overall risk for DVT in women 
using oral contraceptives is approximately three times that of non-users and the 
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risk is highest in the first year of use (Bloemenkamp et al, 2000; Rosendaal et 
al, 2003). HRT is associated with an increased risk of between two and four 
times that in non-users (Rosendaal et al, 2003). In addition, pregnancy is 
associated with a two-fold increased risk for a first episode DVT and the 6 week 
post-natal period has a 14-fold increased risk (Rosendaal, 1999).  
 
Although widely publicised by the media, the link between long haul travel and 
DVT remains controversial. Two case control studies reported an association 
between long distance travel by air or land and DVT with OR of 4.0 (Ferrari et 
al, 1999) and 2.3 (Samama, 2000). However, a study by Kraaijenhagen et al 
(2000) demonstrated no link between long haul travel and DVT. A further study 
by Arya et al (2001) also demonstrated no significant link between any form of 
travel > 3 hours in the preceding four week period and DVT with an OR of 1.4. 
The risk of DVT was, however, significantly increased with an OR of 2.7 (CI 1.2-
6.4) after any form of travel > 3 hours if one other significant risk factor was 
present from: hormonal therapies, malignancy, surgery, immobilisation, obesity, 
previous DVT, pregnancy and significant family history. The risk was further 
increased in those who had undergone air travel of > 8 hours with one 
additional risk factor (OR 3.0, CI 1.1-8.2). It is possible that the strength of 
association specifically between travel and DVT found in previous studies may 
have been over-estimated. 
 
Patients with malignancy have an increased risk of DVT due to a multitude of 
factors including treatment with anti-neoplastic drugs, surgery, central venous 
catheterisation, infection and immobility. DVT also has an association as an 
early indicator of malignancy itself with the incidence of cancer being higher in 
unprovoked DVT compared to provoked (Prandoni et al, 1992). 
1.4.3 Aetiology of DVT 
Venous thrombi are usually formed in the presence of low flow and low shear 
stress. It is thought that most thrombi originate in the valve leaflets of the calf 
veins and extend proximally (Nicolaides et al, 1971). In 1856, Rudolf Virchow 
theorised that thrombus formation occurs as a result of a combination of stasis, 
52 
 
hypercoagulability and vessel wall injury and this concept is traditionally used to 
explain the pathophysiologic mechanisms leading to thrombosis (Wolberg et al, 
2012). The increased risk of DVT as a result of reduced venous flow due to 
immobilisation (Kyrle & Eichinger, 2005) and changes in the coagulation 
cascade (Koster et al, 1995; Weltermann et al, 2003) are well evidenced in the 
literature. The role of vessel wall damage is not however well understood.  
 
Venous thrombosis is thought to be triggered by the expression of pro-
coagulant activity on intact endothelium from inflammation and/or reduced blood 
flow as a result of prolonged immobility (Wolberg et al, 2012). Animal studies 
have demonstrated that inflammatory processes in DVT involve both the 
venous vascular wall (endothelium) and the peri-vascular area (Froehlich et al, 
1997; Meissner et al, 2007). There is much important ongoing research into the 
histological mechanisms underpinning the anti-coagulant and pro-coagulant 
properties of the venous endothelium. The fact that no single abnormality in any 
one of the three components of Virchow’s Triad fully predicts thrombosis a priori 
is indicative of the complex and multi-factorial nature of the coagulation 
processes. 
 
1.4.4 Provoked or unprovoked DVT 
The concept of provocation refers to the presence or absence of an antecedent 
major clinical risk factor for DVT. No clear definition of the concept of 
provocation exists, however, VTE is generally considered to be provoked when 
occurring in patients with a clear transient clinical risk of VTE within the 3 month 
period before diagnosis (NICE, 2012). Transient major clinical risk factors are 
considered to be surgery, trauma, pregnancy, puerperium and significant 
immobility (bedbound, unable to walk unaided or spending a substantial 
proportion of the day in bed or in a chair without mobilising). In United Kingdom 
(UK) national guidelines, provocation also includes the use of hormonal therapy 
(oral contraception or HRT) (NICE, 2012). 
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Consequently VTE is generally considered to be unprovoked when occurring in 
patients with no clear antecedent transient major clinical risk factor for VTE and 
not receiving hormone therapy. Unprovoked DVT also extends to those with 
active cancer, known thrombophilias (abnormalities of blood coagulation that 
increases the risk of thrombosis) or a family history of DVT as these are 
underlying risk factors that remain constant in the patient. 
 
The management strategy for DVT identified in UK national guidelines is based 
upon the concept of provocation (NICE, 2012). It is believed that provoked DVT 
is usually associated with more distal disease and a decreased risk of 
recurrence. Studies have demonstrated low recurrence rates after provoked 
VTE even without anticoagulation (Iorio et al, 2010) and higher risk of 
recurrence in patients with unprovoked VTE (Baglin et al, 2003; Prandoni et al, 
2007; Eichinger et al, 2010; Kyrle et al, 2010). The distinction between 
provoked and unprovoked DVT can, however, be problematic in practice 
(Baglin, 2007). It is not always easy to classify an event as provoked particularly 
as the concept of trauma is open to interpretation and patient recall may not be 
completely accurate. Similarly there may be different interpretations of the 
concept of significant immobility which may vary by patient in terms of a patient 
being more or less mobile than is usual for them. 
 
Two ongoing major prospective registries examining outcomes after VTE 
recommend the use of hormone therapy differently: the Registro Informatizado 
de Enfermedad TromboEmbólica (RIETE) registry (www.riete.org, 2001) 
considers hormone therapy to be a transient risk factor for VTE and hence 
places it in the provoked category whereas the Optimisation de l'interrogatoire 
dans l'évaluation du risque de maladie thromboembolique veineuse (OPTIMEV) 
study (Sevestre et al, 2005) places hormone therapy in the unprovoked 
category. OPTIMEV also includes heart failure, respiratory insufficiency and 
acute infection as transient provoking factors whereas the RIETE registry does 
not.  
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There is also variation in how the timing of the provoking event is interpreted. 
RIETE defines transient risk as being within the preceding 2 months whereas 
OPTIMEV cites variable timings for specific risks. These include surgery within 
45 days and six weeks post-partum. It is however less specific in describing the 
timing of plaster cast immobilisation or long-haul travel for example where the 
term ‘recent’ is used to classify the provocation risk. Until standardisation occurs 
in the classification of provocation risk, care must be taken when translating the 
results of these large registry studies to clinical practice (Baglin, 2007). 
 
The role of infectious and inflammatory diseases in the provocation of VTE is 
also not clearly addressed and where it is accounted for it generally sits in the 
unprovoked category. However, a systematic review of evidence relating to 
infections and inflammatory diseases demonstrated an association between 
transient acute infective/inflammatory disease and an increased incidence of 
VTE (Tichelaar et al, 2012). There is also suggestion that VTE events 
associated with transient infection do not have the same recurrence rate as 
other unprovoked cases and should therefore be treated differently when 
considering long term anticoagulation prevention strategies (Ageno et al, 2012). 
More research is required in this field to clarify the role of infection/inflammatory 
disease in VTE provocation before consensus can be reached. 
 
1.5 Natural History of DVT 
1.5.1 DVT resolution 
Anticoagulation therapy acts on a DVT by preventing further thrombus 
deposition, allowing established thrombus to undergo a process of stabilisation 
and/or endogenous lysis and reduces the risk of recurrent thrombosis during the 
treatment period (Kearon, 2003). DVT is a dynamic process and it is thought 
that progression and resolution can proceed simultaneously at different sites of 
a thrombosis with the balance between these processes subject to change. This 
can therefore lead to both clinical exacerbations and/or remissions (Kearon, 
2003). Several studies have examined the natural history of treated DVT in 
anticoagulated patients with varying durations of follow-up, different methods 
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and variable cohort size. Several other studies have examined DVT resolution 
in relation to health outcomes such as recurrence, venous reflux and the 
development of PTS. These studies were included in the systematic literature 
review and are examined in detail in Chapter 2. 
1.5.2 DVT Recurrence 
The risk of VTE recurrence is highest soon after the acute episode and declines 
over time (Baglin et al, 2003). The risk and consequences of recurrent DVT vary 
by patient. The majority of patients with a first episode of unprovoked DVT will 
not have a recurrent episode. However recurrent VTE is an important risk factor 
for death after PE and recurrent DVT is an important risk factor for PTS (Carson 
et al, 1992; Prandoni et al, 1996). Recurrent DVT is also associated with 
significantly increased long-term health care costs (Bergqvist et al, 1997). It is 
therefore important to try and determine those most at risk and target long term 
treatment accordingly (Baglin, 2007).  
 
Continued treatment with oral anticoagulants after an episode of VTE will 
prevent most cases of recurrence but with this comes a significant associated 
risk of major bleeding (Palareti et al, 1996; Kearon et al, 1999). In theory 
anticoagulation therapy should be continued until the risk of bleeding outweighs 
the benefit. However it is difficult to predict the risk of recurrence and the risk of 
major bleeding on an individual basis (Baglin et al, 2003). 
 
Recurrent VTE events are reasonably common and research has demonstrated 
that recurrent episodes make up approximately 25% of all VTE events (Huang 
et al, 2014). One study reported an annual likelihood of DVT recurrence in 
patients with a first episode of unprovoked DVT of 5-15% with a cumulative 
recurrence rate of about 25% after 4 years (Prandoni et al, 1996). It is well 
documented that the risk of recurrence upon stopping anticoagulation after a 
first episode DVT varies depending on the clinical risk factors associated with 
the primary episode (Baglin, 2007) and risk factors for recurrence are discussed 
further in the literature review in Chapter 2. 
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1.5.3 Diagnosis of recurrent DVT 
Distinguishing between acute and chronic DVT is crucial because thrombus 
becomes more organised as it ages and adheres to the vein wall. It therefore 
becomes less likely to embolise which significantly alters the risk versus benefit 
ratio for anticoagulation therapy (American Thoracic Society, 1999). When 
patients present with recurrent symptoms, for some this will be due to DVT 
recurrence, but others will have PTS.  
 
Real time compression ultrasound has been shown to be a highly accurate, 
objective and reproducible method of diagnosing acute DVT in symptomatic 
patients. However, the role of any of the available diagnostic imaging 
techniques in current practice for acute DVT (ultrasound, Magnetic Resonance 
venography, Computed Tomography venography) has not been firmly 
established for patients with clinically suspected recurrent disease (Hull et al, 
1983) and each test has limitations in diagnosing acute thrombus in the 
presence of previous venous thrombotic disease (Hull et al, 1983).  
 
The diagnostic hallmark of venography (magnetic resonance and computed 
tomography) is a constant intraluminal filling defect but this may be masked by 
impaired visualisation due to obliteration and recanalisation rendering findings 
often inconclusive in patients with previous thrombotic disease (Hirsh and Hull, 
1978).  
 
Duplex Ultrasound (DUS) has been used to try to differentiate between acute 
and chronic thrombus although the evidence for its reliability is limited (Katz et 
al, 2014). In cases of acute thrombosis the vein appears distended on 
ultrasound, the thrombus is seen to be hypoechoic and often not completely 
attached to the vein wall, there is little or no compressibility and collateralisation 
is not visualised. This is contrasted with the appearance of chronic thrombus on 
ultrasound in which the vein is narrow, the thrombus is echogenic and attached 
to the vein wall and often collateralisation can be seen (Karande et al, 2016). 
However, these findings may not be present and thrombus echogenicity is 
highly variable making the distinction between chronic and acute DVT very 
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unreliable, particularly when a lack of previous imaging for comparison exists 
(Katz et al, 2014). In addition, Murphy and Cronan (1990) found that clot 
echogenicity did not accurately distinguish between acute and chronic thrombus 
although a positive correlation between vein distension and the age of the 
thrombus was demonstrated. Other potential pitfalls of DUS for suspected DVT 
recurrence include false negative diagnoses in cases where only one femoral 
vein is visualised in the presence of duplication of the femoral vein (considered 
present in upwards of 50% of individuals) and both false negative and false 
positive diagnoses involving the iliac veins which are generally considered 
challenging to image reliably with ultrasound (Katz et al, 2014).  
 
In order for ultrasound assessment to be useful in the diagnosis of DVT 
recurrence, evidence is needed that real time compression ultrasound had 
normalised prior to symptoms re-occurring (Prandoni et al, 1993). However, 
previous studies have demonstrated that up to 50% of previously abnormal 
compression ultrasound assessments do not normalise within 1 year of follow-
up (Cronan & van Leen, 1989; Murphy & Cronan, 1990; Mantoni, 1991; 
Heijboer et al, 1992; Prandoni et al, 1993; Piovella et al, 2002, Prandoni et al, 
2002; Prandoni et al, 2009). It could be considered appropriate to perform 
follow-up ultrasound assessment 3-6 months post diagnosis of a first episode of 
DVT to serve as a baseline in the event that symptoms do reoccur (American 
Thoracic Society, 1999). The reality in current UK clinical practice is that 
patients diagnosed with a DVT do not currently receive any routine follow-up 
surveillance with ultrasound to confirm the resolution status of the DVT 
(Needleman et al, 2018). The practicalities of implementing such a strategy are 
limited not only by cost implications in terms of service provision but by a lack of 
robust evidence regarding the optimum time to perform such an assessment. 
As a result, it is thought that up to 70% of patients are incorrectly labelled as 
having a DVT recurrence and are hence prescribed a new course of long-term 
(often lifelong) anticoagulation therapy (Leclerc  et al, 1985). 
 
58 
 
1.5.4 The challenge of predicting recurrence and long-term 
anticoagulation 
As discussed in the previous sections, the likelihood of recurrence is difficult to 
predict and diagnose. Although continued long-term anticoagulation would 
probably prevent most cases of recurrence, the incidence of complications 
associated with this is not negligible, with the risk of major bleeding estimated at 
approximately 2% per year of continued anticoagulation (Palareti et al, 1996). 
Although a number of studies have examined outcomes after different 
anticoagulation treatment durations (Schulman et al, 1995; Kearon et al, 1999; 
Agnelli et al, 2001; Pinede et al, 2001) there remains uncertainty around the 
optimal duration of anticoagulation for a first episode of unprovoked DVT with 
no known precedent risk factor (Verhovsek et al, 2008).  
 
Despite this, experts in the field have predicted a move away from a traditional 
disease focussed approach with generic treatment regimens to a more tailored 
approach to anticoagulation. This would lead to more individual patient-
focussed management decisions as more clinical outcome data become 
available from recent and ongoing observational and management studies 
(Baglin, 2007). The key decision that clinicians face is whether to continue 
anticoagulation long-term to prevent recurrence rather than for the duration of 
anticoagulation therapy to manage the initial thrombotic event (Verhovsek et al, 
2008).  
 
Several studies have assessed whether use of the D-dimer test (see Section 
1.3.3) after anticoagulation is interrupted could be useful as a tool to identify 
individuals at risk of recurrence and help clinicians determine whether long-term 
anticoagulation is appropriate (Eichinger et al, 2003; Palareti et al, 2003; 
Palareti et al, 2006; Shrivastava et al, 2006; Tait et al, 2007; Baglin et al, 2008; 
Poli et al, 2008). The lower power of these individual studies to provide 
evidence of the effect of D-dimer levels on the risk for VTE recurrence has led 
to a continuing debate regarding the utility of D-dimer in the decision making 
process regarding long-term anticoagulation. A systematic review was 
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subsequently conducted with the purpose of synthesizing the available 
evidence regarding the value of D-dimer as a predictor of recurrence after a first 
episode of DVT (Verhovsek et al, 2008).  
 
The review included only randomised controlled trials (RCTs) and prospective 
studies that measured D-dimer after stopping anticoagulation for a minimum of 
3 weeks in patients with a first episode of VTE who had received a minimum of 
3 months of anticoagulation therapy. All studies comprised well-defined and 
similar cohorts which underwent regular follow-up schedules. Strengths of this 
review were that all stages were duplicated by independent researchers and all 
patient outcomes were objectively confirmed and independently assessed 
without prior knowledge of the D-dimer results. The review findings reflect the 
pooled analysis of 1900 patients who had an average of 2 years of follow-up 
after stopping anticoagulation. Findings showed that patients with a negative D-
dimer result had an annual risk of recurrence of 3.5% compared to 8.9% in 
those with a positive D-dimer (Verhovsek et al, 2008).  
 
Included studies did not all use the same assays of D-dimer.  Whilst this is a 
limitation it reflects clinical practice as several commercially available D-dimer 
assays are widely used and no worldwide gold standard for D-dimer testing 
exists. Consistency in the findings across the studies, however, suggests that 
this was not a significant limitation. None of the included studies were blinded to 
a history of VTE and therefore represent samples susceptible to disease 
recurrence potentially leading to biased ascertainment of outcomes. Again this 
is unlikely to be a significant limitation as all outcomes were objectively 
confirmed. 
 
The review authors concluded that a negative D-dimer result could be useful in 
combination with other factors associated with low risk of recurrence (e.g. 
female sex and younger age in selecting patients as unlikely to benefit from 
long-term anticoagulation. Ideally clinicians could use D-dimer in conjunction 
with clinical features in a decision making process weighing the risk/benefit of 
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prolonged anticoagulation in the context of an individual patient’s values and 
preferences (Verhovsek et al, 2008). 
 
1.6 Post thrombotic syndrome 
As well as acute symptoms and the risk of mortality from embolisation, DVT 
may lead to persistent chronic disease, which can be severely disabling. This 
condition is known as post thrombotic syndrome (PTS). PTS symptoms usually 
develop within 3-6 months post DVT but can occur at any point up to 2 years 
after DVT (Roumen-Klappe et al, 2005; Wong and Baglin, 2012; Kahn et al, 
2014b) even with adequate anticoagulation (Kahn et al, 2016). 
 
Symptoms of PTS are numerous and vary between patients (Kahn & Ginsberg, 
2004). Symptoms are similar to those of primary venous insufficiency and 
include persistent or intermittent leg pain, cramp, heaviness, itching, tingling, 
parasthesia or tiredness which are typically worsened by walking or standing for 
long periods and tend to improve through rest and elevation (Roumen-Klappe et 
al, 2009). Clinical signs of PTS can include oedema, venous ectasia, new or 
worsening varicose veins and telangectasia, redness, hyperpigmentation, 
venous eczema, dependent cyanosis, lipodermatosclerosis, atrophie blanche, 
and in the worst cases, venous ulceration (Kahn et al, 2004, Kahn et al, 2008a; 
Roumen-Klappe et al, 2009; Kahn et al, 2014b).  
 
Patients report the severity of PTS symptoms as ranging from mild discomfort to 
severe chronic pain with symptoms intensifying over the course of the day 
whilst the leg is dependent (Prandoni and Kahn, 2009). The symptoms are 
generally improved with rest and elevation (Carman, 2016). PTS can also 
present as venous claudication likely caused by residual venous obstruction of 
a major venous confluence such as the popliteal or ilio-femoral veins (Kahn et 
al, 2008a). Patients with venous claudication report bursting leg pain during 
exercise which can resemble arterial claudication (Browse et al, 1999).  
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PTS symptoms may wax and wane and some patients may find they improve 
over time whilst others find that they worsen (Kahn et al, 2008a; Kahn et al, 
2009b). PTS is a costly condition in terms of both patient quality of life and 
health care costs (Kahn et al, 2016). Multiple studies have demonstrated that 
patients with PTS have poorer quality of life than patients without PTS after a 
DVT (Van Korlaar et al, 2003; Kahn et al, 2005a; Broholm et al, 2011; Kahn et 
al, 2008b) and the reduction in quality of life is correlated to the severity of PTS 
(Kahn et al, 2002). Indeed, one study showed that patients with PTS reported 
worse quality of life scores than the average scores for patients with diabetes, 
chronic lung disease and osteoarthritis (Kahn et al, 2008b). In terms of health 
care costs, one study from Canada estimated that the total health care cost per 
DVT patient, mainly as a result of additional healthcare visits and prescription 
medicines, was almost 50% greater in those with PTS than those without PTS 
over the two year period following their DVT diagnosis (Guanella et al, 2011). 
The anxiety and psychological trauma caused by an episode of acute VTE must 
also be considered (Klok et al, 2010; Hunter et al, 2017). 
 
1.6.1 Pathophysiology of PTS 
The pathophysiological mechanisms resulting in the development of PTS after a 
DVT are complex and not yet fully understood (Kahn et al, 2014b; Yamaki, 
2016). However, clinical manifestations of PTS are thought to develop as a 
result of venous hypertension caused by RVO, damage to the venous valves 
resulting in valvular incompetence or a combination of both (Roumen-Klappe et 
al, 2009; Vedantham, 2009).  
 
The venous system, unlike the arterial system, is a low pressure system. 
Venous pressure is determined by hydrostatic pressure (the weight of the 
column of blood between the right atrium and the foot). Venous pressure is 
lowest in the supine position as the pumping action of the heart and pressure 
gradients caused by respiration maintain movement of the blood through the 
arteries and veins.  
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Venous pressure is naturally highest when a person is standing motionless or in 
a seated position with the legs dependent. When a person is walking at an 
average speed (1.7 mph) venous pressure is incrementally reduced to a mean 
of 22 mmHg as the calf muscle pump, aided by competent venous valves, 
returns blood from the lower limb to the lungs and heart hence limiting 
accumulation of blood. These valves act like stop gates, ‘holding’ the blood 
above them and preventing the flow falling back down the leg when pressure is 
below the gravitational pull.  For various reasons, including damage caused by 
DVT, these valves can sometimes fail and impair venous return (Fig. 1.1). 
Failure of the venous valves is called venous incompetence and results in an 
abnormal increase in venous blood pressure.  
 
Figure 1.1 The normal and abnormal functioning of venous valves (researcher’s 
own illustration). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some retrograde flow must occur in order to close the valve leaflets as shown in 
Figure 1.1 (b).  If, however, the valves are incompetent, they allow prolonged 
retrograde flow to occur as shown in Figure 1.1 (c). It is this backward motion of 
blood that is documented during venous reflux testing with DUS. The 
measurement of the duration of reflux following flow augmentation has become 
(a)  
Open 
(c)  
Abnormal  
closed 
(reflux) 
Venous valvular 
function 
(b)  
Normal  
closed 
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the most widely used test to determine venous insufficiency. Reflux lasting 
longer than 0.5 seconds is the accepted threshold for defining abnormal venous 
reflux (Van Bemmelen et al, 1989). DUS has undoubtedly had a large impact on 
the diagnosis and treatment of venous disease. The use of DUS in the 
assessment of the peripheral venous system has become extremely important 
in the management of chronic venous insufficiency (CVI) as this non-invasive 
technique not only permits reflux and obstruction to be precisely localised but 
has also increased knowledge of the pathophysiology of venous disease by 
facilitating epidemiological studies in the general population (Meissner, 2002). 
 
CVI is caused by either superficial or deep venous pathology in which venous 
flow is impaired by valvular incompetence, obstruction or calf muscle pump 
failure which can all lead to sustained venous hypertension. CVI may or may 
not be secondary to DVT. Venous hypertension results in reduced calf muscle 
perfusion and increased tissue permeability and these factors result in the 
clinical manifestations of PTS (Kahn et al, 2016). 
 
After a DVT, the processes of thrombus break-down and recanalisation of the 
involved venous segments occurs through a combination of thrombus 
organisation, fibrinolysis and neovascularisation (Meissner et al, 2002a). This 
process is often not complete however, resulting in RVO (Kahn et al, 2014b). 
Persistent RVO due to incomplete resolution of the initial thrombosis impacts 
the venous return resulting in venous hypertension. Damage to the valve 
leaflets can occur either directly by the thrombus itself or through entrapment in 
the fibrotic processes occurring in the vein wall (Kahn et al, 2014b). The 
process in which fibrosis of the venous wall occurs is thought to be a result of 
the inflammatory response in both the thrombus itself and the endothelium 
(Roumen-Klappe et al, 2009). Indeed, animal studies have demonstrated that 
inflammatory processes in DVT involve both the venous vascular wall 
(endothelium) and the peri-vascular area (Froehlich et al, 1997; Meissner et al, 
2007) and on a cellular level the resolution of DVT has been shown to resemble 
wound healing in terms of the early influx of neutrophils and monocytes, 
collagen disposition and thrombus neovascularisation (Wakefield & Henke, 
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2005). These processes result in late fibrosis which has been shown to increase 
vein wall stiffness (Deatrick et al, 2005; Wakefield & Henke, 2005). 
 
It is now thought that the inflammatory processes that are known to occur 
during the acute phase of thrombosis may also play a role in outcomes post 
DVT and in particular the development of PTS (Roumen-Klappe et al, 2009). It 
has been demonstrated that elevated levels of inflammatory markers such as 
interleukin-6 (IL-6) and C-reactive protein (CRP) are a response to, rather than 
a cause of thrombosis (Roumen-Klappe et al, 2002). This research group also 
demonstrated that increased levels of IL-6 and CRP present at baseline on the 
day of DVT diagnosis were associated with elevated venous outflow resistance 
measured on strain-gauge plethysmography at three months (IL-6: RR 2.4 (1.5 - 
3.9) and CRP RR 1.4 (1.1 – 3.3)). IL-6 was also associated with higher 
thrombus load scores after three months (RR 1.5 (1.1 – 2.1)). No association 
however was demonstrated between reflux and either IL-6 or CRP (Roumen-
Klappe et al, 2009). It is also thought that there may be genetic polymorphisms, 
mainly associated with vein wall remodelling, that promote an underlying 
predisposition to the development of PTS (Bharath et al, 2014). 
 
Whether the development of PTS is predominantly the result of venous outflow 
obstruction, venous valvular reflux, a combination of residual obstruction and 
reflux, inflammatory markers or patient/disease characteristics is unclear from 
existing evidence (Kahn et al, 2014b). 
 
1.6.2 Diagnosis of PTS 
There is no gold standard functional or laboratory test, nor imaging technique, 
to diagnose PTS.  The diagnosis is primarily based on the presence of the signs 
and symptoms described at the start of Section 1.6 in a patient with a confirmed 
episode of previous DVT (Kahn et al, 2016). Although symptoms of PTS often 
develop between three and six months post DVT, it can take several months for 
the symptoms of pain and swelling from the initial presentation of DVT to 
resolve in some patients. For this reason, a diagnosis of PTS should be 
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deferred until after the acute stage (three to six months post DVT) (Kahn et al, 
2016).  
 
Several classification systems for PTS have been developed and evaluated in 
recent years for their reliability, reproducibility, validity, responsiveness to 
change and their use in routine clinical practice. The revised Clinical, Etiologic, 
Anatomic, Pathophysiologic (CEAP) classification system (Eklof et al, 2004) and 
Villalta scale (Prandoni et al, 1997) are the two most widely reported methods in 
the literature but others have been developed.  
 
Ginsberg score 
The Ginsberg scoring system diagnoses patients as having PTS if they report 
lower limb pain and if swelling is present daily for a minimum period of one 
month at least six months after the initial DVT (Ginsberg et al, 2000). Patients 
are diagnosed with PTS only if they present with both pain and swelling and if 
valvular incompetence is objectively confirmed. Residual occlusion is not 
considered in this system and the severity of the condition is not scored 
(Soosainathan et al, 2013). In a study comparing the Ginsberg system and the 
Villalta scale in relation to health-related quality of life, patients diagnosed with 
PTS using the Ginsberg score had lower quality of life scores and higher mean 
Villalta scores. This study also found that using the Villalta score to diagnose 
PTS resulted in five times more positive diagnoses that when using the 
Ginsberg score (Kahn et al, 2006). These findings suggest that the Ginsberg 
scale only identifies those with more severe PTS (Soosainathan et al, 2013). 
 
Brandjes score 
The Brandjes score uses a combination of objective and subjective criteria to 
classify patients based on a score obtained over two consecutive visits, three 
months apart (Brandjes et al, 1997). The Brandjes score has been shown to 
correlate well with ambulatory venous pressure (AVP) with a strong association 
demonstrated between PTS severity when classified using the Brandjes scale 
and higher mean AVP values (Kolbach et al, 2005). This system does grade the 
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severity of the disease but, like the CEAP and Widmer classifications (see 
below), it is a static score. For example, once a patient develops a venous ulcer 
after a DVT, they will always be considered as having severe PTS regardless of 
whether or not it heals (Soosainathan et al, 2013). 
 
Widmer classification 
The Widmer classification was developed to grade CVI but it has since been 
utilised in studies of PTS (Widmer et al, 1981). This system is based purely on 
clinical signs and showed a moderate association with both the Brandjes score 
and the CEAP score (Kolbach et al, 2005).  
 
Venous Clinical Severity Score  
The Venous Clinical Severity Score is based on the CEAP system and was 
developed to address its limitations in assessing change over time (Rutherford 
et al, 2000). The system uses nine clinical descriptors which are scored from 0 
to 3 according to severity. This system was used as an evaluation of 
endovascular treatment for PTS (Wahlgren et al, 2010) but has not been widely 
implemented in PTS research. One of its major limitations is that there is no 
standard VCSS to diagnose or grade the severity of PTS (Soosainathan et al, 
2013). The VCSS also showed poor correlation with all other scoring systems 
(Kolbach et al, 2005) and a validation study demonstrated a statistically 
significant inter-observer variability in assessing pain, inflammation and 
pigmentation using this system (Meissner et al, 2002b). 
 
CEAP classification system 
The CEAP system is based on visible clinical indications that can be objectively 
measured but includes none of the symptoms of pain and discomfort frequently 
reported by patients post DVT. The basic CEAP system first gives a score of 0-
6 in which those with a score of 0 have no visible or palpable signs of venous 
disease, 1 have the presence of telangectasias, reticular veins or malleolar 
flare, 2 have varicose veins, class 3 oedema without skin changes, 4 skin 
changes attributed to venous disease (pigmentation, lipodermatosclerosis), 5 
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skin changes with healed ulceration and 6 skin changes with active ulceration. 
A higher class may also have all or some of the signs from the lower classes. 
The extended CEAP system then further classifies each limb as being either 
symptomatic or asymptomatic, whether the aetiology of the venous disorder is 
congenital, primary or secondary, if the anatomic site of the disease is the 
superficial venous system, deep venous system or perforator sites (any or all 
sites can be involved) and finally whether the venous disease is caused by 
valvular reflux, obstruction or a combination of both. A positive diagnosis of PTS 
is defined as a basic CEAP score of ≥3 (Porter and Moneta, 1988). The CEAP 
system is used widely in classifying venous disease in general but there are 
several challenges when using it to score patients with PTS (Soosainathan et 
al, 2013). 
 
Villalta scale 
The Villalta scale is a disease score specific for PTS which combines both 
visible clinical indications and patient reported symptoms and can be used to 
both diagnose and grade the severity of the condition (Soosainathan et al, 
2013). The system grades each of five symptoms (pain, cramp, heaviness, 
pruritus and parasthesia) and six clinical signs (oedema, skin induration, 
hyperpigmentation, venous ectasia, redness and compression pain) as none, 
mild, moderate or severe using a scale of 0-3 giving a maximum score of 33 in 
the worst cases. PTS is considered present if the Villalta score is ≥5. Scores of 
5-9 indicate mild PTS; 10-14 indicates moderate PTS and the condition is 
considered severe if the score is ≥14. If a venous ulcer is present, the condition 
is described as severe regardless of the presence or absence of other clinical 
indications (Villalta et al, 1994). In contrast to the other scoring systems which 
require multiple assessments at defined intervals, the Villalta scale requires only 
a single assessment (Kahn et al, 2009a).  
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1.6.3 Management of PTS 
Prevention 
Despite PTS being increasingly recognised as an important outcome of DVT 
with its clinical, physical and economic impact, there has been little 
advancement in terms of prevention. It continues to be a difficult condition to 
both manage and prevent. Preventing PTS of course starts with preventing DVT 
and in particular recurrent DVT (Carman, 2016).   
 
Medical therapy 
It is currently not known if the choice of anticoagulation therapy affects the risk 
of developing PTS (Kahn et al, 2016). Poor INR management has however 
been associated with increased risk of developing PTS (Galanaud et al, 2013). 
The REVERSE study (Relationship between subtherapeutic warfarin 
anticoagulation and the development of post thrombotic syndrome after a first 
unprovoked deep vein thrombosis) examined a cohort of 349 patients with a 
first episode of unprovoked DVT (Chitsike et al, 2012). This study reported an 
overall frequency of PTS of 33.5% in patients considered to have a sub-
therapeutic INR (defined as <2) for ≥20% of the period of anticoagulation 
therapy compared to 21.6% for those with a sub-therapeutic INR for ≤20% of 
the period (p=0.01) (Chitsike et al, 2012). A further study in a similar cohort of 
244 patients had previously identified that participants who spent >50% of the 
anticoagulation period with a sub-therapeutic INR (again < 2) were at higher risk 
of PTS over a follow-up period of 5 years compared to those with therapeutic 
INR OR of 2.71, 95% CI: 1.44-5.10 (van Dongen et al, 2005).  
 
Data from a systematic review suggested that the use of LMWH monotherapy 
rather than the LMWH followed by vitamin K antagonists could lead to lower 
rates of PTS development (Hull et al, 2011). This would however require 
confirmation through further research with well-designed RCTs (Kahn et al, 
2016). With a move away from the use of LMWH followed by vitamin K 
antagonists as the first line choice of anticoagulation therapy and towards more 
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widespread use of DOACs such as dabigatran, rivaroxiban, apixaban and 
edoxaban, this information may now however be considered dated. It is not yet 
known whether the use of DOACs in the treatment of DVT influences the risk of 
developing PTS compared to LMWH or vitamin K antagonists (Kahn et al, 
2016). Further work is needed to establish rates of PTS development with the 
use of DOACs that do not require monitoring but rely on patient compliance with 
regular administration of the drug as evidence in this field is currently lacking. 
The potential role of DOACs on the inflammatory processes that are considered 
to be involved in the development of both DVT and PTS also requires 
evaluation (Carman, 2016). 
 
Compression therapy 
The use of compression therapy was until relatively recently a primary 
recommendation for the prevention of PTS. Data from two small, open label 
RCTs had previously demonstrated a 50% lower incidence of PTS at 2 years 
follow-up with the use of 30-40 mmHg knee high graduated compression 
hosiery
 
(Brandjes et al, 1997; Prandoni et al, 2004). Based on these data, 
consensus guidelines had previously recommended the use of compression 
stockings for at least 2 years post DVT to prevent PTS (Kearon et al, 2008; 
Kearon et al, 2012). However, other trials showed no difference in the rate of 
PTS development with the use of compression therapy (Ginsberg et al, 2001; 
Aschwanden et al, 2008). A meta-analysis of data from 5 randomised trials 
comparing treatment with compression therapy with controls reported that mild 
to moderate PTS occurred in 22% and severe PTS occurred in 5% in the 
compression group compared to 37% and 12% respectively in the control 
group. Any PTS occurred in 26% in the compression group compared to 46% in 
the control group (Musani et al, 2010). 
 
The SOX trial (Compression stockings to prevent the post thrombotic 
syndrome) compared the use of compression therapy to a placebo for the 
prevention of PTS (Kahn et al, 2014a). This large randomised trial of 806 
patients reported no significant difference in the rate of PTS development 
between the two groups over a two year follow-up period with 14.2% in the 
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compression group compared to 12.7% in the placebo group. There was also 
no significant difference in both generic and disease specific quality of life 
scores between groups (Kahn et al, 2014a). Due to the level of subjectivity 
involved in a diagnosis of PTS, the blinded, placebo-controlled design of this 
study is an important methodological strength. These findings have led to recent 
recommendations against the routine use of elastic compression stockings for 
the prevention of PTS (Kearon et al, 2016). Unlike the previous trials however, 
the SOX trial did not exclude patients with pre-existing CVI which may have 
masked the effect of compression therapy.  
 
Endovascular therapy 
Given the presumed relationships between RVO and/or damage to venous 
valves and PTS, the restoration of venous patency may have an important role 
to play in its prevention. As discussed previously in Section 1.3.7, the goal of 
endovascular intervention is to rapidly restore venous patency and 
subsequently reduce venous congestion.  The aim of endovascular therapy is 
not only to reduce the immediate symptom burden by improving venous outflow 
but also to prevent or limit venous wall and valvular damage with a view to 
reducing the risk of recurrence and the development of PTS (Carman, 2016).  
 
There have been two randomised trials of endovascular therapy that have 
published results to date. The TORPEDO trial compared pharmaco-mechanical 
catheter directed thrombolysis (PCDT) with standard anticoagulation therapy in 
183 patients with proximal DVT. Results demonstrated the development of PTS 
in 6.8% of patients treated with PCDT compared to 29.6% of patients treated 
with standard anticoagulation therapy (P<0.001) (Sharifi et al, 2012). PTS 
severity was also lower in the PCDT group however PTS was not diagnosed, or 
symptoms levels graded using a validated tool in this trial which lessens the 
validity of the results. In addition, complications associated with PCDT were not 
reported in the study. The CaVenT trial randomised patients with a first episode 
of proximal DVT to CDT versus anticoagulation alone and followed patients for 
5 years post intervention/treatment (Enden et al, 2009; Enden et al, 2012). The 
development of PTS (Villalta score >5) in 176 participants at 5 years was 
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reported as 37 patients (43%; 95% CI 33–53) allocated to CDT compared with 
63 (71%; 95% CI 61–79) allocated to the control group (p<0·0001), 
corresponding to an absolute risk reduction of 28% (95% CI 14–42). There was 
however no difference in ilio-femoral patency nor quality of life scores (using 
both EQ-5D and the disease-specific VEINES-QOL/Sym scoring systems) 
between the two groups (Enden et al, 2012). This suggests that further research 
is required to determine the optimal endovascular thrombolytic approach. 
 
The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-
Directed Thrombolysis (ATTRACT) trial was the first multi-centre, randomised, 
open-label, assessor-blinded, parallel two-arm, controlled clinical trial in this 
field. The trial compared the ability of PCDT with anticoagulation and standard 
anticoagulation therapy alone to reduce the incidence and severity of PTS in 
692 patients with acute proximal DVT. Initial results were presented for the first 
time at the Society of Interventional Radiology Annual Scientific Meeting in 
March 2017. The study found that PTS occurred with equal frequency in both 
groups after two year follow-up and concluded that most patients with DVT 
should continue to be treated with anticoagulant drugs alone without undergoing 
a procedure-based intervention. However, the study also showed that the 
combination of PCDT and blood-thinners provided greater relief of leg pain and 
swelling during the first 30 days of treatment, compared to those who received 
anticoagulation alone and is therefore likely to prevent disability in certain DVT 
patients. In addition, patients who received both PCDT and anticoagulation 
following DVT were 25% less likely (18% with PCDT vs. 24% without) to 
develop moderate-to-severe PTS (Society of International Radiology Press 
Release, 7 March 2017). 
 
Surgical thrombectomy 
Surgical thrombectomy may have a role to play in the prevention of PTS in 
those patients in whom endovascular intervention is contraindicated due to 
bleeding risk or other comorbidities (Carman, 2016). A meta-analysis showed 
that surgical thrombectomy demonstrated a significant risk reduction for the 
development of PTS (RR 0.67; 95% CI, 0.52-0.87) when compared to 
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anticoagulation therapy alone. The quality of the evidence was generally rated 
as low however due to a lack of randomisation, poor follow-up and a lack of 
baseline comparability between cohorts (Casey et al, 2012). Prevention of PTS 
is a challenging prospect. Maintaining optimal oral anticoagulation therapy and 
discriminate use of compression therapy should be used as a first line 
prevention strategy, however, whether the wider use of CDT or PCDT should be 
encouraged remains indeterminate. 
 
Treatment of established PTS 
PTS is both expensive and difficult to treat, can be very debilitating and often 
results in limited mobility and a significant reduction in quality of life. There are 
several potential treatment options but currently only compression stockings are 
in widespread use in clinical practice (Kahn et al, 2016). 
 
A variety of compression-based therapies have been trialled with a view to 
reducing PTS symptoms, in particular pain and swelling. These include 
compression stockings with varying pressures and intermittent compression 
devices. Evidence for their effectiveness however is limited and the few 
controlled studies performed have been small scale with limited follow-up 
duration (Kahn et al, 2016). Recent clinical guidance suggests a prescription of 
20-30 mmHg knee high compression stockings to be worn daily from rising to 
retiring for the treatment of PTS. If this does not adequately control symptoms 
then a stronger pressure stocking (30-40 mmHg or 40-50 mmHg) can be tried 
(Holmes et al, 2014). In the event that compression stockings do not adequately 
control symptoms in patients with moderate to severe PTS, portable 
compression devices can be tried (Kearon et al, 2012). In the most severe 
cases of intractable PTS symptoms, the use of intermittent pneumatic 
compression sleeve devices for 20-30 mins, 2-3 times per day can be tried 
although these units are expensive and cumbersome to use (Ginsberg et al, 
1999). This guidance is however primarily based on the low risk of harm and the 
potential to benefit some patients rather than concrete evidence of the 
effectiveness of these methods (Kahn et al, 2016). 
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To date only two small studies have examined the effectiveness of exercise 
programmes in the treatment of PTS. The first was a sample of 30 participants, 
half of whom had been previously diagnosed with a DVT. This study 
demonstrated an improvement in calf muscle strength and function after a 6 
month programme (Padberg et al, 2004). The second study demonstrated an 
improvement in both the severity of PTS and quality of life scores again after a 
6 month programme (Kahn et al, 2011). These limited data suggest that a well-
designed exercise programme could be of benefit in the treatment of PTS but 
further research is required. Recent clinical guidance suggests that promoting 
venous return by avoiding sedentary lifestyles, elevation of the affected limb 
when resting, maintaining a healthy body weight, avoiding prolonged exposure 
to heat and using a moisturising cream to avoid skin dryness on the leg is 
relevant advice to all patients with any form of CVI including PTS (Kahn et al, 
2016). 
 
Several randomised studies have examined the effect of various venoactive 
medical therapies including rutosides, defibrotide and hidrosmin (Monreal et al, 
1994; de Jongste et al, 1989; Coccheri et al, 2004; Prandoni, 2005) however a 
systematic review of the evidence for the use of these drugs in treating PTS 
found the studies to be of poor quality with many inconsistencies (Cohen et al, 
2012). In addition, little is known about the long term side effects of these 
treatments as treatment duration is typically short term in these studies. 
 
Between 5 and 10% of DVT patients will go on to develop symptoms of severe 
PTS which may include venous ulceration.  Shulman et al (2006) demonstrated 
that the probability of developing a venous ulcer within 10 years of a DVT was 
almost 5%. Post-thrombotic venous ulceration is treated with compression 
therapy and topical dressings but these ulcers are often recalcitrant and prone 
to reoccur. Clinical guidance suggests a multi-disciplinary approach for the 
treatment of post-thrombotic ulceration and should include input from a doctor 
of general medicine, dermatologist, vascular surgeon and specialist wound care 
nurse (Kahn et al, 2016). It has been estimated that around 2% of total health 
expenditure in the National Health Service (NHS) is spent on the treatment of 
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venous disease and that one third of district nursing time is spent on dressing 
leg ulcers (Fowkes, 2001).  
 
Surgical or endovascular intervention 
Venous stenting, venous bypass and valve reconstruction are techniques that 
have the potential to improve PTS in patients in whom residual venous 
obstruction and/or valvular incompetence are the underlying causes of their 
symptoms (Nayak et al, 2012). These techniques are however complex 
procedures that are not routinely practiced in the vast majority of centres. Little 
is therefore known about the long term success or complication rates of these 
interventions (Kahn et al, 2016). 
 
1.6.4 Risk of developing PTS 
One study found that approximately 40% of adults with a first episode of 
symptomatic DVT developed PTS within 2 years of diagnosis (Kahn et al, 
2008a). Other studies have demonstrated that between 20-50% of patients with 
symptomatic DVT will develop PTS within 2 years despite `adequate' treatment 
of DVT (Bernardi and Prandoni, 2000; Saarinen at al; 2000; Kahn and 
Ginsberg, 2002). PTS is reported to be severe in 5-10% of cases (Kahn et al, 
2016). Therefore on average, 60% of people with a DVT will go on to make a 
full recovery with no residual symptoms, 30% will develop some degree of PTS 
and 5-10% will develop severe PTS (Kahn et al, 2016). PTS has become 
increasingly recognised as an important outcome post DVT over the last 10-15 
years (Kahn et al, 2016) and the occurrence and severity of PTS have been 
shown to represent the primary determinant of quality of life over 2 years follow-
up in patients with DVT (Kahn et al, 2008b). 
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1.7 Motivations for undertaking the study 
1.7.1 Personal perspective 
As a Clinical Vascular Scientist, I have performed diagnostic ultrasound for DVT 
for over ten years at University Hospitals Bristol. In my hospital Trust, when a 
DVT is detected in a patient’s leg, we inform them of the result and explain that 
they will be reviewed by a specialist nurse who will discuss the treatment with 
them. From my experience, there are two common questions that patients 
subsequently ask about their DVT:  
 
 When will it go away? 
 Will my leg go back to normal? 
 
These are two questions that I have always found challenging to answer from 
the existing research evidence and this is the main reason I decided to conduct 
research in this area. Part of the reason why these questions are difficult to 
answer is because we do not routinely re-scan patients at the end of their 
treatment to determine if their DVT has resolved. Nor are they routinely re-
assessed at any point to determine if the symptoms associated with their DVT 
have resolved. We do however know that some patients may recover fully from 
having had a DVT and others may be left with on-going symptoms of pain and 
swelling, grouped under the umbrella term PTS (Baxter & Goss, 2011). We 
know this partly because these patients re-present, often multiple times in the 
months or years following their initial DVT, for a query new DVT.  
 
1.7.2 Justification for the research study 
The research evidence to date suggests variability in the response to treatment 
in terms of thrombosis resolution and residual venous function. Some 
thromboses may resolve before the course of anticoagulation treatment is 
completed and some may not be resolved upon completion of the treatment 
cycle. Whether this is important to longer term outcomes is not clear and there 
remains considerable uncertainty regarding the underlying pathophysiology of 
PTS.  
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Whether PTS is predominantly the result of venous outflow obstruction, venous 
valvular reflux, or a combination of both, inflammatory markers or 
patient/disease characteristics is unclear from the literature and the existing 
evidence is conflicting (Kahn et al, 2015). Research conducted in the last 10 
years has provided new information regarding several risk factors that have 
been shown to be associated with increased risk of the development of PTS; 
however, with the exception of recurrent DVT, there is currently no consensus 
on strong risk factors for developing PTS (Yamaki, 2016). 
 
Not every patient that has a first episode of DVT will go on to develop PTS but 
identification of those most at risk is currently not clear from existing research 
evidence. PTS can become established within two years following acute DVT 
(Wong and Baglin, 2012; Kahn et al, 2014b) even with adequate anticoagulation 
(Kahn et al, 2016). It has become increasingly recognised as an important 
outcome post DVT over the last 10-15 years (Kahn et al, 2016) and the 
occurrence and severity of PTS have been shown to represent the primary 
determinant of quality of life over 2 years follow-up in DVT patients (Kahn et al, 
2008b). It is a difficult condition to both prevent and treat and is associated with 
significant financial burden in terms of healthcare costs (Guanella et al, 2011).  
 
Ultrasound imaging is the standard method of diagnosing DVT but it is not 
routinely used on completion of the course of anticoagulation treatment to 
establish the status of the thrombosis or residual venous function. The length of 
the initial anticoagulation treatment and the decision to stop or continue 
treatment at the end of this period are not informed by either the degree of 
resolution of the DVT (that is, the presence of residual thrombus determined by 
ultrasound) or the residual venous function. There is however debate whether 
prolonged anticoagulation could benefit certain patient groups in terms of 
reducing the risk of recurrence and the development of PTS.  
 
In addition, in recent years, more aggressive endovenous treatments such as 
catheter directed thrombolysis, mechanical clot retrieval techniques and venous 
stenting procedures are becoming more commonly used in certain patients that 
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meet specific criteria. These techniques are however invasive, expensive and 
require careful risk stratification to ensure that they are directed only to those 
patients most at risk of short or long term complications from their DVT and are 
therefore most likely to benefit from aggressive intervention but are also low risk 
for procedural complications (Vedantham et al, 2016). Evidence indicates that 
endovenous techniques are most effective in the treatment of acute rather than 
chronic thrombus which promotes early intervention rather than a ‘wait and see’ 
strategy. The difficulty however lies in predicting at the acute stage of DVT 
whether a patient is likely to go on to develop PTS in the longer term. Early 
identification and selection of candidates for long term anticoagulation or 
endovenous intervention therefore remains challenging.  
 
Clinicians are therefore frequently faced with difficult decisions regarding 
appropriate individualised treatment to mitigate both short and long-term risks. 
Increased knowledge of the clinical course of DVT and its relationship alongside 
other characteristics present at baseline with recurrence and the development 
of PTS could inform both future risk profiling and treatment strategies. Early 
identification of an increased risk of developing PTS would allow 
implementation of the best available prevention strategy on an individual basis.  
 
1.7.3 What this study adds 
These areas of uncertainty surrounding the pathophysiology of PTS and the 
lack of clear agreement in terms of risk factors for the condition formed the 
basis for this research study. A new study in this field using the latest ultrasound 
technology also allowed for improved visualisation of smaller vessel DVT and 
more accurate imaging of residual thrombus. This research was designed and 
carried out by an ultrasound specialist with substantial experience of diagnosing 
DVT. Previous research in this field has largely been designed and led by 
academic surgeons or medics; where ultrasound specialists were involved this 
has mainly been limited to data collection. 
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Furthermore, with a move away from the use of LMWH followed by vitamin K 
antagonists as the first line choice of anticoagulation therapy and towards more 
widespread use of DOACs, previous evidence on this subject may now be 
considered dated. It was not known whether the use of DOACs in the treatment 
of DVT influences the risk of developing PTS and further work was needed to 
establish rates of PTS development with these new oral anticoagulants 
(Carman, 2016).  
 
1.8 Aims of the research and the thesis 
 
The primary aims of the research were as follows: 
 
1) To determine expert opinion regarding risk factors for the development of 
PTS. 
 
2) To identify the level of variation in response to oral anticoagulation 
treatment including DOACs and provide more precise and quantitative 
disease characterisation. 
 
3) To statistically assess associations between characteristics present at 
baseline and those that present during follow-up and four main outcomes 
after DVT: resolution, recurrence, the development of venous 
incompetence, and the development of PTS. 
 
1.9 Objectives 
 
1) To conduct a high quality SLR to summarise and appraise published and 
unpublished evidence of factors associated with the development of PTS 
in studies using duplex ultrasound to assess residual obstruction and 
venous incompetence. 
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2) To examine and critically appraise the study design of the individual 
studies included in the SLR to inform the design of the prospective cohort 
study. 
 
3) To use the results of the SLR to design and conduct a questionnaire to 
gather professional opinion from the membership of the Society for 
Vascular Technology of Great Britain and Ireland (SVT) regarding the 
potential risk factors for the development of PTS they considered to be 
important.  
 
4) To use the results of the SLR and peer group opinion study to identify 
and refine those risk factors known or perceived to be predictive of PTS 
for examination in the prospective cohort study.  
 
5) To design and conduct a prospective cohort study using ultrasound to 
systematically examine changes in thrombus burden and resolution over 
time in patients with a first episode of acute DVT. 
 
6) To establish patient outcomes after a first episode of acute DVT following 
anticoagulation in terms of DVT resolution, recurrence, the development 
of venous incompetence and PTS in a cohort where the majority of 
participants were treated with DOACs.  
 
7) To conduct statistical analyses to examine associations between 
characteristics present at baseline and those that present during follow-
up and the four primary endpoints of the study: DVT resolution, DVT 
recurrence, the development of venous incompetence, and a diagnosis 
of PTS.  
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1.10 The role of the PhD student 
To enhance understanding it is important to clarify my role in the research 
project. I thought out the research question, developed the study design, wrote 
the protocol and secured the NIHR funding to undertake the research through a 
competitive process. I designed the SLR, conducted the searches and critically 
appraised the included studies with a fellow Clinical Vascular Scientist from a 
different Trust. I also designed and conducted the peer group opinion study, 
completed the risk assessments and ethical approval processes for both the 
peer group opinion study and the prospective cohort study.  
 
I recruited and consented all of the participants to the study, completed all of the 
administration in terms of appointment scheduling and undertook all verbal and 
written communication with participants. I took the clinical history at each visit 
and performed all of the ultrasound assessments for residual thrombus and 
venous function during follow-up. In some of the cases I was also the clinician 
who diagnosed the initial DVT as part of my clinical role. I am the researcher 
who assessed the participants for PTS at their final visit and I completed all of 
the data analysis for every part of the study.  
 
1.11 The structure of the thesis 
To assist the reader with navigation of this thesis, the following paragraphs 
provide a brief description of each chapter’s content. 
 
Chapter 1 provides background information regarding the diagnosis and 
management of DVT and PTS. It highlights the challenges clinicians face in 
deciding how long to continue treatment, the importance of individualised 
management and the gaps in the evidence of the underlying pathophysiology of 
both conditions.  
 
Chapter 2 provides a review of the existing evidence specifically concerning risk 
factors for the development of PTS. It presents the design, methodology and 
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results of the SLR of existing evidence for the risk factors associated with the 
development of PTS, specifically in studies using duplex ultrasound to assess 
for residual obstruction and venous incompetence. This chapter provides both 
critical analysis of the existing evidence in this area and the design of previous 
research studies in this field to inform both the peer group opinion study 
questionnaire and the design of the prospective cohort study. 
 
Chapter 3 presents the methodology and results of the consensus opinion study 
amongst clinical vascular scientists on this topic.  
 
Chapter 4 describes the study design and methodology of the prospective 
observational study, the presentation of which forms the main focus of this 
thesis.  
 
Chapter 5 is the first of six results chapters and presents the demographic data 
for prospective observational study. 
 
Chapter 6 is the second of six results chapters and presents the results from the 
prospective observational study pertaining to thrombus evolution. 
 
Chapter 7 is the third of six results chapters and presents the results from the 
prospective observational study pertaining to DVT resolution. 
 
Chapter 8 is the fourth of six results chapters and presents the results from the 
prospective observational study pertaining to DVT recurrence. 
 
Chapter 9 is the penultimate of the six results chapters and presents the results 
from the prospective observational study pertaining to venous incompetence. 
 
Chapter 10 is the last of the six results chapters and presents the results from 
the prospective observational study pertaining to the development of post 
thrombotic syndrome. 
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Chapter 11 reviews all of the findings in light of the existing evidence and 
discusses their implications for clinical practice and further research.  
 
Chapter 12 concludes the thesis. It reviews the research aims and objectives 
and evaluates the extent to which they were achieved.   
 
1.12 Chapter summary 
This chapter has laid the foundation and set the scene for the research project 
and thesis by reviewing the clinical presentation, pathophysiology, diagnosis, 
epidemiology and treatment options for DVT and PTS as well as the personal 
perspectives that inspired the research. The following chapter examines the 
existing evidence regarding risk factors associated with the development of 
PTS. This includes a focused systematic review of the evidence from 
prospective studies specifically using DUS to assess for residual obstruction 
and venous incompetence and a brief overview of the findings from significant 
studies of all design types relating to factors potentially associated with PTS.  
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CHAPTER 2: LITERATURE REVIEW  
  
2.1 Introduction  
The purpose of the literature review was two-fold: to examine the existing 
literature relating to DVT resolution and factors associated with the 
development of PTS and to critically appraise the literature to inform the design 
and methodology of the prospective cohort study that forms the main 
component of this thesis.  
 
2.2 Systematic literature review aims 
The first objective of the SLR was to identify, appraise and where appropriate 
synthesise the existing research evidence for factors associated with the 
development of PTS in studies using DUS to assess for residual obstruction 
and venous incompetence. The SLR was designed to use rigorous 
methodology (Higgins and Green, 2011) in order to give the researcher an 
understanding of the breadth, purpose and extent of any previous research 
activity in this area. The review aimed to identify any differences between real 
knowledge and that assumed by the researcher and their peers through clinical 
practice (Petticrew and Roberts, 2006).  
 
The second aim of the review was to assess the relative strengths and 
weaknesses of previous research studies in this field in order to inform 
subsequent study design (Gough et al, 2012) and to identify improvements that 
could be made in implementing new research in this area (Petticrew and 
Roberts, 2006).  
 
The structure of this review was based on reporting guidance from the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses: “PRISMA” (Moher 
et al, 2009) and the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins and Green, 2011). 
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2.3 Justification for the SLR 
Although initial scoping of the literature found several SLRs linked to PTS, these 
were focused mainly on prevention and/or treatment of PTS: compression 
therapy and pharmacological and compression therapy combined (Kolbach et 
al, 2003; Cohen et al, 2012), long term LMWH (Hull et al, 2011), rutosides 
(Morling et al, 2015) and venous stenting (Wen-da et al, 2015). Other SLRs in 
this field examined asymptomatic post-operative DVT and the development of 
PTS (Wille-Jorgensen et al, 2005) and PTS in the upper limb (Elman and Kahn, 
2006). Only two SLRs (published by the same research group in the same year) 
examined risk factors for PTS but these were highly focused reviews solely on 
the relationships between thrombophilia and inflammatory markers respectively 
and the development of PTS (Rabinovich et al, 2014a; Rabinovich et al, 2014b). 
No SLR was found examining the evidence base specifically relating to the 
relationship between factors associated with the development of PTS and 
findings on DUS of residual thrombus and venous incompetence. 
 
Several review articles were found on the subject of PTS however these were 
mainly broad ranging reviews covering prevention and management strategies 
rather than focused reviews of risk factors for the development of this condition 
(Kahn et al, 2004; Prandoni and Kahn, 2009; Vedantham, 2009; Guanella and 
Kahn, 2012; Kahn et al, 2014; ten Cate-Hoek et al, 2015; Galanaud et al, 2016; 
Kahn et al, 2016; Rabinovich and Kahn, 2016). None of these reviews were 
undertaken using systematic methodology. It was considered important to 
undertake a review systematically to minimise the risk of bias by ensuring that 
as much of the available evidence as possible was captured in a systematic, 
transparent and reproducible manner that could be replicated.  
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2.4 Methodology 
2.4.1 Inclusion/exclusion criteria 
Cohort studies are the most appropriate data collection method to answer the 
research questions and the scoping exercise revealed that this was also the 
most commonly implemented study design in this field of research. The study 
design for the selected research was prospective cohort studies of adult 
humans aged 18 years or older with a confirmed diagnosis of symptomatic DVT 
on medical imaging: DUS, MRV or CTV.   
 
Observational studies are the most appropriate method of studying large, 
heterogeneous patient populations with complex, chronic diseases such as PTS 
(Ligthelm et al, 2007). It was decided to limit the review to prospective studies 
as these allow for specific variables and data to be collected with increased 
confidence in its reliability and accuracy when compared to a retrospective 
study. A limitation of retrospective studies is that the data recorded are not 
always specific to the variables being examined, are potentially incomplete and 
sometimes inaccurately recorded. From the reviewer’s experience in clinical 
practice, much of the data required for a full assessment of risk factors in the 
development of PTS are not routinely recorded as part of a standard lower limb 
DVT assessment. In addition, the level of detail required for an observational 
study of DVT evolution in which the precise location and extent of any thrombus 
is of paramount importance is generally not recorded in a clinical ultrasound 
report. Studies in which DVT diagnosis was based on clinical symptoms alone 
would seriously compromise both the internal and external validity of a study as 
the symptoms of pain and swelling that characterise DVT are not specific to this 
condition. The decision to limit the review to studies of adults aged 18 years or 
older was made reflecting the author’s own area of proposed research which 
would not involve paediatric patients.  
 
The primary outcome measurement was a diagnosis of PTS which was 
classified and measured using one of the two validated assessment tools 
available: either the CEAP classification system or Villalta Scale. Objective 
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evidence of residual thrombus and venous valvular incompetence also required 
confirmation with DUS in the included studies. Studies in which the diagnosis of 
DVT was not confirmed by medical imaging, studies involving patients with 
asymptomatic DVT, retrospective studies, and studies that did not use both 
objectively measured venous valvular incompetence and a validated 
assessment tool for the diagnosis of PTS were therefore excluded.  
 
2.4.2 Search strategy 
Searches were conducted in English but language was not used as the basis 
for exclusion. It was considered important to include all potentially relevant 
research in all languages. Searches were not restricted by publication date.  
 
Electronic database searches 
The search strategy was developed with assistance from two specialist subject 
librarians at the University of the West of England. Search terms combining key 
terms relating to DVT and PTS were used. Care was taken to search both the 
controlled vocabulary and free text fields. MeSH (Medical Sub-headings 
categories used in the Medline database) terms for postthrombotic syndrome 
(C14.907.952.880) and postphlebitic syndrome (C14.907.952.760) were used to 
take into account synonyms, spelling variation and word forms of the same 
word. This was especially important in this subject area as these terms have 
several spelling variations; for example, post-thrombotic syndrome, post 
thrombotic syndrome, postthrombotic syndrome, post-phlebitic syndrome, post 
phlebitic syndrome and postphlebitic syndrome. See Appendix A1.1 for search 
strings.  
 
Specialist librarian experience in dealing with the multiple linguistic variations in 
the subject area ensured that the searches were both inclusive yet did not 
return thousands of irrelevant papers. The search strategy was tested using the 
‘related items’ function to ensure that, where relevant studies were not picked 
up by the original search, these were subsequently identified and an 
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examination of their index terms and the language used was undertaken to 
amend the search strategy. 
 
The following biomedical and allied health databases were selected: AMED 
(Allied and Complementary Medicine), CINAHL Plus (Cumulative Index to 
Nursing and Allied Health Literature), Cochrane Controlled Trials Register, 
EMBASE, MEDLINE and Science Citation Index. These databases were 
selected as they include those that readers would expect to be searched in a 
SLR in this field, they lend themselves to searching with MeSH headings to 
nucleate search concepts and in combination cover significant depth of both 
international and national first and second tier journals to identify all relevant 
significant publications. Searches were initially carried out between 20th and 31st 
May 2013 and re-run to update the review between 28th and 29th June 2017. 
 
An electronic alert was set up on Mimas Zetoc Alert Service and included all the 
key search terms for the review. The alert was renewed annually and continued 
to run from the end of the initial searches in May 2013 through to June 2018. 
The aim of the alert was to identify any new publications that were published 
during the time period between the initial searches being carried out, the repeat 
of the searches and preparation of the thesis for examination.  
 
Subject expert opinion 
It was considered important to seek out literature from non-electronic sources to 
obtain information on any current studies not yet published, to determine any 
gaps in the search yield obtained and to address the issue of the time lag 
between publication and the indexing of that publication in a database. This 
included contacting two widely published key experts in the field of 
thromboembolic disease: Professor Susan Kahn MD, FRCPC, MSc (Epid) and 
Professor Paolo Prandoni PhD.  
 
Susan Kahn is Professor of Medicine and Associate Director for Clinical 
Research at The Lady Davis Institute for Medical Research, Montreal, Canada 
and is an internationally recognised researcher in venous thromboembolism. 
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Her research activities primarily focus on the epidemiology of venous 
thromboembolism, specifically etiologic mechanisms and health outcomes. 
Peer-review funded projects that are underway include the study of long-term 
clinical, economic and quality of life outcomes after venous DVT and pulmonary 
embolism, the influence of inflammation and thrombophilia on long term 
adverse outcomes of DVT and the role of exercise training to treat the PTS.  
 
Paolo Prandoni is professor of the Department of Medical and Surgical 
Sciences, Thromboembolism Unit, at the University of Padua, Italy. Professor 
Prandoni’s research and professional experiences encompass the 
epidemiology, diagnosis, and management of thromboembolism.   
 
Hand searches & grey literature 
There is a significant body of research that is available as non-journal reports, 
books, book chapters, unpublished theses and conference proceedings which 
may not be listed in large bibliographic databases. Hand searching of the 
reference lists of 18 key review papers and the indexes of two journals which 
regularly publish haematological and vascular studies: the Journal of Vascular 
Surgery (1993-2017) and the Journal of Thrombosis and Haemostasis (2003-
2017) was undertaken to supplement the search strategy. Google Scholar was 
used for prospective reference list checking to identify research reports and 
dissertations as well as some journal papers. Web of Science was used to cite 
additional journal papers that may have been missed by EMBASE and 
MEDLINE.  Generic search engines were used to identify organisations that 
may have published relevant research.  
 
Grey literature, including conference proceedings and abstracts from the period 
1993 to July 2017, was searched to identify non-commercially published 
information. Theses from the UK and Ireland were searched using EThOS 
(Electronic Theses Online Search) and Index to Theses databases. To minimise 
publication bias it was considered important not to exclude any findings from 
small sample studies as well as studies that may have been terminated early or 
any research in progress.  
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2.4.3 Data collection and analysis 
 
Data handling 
Studies identified in the searches were imported into RefWorks web-based 
bibliographic management software and duplicates were removed. Full records 
of the search logs, a record of screening at both the title/abstract level and full 
report level were kept for each document to trace the progress of each item and 
records of all attempts to retrieve full reports and why some could not be 
retrieved were kept.  
 
The log of search strategies included the search parameters used for each 
database, when the search was carried out, who conducted the search and the 
number of results returned. The retrieval of the full text documents was tracked 
along with final decisions about whether a study should be included or 
excluded. A PRISMA diagram was used to account for all the references 
retrieved in the review (Moher et al, 2009). 
 
Screening process 
A two-stage screening process was used in which the titles were initially 
screened for suggested relevance and abstracts of all potentially relevant 
studies were then subsequently screened to identify those that potentially met 
the inclusion criteria. Where it was not clear whether a paper should be included 
full text papers were obtained for further screening. Following the screening of 
the remaining full text publications any uncertainty or ambiguity regarding 
inclusion of a study was discussed with the PhD Director of Studies, Professor 
Fiona Cramp (FC). The screening process was undertaken by the first reviewer 
alone due to the practicalities of two reviewers independently reviewing the 
search yield.  
 
All literature was assessed for its relevance and quality and the transparency of 
its methods and sources were carefully examined. The quality assessment and 
data extraction was conducted by two accredited Clinical Vascular Scientists 
from different Health Trusts. Both reviewers were trained in and regularly 
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performed DUS to diagnose DVT. Both reviewers had also received formal 
training in performing critical appraisal and both had previous research 
experience having completed an MSc in Medical Ultrasound.  
 
Data extraction 
The data extraction form (Appendix A1.2) was developed by first identifying the 
key information that was required to answer the research question. All of the 
original papers were first examined to determine the most useable format for 
the data extraction form so that the data could be extracted in a form as close to 
the original reporting format as possible for the majority of studies so that 
disputes could be easily resolved. The design of the data extraction form was 
carefully considered to make this labour intensive process as logical as possible 
in order to minimise the effort required and the likelihood of error. The design of 
the form aimed to strike a balance between having a logical, well clarified 
structure for ease of comparison of the studies whilst retaining a degree of 
flexibility in the form design to take into account the different methods of data 
presentation. 
 
The data extraction form was piloted on one paper by the two reviewers who 
subsequently discussed both the process of data extraction and the findings to 
ensure that both reviewers had the same understanding of the instructions on 
how to extract and record information in the form.  
 
Quality assessment 
The quality assessment of the included studies was undertaken and recorded 
simultaneously to the data extraction. The Critical Appraisal Skills Program 
(CASP) tool for the appraisal of non-randomised cohort studies (Public Health 
Resource Unit, 2006) was selected for critical appraisal of the studies. Both 
reviewers were already familiar with the tool and had both received training in 
using the tool. The tool has also been evaluated with pilot testing in workshops, 
including feedback and review of materials, using successively broader 
audiences (National Collaborating Centre for Methods and Tools, 2011).  
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The reviewers met to compare the findings of their independent critical 
appraisal for each study and disagreement was resolved through discussion. 
There was provision for third party moderation in the event that agreement 
could not be reached through discussion. An analysis was made of the patterns 
of reviewer opinion change to ensure that no bias was present with one 
reviewer more readily conforming to the agreed opinion than the other. It was 
important that both reviewers felt equally empowered to defend their viewpoint.  
 
Quantitative synthesis of the data 
An a priori decision was taken not to perform a quantitative synthesis of the 
data for this review.  This was based upon the reviewer’s prior knowledge of 
existing literature as well as the initial scoping review which suggested that 
there would be large heterogeneity within the studies identified for inclusion. 
 
2.5 Results 
2.5.1 Introduction 
This section presents the results of the literature search including tabular data 
detailing the included studies including their key characteristics and key 
findings. 
 
An educational article on the methodology of conducting this review was 
published as an open access ‘how to’ paper in the ‘Methodologist’s Corner’ 
section of the Journal of Allied Health in September 2018.  This was written as a 
shared knowledge resource aimed at other allied health professionals who may 
be considering undertaking a SLR. A copy of this publication is included in 
Appendix A1.3. 
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2.5.2 Research studies identified 
Combined data from the initial electronic search and the updated electronic 
search gave a search yield of 4706 records. Duplicates were removed and an 
additional 90 records identified through hand searching.  The remaining 2762 
titles were screened for relevance leaving 342 abstracts for further screening. 
Finally, 161 full texts were screened for eligibility. Three papers were not held 
by the British Library and all possible locations were searched but they 
remained unobtainable. Three articles were translated from French to English 
and three were translated from Spanish to English. In total 23 papers met the 
inclusion criteria and were included in the review, reasons for excluding the 
remaining full text articles are provided in Table 2.1. The main reasons for 
exclusion were that the data were not collected prospectively, the papers were 
a literary review rather than original research, venous reflux or PTS had not 
been assessed in the study or that a validated assessment tool had not been 
used for the assessment of PTS.  A summary of the overall study selection 
process, including numbers of studies screened is presented in Figure 2.1.  
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Figure 2.1 PRISMA flow diagram detailing study selection process. 
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 Table 2.1 Overview of characteristics of papers excluded at full text review 
 
 
2.5.3 Research focus of the included studies 
The main focus of each of the studies is presented in Table 2.2. Although all of 
the studies used DUS to objectively measure residual occlusion and venous 
reflux, the association between the findings on DUS and PTS was not the prima 
foci of all studies. Only 13 of the included studies examined the relationship 
between DVT extent, residual thrombus/re-canalisation rate, recurrence and 
venous reflux specifically in relation to the development of PTS (Van Romshorst 
et al, 1994; Franzeck et al, 1997; Meissner et al, 1998; Haenen et al, 2002; 
Prandoni et al, 2005; Roumen-Klappe et al, 2005; Labropoulos et al, 2008; 
Labropoulos et al, 2009; Tick et al, 2010; Haig et al, 2013; Van Rij et al, 2013; 
Vedovetto et al, 2013; Jeraj et al, 2017). Two studies examined the association 
between reflux duration and velocity with the development of PTS (Yamaki et al, 
2007; Yamaki et al, 2010), one study examined calf muscle pump indices in 
relation to PTS (Yamaki et al, 2011) and one study specifically examined 
oxygenated haemoglobin levels in the calf muscle as predictor of PTS (Yamaki 
et al, 2016). Two of the studies examined the relationship between inflammatory 
biomarkers and the development of PTS as their main focus (Roumen-Klappe 
et al, 2009; Shbaklo et al, 2009) and the study by Latella et al (2010) primarily 
examined the association between D-dimer and the development of PTS. In 
addition, three of the studies met the inclusion criteria but did not specifically 
examine risk factors for PTS as the prima foci (Asbeutah et al, 2004; Asbeutah 
et al 2007; O’Shaunessy and Fitzgerald, 2001).  
Number 
Excluded 
Reason for exclusion 
35 Retrospective studies 
31 Literary review only 
30 Venous reflux not assessed 
27 PTS/risk factors not assessed or validated assessment tool not used 
4 Participants with asymptomatic DVT only 
4 Other study types e.g. Case study/animal study/protocol only 
1 DVT not objectively confirmed 
5 DUS not used in follow-up 
1 Duplicate study sample 
138 Total 
95 
 
Table 2.2 Overview of the main research focus of each of the included papers. 
Authors 
Pub. 
Year 
Study Focus 
Van Ramshorst et al 1994 DVT extent and venous reflux in relation to PTS development 
Franzeck et al 1997 Thrombosis resolution and reflux in relation to PTS development 
Meissner et al 1998 Thrombotic risk factors, DVT extent, re-canalisation and recurrence in relation to PTS development 
O'Shaughnessy et al 2001 Natural history of DVT 
Haenen et al 2002 Reflux, obstruction and CMP dysfunction in relation to PTS development 
Asbeutah et al 2004 DVT re-canalisation rates in relation to the development of venous reflux 
Prandoni et al 2005 Residual thrombus & popliteal vein incompetence in relation to the development of PTS 
Roumen- Klappe et al 2005 Predictive value of non-invasive venous examinations for development of PTS 
Asbeutah et al 2007 DVT re-canalisation rates in relation to the development of venous reflux 
Yamaki et al 2007 Reflux duration & velocity, calf filling index, retention index and ejection index in relation to PTS development 
Labropoulos et al 2008 Recurrence, re-canalisation and reflux in relation to PTS development 
Labropoulos et al 2009 Only recurrence, re-canalisation and reflux studies in relation to PTS development 
Roumen- Klappe et al 2009 Inflammatory markers IL-6 and CRP in acute phase of DVT in relation to PTS development 
Shbaklo et al 2009 Biomarkers IL-6, IL-8. IL-10, MCP-1, ICAM-1, VCAM-1 in relation to PTS development or venous reflux. 
Latella et al 2010 D-dimer and reflux and in relation to PTS development 
Tick et al 2010 Demographics, DVT extent, re-canalisation, reflux, CMP function & VOR in relation to PTS 
Yamaki et al 2010 Reflux duration and reflux velocity in relation to PTS development 
Yamaki et al 2011 Calf venous blood filling index, retention index and ejection index in relation to PTS development 
Van Rij et al 2013 DVT extent, recurrence, re-canalization, reflux and venous outflow in relation to PTS development 
Haig et al  2013 Residual obstruction and reflux and correlation to PTS in randomised study on CDT 
Vedovetto et al 2013 Residual obstruction and popliteal vein reflux in relation to PTS development 
Yamaki et al 2016 Oxygenated haemoglobin levels in calf muscle as predictor of PTS 
Jeraj et al 2017 Residual occlusion and reflux in relation to PTS development 
Key: 
DVT – deep vein thrombosis IL – Interleukin     VCAM – Vascular Cell Adhesion Molecule 
PTS – post-thrombotic syndrome CRP – C-reactive protein    CDT – Catheter directed thrombolysis 
CMP – calf muscle pump  MCP – Monocyte chemoattractant protein  VOR – venous outflow resistance  ICAM - Intercellular Adhesion Molecule   
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2.5.4 Recruitment and treatment in the included studies 
A minimum of 3285 participants with confirmed DVT were entered into the 23 
studies. A definitive number of recruited participants cannot be given as four of 
the studies did not make a clear distinction between the number recruited and 
the final sample for analysis. The mean age of the participants in each of the 
studies ranged from 41 to 63 years. The duration of follow-up ranged from one 
year to 12 years with varying patterns of intermittent follow-up intervals as 
shown in Table 2.3.  
 
Treatment for the initial DVT was, for the majority of the studies, either initially 
with standard un-fractionated heparin or LMWH followed by oral anticoagulation 
with a vitamin K antagonist (VKA) as described in Table 2.4.  
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Table 2.3 Sample size, duration and frequency of follow-up schedule of each of the included studies. 
Authors 
Pub. 
Year 
Recruited sample 
size 
Length of follow-
up 
Follow-up intervals 
Van Ramshorst et al 1994 ? 5 years Once at mean 34 months (range 18 to 51 months) 
Franzeck et al 1997 58 12 years Baseline, 3, 6 & 12 months, yearly for 5 years, then final visit at 12 
years 
Meissner et al 1998 176 2 years 1 day, 1 week, 1, 3, 6, 9, 12 & 24 months 
O'Shaughnessy et al 2001 100 Mean 3 years Baseline, 1 week, 1, 6 &12 months, then yearly 
Haenen et al 2002 83 2 years Not stated 
Asbeutah et al 2004 ? 5 years Baseline, 3, 6, 12 months, then yearly 
Prandoni et al 2005 180 5 years Baseline, 3 & 6 months then every 6 months 
Roumen- Klappe et 
al 
2005 93 6 years Baseline, 1, 3, 6, 12, 24 months and 6 years 
Asbeutah et al 2007 20 1 year Baseline, 1 week, 1, 3, 6 and 12 months 
Yamaki et al 2007 ? 6 years Baseline, 2 weeks, 1, 3 and 6 months, then every 6 months 
Labropoulos et al 2008 192 Mean 3.4 years Baseline, 6 months, clinical exam & DUS at 1 year then yearly  
Labropoulos et al 2009 86 5 years Baseline,3, 6 & 12 months, then yearly  
Roumen- Klappe et 
al 
2009 114 1 year Baseline, 7, 30, 90 days and 1 year 
Shbaklo et al 2009 387 2 years Baseline, 1, 4, 8, 12 and 24 months 
Latella et al 2010 387 2 years Baseline, 1, 4, 8, 12 and 24 months 
Tick et al 2010 111 2 years Baseline, 6 weeks, 3, 6, 12 and 24 months 
Yamaki et al 2010 124 2 years Not stated 
Yamaki et al 2011 124 5 years Baseline, 2 weeks, 1, 3 & 6 months, then every 6 months 
Van Rij et al 2013 ? 5 years Baseline, 7 days, 3, 6, 12, 24, 36, 48 and 60 months 
Haig et al  2013 209 2 years 6 months and 24 months 
Vedovetto et al 2013 290 3 years Ultrasound only at 3 and 6 months, Villalta Score at 3 years 
Yamaki et al 2016 129 6 years 2 weeks, 1, 3 and 6 months then every 6 months  
Jeraj et al 2017 100 1-3 years Single follow-up visit at between 1-3 years  
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Table 2.4 Type and duration of anticoagulation therapy used in each of the included studies.  
 
 
Authors 
Pub. 
Year 
Initial heparin anticoagulation Oral Anti-coagulants 
Van Ramshorst et al 1994 Unfractionated Heparin (duration not stated) VKA (min 3 months) 
Franzeck et al 1997 Unfractionated Heparin (5 days) VKA (6-12 months) 
Meissner et al 1998 Not stated Not stated 
O'Shaughnessy et al 2001 Unfractionated Heparin (5-7 days) VKA (min 3 months) 
Haenen et al 2002 Unfractionated Heparin or LMWH (min. 5 days) VKA (3 – 24 months) 
Asbeutah et al 2004 LMWH (minimum 5 days) VKA (min 3 months) 
Prandoni et al 2005 Unfractionated Heparin or LMWH (min. 5 days) VKA (3 - 6 months) 
Roumen- Klappe et al 2005 Unfractionated Heparin or LMWH (duration not stated) VKA (min 3 months) 
Asbeutah et al 2007 LMWH (min. 5 days) VKA (min 3 months) 
Yamaki et al 2007 Unfractionated Heparin (5-14 days) VKA (min 8 weeks) 
Labropoulos et al 2008 Unfractionated Heparin (duration not stated) VKA (duration not stated) 
Labropoulos et al 2009 Unfractionated Heparin (duration not stated) VKA (min 6 months) 
Roumen- Klappe et al 2009 Unfractionated Heparin or LMWH (duration not stated) VKA (min 3 months) 
Shbaklo et al 2009 Unfractionated Heparin or LMWH (mean 7.4 days) VKA (mean 34.1 weeks) 
Latella et al 2010 Not stated VKA (mean 26.5 (prox. DVT), 38.8 weeks (dist. DVT)) 
Tick et al 2010 LMWH (duration not stated) VKA (6 months) 
Yamaki et al 2010 Unfractionated Heparin (5-14 days) VKA (min 8 weeks) 
Yamaki et al 2011 Unfractionated Heparin (5-14 days) VKA (min 8 weeks) 
Van Rij et al 2013 LMWH duration not stated VKA (duration not stated) 
Haig et al  2013 Unfractionated Heparin or LMWH (duration not stated) VKA (duration not stated) 
Vedovetto et al 2013 Not stated Type not stated, duration mean 6 months 
Yamaki et al 2016 Unfractionated Heparin (5-14 days) (except distal DVT) VKA (min 8 weeks, mean 18 months) 
Jeraj et al 2017 None or LMWH DOAC or VKA  
 
Key: 
LMWH – low molecular weight heparin  DOAC – direct oral anticoagulant  VKA – vitamin K antagonist (warfarin)  
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The two subject experts responded in writing.  Professor Kahn commented that 
the search strategy employed in this SLR was acceptable and that the relevant 
studies had been retrieved. Professor Prandoni responded that he was unable 
to disclose the most important and innovative information that he had at that 
time as these data would be submitted for publication in a major scientific 
journal and would be available from Spring 2014. This paper was subsequently 
identified when the initial searches were re-run for the update of the SLR but did 
not meet the inclusion criteria.  
 
2.5.5 Main findings from the included studies 
Excluding data relating to various inflammatory markers, discussion of which is 
not a focus of this thesis, four key themes relating to risk factors for PTS were 
identified from the included studies: thrombus location and extent, residual 
occlusion, venous reflux and recurrent ipsilateral DVT.  
 
Thrombus Location and Extent 
Proximal thrombi (popliteal, femoral, common femoral and iliac veins) was 
associated with worse clinical and haemodynamic outcomes than distal thrombi 
(isolated calf vein thrombi) (Meissner et al, 1998; Asbeutah et al, 2004; Tick et 
al, 2010; Yamaki et al, 2010; Yamaki et al, 2016). An association between multi-
level DVT and PTS was demonstrated by Labropoulos et al (2008) and van 
Romshort et al (1994) showed thrombus extent to correlate well with the 
number of refluxing vein segments at follow-up but no association was found 
with clinical severity. Conversely, Prandoni et al (2005) demonstrated no 
association between the extent of the initial DVT and the development of PTS. 
 
Residual occlusion 
Most studies detected a modest or strong statistical association between 
residual occlusion and PTS (Meissner et al, 1998 (specifically popliteal vein 
occlusion); Prandoni et al, 2005; Labropoulos et al, 2008; Roumen-Klappe et al, 
2009; Tick et al, 2010; Haig et al, 2013; Vedovetto et al, 2013), but this was 
found to be dependent on the simultaneous presence of venous incompetence 
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in several of the studies in which it was assessed (Franzeck et al, 1997; 
Prandoni et al, 2005 (specifically in combination with popliteal vein reflux); 
Yamaki et al, 2016). Van Rij et al (2013) also found that <50% thrombus 
resolution at 6 months was associated with PTS but only when found in 
combination with two of: extensive thrombus burden at diagnosis, venous filling 
index >2.5 mL/sec or abnormal venous outflow rate <0.6. In their earlier study 
however, Yamaki et al (2007) found no difference in the proportion of venous 
occlusion between patients with CEAP scores of C0-C3 (no significant venous 
disease) and those with CEAP scores of C4-C6 (moderate to severe venous 
disease). 
 
Venous reflux 
There was little consistency between eligible studies in the association between 
venous reflux and subsequent risk of PTS. Yamaki et al (2007) reported a high 
correlation between peak reflux velocity in the popliteal and femoral vein (OR of 
60.32 for the popliteal vein and 25.77 for the femoral vein) and the severity of 
CVI but found that reflux duration was not related to PTS. The association with 
peak reflux velocity was also reported in the two later papers from this group 
(Yamaki et al 2011; Yamaki et al, 2016) but it is not clear if this is from the same 
sample.  Haenen et al (2002) showed superficial venous reflux to be the most 
important risk factor for the development of PTS and that 64% of patients in the 
study with severe PTS had a combination of superficial and deep venous reflux. 
Meissner et al (1998), Roumen-Klappe et al (2005), Roumen-Klappe et al  
(2009), Latella et al (2010), Tick et al (2010) and Haig et al (2013) all 
demonstrated association between venous reflux in some form (deep or 
superficial or both) and PTS. Franzeck et al (1997), Prandoni et al (2005) and 
Yamaki et al (2016) only found an association between PTS and reflux in 
combination with residual obstruction and that reflux alone was not associated 
with PTS. Haenen et al (2002) also found that deep reflux alone was not 
associated with PTS but that superficial venous reflux was associated with PTS. 
Shbaklo et al (2009) found no association between reflux and PTS and 
Labropoulos et al (2009) demonstrated that the progression of reflux was not 
related to the clinical severity of venous disease. 
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Recurrent DVT 
Prandoni et al (2005), Labropoulos et al (2009) and Jeraj et al (2017) all found 
an association between ipsilateral recurrent DVT and the development of PTS. 
 
Various other factors present at baseline were found either to have or not have 
an association with PTS and again these results were conflicting.  The main 
findings from each of the included studies are documented in detail in Table 2.5 
along with the key strengths and limitations of each study. For ease of 
comparison, a simplified overview of all positive and negative associations 
reported is also presented in Table 2.6. 
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Table 2.5 Summary of main findings, key limitations and key strengths for individual studies 
 
Authors Year Summary of main findings Key limitations Key strengths 
Van Ramshorst 
et al 
1994 
• No correlation between late symptoms and 
the initial extent of the thrombosis or between 
the number of incompetent segments and 
PTS symptoms. 
• Small cohort 
• Lack of information regarding the recruitment 
process such as inclusion/exclusion criteria 
• Lack of definition regarding the study population 
with an absence of baseline demographic data  
• Not clear if only acute DVT cases included 
• Lack of standardisation in the data collection 
methods 
• Limited follow-up intervals 
• Compression therapy use not reported 
• Residual thrombus and venous 
incompetence assessment 
methods described. 
• Thrombus burden reported. 
• Treatment duration described. 
• Adequate length of follow-up 
• Both proximal and distal DVT 
included 
Franzeck et al 1997 
• 64% had normal clinical findings at 12 years, 
28% developed mild PTS, 5% moderate PTS 
and 3% severe PTS.  
• 63% of the 114 proximal vein segments that 
were analysed demonstrated complete 
recanalisation, 18% partial recanalisation and 
19% remained occluded.  
• 37% of those patent or partially patent 
segments demonstrated venous reflux  
• Recurrent DVT developed in 24% of 
participants during follow-up and after 
completion of their anticoagulation regime.  
• Obstruction and reflux as single factors were 
present in participants with PTS in 8.5% and 
33% of cases respectively and a combination 
of both was present in 50% of PTS cases.  
• Only descriptive statistics used for the analysis - 
any associations found can only be inferred and 
no indication of strength of association.  
• Venous reflux defined as present where reflux 
duration > 2 seconds rather than standard 0.5 
seconds commonly accepted as definition of 
abnormal reflux (Van Bemmelen et al, 1989) - 
may have led to underestimate of reflux cases.  
• Mixed methods (valsalva or proximal 
compression) used to augment flow in the 
demonstration of presence/absence reflux.  
•CEAP classification system used to determine 
PTS has been revised since study was 
undertaken. 
• Exclusion criteria described 
• First episode DVT only 
• Consecutive recruitment 
• Both proximal and distal DVT 
included 
• Treatment duration described 
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Authors Year Summary of main findings Key limitations Key strengths 
Meissner et al 1998 
• CVD classification was correlated with reflux 
score (p=0.003) on univariate analysis but 
among the seven individual venous segments, 
only the initial tibial vein score was significantly 
correlated with CVD severity classification 
(p=0.05).  
• Multivariate analysis using a stepwise model 
found that only the initial tibial thrombosis 
predicted classification (p=0.04).  
• In a forced entry model, the final popliteal 
vein score, final reflux score and the time to 
50% recanalisation (p= 0.01, p=0.008, and 
p=0.06 respectively) were retained as 
predictors of CVD/PTS.  
• Reflux score was also found to be significant 
(p= 0.003) however when the strength of the 
relationship was examined, it was only weakly 
related (r=0.3).  
• Small cohort on which to produce regression 
analysis - precision of the results debatable.  
The stepwise and forced entry models have an r 
squared value of 0.06 and 0.29 respectively 
indicating that 6% and 29% of the variation is 
explained by these models respectively.  
•No detail on how well these models fitted the 
data is provided - analysis of the residual plots not 
performed.  
• An examination of the individual variables 
suggested that the final popliteal score appeared 
to have a strong association with PTS and a p 
value of 0.01 however the 95% CI for this 
association was 0.2 to 1.8 which was also the 
case for both the initial tibial score and final reflux 
score.  
• Calculation of the thrombotic score was done 
retrospectively - may have produced bias  
• Wide range of follow-up duration (18 months to 
110 months).  
• First episode DVT only 
• Inclusion/exclusion criteria 
described 
• Regression analysis performed 
(but small sample) 
O'Shaughnessy 
et al 
2001 
• The level of venous dysfunction in the 
contralateral limb was indicative of the severity 
of disease in the ipsilateral limb and PTS is 
more likely to develop in those patients with 
venous reflux after a DVT than those without. 
• Small sample size - not possible to examine the 
effect of any of the multiple confounding factors 
that may have impacted these findings.  
• Group 2 was more than half the size of Group 1 
making comparison between the groups 
unreliable and potentially falsely elevating the 
significance of these findings. 
• Consecutive patients 
• Completeness of 
data/withdrawals  described 
• Addressed some potential 
confounders 
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Authors Year Summary of main findings Key limitations Key strengths 
Haenen et al 2002 
• Superficial venous reflux at 3, 6 and 12 
months was the most important risk 
factor for early signs of PTS (p=0.02) 
• However, neither deep venous reflux 
nor calf muscle pump dysfunction were 
correlated to the development of PTS.  
• Small sample - only 83 participants recruited from all 
positive DVT presentations at a Radiology Department 
of a university hospital in The Netherlands over a three 
year period - likely to be highly selected. 
• Lack of detail concerning recruitment to the study 
and/or exclusions - selection bias cannot be ruled out. 
• Lack of detailed demographics for the cohort 
• Complete case analysis only 
• Not  known how many participants had pre-existing 
superficial venous incompetence or what proportion 
developed as a result of concurrent superficial venous 
thrombosis at the time of their DVT diagnosis. 
• Lack of detail reported regarding the analysis methods 
and the regression model. 
• Data collection methods are 
robust and well documented 
Asbeutah et al 2004 
• More severe symptoms of CVI at 5 
years greater in those with proximal 
DVT (CEAP categories 4-6 in 14/26 with 
proximal DVT compared to 3/28 with 
distal DVT).  
• Symptoms more severe in limbs with 
superficial venous reflux (including deep 
plus superficial reflux) compared to 
deep reflux alone  
• Most common reflux pattern in CEAP 
categories 4-6 was deep and superficial 
with perforator incompetence (12/17 
with CEAP 4-6) but not statistically 
significant.  
• Unexpectedly high incidence of reflux 
in segments/limbs not affected by DVT. 
• No details given regarding how participants were 
recruited - selection bias cannot be assessed.  
• Inclusion and exclusion criteria not described.  
• High proportion of participants with thrombophilic 
disorders (n = 36, 71%) - threatens the generalisability 
of the findings.  
• Not possible to determine if measurement or 
classification bias present in the initial diagnosis of DVT 
as insufficient detail in the methods regarding the 
protocol for the imaging modalities used.  
• No clinical assessment for PTS - CEAP assessment 
performed as a telephone questionnaire based on 
patient reported signs and symptoms - reduces the 
reliability of the classification considerably. 
• Analysis limited to descriptive statistics calculated to 
test the associations. 
• Protocol for ultrasound 
assessment of venous reflux well 
described and robust  
• Consistent augmentation 
achieved using a pneumatic cuff  
• Assessment undertaken by a 
vascular scientist (ultrasound 
specialist). 
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Authors Year Summary of main findings Key limitations Key strengths 
Prandoni et al 2005 
• Residual DVT alone was found in 37% 
of patients with PTS compared to 24% 
of patients without PTS.  
• Popliteal vein incompetence alone was 
equally distributed between patients with 
PTS and those without.  
• Both residual DVT and popliteal vein 
incompetence found in 22% of those 
with PTS compared to only 12% of 
those without. 
• Only recurrent ipsilateral DVT and age 
associated with PTS (HR 3.32 (CI 1.04 
– 10.62, p= 0.04)) for recurrent DVT and 
1.36 (CI 1.15 to 1.60, p= 0.003) for 
every 10 year increase in age. 
• Sex, extent of the index thrombosis, 
clinical presentation, thrombophilic 
status and type of initial treatment were 
not associated with the development of 
PTS. 
• Suffered from a large loss to follow-up - only 35/90 
remaining in the stocking group and 29/90 in the control 
group (although using Kaplan-Meier takes into account 
incomplete follow-up when assessing cumulative 
probability)  
• Only included participants with proximal DVT - limits 
generalisability.  
• Reported negative findings as 
well as positive findings. 
• The hazard ratio equals a 
weighted risk ratio over the 
duration of the study and is derived 
from time to event curve or Kaplan- 
Meier curve. The strength of this 
type of analysis is that it needs to 
be adjusted for differences in both 
groups at baseline and this was 
achieved by applying a Cox 
proportional hazards regression 
model to take into account such 
imbalances.  
Roumen- 
Klappe et al 
2005 
• Prognostic value to predict PTS 
highest for the combination of TS, VOR 
and reflux measured 3 months after 
diagnosis - showed an area under the 
curve of 0.77 (0.65-0.90) for PTS after 1 
year. 
• Small cohort.  
• Diagnosis of index DVT not standardised  
• Half of the cohort lost to follow-up by the six year point  
• Potential influence of confounding factors such as 
demographic data, stocking use and treatment duration 
not accounted for. 
• Assessment methods in follow-up 
well described and robust. 
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Authors Year Summary of main findings Key limitations Key strengths 
Asbeutah et 
al 
2007 
• 80% of the participants developed venous reflux 
within 1 year of DVT diagnosis.  
• None of those enrolled in the study had 
evidence of pre-existing chronic venous disease 
at the time of recruitment.  
• Very small cohort - strength of associations not 
assessed. 
• Poorly defined cohort 
• Proximal DVT only 
• Inclusion/exclusion criteria not described.  
• Limited information provided regarding initial DVT 
diagnosis - lack of protocol regarding the B-mode 
ultrasound assessment of diagnostic scan  
Flow augmentation not standardised for reflux 
assessment. 
• Data analysis concentrated on vein diameter which 
was not the primary research question - analysis of 
reflux data limited to basic descriptive statistics.   
• Methods for venous 
reflux assessment were 
adequately described. 
• PTS diagnosis 
undertaken through clinical 
assessment by a vascular 
physician - improves 
reliability of results. 
• Reflux assessment 
performed by a single 
vascular scientist - 
improved reproducibility 
(although not assessed).   
Yamaki et al 2007 
• No significant difference in proportion of residual 
occlusion between CEAP 0-3 group & CEAP 4-6 
group (p=0.138).  
• More reflux in the CEAP 4-6 group (p<0.0001).  
• Peak reflux velocity (PRV) and mean reflux 
velocity (MRV) in femoral vein displayed 
significantly higher values in CEAP 4-6 group 
(p=0.002 at 2 years & 6 years for PRV & p=0.003 
at 2 years and p=0.002 at 6 years for MRV).  
• PRV and MRV in popliteal vein significantly 
higher values in CEAP 4-6 group (p=0.0001 at 2 
and 6 years for PRV and p=0.0001 at 2 years and 
6 years for MRV).  
• No significant difference in reflux duration 
between the two groups.  
• PRV of > 25.4 cm/s in the popliteal vein was 
strongest predictor of advanced CVI (OR 60.32, 
95%CI 43.1-1238.97, p< 0.0001). 
• Population from which the study sample was drawn is 
not clearly defined - not indicated how many patients 
were excluded from the study. 
• Participants were part of another long term follow-up 
study after acute DVT so were exposed to other 
selection criteria not reported in this study.  
• No information on those participants that were lost to 
follow up.  
• No confounding factors addressed in the study 
except recurrent DVT during follow-up and compliance 
with compression which were in exclusion criteria. 
• A range of 43.7-1238.97 for the discriminatory power 
of PRV in the popliteal vein is extremely large.  
• Method of index DVT well 
described 
• Study methods were 
generally well described 
and suitably robust. 
107 
 
Authors Year Summary of main findings Key limitations Key strengths 
Labropoulos 
et al 
2008 
• A greater proportion of symptomatic limbs and 
more severe PTS (using the CEAP classification 
system) seen in participants with multi-segment 
DVT compared to those with single segment DVT 
(p<0.001) a 
• Participants in whom the extent of the DVT 
involved both the calf and proximal veins had the 
highest prevalence of PTS.  
• Limbs with both reflux and obstruction were 
more likely to develop skin damage indicative of 
severe PTS & these were more common in the 
group with multi-segment DVT (p<0.0001). 
• Diagnostic methods varied in different patients and 
some details of the process were missing.  
• Treatment for the original DVT was not standardised 
for all participants which may have influenced the 
outcome. 
• Treatment type and duration was not analysed as a 
potential confounding factor so the effect of this cannot 
be known.  
• Limited data analysis with only crude descriptive 
statistics and no odds ratios calculated and no chi-
squared values stated (although the methods report 
that chi squared analysis was undertaken along with a 
t-test).  
• Demographic data were not examined in relation to 
PTS and no regression analysis was used to analyse 
the data. 
• The diagnostic methods, 
screening process, 
inclusion criteria and study 
methods were all 
described in this study. 
Labropoulos 
et al 
2009 
• Ipsilateral recurrent DVT was identified as a 
significant risk factor for the development of PTS 
with a risk ratio of 4.4.  
• Limbs with ipsilateral recurrence were more 
likely to have partial recanalisation, reflux and 
more segments involved (11/15) compared to 
those with contralateral or no recurrence (16/58) 
(RR 4.7; 95% CI 1.7-13.3, P=0.002). 
• Reflux was more likely with partial compared to 
complete recanalisation (P = 0.0072). 
• Small cohort  
• Lack of detailed demographics for the cohort 
• Not clear whether there is an overlap in cohorts from 
earlier study by same group - similarities in recruitment 
processes & demographic data suggest so. 
• Not all patients underwent ultrasound at all visits so 
interim changes in thrombus characterisation not 
examined-all had ultrasound examination at 1&5 years.  
• Patients with isolated calf DVT were excluded 
creating a narrowly defined population with findings 
harder to generalise.  
• Baseline characteristics of study sample not 
described in any detail.  
• The methods of the original diagnosis of DVT were 
not described. 
•Long duration of follow up 
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Authors Year   Summary of main findings Key limitations Key strengths 
Roumen- 
Klappe et al 
2009 
• Higher levels of residual thrombus and the 
presence of venous reflux at 90 days were related 
to a higher incidence of PTS after 1 year (RR 2.0, 
95% CI 1.1-3.7 and RR 1.7, 95% CI 1.0-2.2 
respectively using the CEAP classification and RR 
2.1, 95% CI 1.1-4.1 and RR 1.7, 95% CI 0.9-3.0 
respectively using the Villalta scale).  
• Issues with potential confounding in terms of 
treatment regimens which were not addressed in the 
analysis 
• Lack of description of the Poisson regression analysis 
methods with no information provided regarding the fit 
of the regression model which did not appear to have 
been tested for over-dispersion. 
• The methods of both the 
original DVT diagnosis and 
all follow-up assessment 
methods are robust and 
well documented. 
• Dermatologist performing 
CEAP assessment was 
blinded to the results of the 
other tests. 
Shbaklo et al 2009 
• Venous reflux was present in 46.2% of patients 
at 12 months but the percentage of patients who 
had ipsilateral reflux did not differ according to 
PTS status.  
• Levels of the inflammatory markers tested did 
not differ according to the presence or absence of 
venous reflux.  
• The relationship between venous function and the 
development of PTS was not the main focus of the 
study and as such some of the details of the method of 
reflux detection and the analysis of this relationship are 
absent from the methods.  
• The methods of the original DVT diagnosis lack 
detail. 
• Lack of description of the methods for reflux 
assessment. 
• Did not report residual occlusion in the results or 
include this as a factor in the analysis. 
• Reasonably large sample 
size. 
• PTS assessment 
methods adequately 
described. 
• The PTS assessors were 
blinded to patients’ 
responses to the 
symptoms component of 
the scale and did not have 
access to scores obtained 
on previous visits.  
Latella et al 2010 
• Ipsilateral reflux present in 51% of participants 
with PTS & 43% of participants without (P=0.21).  
• Positive correlation between PTS severity & 
reflux (P=0.01).  
• Regression analysis, adjusted for confounders 
(age, sex, BMI, previous ipsilateral DVT, 
provoking cause, DVT extent and compression 
use), reflux independently associated with the 
development of moderate/severe PTS compared 
to mild or no PTS (OR 2.72, 95% CI 1.25-5.90, 
P=0.01).  
• Diagnostic method for the index DVT was poorly 
described. 
• Treatment not standardised and not well reported. 
• Well-designed study with 
clearly described follow-up 
methods. 
• Large sample size. 
• Clear where the 
participants were recruited 
from.  
• Used consecutive 
sampling.  
• Comprehensive and clear 
patient demographics.  
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Authors Year Summary of main findings Key limitations Key strengths 
Tick et al 2010 
• Increased risk of developing PTS associated 
with male sex (RR 1.4, 95% CI 0.9-2.2), age >50, 
(RR 1.4, 95% CI 0.9-2.1), proximal thrombosis 
(RR 2.3, 95% CI 1.0-5.6), residual proximal 
thrombosis at 6 weeks (RR 1.6, 95% CI 1.0-2.5) 
and the presence of reflux in the superficial veins 
at 6 weeks (RR 1.6, 95% CI 1.1-2.3), (p=≤01 for 
all). 
• Multivariate analysis of these predictors yielded 
an area under the curve of 0.72 (95% CI 0.62-
0.82).  
• BMI, the presence of varicose veins at 
diagnosis, CMP function and VOR and idiopathic 
DVT were not associated with the development of 
PTS.  
• Majority of the results presented in the form of risk 
ratios with confidence intervals which did not account 
for potential confounding. 
• The study did produce a regression model with 
predictors significant on chi-square but the results 
were poorly presented with only the ability of the model 
as a whole to discriminate between patients with and 
without PTS described. 
• Cannot be determined from the data whether the 
individual predictors were still significant in the model 
or the size of the effect of other important confounding 
factors.  
• Neither the construct nor fit of the model were 
described with only very general area under the curve 
data provided. 
• Sampling frame 
identified. 
• Consecutive sampling.  
• Timeframe identified. 
• Eligible and participating 
patients stated. 
• Inclusion and exclusion 
criteria described. 
• Detailed protocol for DVT 
diagnosis and reflux 
assessment. 
• Dermatologist blinded to 
results of other tests for 
CEAP assessment for 
PTS. 
Yamaki et al 2010 
• Significantly more ilio-femoral DVTs reported in 
PTS group (p=0.043) compared to no PTS group. 
• Calf venous blood filling index significantly 
increased in PTS patients (p=0.040).  
• Calf venous blood retention index (RI) was 
significantly higher in PTS patients (p=0.0001) 
and a RI of 2.9 displayed the strongest ability to 
predict PTS (sensitivity 100%, specificity 82.1%, 
PPV 66.7% and NPV 100%, area under the curve 
0.91 95% CI 0.82-0.96), p=0.0001).  
• No significant difference was found in age, sex, 
cancer, congestive heart failure, the use of 
hormone replacement therapy, immobilization, 
inflammatory bowel disease, surgery or trauma, 
previous DVT, renal failure, stroke or 
thrombophilia between those participants that 
developed PTS and those that did not.  
• Unclear from the publications if these four reports 
relate to separate cohorts but the limited information in 
the methods suggest there may have been some 
overlap. 
• No regression analysis was undertaken to investigate 
confounding variables. 
• Study only included participants who could complete 
24 months of follow-up without gaps which may have 
produced a biased sample of highly compliant 
volunteers who would be more willing to adhere to 
treatment intervention such as the use of compression 
therapy.  
• Study methods were 
generally well described 
and suitably robust. 
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Authors Year Summary of main findings Key limitations Key strengths 
Yamaki et al 2011 
• Ilio-femoral DVT (OR 3.4, 95% CI 1.4-8.6), 
combination of residual occlusion and reflux at 6 
months (OR 4.4, 95% CI 2.9-20.7), a peak reflux 
velocity of >29.7 cm/s-1 (OR 13.7, 95% CI 4.1-
45.7) and a mean reflux velocity of >8.6 cm/s-1 
(OR 4.4, 95% CI 1.5-12.9) in the popliteal vein 
were all associated with the development of PTS.  
• Paper repeated some of the findings reported in the 
2010 paper suggesting an overlap but the extent of this 
is not clear. 
• Study did not assess the contribution of superficial 
reflux and combined deep and superficial reflux as a 
possible predictor of PTS.   
• Construct of the regression model or how well it fitted 
the data were not described.  
• Confounding factors were only entered into the 
regression model if they had a p value of <0.1 on chi-
square analysis - may have excluded some potentially 
important confounders.   
• The authors also did not identify compression 
compliance as a confounding factor which is a further 
limitation and for these reasons the results should be 
viewed with caution.   
• The statistical analysis 
undertaken was generally 
more robust than many of 
the other papers. 
Van Rij et al 2013 
• Identified four significant risk factors for the 
development of PTS:  
- extensive thrombus load on presentation 
- <50% clot regression at 6 months  
- venous filling index (VFI)  > 2.5 ml/second  
- abnormal flow rate <0.6.   
• Patients with three or more of these risk factors 
had a significant risk of developing PTS 
(sensitivity 100%, specificity 83% and PPV 67%).  
• Patients scoring two or less did not have PTS at 
five years with a NPV of 100%.  
• Little detail provided regarding the methods of the 
univariate and multivariate analyses.  
• The scoring system used for predicting PTS at 5 
years was simplistic. 
• Potential confounding was not adequately addressed.  
• Data collection methods 
were robust and well 
described. 
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Authors Year Summary of main findings Key limitations Key strengths 
Haig et al  2013 
• Independent of treatment allocation, patients 
with fully recanalised and competent deep 
veins at six month follow-up had a 40.5% 
(95% CI 26.4-54.7) absolute risk reduction of 
developing PTS compared to patients with an 
abnormal vein assessment (residual thrombus 
and/or the presence of deep venous reflux).  
• On multivariate logistic regression, venous 
reflux and lack of patency at 6 months were 
found to be independent predictors of PTS in 
patients treated with CDT (OR 8.3, 95% CI 
2.6-26.8 for reflux and OR 0.17, 95% CI 0.06-
0.49 for patency) but not in the control group 
which received standard oral anticoagulation 
therapy.  
• Only included participants with a first episode of 
proximal DVT which they defined as mid-thigh 
level and above 
• Only two follow-up intervals at 6 and 24 months 
• The main focus of the study was outcomes after 
catheter directed thrombolysis which is not yet 
part of standard clinical practice in every centre 
and where it is available is limited to those with 
proximal DVT that meet certain criteria - this 
reduces the applicability of the findings to routine 
clinical practice. 
• These results come from a high 
quality randomised study in which 
the sample population was well 
defined (although limited)  
• All participants were recruited 
within 21 days of their objectively 
diagnosed DVT symptoms onset.  
• The methods of this study are 
well described and robust as one 
would expect from a randomised 
study. 
Vedovetto et al 2013 
• PTS developed in 41% of participants  
• After adjustment for age and sex, the risk 
ratios for PTS were:  
1.92 (95% CI 1.39-2.64) in participants with 
residual thrombus alone 
1.11 (95% CI 0.66-1.89) in participants with 
popliteal vein incompetence alone  
1.86 (95% CI 1.26-2.66) in participants with 
both residual thrombus and reflux  
• Results suggested that lack of recanalisation 
within 6 months is an important factor in the 
development of PTS but popliteal vein 
incompetence is not, unless associated with 
residual thrombus.  
• Lack of information in methods regarding initial 
DVT diagnosis - only says objectively diagnosed 
• Key methodological details missing regarding 
ultrasound assessment for residual DVT & reflux.  
• Although the final outcome measure of PTS was 
recorded at 3 years post DVT, the assessment of 
residual vein thrombosis and venous 
incompetence only took place at the three and six 
month surveillance intervals and was limited to the 
femoral and popliteal veins for residual thrombus 
and the popliteal vein for reflux. 
• The statistical analysis of the data was limited as 
without the use of multivariate regression 
analysis, the results cannot be interpreted without 
the bias of the multiple confounding factors in 
studies of this nature. 
• Long duration of follow-up. 
• Large sample size 
• Consecutive patients 
• Analysis adjusted for age and sex 
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Authors Year Summary of main findings Key limitations Key strengths 
Yamaki et al 2016 
• On multivariate logistic regression analysis, 
the presence of residual obstruction and reflux 
at six months post DVT diagnosis was 
independently associated with a greater risk of 
developing PTS at some point during the six 
year follow-up period after DVT diagnosis (OR 
4.80, 95% CI 1.03-22.36, p = <0.05).  
• Changes in tissue levels of oxygenated 
haemoglobin ≤ 48 seconds was also found to 
be associated with PTS progression (OR 
53.73, 95% CI 8.43-342.41; p = <0.010).  
• Absence of detail regarding the methods of 
diagnosis of the original DVT, venous reflux and 
PTS assessment. It is not described how these 
assessments were undertaken and by whom.  
• The follow-up duration was six years in terms of 
the outcome of a PTS diagnosis. However, 
ultrasound assessment was only performed once 
at 6 months post the original DVT.  
• None of the participants experienced a DVT 
recurrence during 6 years of follow-up which 
seems highly unlikely given recurrence rates 
reported widely in the literature - reduces the 
confidence in the level of follow-up the study 
participants received. 
• Long duration of follow-up 
• Cohort demographics described 
 
Jeraj et al 2017 
• Patients with PTS were older (64.0 years 
versus 55.5 years; P=0.007), more frequently 
experienced recurrent DVT (15% versus 3%, 
P=0.030) and had a lower percentage of 
completely recanalised veins (9% versus 38%) 
than those without PTS.  
• Logistic regression analysis however only 
confirmed residual thrombus as having a 
significant association with PTS development 
with an odds ratio of 6.0 compared to 
complete recanalisation.  
• Lack of detail regarding initial DVT diagnosis - 
impossible to determine if objectively diagnosed & 
if all participants classified using the same 
procedure or even if this was 1st episode of DVT. 
• Details of recurrent DVTs reported - not clear if 
index DVT or recurrence during follow-up.  
• The length of follow-up differed between 
participants ranging from 12 to 36 months. 
• Some key methodological details were missing 
regarding the duplex ultrasound assessment for 
residual thrombosis and reflux. 
• Regression analysis performed but limited to a 
univariate model due to the small sample size so 
confounding is a likely issue. 
• No details provided regarding the model used or 
how it fitted the data. 
• Consecutive patients 
• Single assessor for PTS 
• Cohort demographics described 
• Regression analysis underaken 
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Key: 
BMI – body mass index   CEAP - Clinical Etiologic Anatomic Pathophysiologic CDT – catheter directed thrombolysis 
CI – confidence interval   CRP – C-reactive protein     CHF – congestive heart failure 
CMP – calf muscle pump   CVD – chronic venous disease    CVI – chronic venous insufficiency  
DVT – deep vein thrombosis   HRT – hormone replacement therapy    IBD – inflammatory bowel disease  
ICAM - Intercellular Adhesion Molecule IL – Interleukin       MRV – mean reflux velocity  
NPV – negative predictive value  OR – odds ratio      PPV – positive predictive value  
PRV – peak reflux velocity   PTS – post-thrombotic syndrome    RR – risk ratio 
VFI – venous filling index   VOR – venous outflow resistance  
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Table 2.6 Overview of factors associated and not associated with PTS in each 
of the individual studies included in the review. 
Authors Year Association with PTS No association with PTS 
Van Ramshorst et al 1994 None identified 
Extent of initial DVT 
Reflux 
Franzeck et al 1997 
Combination of reflux and 
obstruction 
Reflux alone 
Obstruction alone  
Meissner et al 1998 
Reflux extent 
Popliteal vein obstruction 
Recanalisation rate 
None identified or reported 
O'Shaughnessy et al 2001 
Recurrent DVT 
Bilateral DVT 
Reflux 
Haenen et al 2002 Superficial venous reflux  
Deep venous reflux alone 
Calf muscle pump dysfunction  
Asbeutah et al 2004 Proximal DVT Distal DVT 
Prandoni et al 2005 
Residual obstruction 
Combination popliteal vein 
reflux & residual obstruction 
Ipsilateral recurrent DVT 
Advanced age 
Popliteal vein reflux alone 
Sex 
Extent of initial DVT 
Thrombophilic status 
Treatment type 
Roumen-Klappe et al 2005 
Combination of thrombus 
load, reflux and VOR 
None identified or reported 
Asbeutah et al 2007 None identified None identified or reported 
Yamaki et al 2007 
Reflux 
Peak reflux velocity 
Mean reflux velocity 
Reflux duration 
Residual obstruction 
Labropoulos et al 2008 
Multi-level DVT  
Reflux and obstruction 
Single level DVT  
Labropoulos et al 2009 
Ipsilateral recurrent DVT 
associated with reflux 
Progression of reflux not 
related to clinical progression 
Roumen- Klappe et al 2009 
Venous hypertension 
Increased VOR 
Residual thrombus 
Reflux 
IL-6 and CRP not associated 
with reflux. 
Shbaklo et al 2009 
IL-6 and ICAM-1 
inflammatory markers 
Reflux 
Latella et al 2010 Popliteal reflux None identified or reported 
Tick et al 2010 
Male sex 
Advanced age 
Residual obstruction 
Deep venous reflux 
Superficial venous reflux 
Proximal DVT 
BMI 
Varicose veins at diagnosis 
Idiopathic DVT 
CMP function  
VOR 
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Authors Year Association with PTS No association with PTS 
Yamaki et al 2010 
Proximal DVT 
Calf venous blood filling 
index 
Calf venous blood retention 
index 
Calf venous blood ejection 
index 
Age, sex, cancer 
CHF, HRT, IBD 
Immobility 
Surgery or trauma 
Previous DVT 
Renal failiure 
Stroke 
Thrombophilias 
Yamaki et al 2011 
Proximal DVT 
Residual obstruction and 
reflux 
Peak reflux velocity 
Mean reflux velocity 
As above 
Van Rij et al 2013 
Combination of three of the 
following: 
Extensive thrombus burden 
at diagnosis 
<50% thrombus resolution 
at 6 months 
Venous filling index >2.5 
mL/sec 
Abnormal venous outflow 
rate <0.6 
None identified or reported 
Haig et al  2013 
Deep venous reflux, 
residual obstruction 
None identified or reported 
Vedovetto et al 2013 
Residual obstruction, 
advanced age, female sex 
Popliteal vein reflux 
Yamaki et al 2016 
Stroke, ideopathic DVT, 
ilio-femoral DVT, 
combination of residual 
occlusion and reflux, 
oxygenated hemoglobin 
≤48 secs 
Age, sex, BMI, anticoagulation 
duration, calf DVT, femoral- 
popliteal DVT 
Jeraj et al 2017 
Advanced age, residual 
obstruction 
Reflux 
 
Key: 
DVT – deep vein thrombosis  IL – Interleukin  
PTS – post-thrombotic syndrome  ICAM - Intercellular Adhesion Molecule 
CRP – C-reactive protein   
CHF – congestive heart failure  HRT – hormone replacement therapy 
IBD – inflammatory bowel disease BMI – body mass index 
VOR – venous outflow resistance  CMP – calf muscle pump 
 
 
116 
 
In summary, results for all associations remain equivocal. This creates a 
confusing picture of the role of residual occlusion, thrombus extent and venous 
reflux in the development of PTS.  In addition to this lack of consensus, many of 
the studies were limited by their quality and this is examined further in the 
following section. 
 
2.5.6 Quality assessment of the included studies  
An examination of the combined results for each of the CASP questions with 
‘yes’, ‘no’ or ‘not clear’ answers (Table 2.7) revealed that the main limitations 
common to many of the included studies related to inadequate reporting of the 
methods and a lack of identification of and accounting for all potentially 
important confounding factors which are numerous in cohorts with this 
condition. Another main area of potential bias was the recruitment process in 
many of the studies. All of these factors combined to reduce the confidence in 
the results and the generalisability of the findings as demonstrated by the 
overwhelmingly negative answers to questions nine and ten of the CASP 
assessment although the subjective element to these questions is recognised.  
 
Table 2.7 Combined totals of quality assessment judgements for each CASP 
question with ‘yes’, ‘no’ or ‘not clear’ answers across all included. 
 
 CASP Question Y N NC 
1 Did the study address a clearly focused issue? 18 5 0 
2 Was the cohort recruited in an acceptable way? 4 12 7 
3 
Was the exposure accurately measured to minimise 
bias? 
3 3 17 
4 
Was the outcome accurately measured to minimise 
bias? 
14 2 7 
5 
Have the authors identified all important confounding 
factors? 
1 21 1 
6 Was the follow up of participants complete enough? 15 7 1 
9 Do you believe in the results? 0 21 2 
10 
Can the results of the study be applied to the local 
population? 
1 21 1 
11 Do the results fit with other available evidence? 11 12 0 
117 
 
 
 
The outcomes of the formal assessment of quality and risk of bias using the 
CASP tool are reported in Table 2.8. There was good agreement between 
reviewers with discussion required for only 33% of the 207 decision based 
questions across the 23 studies. Following discussion, agreement was reached 
in favour of the decision from Reviewer 1 in 15%, the decision of Reviewer 2 in 
14% and both reviewers changed their original decision in 4% of cases.  
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Table 2.8 Consensus reviewer results of CASP findings for the individual studies included in the review.     
 
Key: 
 
 
 
  Complete initial agreement 
  Both reviewers changed opinion 
  Changed to Reviewer 1 opinion 
  Changed to Reviewer 2 opinion 
Y Yes 
N No 
NC Not Clear 
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2.5.7 Identification of main quality issues in the studies  
Using the formal quality assessment tool facilitated the identification of several 
key themes which both illustrated the challenges associated with undertaking a 
study of this nature and highlighted key areas where improvements could be 
made when conducting future research in this field. 
 
Cohort selection  
It must be considered that there are differences in the health of individuals, 
including those recruited to the reviewed studies, that arises from complex 
interactions linking environmental, economic, social, lifestyle and biological 
factors (Dahlgreen and Whitehead, 1991). Although participants in all of the 
included studies were recruited appropriately in hospital settings, personal 
characteristics such as age, disability and sexual orientation often present 
barriers to a full integration in society, which includes the use of health services 
(Krieger, 1999). Moreover there are other people who are potentially vulnerable 
or socially excluded meaning that the participants in the research are not 
necessarily representative of the population as a whole.  
 
It should also be considered that there may be a significant number of people 
who have suffered a DVT but do not seek hospital attention for their condition 
and may have different characteristics and outcomes from the population that 
present to hospital outpatient settings. This could potentially be particularly 
evident in patients with isolated calf vein DVT which may not produce 
symptoms significant enough to provoke a hospital visit. These unknown factors 
may then have significant differences in terms of co-morbidities, lifestyle, and 
other potential risk factors for PTS as well as the obvious differences in terms of 
treatment received.  
 
In addition, amongst the population who do present at a hospital setting with a 
DVT, those patients that consent to participate in a research study may also 
have differences in terms of co-morbidities, lifestyle and adherence to treatment 
regimen (especially compliance with compression therapy which is particularly 
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relevant to PTS) compared to those that do not consent to participate. It is 
therefore very important that any observational study of this kind, where 
associations are being examined between variables present at baseline or 
presenting during follow-up and outcome variables at a defined time point, is as 
inclusive as possible in order to capture as much information from as wide a 
population as possible.  
 
Although the participants were generally recruited for a clearly defined objective 
in most of the studies, some of the main areas of potential bias related to the 
recruitment process, with several limitations common to many of the studies in 
terms of participant selection. Many of the studies suffered from a lack of 
reported information regarding the recruitment of participants which made it 
difficult to determine if the results obtained were generalizable to a wider 
population. As detailed in Table 2.9, three of the studies did not recruit 
consecutively which may have significantly impacted the level of population bias 
in the sample, five did not describe their exclusion criteria at all making it 
impossible to establish the degree of sampling bias and, where the exclusion 
criteria were described, five of the studies had extensive exclusions resulting in 
a highly selected sample population.  
 
Furthermore there were several limitations common to many of the studies 
relating to the condition under examination itself. Four of the studies did not 
restrict inclusion to first episode of ipsilateral DVT and a further five studies did 
not make this clear. The potential inclusion of non-acute or chronic DVT cases 
introduces confounding factors, the extent of which cannot be completely 
known. In an observational study of the evolution of a condition such as DVT, 
the likelihood of capturing information from the starting point of the condition is 
of great importance.  Not knowing with any degree of certainty if the DVT was 
acute or non-acute has the potential to significantly limit the reliability of the 
findings. In addition, eight of the studies did not include both proximal and distal 
DVT and were therefore limited in their applicability to all extents of the 
condition.   
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Table 2.9 Overview of the quality issues relating to cohort selection for the individual studies included in the review. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant selection 
Study Year 
Recruited 
sample 
size 
Complete 
sample 
size 
Exclusions 
described 
Exclusion 
level 
Consecutive 
recruitment 
Recruited 
for defined 
objectives 
Cohort 
description 
Proximal 
and distal 
included 
First 
episode 
DVT only 
Van Ramshorst et al 1994 ? 27 X ? ?  Adequate  ? 
Franzeck et al 1997 58 39  Medium   Adequate  
Meissner et al 1998 176 68  Low   Adequate  
O'Shaughnessy et al 2001 100 63 X ?   Limited X X 
Haenen et al 2002 83 70 X ?   Adequate  X 
Asbeutah et al 2004 ? 51 X ? ? ? Limited  X 
Prandoni et al 2005 180 64  Medium   Good X 
Roumen- Klappe et al 2005 93 48  Low  X Limited  ? 
Asbeutah et al 2007 20 20  Medium ?  Adequate X 
Yamaki et al 2007 ? 130  High   Adequate X 
Labropoulos et al 2008 192 105  Medium   Adequate  
Labropoulos et al 2009 86 64  High   Limited X 
Roumen- Klappe et al 2009 114 110  High   Limited  
Shbaklo et al 2009 387 223  Medium   Limited  ? 
Latella et al 2010 387 233  Medium   Adequate  ? 
Tick et al 2010 111 94  Low   Adequate  
Yamaki et al 2010 124 121  High   Adequate  
Yamaki et al 2011 124 121  High   Adequate  
Van Rij et al 2013 ? 114  Medium   Adequate  X 
Haig et al  2013 209 189  Medium   Adequate X 
Vedovetto et al 2013 290 290 X ?   Adequate X 
Yamaki et al 2016 129 116  Medium   Good  
Jeraj et al 2017 100 100  Medium   Adequate X ? 
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Another significant shortcoming was the limited reporting of the cohort 
demographics with six of the papers presenting only very limited information on 
the study sample demographics and only two of the studies providing 
comprehensive demographic description from which a judgement could be 
made regarding the generalisability of the findings to a wider population. All of 
the included studies were potentially subject to an element of reporting bias in 
terms of the possible selective revealing or suppression of information from 
participants. This included factors such as previous medical history, smoking 
status, diet, exercise, compliance with compression therapy/medication as well 
as selective reporting of PTS symptoms which could all have the potential to 
confound the results. None of the included studies published a protocol so it 
was not possible to know definitively if there was reporting bias. 
 
Small sample size was an issue for several of the studies with only 14 of the 23 
studies having a recruited cohort of 100 participants or more and of those only 
12 studies retained a final sample of this size for the analysis. While the 
adequacy of the sample size is largely determined by the analysis undertaken, 
a minimum number of cases would be recommended in order for the results to 
be meaningful. The adequacy of the sample sizes in the individual studies was 
assessed using the work of Peduzzi et al (1996) and reported by van Belle 
(2008) as a guideline for the minimum number of participants required to 
quantify regression coefficients with reasonable precision. This uses a 
calculation where p is the smallest of the proportions of negative or positive 
cases of PTS in the population (taken as 20%) and k the number of covariates, 
the minimum number of participants proposed is N = 10 k / p. 
 
Adequacy of follow-up 
As previously described in Table 2.3, the duration and frequency of follow-up 
schedule varied between studies and this was a source of limitation in several 
of the studies. As the evidence to date suggests that PTS can develop at any 
point up to 2 years after DVT (Roumen-Klappe et al, 2005; Wong and Baglin, 
2012; Kahn et al, 2014b) as described previously in Section 1.6, the duration of 
follow up was considered insufficient to allow for all potential cases of PTS to 
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develop in two of the studies (Table 2.10). The frequency of the follow-up 
intervals was considered inadequate in four of the studies and was not clearly 
described in three further studies. In addition, the early stages of DVT evolution 
were not captured in 11 of the studies and, in those three studies with 
insufficient description of the follow-up schedule, the adequacy of early follow-
up could not be determined. The outcome of a DVT recurrence during follow-up 
did not appear to be recorded in 10 of the 23 studies which raises other issues 
around the quality of the follow-up assessments for residual occlusion.  
 
Finally the details of participants that were lost to follow-up was not reported in 
11 of the studies and, as previously described in Table 2.9, in four of the studies 
it was not clear if the paper only reported on the complete data final sample size 
rather than the recruited sample as this information was not presented. This 
lack of detail in the reporting impedes the judgement of sample bias. It is 
possible that those remaining in the studies may have been more or less 
symptomatic for PTS and may have been more compliant with compression 
therapy which could have affected patient outcome post DVT.  
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Table 2.10 Overview of the quality issues relating to the follow-up schedule for 
the individual studies included in the review. 
 
Follow-up 
Study Year 
Long 
enough* 
Enough 
intervals** 
Early 
stages 
captured*** 
Recurrence 
documented 
Loss to 
FU 
reported 
Van Ramshorst et al 1994  X X X X 
Franzeck et al 1997   X  
Meissner et al 1998     X 
O'Shaughnessy et al 2001   X X 
Haenen et al 2002  ? ?  
Asbeutah et al 2004     X 
Prandoni et al 2005   X  
Roumen- Klappe et 
al 
2005 
    
Asbeutah et al 2007 X  X  X 
Yamaki et al 2007  ? ?  X 
Labropoulos et al 2008   X  
Labropoulos et al 2009   X  
Roumen- Klappe et 
al 
2009 X 
   
Shbaklo et al 2009    X X 
Latella et al 2010     X 
Tick et al 2010   X X 
Yamaki et al 2010  ? ? X 
Yamaki et al 2011    X 
Van Rij et al 2013    X X 
Haig et al  2013  X X  
Vedovetto et al 2013  X X X X 
Yamaki et al 2016    X X 
Jeraj et al 2017  X X X X 
* The duration of follow-up was considered adequate at a minimum of 2 years. 
 
** The number of follow-up intervals was considered adequate if there were 5 or more. 
 
*** The early stages of DVT progression were considered to be adequately assessed if follow-
up imaging first occurred within 7 days to 1 month. 
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Diagnostic accuracy 
The inclusion/exclusion criteria for the review were designed to minimise 
detection bias as only studies of participants with an objectively confirmed 
diagnosis of DVT and those using validated assessment methods for the 
diagnosis of venous reflux and PTS were included. The initial DVT diagnosis 
was made using ultrasound in 11 of the studies, venography in three of the 
studies and a mix of ultrasound or venography in two studies. In seven of the 
studies however the original DVT was stated as being objectively confirmed but 
the method of diagnosis was not described. As detailed in Table 2.11, there was 
a noticeable absence in terms of the protocol description for the initial DVT 
diagnosis across all of the studies with only four of the studies (all from the 
Yamaki et al research group) describing the imaging protocol in any detail. It 
was therefore unknown who performed the diagnostic imaging or reported the 
results, their level of expertise, the techniques or equipment used and the 
conditions under which it was performed. This made it very difficult to assess 
the reliability and reproducibility of the original diagnosis of the condition under 
scrutiny in the majority of the studies.  
 
Also demonstrated in Table 2.11, six of the studies did not specifically address 
the issue of the timing of the initial diagnostic imaging and were therefore at risk 
of including cases of non-acute or chronic DVT leading to the potential issues 
with confounding previously described. The thrombus burden of the index DVT 
was only described in five of the 23 studies. The extent of a DVT in terms of its 
thrombus burden can vary significantly between cases and simply categorising 
DVTs as either distal or proximal does not account for the true extent of the 
thrombus. For example, an extensive distal DVT involving occlusive thrombus 
throughout all of the calf veins would have a significantly higher thrombus 
burden than a proximal DVT with the presence of a partial thrombus in the 
common femoral vein resulting from an extending superficial thrombophlebitis in 
the greater saphenous vein. In addition, the method of assessment for the 
presence of residual thrombus was not described at all in eight of the studies 
and there was insufficient detail in a further four of the studies to determine if 
the process was robust, reliable and reproducible. 
126 
 
Table 2.11 Overview of the quality issues relating to the diagnostic accuracy of the index DVT as well as the diagnostic tests undertaken  
during follow-up for the individual studies included in the review. 
Diagnostic accuracy 
Study Year 
DVT 
diagnosis 
method 
described 
DVT 
diagnosis 
method 
robust 
Acute 
DVT 
only 
Thrombus 
burden 
reported 
Residual 
thrombus 
assessment 
method 
described 
Residual 
thrombus 
assessment 
method 
robust 
Reflux 
diagnosis 
method 
described 
Reflux 
diagnosis 
method 
robust 
PTS 
diagnosis 
method 
described 
Van Ramshorst et al 1994 X ? ?   ?   X 
Franzeck et al 1997 X ?    ?  X X 
Meissner et al 1998 X ?       
O'Shaughnessy et al 2001 X ?  X X ? X ? X 
Haenen et al 2002 X ?  X     
Asbeutah et al 2004 X ? ? X     
Prandoni et al 2005 X ? ? X X ?  X X 
Roumen- Klappe et al 2005 X ? ? X X ?   
Asbeutah et al 2007 X ?  X     
Yamaki et al 2007    X     
Labropoulos et al 2008 X ?  X     
Labropoulos et al 2009 X ?  X  ?   X 
Roumen- Klappe et al 2009 X ?  X  X   
Shbaklo et al 2009 X ?  X X ?  ? 
Latella et al 2010 X ?  X X ?  ? 
Tick et al 2010 X ? ?    X ? 
Yamaki et al 2010    X    X 
Yamaki et al 2011    X    X 
Van Rij et al 2013 X ?       
Haig et al  2013 X ?  X X ?   
Vedovetto et al 2013 X ?  X X ?   
Yamaki et al 2016  ?  X X ? X ? X 
Jeraj et al 2017 X ? ? X  ? X ? 
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Venous reflux was diagnosed using DUS in all of the studies except two. The 
study by Prandoni et al (2005) used continuous wave hand-held Doppler and 
the study by Yamaki et al (2010) used near-infrared spectroscopy to assess 
venous valve function. Again, four of the studies did not describe the methods 
used for reflux diagnosis and in two further studies there was insufficient detail 
in the method description to assess its suitability. In four of the studies where 
the method of reflux diagnosis was described in sufficient detail, it was not 
considered robust, reliable or reproducible. The reasons for this are described 
in detail for the individual studies in Table 2.5 and included non-standardised 
methods of flow augmentation for all participants, using a classification for reflux 
diagnosis that did not align with current practice, limited number of assessments 
or inappropriate timing of assessments (too early). The study by Asbeutah et al 
(2004) for example did not undertake a baseline assessment of venous valve 
function and therefore did not assess for the presence of any pre-existing 
venous reflux.  
 
The CEAP classification system was used to diagnose PTS in 10 of the studies, 
the Villalta Scale in 10 of the studies and both systems were used in three of 
the studies. Whilst both systems were considered acceptable tools for 
diagnosing PTS, six of the studies suffered from a lack of detail when describing 
the method in which they were employed in terms of who undertook the 
assessment, when and where it was performed. For example the study by 
Asbeutah et al (2004) performed a CEAP assessment as a telephone 
questionnaire and was therefore based entirely on patient reported signs and 
symptoms rather than including a clinical assessment.  
 
These factors combine to reduce the reliability and validity of the classification 
of conditions such as venous incompetence and PTS considerably and highlight 
the potential for other unknown limitations in the assessments of those studies 
where the diagnostic assessment methods were not described in sufficient 
detail to assess their reliability and validity.  
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Treatment for the index DVT 
As previously described in Table 2.4, there was significant variation in the 
treatment regimen for the initial DVT.  This is expected in clinical practice, as 
not all patients will be suited to all types of treatment and is therefore 
unavoidable. However, in longitudinal studies of this nature, transparency over 
the type and duration of the treatment regimen of the participants is important 
as this could be a significant confounding factor in any analysis of participant 
outcomes after DVT. Not all of the studies reported information on the type 
and/or duration of anticoagulation therapy. Where the information was reported, 
the way in which it was reported varied between studies with some giving the 
minimum duration, some giving the range and some presenting the mean 
(Table 2.4). Whilst 10 of the 23 studies did not report the duration of the initial 
treatment with heparin, those that did, involved patients taking it for between a 
minimum of five days and a maximum of 14 days (n = 11), usually until a target 
INR of between two and three was reached. Similarly, five of the 23 studies did 
not report the duration of the oral anticoagulation treatment, but those that did 
(n=18) involved patients taking it for a minimum of eight weeks (n=4), a 
minimum of three months (n=8), a minimum of six months (n=3), or a mean of 
between seven and ten months (n=3). The majority of the studies did not report 
the maximum treatment duration but in one study (Haenen et al, 2002) 
treatment continued in some patients for up to 2 years. As described in Table 
2.12, two of the studies reported no information regarding the anticoagulation 
treatment at all, neither in terms of type nor duration.  
 
In 18 of the 23 studies, patients were advised to wear compression hosiery for 
durations ranging from two weeks to two years but compliance with the therapy 
was only reported in three of the studies. 
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Table 2.12 Overview of the quality issues relating to the treatment regimen for the index DVT in participants in the individual studies 
included in the review. 
Treatment 
Study Year 
Treatment duration 
described 
Compression 
therapy use reported 
Duration compression 
therapy reported 
Compliance compression 
therapy assessed 
Van Ramshorst et al 1994  X X X 
Franzeck et al 1997   X 
Meissner et al 1998 X X X X 
O'Shaughnessy et al 2001   X 
Haenen et al 2002    X 
Asbeutah et al 2004    X 
Prandoni et al 2005    
Roumen- Klappe et al 2005    X 
Asbeutah et al 2007    X 
Yamaki et al 2007   X 
Labropoulos et al 2008 X X X X 
Labropoulos et al 2009   X X 
Roumen- Klappe et al 2009    
Shbaklo et al 2009   X 
Latella et al 2010   X 
Tick et al 2010    
Yamaki et al 2010   X X 
Yamaki et al 2011   X X 
Van Rij et al 2013 X  X X 
Haig et al  2013 X   
Vedovetto et al 2013 X X X X 
Yamaki et al 2016    X 
Jeraj et al 2017    
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Data analysis 
Further limitations common to many of the included studies related to the data 
analysis undertaken and in particular the lack of identification of and accounting 
for all potentially important confounding factors which will be numerous in 
cohorts with this condition. The sample size of several of the studies prevented 
any multivariate regression analysis in order to deal with potential confounding 
and regression analysis was only performed in 12 of the 23 studies (Table 
2.13). From all of the different data analyses performed across the studies, the 
strengths of any associations found were only described in 16 of the 23 studies.  
 
Table 2.13 Overview of the quality issues relating to the treatment regimen for 
the index DVT in participants in the individual studies included in the review. 
  Analysis 
Study Year 
Regression 
analysis 
performed 
Multivariate 
regression 
analysis 
Strength of 
associations 
described 
Missing 
data 
dealt 
with in 
analysis 
Van Ramshorst et al 1994   X X 
Franzeck et al 1997 X X X X 
Meissner et al 1998    X 
O'Shaughnessy et 
al 
2001 
X X X X 
Haenen et al 2002    X 
Asbeutah et al 2004 X X X X 
Prandoni et al 2005 X X  X 
Roumen- Klappe et 
al 
2005 
 X  X 
Asbeutah et al 2007 X X X X 
Yamaki et al 2007    X 
Labropoulos et al 2008 X X X X 
Labropoulos et al 2009 X X  X 
Roumen- Klappe et 
al 
2009 
   X 
Shbaklo et al 2009 X X  X 
Latella et al 2010 X X  X 
Tick et al 2010    X 
Yamaki et al 2010 X X  X 
Yamaki et al 2011 X X  X 
Van Rij et al 2013    X 
Haig et al  2013    X 
Vedovetto et al 2013 X X  X 
Yamaki et al 2016    X 
Jeraj et al 2017  X X X 
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A common theme across all studies, particularly those where regression 
analysis was performed was the generally poor description of the statistical 
methods employed. Neither the construct nor fit of the model were described in 
the majority of cases nor was analysis of the residual plots described in any of 
the studies. This highlights the importance of well described statistical methods 
in order to permit critical appraisal of the results without which confidence in the 
findings and the generalisability to a wider population are reduced.  
 
Finally, with the exception of the study by Prandoni et al (2005) in which 
Kaplan-Meier analysis was used which takes into account incomplete follow-up 
when assessing cumulative probability, none of the studies documented how 
they dealt with missing cases in their analysis. From the recruitment data it is 
obvious that loss to follow-up occurred as is inevitable in longitudinal studies. 
Three of the studies, however, reported no apparent losses to follow-up 
(Asbeutah et al, 2007; Vedovetto et al, 2013 and Jeraj et al, 2017), the last two 
of which were large cohorts. This suggests that either the reporting was limited 
to complete data sets only or that some form of data imputation was performed 
but was not described which is unlikely.  It is therefore not possible to make any 
judgement on how likely the results described might differ from those cases that 
were lost to follow-up.  
 
2.6 Discussion 
2.6.1 Information from studies not included in the review.  
Whilst the review was limited to prospective studies in which DVT was 
confirmed with medical imaging, included objective assessment for venous 
incompetence and used a validated tool to diagnose PTS, it was considered 
that some potentially important information may have be missed by exluding 
some key studies due to their study design. A brief overview of the findings from 
these key studies is included in the following section. 
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DVT Resolution 
One key study examined DVT resolution in patients with a DVT confined to the 
femoral or more distal veins at six months post diagnosis. This study of 164 
participants found that complete resolution of the DVT occurred in only 38% of 
cases, whilst partial resolution occurred in 54%. The study also found that the 
DVT extended in 7% of patients (Holmstrom et al, 1997). Other, mostly small 
scale, studies have demonstrated that up to 50% of previously abnormal 
compression ultrasound assessments do not normalise within 1 year of follow-
up (Cronan & van Leen, 1989; Murphy & Cronan, 1990; Mantoni 1991; Heijboer 
et al, 1992; Prandoni et al, 1993, Piovella et al, 2002, Prandoni et al, 2002). 
 
DVT recurrence 
A large scale retrospective study of 1719 patients with VTE examined 
recurrence rates retrospectively from medical notes over a 25 year period. This 
study reported overall recurrence rates of 12.9% and 30.4% at 1 year and 10 
years respectively and probable/definite recurrence in 5.6% and 17.6% at 1 
year and 10 years respectively (Heit et al, 2000). Although this study suffered 
from the limitations of a retrospective study in a defined but limited geographic 
population, its strengths were that it included the full spectrum of 
thromboembolic disease in all clinical settings where VTE may occur 
(community, hospitals, nursing homes) and that the analysis was stratified to 
give estimates of the maximum and minimum values (overall recurrence versus 
probable/definite recurrence).  
 
A further longer-term study found that the risk of recurrence in those with an 
unprovoked VTE exceeds 50% over 10 years if not treated with extended 
duration anticoagulation and 20% over 10 years in those with reversible 
provoking factors (Prandoni et al, 2007). Another prospective study found that 
the cumulative recurrence at 2 years was 19% in those with a first episode of 
unprovoked DVT and 8% in those with a non-surgical provoking risk (Baglin et 
al, 2003). It is well documented that the risk of recurrence upon stopping 
anticoagulation after a first episode DVT varies depending on the clinical risk 
factors associated with the primary episode (Baglin, 2007). 
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Provoking risk of the initial DVT 
The risk of recurrence is much lower in those with a post-operative DVT 
(Prandoni et al, 1996).  One study reported a 0% recurrence rate in those 
whose DVT occurred within 6 weeks of surgery (Baglin et al, 2003).  
 
Extent of the original DVT 
The double-blind CALTHRO study (evolution of untreated CALf deep vein 
THRombosis in high risk symptomatic Outpatients) used serial ultrasound scans 
to assess recurrence in cases of calf DVT (Palareti et al, 2010). Sixty five cases 
of calf DVT were included in this study; 22 had more than one calf vein 
involvement. In three months one was lost to follow-up and 1/64 had recurrent 
calf DVT. Interestingly, the mean duration of the ultrasound examination for the 
whole leg was eight minutes which may lead one to question the extent of such 
a swift examination as well as the limited duration of the follow-up. 
 
Residual vein obstruction (RVO) 
RVO may be an important factor in VTE on two levels: as the result of 
impairment in venous flow leading to stasis or, as a surrogate marker for a 
hyper-coagulable state. Carrier et al (2011) performed a systematic literature 
review (SLR) and meta-analysis of the evidence relating to the association 
between RVO and VTE recurrence. Inclusion criteria for the review were 
prospective studies of patients with first episode of DVT confirmed with 
compression ultrasound or venography that were treated for a minimum of three 
months with a vitamin K antagonist and underwent compression 
ultrasonography for RVO. All recurrences were symptomatic and objectively 
confirmed. The 14 studies included in the review demonstrated that RVO 
detection ranged from 10% to 81%. Recurrence rates in the different study 
populations ranged from 3% to 24%. From the 14 papers included in the review, 
the presence of RVO was not associated with an increased risk of VTE 
recurrence in patients with an unprovoked DVT that were not taking oral anti-
coagulation at the time of assessment (OR 1.24, 95% CI 0.9-1.7). However 
when data from patients with any DVT, whether provoked or unprovoked, was 
combined RVO was found to be associated with VTE recurrence (OR 1.5, 95% 
CI 1.1-2.0).  
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The review has several limitations that impact its internal validity and relevance 
to current practice. Importantly, it did not include data from studies where 
patients were treated with DOACs and it did not qualify who performed the 
ultrasound assessment. It also included PE which may or may not have 
originated from lower limb DVT. Included studies had different follow-up 
durations ranging from 11 months to 44 months. Nine of the 14 studies were of 
proximal DVT only and the extent/location of the DVT was not recorded in three 
of the studies. There was a large degree of heterogeneity in the included 
populations in the review (provoked/unprovoked DVT, proximal/distal DVT, 
completed/not completed anticoagulation) as well as a degree of heterogeneity 
in the definition of RVO. RVO was defined as thrombus with a diameter in the 
transverse plane of >2mm on a single test or >3mm on two consecutive tests 
(Prandoni, 2002), thrombus occupying >40% of the vein diameter (Siragusa, 
2008) or any thickness >1mm of residual thrombus detected (Young, 2006).  
 
Inter-observer variability is undoubtedly an issue in assessing RVO. A study 
using the Prandoni method (Prandoni et al, 2002) of qualifying RVO in which 
inter-observer agreement was evaluated, demonstrated considerable error 
associated with residual vein diameter measurements, echogenicity and flow 
(Linkins et al, 2006). Recurrent contralateral DVT was diagnosed using 
compression ultrasound but only included proximal DVT (popliteal vein or 
proximal). Recurrent ipsilateral DVT was defined as a new thrombus on 
compression ultrasound which was previously free from thrombus or which had 
been completely recanalised, proximal extension of a thrombus from the 
previous measurement or an increase of 4 mm or more in the diameter of the 
residual thrombus (Prandoni 2002). 
 
The review concluded that further prospective studies were required to 
determine the true relationship between RVO and the increased risk of VTE in 
patients with an unprovoked DVT and there was no consensus on whether the 
RVO increases the risk of recurrence with some studies demonstrating an 
association between RVO and recurrent VTE in patients with an unprovoked 
DVT (Siragusa et al, 2008; Prandoni et al, 2009) and some demonstrating no 
association (Cosmi et al, 2005; Cosmi et al, 2010). 
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Familial thrombophilia 
The evidence relating to whether inherited thrombophilia increases the risk of 
VTE recurrence is contradictory. Certain biochemical abnormalities have been 
associated with an increased risk of DVT recurrence. Several studies have 
demonstrated an association between the presence of an anti-phospholipid 
antibody (lupus anticoagulant or anticardiolipin antibody) and an approximate 
two-fold increased risk of DVT recurrence (Kearon et al, 1999; Schulman, 1999; 
Levine et al, 2002). Anti-thrombin deficiency and deficiencies of proteins C and 
S (Prandoni et al, 1996; Kearon et al, 2000), elevated levels of homocycsteine 
(Eichinger et al, 1998), coagulation factor VIII (Kryle et al, 2000) and 
homozygous Factor V Leiden (Lindmarker et al, 1999) have also been 
associated with increased risk of DVT recurrence. 
 
Other studies however have found that recurrence rates are not associated with 
thrombophilia. A large prospective cohort study examined recurrent VTE in 
relation to clinical and thrombophilic risk factors (Baglin et al, 2003). In this 
study, 570 patients treated with warfarin and compression stockings for their 
initial VTE were followed up at 6 months, 1 year and 2 years and all episodes of 
objectively diagnosed recurrent VTE were recorded. The radiological evidence 
was reviewed by a single investigator who was blinded to the results of 
thrombophilia testing (Baglin et al, 2003). Of the cohort, 85% were tested for 
heritable thrombophilic defects (Factor V Leiden, F2G20210A mutation, anti-
thrombin deficiency, protein C and protein S deficiencies).   
 
The study demonstrated that recurrence rates were not related to the presence 
or absence of these traits on laboratory test results (hazard ratio (HR) 1.5, 95% 
CI 0.82-2.77, p=0.187). In patients with a first event that was unprecipitated or 
not related to surgery, there was no difference in recurrence rates between 
those with or without thrombophilia (HR 1.34, 95% CI 0.73-2.46, p=0.351) 
(Baglin el al, 2003). The study concluded therefore that testing for heritable 
thrombophilias did not aid prediction of recurrence. This and evidence from 
other studies (Meinardi et al, 2001; Simioni et al, 2002) presents a strong 
argument for not routinely screening patients for thrombophilic defects after a 
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first episode of unprecipitated VTE although testing patients with a significant 
family history of thrombosis may be warranted (Baglin et al, 2003). 
 
It is important to distinguish between studies undertaken on unselected patients 
and those undertaken on individuals from thrombophilic families as the latter are 
thought to have a much higher risk of recurrence. In a multi-centre study, 
Vossen et al (2005) prospectively examined recurrence rates after a first 
episode of VTE in patients with familial thrombophilia (Factor V Leiden or 
protein S, C and antithrombin deficiencies). They found that 24% of the 180 
patients who did not receive long-term anticoagulation therapy during the mean 
follow-up period of 5.6 years experienced a recurrent thrombotic event 
compared to only 6% of the 124 patients on long-term anticoagulation. The 
recurrence rate was 5.0% per year (95% CI 3.6-6.7) in the non-anticoagulated 
group compared to 1.1% per year (95% CI 0.4-2.2) in the anticoagulated group.  
 
The risk of recurrence was therefore 80% lower in patients on long-term 
anticoagulation therapy (Risk Ratio (RR) 0.2. 95% CI 0.1-0.4) and risk was 
unchanged when adjusted for sex, age and recruiting centre. An exception, 
however, was women with antithrombin deficiency who demonstrated a 
recurrence rate of 5.1% despite long-term anticoagulation. The study also found 
that the highest recurrence rates were in men with a deficiency in natural 
anticoagulants or multiple defects and that a substantial proportion of 
recurrences occurred at times of increased risk.  
 
This was not a randomised study so it must be considered that the two groups 
of patients were potentially not comparable. Due to the low prevalence of 
familial thrombophilia, a randomised study may not however be practical. In 
addition, it is difficult to imagine how selective prescription could have led to the 
overestimation of the effect of long-term anticoagulation. The overall risk of 
recurrence in this study is not dissimilar to recurrence rates quoted from other 
studies of consecutive patients.  This suggests that the case for long-term 
anticoagulation may be no more justified in patients with inherited 
thrombophilias than patients with a first episode of VTE who are not normally 
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anticoagulated long-term. Short-term prophylactic anti-coagulation may 
however be warranted in certain groups at times of increased risk (Vossen et al, 
2005). The risk benefit balance may however change with the current 
widespread use of DOACs and this warrants further investigation. 
 
Transient versus permanent risk factors for DVT 
A large population based cohort study of 1719 patients with VTE or DVT 
examined 25 baseline characteristics in relation to VTE recurrence (Heit et al, 
2000). This study, like others (Prandoni et al, 1996; White et al, 1998; Baglin et 
al, 2003) confirmed that patients with active cancer were more likely to 
experience recurrence than those without cancer but that this risk could be 
further refined to male cancer patients undergoing chemotherapy, female 
cancer patients not undergoing chemotherapy and for older patients regardless 
of sex or therapy. 
 
This study also demonstrated that increasing age was an independent predictor 
of increased overall recurrence risk as reported earlier (White et al, 1998). The 
study by Heit et al (2000) also demonstrated that neither incident PE, evidence 
of other venous disease (varicose veins or previous superficial 
thrombophlebitis), smoking, immobility, surgery, trauma, HRT, pregnancy, or 
oral contraceptive use were associated with an increased risk of recurrence. 
Baglin et al (2003) also examined the relationship between DVT recurrence and 
clinical risk factors. They found that patients with permanent risk factors for DVT 
such as immobility and active cancer had a higher risk of recurrence than those 
with transient risk factors such as minor injury, pregnancy, long distance travel 
and HRT. The risk for recurrent DVT has also been found to be higher in men 
than women (Cushman et al, 2004; Kyrle et al, 2004). 
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Development of post-thrombotic syndrome 
Factors associated with the development of PTS can generally be divided into 
two categories: those present at baseline and those that become apparent 
during the treatment phase of DVT and during follow-up (Kahn et al, 2014b) and 
an overview of the findings from these excluded studies is presented in this 
format.  
 
Early risk factors  
Age 
Several studies have demonstrated that advanced age is associated with an 
increased likelihood of developing PTS after a DVT (van Dongen et al, 2005; 
Schulman et al, 2006; Kahn et al, 2008a, Tick et al, 2008). 
 
Sex 
The Multiple Environmental and Genetic Assessment (MEGA) study of 1916 
patients examined factors associated with DVT, with a cumulative incidence of 
PTS of 25%. It was found that female participants were more likely to develop 
PTS than male participants (RR 1.5, 95% CI 1.3-1.8) (Tick et al, 2008). Stain et 
al (2005) found however that male sex had a weak association with PTS (OR 
1.6, 95% CI 1.0-2.8). 
 
High body mass index (BMI) 
Elevated BMI and obesity have been shown to increase the likelihood of 
developing PTS as much as two-fold (Stain et al, 2005; van Dongen et al, 2005; 
Kahn et al, 2008a; Tick et al, 2008, Galanaud et al, 2013). The Tick et al (2008) 
MEGA study found that obese patients had a 1.5-fold increased possibility of 
developing PTS when compared to those with a normal BMI (RR 1.5, 95% CI 
1.2-1.9).  The role of high BMI in the development of PTS is however still under 
debate (Soosainathan et al, 2013).  
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Proximal DVT 
The study by Stain et al (2005), which specifically aimed to establish risk factors 
for PTS, found that proximal DVT had the strongest association with the 
development of PTS (OR 2.1, 95% CI 1.3-3.7). This was a large scale study of 
406 patients with a long follow-up period of a median of 60 months however it 
did not include an examination of the presence of residual thrombus which may 
be a significant factor in the development of recurrent DVT or PTS. The Tick et 
al (2008) MEGA study found that patients with a DVT involving the ilio-femoral 
veins had a 1.3-fold higher likelihood of developing PTS than those with a 
femoral-popliteal DVT (RR 1.3, 95% CI 1.1-1.6). One study however has also 
revealed a high possibility of developing PTS in cases of isolated calf vein 
thrombosis (McLafferty et al, 1998).  
 
Pre-existing venous incompetence 
The Tick et al (2008) MEGA study found that patients with pre-existing varicose 
veins were more likely to develop PTS than those without varicose veins (RR 
1.5, 95% CI 1.2-1.8). Two later studies also demonstrated that the presence of 
pre-existing venous insufficiency was associated with PTS (Bouman et al, 2012, 
Galanaud et al, 2013).   
 
Thrombophilia 
One study found that the presence of the Factor V Leiden or prothrombin gene 
mutation was an independent predictor of a lower risk of developing PTS (Kahn 
et al, 2005b). A more recent systematic review and meta-analysis however 
revealed that no consistent relationship has been demonstrated between 
inherited thrombophilia and the risk of developing PTS (Rabinovich et al, 
2014a). 
 
Provoked/unprovoked DVT 
Whether the presenting DVT was provoked or unprovoked has not been 
identified as having a significant association with PTS (Prandoni et al, 2004, 
Kahn et al, 2008a). 
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Late risk factors 
Recurrent ipsilateral DVT 
Several studies have identified recurrent ipsilateral DVT as being strongly 
associated with the development of PTS (Prandoni et al, 1996; Prandoni et al 
2004; Van Dongen et al, 2005). Recurrent ipsilateral DVT has been shown to 
increase the possibility of developing PTS by 4-6 times (Prandoni et al, 1996; 
Kahn et al, 2008a). Several factors are known to affect the development of 
recurrent DVT during the course of treatment including sub-therapeutic 
anticoagulation which was shown to increase the chance of recurrence 15-fold 
in one study (Hull et al, 2009) and residual thrombus on DUS (HR 2.2) (Young 
et al, 2006). 
 
Duration, quality and type of anticoagulation 
The duration and quality of anticoagulation has been linked to both PTS and 
DVT recurrence (in itself linked to an increased risk of PTS) (Yamaki, 2016). 
Two studies demonstrated that the risk of developing PTS increases two-fold if 
the level of anticoagulation is inadequate (defined as a sub-therapeutic INR 
>50% of the time) during the first three months of treatment with vitamin K 
antagonists (van Dongen at al, 2005, Chitsike et al, 2012). Kahn et al (2005), 
however, found no significant difference in the risk of developing PTS in those 
with a sub-therapeutic INR of 1.5-1.9 compared to those in the therapeutic 
range with INR of 2-3.  
 
A multicentre study comparing six weeks versus six months of oral 
anticoagulation therapy in 897 patients with a first episode of DVT found lower 
incidence of recurrence in the group on the longer term treatment (Schulman et 
al, 1995).The longer term results from the study however found no additional 
benefit from longer term anticoagulation with warfarin in terms of reduced risk of 
recurrence or PTS of at 10 years post DVT (Schulman et al, 2006). One study 
found that treatment with LMWH compared to a vitamin K antagonist (warfarin) 
was associated with greater thrombus resolution and a lower prevalence of both 
recurrence and PTS (Gonzalez-Fajardo et al, 2008). At the time when the 
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review was complete no studies had reported DVT recurrence, thrombus 
resolution or PTS for those individuals using DOACs. 
 
Residual thrombus and associated impaired venous function 
Comerota et al (2012) found a significant direct correlation between residual 
thrombus and both higher CEAP (r2 = 0.74) and Villalta scores (r2 = 0.61) 
suggesting that there is a strong association between the presence of residual 
thrombus and PTS.  
 
The CaVenT Trial examined outcomes after treatment with CDT in patients with 
acute proximal DVT (Enden et al, 2009; Enden et al, 2012). The study found 
that ilio-femoral venous patency was achieved in 65.9% of those in the CDT 
group compared to 47.4% of those in the standard oral anticoagulation group 
but the prevalence of venous incompetence was similar in both groups (Enden 
et al, 2009). The risk of PTS was reduced by 14.4% (95% CI 0.2-27.9) in the 
group that underwent CDT compared to those on standard anticoagulation 
alone (Enden et al, 2012). The results from this study suggest that residual 
obstruction is more important than venous reflux in the development of PTS. 
 
In contrast however, an earlier study by Haenen et al (1999) reported a 
significant positive correlation between the presence of venous reflux in the 
proximal femoral vein (P<0.001), distal femoral vein (P<0.05) and popliteal vein 
(P<0.05) and the severity of PTS. This study also found that venous obstruction 
alone or in combination with venous reflux was not related to severe PTS.  
 
Ongoing symptoms 
Persistent symptoms of pain and or swelling 1 month after DVT diagnosis have 
been associated with PTS (Kahn et al, 2008a; Roberts et al, 2013). 
 
Persistently elevated D-dimer and the presence of inflammatory markers 
Several studies not included in my SLR examined the possible correlation 
between raised D-dimer levels and the development of PTS. Stain et al (2005) 
found that the presence of elevated D-dimer levels had a weak association with 
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PTS (OR 1.9, 95% CI 1.0-3.9) however Galanaud et al (2013) found no 
significant association between raised D-dimer after completion of 
anticoagulation therapy and the development of PTS. In a systematic review 
that specifically examined the evidence relating to inflammatory markers and 
the development of PTS, Rabinovich et al (2014b) reported that results were 
conflicting although they did suggest that elevated D-dimer levels in the weeks 
to months following DVT could be a modest risk factor for PTS development. 
 
This information from these studies supports the findings from my SLR that  
whether PTS is predominantly associated with venous outflow obstruction, 
venous valvular reflux, or a combination of both, inflammatory markers or 
patient/disease characteristics is unclear from the literature and the existing 
evidence is conflicting (Kahn et al, 2015). This suggests that whilst a 
prospective design with objectively measured data using validated tools is 
important, these were not the only considerations that would be important in 
designing the observational study. 
  
2.6.2 How the quality appraisal informed the design of the 
prospective cohort study  
It was necessary to confront the fact that data were being synthesised from 
different places, involving different people, at different times and often using 
different measurement tools which is the reality of conducting a systematic 
review of cohort studies of this nature. The methodological heterogeneity in the 
included studies, including different assessment techniques, evaluation 
methods, variation in outcome measures and quality issues contraindicated 
quantitative synthesis of the data but did provide the opportunity to compare the 
efficacy of different methods.  
 
The clearest overall message learnt from critical appraisal was the importance 
of being transparent by providing a clear description of the methods used in all 
aspects of the study, including data analysis. As described in the previous 
section, there was wide variation in the level of detail reported regarding the 
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methods of the included studies. As the maximum word count for many journal 
papers prohibits detailed explanations of all elements of methods and 
methodology in a large study, this is best achieved through the publication of 
the study protocol.  
 
The potential sources of bias that were common throughout the included 
studies, related primarily to the protocols for the diagnostic tests/measurement 
tools used in the diagnosis of the original DVT, the assessment of residual 
thrombus, venous reflux and PTS. Although the inclusion/exclusion criteria were 
designed to minimise detection/measurement error, the potential for error exists 
in the way that the diagnostic tests/measurements are undertaken. This 
includes by whom and at what time point any assessment is made, the patient 
positioning and environment for all assessments, the equipment used and most 
importantly that all aspects of any protocol were standardised to be the same 
for all participants. In studies where high degrees of potential confounding is 
implicit in the nature of the conditions under examination (DVT and PTS), it 
would be important to control for as many potentially confounding factors as 
possible whilst keeping the study as inclusive as possible to ensure that it is as 
representative of the wider population with the conditions as possible.  
 
Finally, the examination of the independent variables examined for their 
potential association with the development of PTS in the individual studies 
included in the review and the findings regarding those associations informed a 
list of possible predictors of PTS that warranted further consideration. 
 
2.6.3 Strengths and limitations of the review  
Publication bias 
It is acknowledged that systematic reviews affected by publication bias are 
more likely to overestimate positive results (Goodchild van Hilten, 2015) and 
this was noted in the way that many of the included studies did not report the 
findings of all negative associations between independent variables and the 
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development of PTS. Statistically significant positive research results are more 
likely to be published and published quickly (time lag bias), more likely to be 
published in English (language bias), more likely to be published more than 
once (multiple publication bias) and are more likely to be cited by others 
(citation bias) (Alderson and Green, 2002). Using MeSH terms in the electronic 
searches ensured that publications in any language were included as foreign 
language titles are translated into English and the original title is retained below 
the translation. Including papers published in any language, using translation 
facilities and examining non-published material in the grey literature and 
through contact with key experts aimed to reduce publication bias. 
 
SLR design and reviewers 
It must also be considered that the design of the review is potentially affected by 
the subjectivity of the review team and any advisory input into the review due to 
the knowledge and experience of both the reviewers and advisors (Petticrew 
and Roberts, 2006). Both reviewers had good knowledge in the research 
subject and a solid understanding of the fundamentals of a robust research 
study. The reviewers needed knowledge in the specific field to assess the 
quality of the diagnostic and follow up assessment methods, the level of 
blinding achievable and to be able to correctly identify the important 
confounding factors. A good grasp of recruitment procedures and potential bias 
in research generally was also important. The two reviewers were both 
experienced vascular scientists who regularly assess people for both DVT and 
CVI and are therefore very familiar with the assessment methods in many of the 
studies. Whilst this is an obvious strength in terms of conducting the quality 
assessment it must also be considered that this may also have biased their 
critical appraisal and data extraction. Both reviewers may also have inherent 
preconceived beliefs regarding potential risk factors for PTS from their clinical 
experience which may have affected their ability to be objective in the quality 
assessment. 
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Choice of appraisal tool 
There are potentially issues associated with the selection of the appraisal tool 
used to determine study quality. At first glance, the CASP tool appears to be a 
relatively straightforward document, with twelve individual questions that inform 
the answers to three broad questions: ‘are the results of the study valid?’, ‘what 
are the results?’, ‘will the results help locally?’ Each of the questions has hint 
questions to help the user answer ‘yes’, ‘can’t tell’ or ‘no’.   
 
Despite the simple pro-forma of the tool, the multi-faceted nature of the 
questions meant that several factors had to be considered to answer each 
screening question. For example, question two asks whether the cohort was 
recruited in an acceptable way. The cohort may have been recruited in an 
acceptable way, such as consecutive sampling over a defined period; however 
the study may have had limited detail on the inclusion/exclusion criteria which 
threatened the study sample. Similarly, sample size may have been small and 
despite acceptable recruitment, may have produced a major limitation to the 
study. Question nine asks if the results are believable. The reviewer may have 
judged that appropriate statistical methods were used and that confounding was 
appropriately dealt with; however the study may have been fundamentally 
flawed by the recruitment process.  The results may not have been fully 
believed; not due to the statistical methods but to do with the recruitment and 
study design. This highlights the importance of a robust review process in which 
an overview question of this nature is not answered solely on the basis of the 
data analysis.  
 
The two reviewers took the approach of answering the questions ‘on balance’ 
with a weighing up of the information to decide a ‘yes’, ‘no’ or ‘not clear’.  Critical 
appraisal has an element of subjectivity and relies on a thorough and dedicated 
approach to each question to arrive at an ‘on balance’ answer.  This becomes 
particularly challenging when the critical appraisal involves an independent 
second reviewer, as ultimately both reviewers have to agree on all 12 questions 
for each paper. The element of subjectivity increases the chances of the 
reviewers not arriving at the same conclusion. 
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2.7 Conclusion 
The review met the aim of conducting a high quality SLR through the use of 
robust systematic search methods aimed at reducing bias that were 
documented and reported at each stage and conducted by two reviewers 
experienced in carrying out both research and clinical practice in the subject 
area. This process achieved its objective of producing a detailed overview of the 
existing evidence base in this field from which to build on. 
 
The review was successful in confirming that the range of variables considered 
by the researcher to be potentially important in the development of PTS was 
consistent with those that had previously been examined in the existing 
evidence. Any potentially important variables that had been previously 
overlooked in the research undertaken to date would be addressed in the peer 
group opinion study which is described in the following chapter, by asking peers 
to specifically comment on any additional variables they considered potentially 
important. 
 
The review confirmed that the risk factors identified in the existing literature 
were inconsistent and that other than recurrent ipsilateral DVT, there was no 
complete consensus regarding the importance of the DVT extent, residual 
thrombus and venous incompetence, either in combination or isolation, in the 
development of PTS. The review was also successful in highlighting that, of all 
of the variables examined in each of the studies, there were also no specific 
variables that were consistently identified as having no association with PTS 
and could therefore be ruled out of inclusion in subsequent research.  
 
The methodological quality of the individual studies was successfully critically 
evaluated using both a recognised tool and the interpretation of the two 
reviewers. This identified that, for most of the included studies, limitations in 
methodological quality were likely due to inadequate reporting of methods and 
emphasised the need for detail and transparency when disseminating research 
findings.  
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Identifying key studies not included in the SLR met the aims of providing both a 
short overview of the potentially important evidence from these key studies that, 
due to their design, were not included in the SLR and the critical appraisal of the 
design and methodology of some of these studies further informed the 
prospective observational study. 
 
In summary, the findings from the existing evidence to date not only confirmed 
that there was justification for a well-designed prospective observational cohort 
study in terms of gaps in the existing knowledge and conflicting results between 
studies but also that careful examination of the quality issues in the studies was 
necessary to inform the methodology of this observational study. The 
methodological heterogeneity of the studies included in the review provided a 
platform for informing and improving design of future research in this field. The 
review provided useful information about how primary research had been 
undertaken in this field to date, how different approaches and methods were fit 
for purpose and the implications for developing future research agendas. To 
supplement this information and to ensure that the wealth of expertise from the 
professional perspective of specialists in diagnostic ultrasound for DVT and who 
see many cases of DVT and PTS in their clinical practice was accessed and 
could also inform the prospective observational study,  a peer group opinion 
study was undertaken and is documented in the following chapter. 
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CHAPTER 3: PEER GROUP OPINION 
 
This chapter presents information regarding the design, methodology and 
results of a peer group opinion study aimed at providing knowledge of factors 
that the researcher’s peer group weighed up to be significant factors in the 
development of PTS. The results of this peer group opinion study were used in 
combination with the information gained from the SLR to determine the set of 
variables that warranted further investigation. 
  
3.1 Introduction and aim of the opinion study 
Vascular Scientists are routinely involved in the diagnosis of DVT in their clinical 
practice and see a significant number of patients who re-present for 
assessment following a DVT for either query recurrent DVT or CVI. They 
therefore have considerable experience of assessing patients with symptoms of 
PTS and are likely to have a clinically informed opinion of the factors associated 
with its’ development. It was considered important to explore these opinions to 
inform the data to be collected in future observational studies.   
 
3.2 Opinion study population 
The peer group opinion questionnaire was e-mailed to the membership of the 
SVT on 5th November 2013. The SVT was formed in 1992 to advance non-
invasive vascular diagnostic services by promoting training and research in 
vascular technology and to disseminate the results of such research for the 
benefit of the public. The main goal of the society is to promote education, 
training and research in the field of vascular science. In doing this, the society 
developed national standardised professional training and an accreditation 
scheme that grants Accredited Vascular Scientist (status to those members who 
successfully complete theory and practical examinations. The aim of the SVT 
accreditation process is to ensure the achievement and maintenance of high 
standards of diagnostic vascular ultrasound investigations for the benefit and 
safety of patients. 
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At the time of undertaking the opinion study, accreditation as an AVS was the 
primary professional qualification route available to Vascular Scientists in the 
UK. At this time point, the Modernising Scientific Careers Scientist Training 
Program, leading to registration as a Clinical Scientist on completion, had not 
yet produced its first cohort of scientists. Accreditation as an AVS is still 
currently recommended for all individuals practising vascular ultrasound in the 
UK or Ireland. The accreditation process is aimed at the advanced scientist with 
a minimum of three years full-time postgraduate experience (or part-time 
equivalent) in a range of key diagnostic vascular investigations. The 
accreditation certification provides employers and patients with the confidence 
that the individual has reached, and continues to maintain, the national 
standards set for vascular ultrasound investigations. In bringing together all 
those engaged in providing vascular laboratory services, the SVT now functions 
as the national scientific and educational society for Vascular Scientists working 
in Great Britain and Ireland.  
 
The membership of the SVT is made up of three categories of membership: 
ordinary members, associate members and special interest group members 
who all were sent the questionnaire. Ordinary members are people whose 
primary skill is non-invasive vascular investigations using ultrasound and this 
was the target audience for the questionnaire. Their practice is primarily in a 
clinical setting but may also include members in an educational role which is 
why they were asked to specify if they were currently practicing clinical vascular 
ultrasound. Associate members are people who are interested in the field of 
vascular ultrasound but who are not directly involved in non-invasive vascular 
investigations. Special interest group members are people working within a 
specific area of vascular ultrasound such as those working within the National 
Abdominal Aortic Aneurysm Screening Programme, or Vascular Specialist 
Nurses performing venous access fistulae scanning. At the time the study was 
carried out, the membership consisted of approximately 400 members of which 
approximately 180 held the status AVS. 
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3.3 Method of data collection 
An e-mail explaining the project (Appendix A2.3) and with an attached 
questionnaire was sent to the entire membership via the society’s secretary. 
The questionnaire took the form of a list of potentially important factors in the 
development of PTS which had been identified in the literature review described 
in Chapter 2. The list of potentially important factors is detailed in Table 3.1.  
 
Table 3.1 List of variables included in the peer group opinion study.  
Potentially important factors in the 
development of PTS 
Not 
related 
Possibly 
related 
Related 
Related & 
very 
important 
Don’t 
Know 
Age      
Sex      
BMI      
Previous ipsilateral DVT      
Previous contralateral DVT      
D-dimer at presentation      
Extent of original DVT      
Iliac involvement in original DVT      
Residual thrombus      
Presence of deep venous reflux      
Combination of residual obstruction and reflux      
Pre-existing perforator incompetence      
Pre-existing superficial venous reflux      
Thrombophilic status      
Physical activity levels      
Inflammatory markers      
Venous outflow resistance      
Original DVT during pregnancy      
Calf muscle pump function      
Bilateral DVT at presentation      
Type of anticoagulation treatment      
Insufficient quality of anticoagulation      
Poor compliance with compression hosiery      
Original DVT provoked or unprovoked      
Location of original DVT      
Malignancy      
Transient v permanent risk factors      
Peak reflux velocity      
Reflux duration      
Smoking      
Diabetes      
Hypertension      
Congestive heart failure      
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Participants were asked to give their opinion using a Likert scale as to whether 
they considered the potential variable for examination to be not related, possibly 
related, related, related and very important or if they were unsure. They were 
also given space to add any variables that were not on the list that they 
considered being important. If additional variables were given, respondents 
were asked to rate them as being either possibly related, related or related and 
very important. The information sheet and questionnaire can be found in 
Appendices A2.4 and A2.5 respectively. 
 
The name and contact details of the researcher were provided so that the 
participants had the choice of replying by e-mail, or, by post or fax if they 
wished to remain anonymous. The deadline for returning the questionnaires 
was 27th November 2013 as the results of the SLR, detailed in the previous 
chapter, were to be presented at the Annual Scientific Meeting of the SVT on 
28th November 2013. It was considered good practice to complete the peer 
group opinion study prior to this to avoid any influence of opinion from the 
content of the presentation.  
 
Data were collected and retained in accordance with the Data Protection Act 
1998. Respondents were not asked to provide their name or contact details but 
were asked to provide information regarding their AVS status (AVS Yes or No), 
their length of practice and whether they are currently in clinical practice (Yes or 
No). The questionnaire itself did not ask for the respondent’s name or contact 
details but if sent by return e-mail then the e-mail address was known to the 
researcher. All questionnaires received electronically were detached from the e-
mail message and stored anonymously and electronically on an NHS Trust 
server behind a secure password-protected firewall. The e-mail containing the 
respondent’s contact information was then deleted from the researcher’s 
mailbox.  
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3.4 Research Governance & Ethical Approval 
Due to the nature of the study no safety issues were expected beyond those 
associated with sitting at a desk for a short period of time to complete the 
electronic questionnaire. A formal risk assessment was however undertaken as 
part of the University of the West of England (UWE) Faculty of Health and 
Applied Sciences research ethics application for ethical approval (Appendix 
A2.2). Participants did not remain in the study beyond completing the 
questionnaire; however, if they wished for their data to be removed at any point 
then they were able to request this by contacting the researcher to inform them 
as explained in the information sheet. 
 
The research did not require Local Research Ethics Committee (LREC) 
approval or Trust Research and Development approval as the participants were 
not recruited via the NHS. Ethical approval was sought from the Faculty 
Research Ethics Committee of the University of the West of England (FREC) 
(Appendix A2.1). The study was conducted in accordance with the Research 
Governance Framework for Health and Social Care and Good Clinical Practice 
(Department of Health, 2005). The researcher had undertaken the relevant 
Good Clinical Practice (GCP) training in order to ensure compliance.  
 
The research did not present any substantive ethical issues and participants 
could choose to remain anonymous if they desired.  Where participants 
returned their responses by email the information was immediately anonymised 
so that their responses could not be attributed to them personally.  The study 
did not include minors or any participants that were considered to be vulnerable. 
The research participants did not receive any personal payment or any other 
benefits or incentives for taking part in this research. There were no conflicts of 
interest to report.  
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3.5 Data Handling & Record Keeping 
The data from the returned questionnaires was extracted and entered into an 
Excel spreadsheet for data handling.  It was not possible to identify participants 
from this information. The data generated by the study were analysed by the 
author using the same NHS computer on which the data were stored. All data 
were stored in a Microsoft Excel spreadsheet which was password protected 
and placed on a personal computer that was also password protected and 
protected by a firewall.  All fields in the spread sheet were clearly labelled and 
logical categorisation was used. Measures were taken to ensure that all data 
were entered in a consistent manner and data entry was undertaken by the 
single researcher to minimise errors. Limits on allowable data were incorporated 
in the spreadsheet to minimise data entry errors. The data were saved regularly 
and backed up. All analysis and data sorting was undertaken on a separate 
copy of the spread sheet so that if mistakes were made it was possible to return 
to the original unaltered copy of the data. 
 
Study documents (paper and electronic) were retained in a secure location during 
the study. All source documents will be retained for a period of five years 
following the end of the research study. The data were analysed using 
descriptive statistics to identify a rank order of the most important variables 
identified 
 
3.6 Results 
Completed questionnaires were received from 52 respondents, 38 of whom 
were AVS and 14 of whom did not hold AVS status.  All 14 members who did 
not hold AVS status were in current clinical practice with a length of service 
ranging from 12 months to 7 years. Responses were also received from several 
SVT members practising outside of the UK and Ireland: Australia (1), New 
Zealand (1) and Saudi Arabia (1). The majority of AVS respondents had been 
accredited for between five and 20 years (Figure 3.1).  
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Figure 3.1 Graph of the number of participants by accreditation duration 
category (n = 52 respondents). 
 
 
An overview of the combined results obtained from the 52 respondents for each 
of the individual variables proposed in the questionnaire is presented in Table 
3.2 and is presented graphically in Appendix A2.6). Nineteen of the 33 variables 
proposed in the questionnaire were identified as being “related” or “related and 
very important” by the largest percentage of the respondents. Twelve further 
potential risk factors were considered possibly related and only sex and 
diabetes mellitus were considered unrelated to the development of PTS by the 
largest percentage of the respondents.  
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Table 3.2 Combined number of responses in each category obtained from the 
52 respondents for each of the individual variables proposed in the 
questionnaire. 
 
Potentially important 
factors in the 
development of PTS 
Not 
related 
Possibly 
related 
Related 
Related & 
very 
important 
Don't 
know 
Total 
Age 10 22 15 3 2 52 
Sex 31 13 6 1 1 52 
BMI  0 16 25 11  0 52 
Previous ipsilateral DVT  0 4 13 35  0 52 
Previous contralateral DVT 14 19 9 9 1 52 
D-dimer at presentation 14 16 12 3 7 52 
Extent of original DVT  0 1 12 38 1 52 
Iliac involvement of original 
DVT 
 0 8 19 22 3 52 
Residual thrombus 0  2 21 29  0 52 
Presence of deep venous 
reflux 
 0 4 13 35  0 52 
Combination of residual 
obstruction and reflux 
 0 1 14 37  0 52 
Pre-existing perforator 
incompetence 
8 16 16 8 4 52 
Pre-existing superficial 
venous reflux 
7 16 17 10 2 52 
Thrombophilic status 1 11 17 15 8 52 
Physical activity levels 2 24 20 5 1 52 
Inflammatory markers 9 18 9 6 10 52 
Venous outflow resistance 1 18 17 10 6 52 
Original DVT during 
pregnancy 
14 17 14 2 5 52 
Calf muscle pump function 2 13 23 13 1 52 
Bilateral DVT at 
presentation 
8 13 14 12 5 52 
Type of anticoagulation 
treatment 
5 24 12 8 3 52 
Insufficient quality of 
anticoagulation 
0  12 18 21 1 52 
Poor compliance with 
compression hosiery 
1 5 27 18 1 52 
Original DVT provoked or 
unprovoked 
7 17 10 9 9 52 
Location of original DVT 0  5 24 23  0 52 
Malignancy 7 13 15 12 5 52 
Transient versus 
permanent risk factors 
3 14 20 8 7 52 
Peak reflux velocity 11 15 16 3 7 52 
Reflux duration  0 13 26 10 3 52 
Smoking 15 21 12 0  4 52 
Diabetes 19 16 8 0 9 52 
Hypertension 17 18 6 1 10 52 
Congestive heart failure 3 29 11 4 5 52 
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Twelve factors not proposed in the opinion questionnaire were identified by 
respondents as possibly having or having a relationship with PTS as presented 
in Table 3.3. 
 
 
Table 3.3 Additional factors cited by respondents but not listed in the 
questionnaire and the number of respondents who cited them as being 
potentially associated with the development of PTS. 
 
Additional factors identified by 
respondents as potentially associated 
with the development of PTS 
Importance Rating 
Possibly 
related 
Related 
Related & 
very 
important 
Combination of deep & superficial reflux 0 0 1 
Previous venous ulcer 0 0 1 
Intravenous drug use 1 0 0 
Previous ankle injury or fracture 0 1 0 
Rheumatoid arthritis 0 1 0 
Previous pulmonary embolism 1 0 0 
Presence of arterial disease 0 1 0 
Race/ethnicity 0 1 0 
Family history of thrombosis 2 1 0 
Duration of symptoms prior to diagnosis 0 0 1 
Occupation 1 1 0 
Previous intervention for venous disease 0 1 0 
 
 
When the variables were ranked in order of importance as considered by the 
largest percentage of respondents for each variable (Table 3.4), respondents 
considered seven of the variables to be related to the development of PTS and 
very important and a further 11 as related.  
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Table 3.4 Potentially important factors in the development of PTS ranked in 
order of importance as considered by the largest percentage of respondents for 
each variable. 
 
Potentially important factors in the development of 
PTS 
Category with the largest 
% of the respondents 
% 
Extent of original DVT Related & very important 73 
Combination of residual obstruction and reflux Related & very important 71 
Previous ipsilateral DVT Related & very important 67 
Presence of deep venous reflux Related & very important 67 
Residual thrombus Related & very important 56 
Iliac involvement of original DVT Related & very important 42 
Insufficient quality of anticoagulation Related & very important 40 
Poor compliance with compression hosiery Related 52 
Reflux duration Related 50 
BMI Related 48 
Location of original DVT Related 46 
Calf muscle pump function Related 44 
Transient versus permanent risk factors  Related 38 
Pre-existing superficial venous reflux Related 33 
Thrombophilic status Related 33 
Peak reflux velocity Related 31 
Malignancy Related 29 
Bilateral DVT at presentation Related 27 
Pre-existing perforator incompetence 
Equal split related/possibly 
related 
31 
Congestive heart failure Possibly related 56 
Physical activity levels Possibly related 46 
Type of anticoagulation treatment Possibly related 46 
Age Possibly related 42 
Smoking Possibly related 40 
Previous contralateral DVT Possibly related 37 
Inflammatory markers Possibly related 35 
Venous outflow resistance Possibly related 35 
Hypertension Possibly related 35 
Original DVT during pregnancy Possibly related 33 
Original DVT provoked or unprovoked Possibly related 33 
D-dimer at presentation Possibly related 31 
Sex Not related 60 
Diabetes Not related 37 
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3.7 Discussion 
3.7.1 How the opinion study informed the design of the prospective 
cohort study  
The results of the opinion study reflected the findings from the SLR, that those 
potentially important factors to study in relation to the development of PTS 
related to both the extent of the index DVT, how it responds to treatment in 
terms of thrombus resolution and venous valvular function and various factors 
present at baseline. This affirmed the suitability of a well-designed prospective 
observational study using DUS to evaluate changes in thrombus burden and 
measure changes in venous valve function over time to investigate the role of 
these variables in the development of PTS. 
 
Recording and measuring the majority of the variables that were rated as 
“possibly related”, “related” or “related and very important” could easily be 
incorporated into the design of a prospective observational study. Several of the 
factors determined by a significant percentage of respondents to be “possibly 
related”, “related”, and “related and very important” to the development of PTS 
would however required careful consideration regarding their inclusion as 
variables for examination in an observational study due to the challenges of 
collecting accurate data and economic implications.  
 
Potentially, the most important of these variables for consideration was that of 
previous ipsilateral DVT. From the researcher’s experience in clinical practice, 
this group was likely to form a not insignificant proportion of the sample 
available for screening. As previously discussed in Section 1.5.3 however, the 
challenges of differentiating between acute and chronic thrombus was the main 
issue surrounding the possible inclusion of this group.  
 
Malignancy was classified as related to the development of PTS and DVT 
during pregnancy was cited as possibly related by approximately a third of 
respondents. Intra-venous drug use was also cited as one of the additional risk 
factors that had not been included in the list of variable sent to participants. 
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These are groups of potential participants that are often challenging to include 
in research and were indeed absent in the studies included in the SLR. Given 
the strong association that exists between cancer and thrombosis, those with 
active malignancy were likely form a large group. Again, reasonable 
consideration was therefore given whether to include these groups in the 
observational study.  
 
D-dimer at presentation and the presence of various inflammatory markers were 
also considered to be possibly related by a significant percentage of 
respondents however this potential association was not evidenced in the 
studies included in the SLR. Including these variables would incur significant 
laboratory costs that had not been accounted for in the research grant which 
had been secured ahead of undertaking the consensus study. The inclusion of 
laboratory tests would also alter the direction of the research and significantly 
increase the scope of the study. Following careful consideration it was felt this 
would put it beyond the remit of a manageable postgraduate research study by 
a lone investigator. 
 
3.7.2 Strengths and limitations of the study  
One of the key strengths of the opinion survey was that it enabled data to be 
gathered from a wider geographic area than would have been possible using 
another means of gathering similar data such as a focus group. Reponses were 
received from throughout the United Kingdom and even some from overseas.  It 
was possible to deliver the survey to a large number of people in the target 
group via e-mail making it a convenient and low cost way of reaching its target 
audience rather than distributing the survey at a conference for example which 
would have limited the respondents to those who were able to attend. This 
made the results more generalizable to the group from whom opinion was 
sought.  
 
As shown in Figure 3.1, responses were received from participants with a range 
of experience and this can be considered the most appropriate method to use in 
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order to gain a representative picture of the opinions of a large group. This was 
also a time efficient way to collect the data which was required to be completed 
ahead of the presentation of the results of the SLR at the Society’s annual 
scientific meeting. 
 
The design of the survey provided all participants with a standardised stimulus 
which resulted in reliable data from which any researcher bias was mostly 
eliminated. Some bias remained in that the list of potentially relevant variables 
had been selected by the researcher but this was based on information gained 
from the SLR rather than researcher opinion. Participants were given only four 
categories on the Likert scale to avoid the overuse of neutral midline responses. 
In addition, the study design allowed for the proposal of variables that had not 
been included in order to capture any potentially important novel suggestions. 
The data can be considered consistent and precise due to the simple nature of 
the survey in which the same question, in the same format, was posed to every 
participant and was not open to interpretation. The data obtained were also 
quick and easy to analyse.  
 
A key limitation of the survey was the low number of responses. The survey 
relied upon the willingness of respondents to take the time to complete the 
survey which was of no direct benefit to them and the low response numbers 
may indicate a lack of time amongst the clinical profession to engage with such 
activity. It must also be considered that this is potentially representative of a 
lack of interest and evidence of a professional group where many members still 
disassociate themselves from research activity. As the survey was 
communicated by e-mail, its’ success was also partly dependent on members of 
the target audience having provided correct and current e-mail addresses. 
Whilst the design of the survey made it reliable and reproducible, the 
disadvantage of this was that it made it inflexible compared to a focus group for 
example. A more flexible design achieved through conducting in-depth 
interviews or holding a focus group could have captured more complex opinions 
but this was considered unnecessary to meet the aims of the study.  
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3.8 Conclusion 
The peer group opinion study met the aim of providing knowledge of the factors 
that the researcher’s peer group weighed to be significant in the development of 
PTS and provided key information in justifying and determining the variables for 
which data should be collected in a future observational study.  
 
The results of the opinion study supported the researcher’s belief and the 
existing evidence that important factors to study in relation to the development 
of PTS related to the location and extent of the original DVT, its’ response to 
treatment in terms of resolution and the residual venous function. The results 
also confirmed the importance of examining the relationship between the 
development of PTS and various demographic and lifestyle data from the 
proposed cohort. The data collection methods for the prospective observational 
study were subsequently developed to incorporate the information gained from 
this peer group opinion study and the SLR. 
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CHAPTER 4: PROSPECTIVE COHORT STUDY 
METHODOLOGY 
  
This chapter outlines the research and study methods, patient recruitment, 
consent process, data collection techniques, research governance and data 
analysis methods for the prospective observational study that was designed 
following information gained from the literature review and professional opinion 
study reported in Chapters 2 and 3 respectively. The study protocol was 
published as an open access paper in BMC Haematology in September 2016 
and a copy of the publication can be found in Appendix A3.11. 
 
4.1 Study design overview 
This single centre study was a prospective observational study using DUS to 
examine changes in thrombus evolution and resolution in patients with a DVT 
over a two year period with the aim of identifying the level of variation in 
response to oral anticoagulation treatment including DOACs, to provide more 
precise and quantitative disease characterisation and examine possible 
associations and identify any possible causative relationships between those 
independent variables for which data were collected and the four key dependent 
variables of: 
 
 Resolution of the index DVT within 24 months 
 DVT recurrence within 24 months 
 The development of new venous incompetence within 24 months 
 The development of PTS within 24 months.  
 
Recruitment to the study took place at UHBristol, U.K. between January 2014 
and January 2016. The primary endpoints of the study were DVT resolution, 
DVT recurrence and the development of PTS. 
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The study design was that of a quantitative analysis which provided quantifiable 
data. This type of study has the advantage of minimising bias and is considered 
more robust than a qualitative design (Brophy et al, 2008). The nature of the 
research question indicated a fixed design should be used (Robson, 2002). The 
research design incorporated aspects of a methodological study in which it was 
important to ensure that the conditions under which the measurements were 
taken were identical, the equipment was identical and the same protocol was 
followed on each occasion. Each subject had the same number of observations 
(Peat, 2002) and the data collection was structured and taken from consecutive 
samples using a recording instrument that was standardised for all participants 
(Corbetta, 2003).  
 
4.2 Study methods  
4.2.1 Study sample  
This was a single centre study on patients referred to the rapid access 
Thrombosis Clinic at UHBristol for suspected DVT and subsequently diagnosed 
with a DVT on ultrasound. Patients are referred to the Thrombosis Clinic at 
UHBristol from both primary care and from within the hospital Trust. The clinical 
population from which the patients were to be recruited mainly comprised 
outpatients but included patients diagnosed with a DVT as an inpatient 
providing they met the inclusion criteria.  
 
4.2.2 Clinical Diagnosis of DVT 
Complete diagnostic ultrasound assessment of the proximal and distal lower 
limb veins using a combination of colour and spectral Doppler and compression 
ultrasound was undertaken on initial presentation using an Antares Sonoline 
ultrasound machine (Siemens Healthcare GmbH, Germany). This was 
performed as part of the standard clinical care on the DVT diagnostic pathway.  
 
The diagnostic ultrasound was undertaken by Clinical Vascular Scientists (CVS) 
from the Vascular Science Unit, UHBristol who were all trained locally under the 
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standards of the National School of Healthcare Science NHS Scientist Training 
Program. The unit performs between 2000-2400 diagnostic ultrasound 
assessments for DVT annually and has a detection rate of 20-24%. Each 
scientist is required to reach a level of competency that is measured and 
assessed locally against the standards of the national training program (NHS 
Scientist Training Program and professional body (SVT). Inter-operator quality 
assurance processes are routinely undertaken as part of this process and this is 
discussed further in Chapter 11, Section 11.6.2. The diagnosis of DVT was 
made where partial (Figure 4.1) or occlusive thrombus (Figure 4.2) was present 
in any of the proximal or distal deep veins of the lower limb as diagnosed by 
either direct ultrasonic visualisation of intra-luminal thrombus, lack of complete 
compressibility (Figure 4.3) or absence of flow following distal compression. 
 
 
Figure 4.1 Split screen B-mode ultrasound image showing non-occlusive 
thrombus in the common femoral vein. Left hand image without compression, 
right hand image with compression. Right hand image demonstrates partial 
incompressibility of the vein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Common femoral vein 
Without compression With compression 
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Figure 4.2 B-mode ultrasound image showing occlusive thrombus in the 
common femoral vein demonstrated as complete incompressibility of the vein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 B-mode ultrasound image showing normal full compressibility of the 
vein indicating the absence of any thrombus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Common femoral vein 
With compression 
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4.2.3 Inclusion and exclusion criteria 
The study was undertaken on symptomatic adult patients aged between 18 and 
85 years old that had been diagnosed as having a first episode of DVT in that 
limb. This was defined as a first episode diagnosed at the study centre and 
verified from hospital records. Potential participants were also asked to confirm 
that they did not recall any other previous diagnosis of DVT from another centre 
and/or that they recalled any period when they may have had symptoms of a 
DVT episode for which they did not seek medical attention. The inclusion and 
exclusion criteria for the study are listed in Table 4.1.  
 
Table 4.1 Study inclusion and exclusion criteria. 
 
Inclusion criteria Exclusion criteria 
First episode of ipsilateral DVT confirmed on 
ultrasound 
Previous ipsilateral DVT 
Age 18-85 years Active Cancer 
 Immobility 
 Pregnancy 
 Intra-venous drug use 
 Age <18 years 
 Age >85 years 
 Unable to consent 
 
 
Patients with mobility issues that prevented them returning for follow-up 
appointments without the use of hospital transport were excluded due to the 
additional burden this would place on the ambulance service. In addition, those 
that were unable to lie down or unable to transfer to a couch for the ultrasound 
scan were excluded as visualisation is greatly reduced if the patient cannot lie 
supine. This results in poor quality ultrasound images and hence limited 
confidence in the result. Patients that had previously been diagnosed with an 
ipsilateral DVT were also excluded due to the challenges of distinguishing 
between acute and chronic thrombus and results in the extent of the resolution 
of their previous DVT being unknown as previously discussed in Section 1.5.3. 
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Much consideration was given to whether to include those patients with a 
previous ipsilateral DVT. From the researcher’s experience in clinical practice, 
this group was likely to form a not insignificant proportion of the sample 
available for screening. Again, as previously discussed however, the challenges 
of differentiating between acute and chronic thrombus was the main issue 
surrounding the possible inclusion of this group. There is currently no 
recognised, standardised practice or protocol for determining between acute 
and chronic thrombus with any form of medical imaging including ultrasound. 
Many ultrasound professionals consider non-acute thrombus to be more 
echogenic (appearing white in colour) on a black and white ultrasound image, 
however, there is no consensus in ageing thrombus and the researcher’s 
experience from clinical practice is that there is a lack of certainty and precision 
in determining if thrombus is non-acute with many influencing variables.  
 
It was felt that the potential inclusion of non-acute or chronic DVT cases would 
not only introduce an element of uncertainty in the nature of any residual 
thrombus but would also introduce many potential confounding factors, the 
extent of which could not be completely known. As previously discussed in the 
SLR, capturing information from the starting point of the condition is of great 
importance in an observational study of this nature. Not knowing with any 
degree of certainty if the DVT was acute or non-acute could significantly limit 
the reliability of findings. For these reasons it was decided that it was 
appropriate to limit the observational study to those participants for whom we 
could be reasonably confident this was their first episode of DVT in that leg.  
 
As previously reported in Section 3.7, malignancy, DVT during pregnancy and 
intravenous drug use were potentially important variables to examine for their 
relationship with outcomes after DVT. Reasonable consideration was therefore 
given whether to include these groups in the observational study. It was decided 
to exclude both patients that were pregnant and those with active cancer due to 
the additional burden that participation would place on these groups that are 
already undergoing multiple medical visits. Patients with active cancer were 
also excluded on consideration of possible drug interactions from their cancer 
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treatment and the effect of hypercoagulability associated with malignancy which 
could both potentially have an unquantifiable effect on how their DVT 
responded to anticoagulation treatment.  
 
Intra-venous drug users were also likely to form a large group of potential 
participants and again careful consideration was given whether to include this 
group. Due to the very specific nature of the pathology of the DVT in this group 
in which the DVT was most likely induced through direct vein injury resulting 
from needle use, it was determined to also exclude this group. In addition, it 
was recognised that there may be issues in retaining this patient group in the 
study follow-up programme as many are of transient abode and not easily 
contactable to arrange follow-up appointments. Due to the nature of the 
research question and the paramount importance of longitudinal follow-up, all 
reasonable measures needed to be taken to maximise the cohort integrity by 
excluding those at risk of dropping out of the study. It was therefore decided to 
exclude this group to minimise the potential for missing data. Intra-venous drug 
users were identified through clinical history taking and physiological evidence 
of recent needle use. 
 
4.2.3 Participant recruitment 
Records were kept of all patients that were referred to the Thrombosis Clinic 
service for ultrasound assessment for lower limb DVT, including those with a 
negative diagnosis, to provide denominator data for the study. Details were kept 
of the screening process including the reasons for exclusion and reasons for 
refusal to participate if given. The participant recruitment flow is detailed in 
Figure 4.4. Potential suitable participants were first identified by the CVS 
undertaking the diagnostic ultrasound scan who reported the diagnosis of DVT 
to the Thrombosis Clinic nurses as per the usual clinical protocol. On diagnosis 
of a DVT the patient was immediately referred back to the Thrombosis Clinic 
where they received counselling regarding their diagnosis and were informed 
about the anticoagulation treatment options and protocol. At this point 
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participants were informed about the study and offered the option to consider 
participation. 
 
A patient information leaflet (Appendix A3.6) detailing exactly what was required 
from the patient, how long each examination would take and how often they 
were required to attend for follow-up appointments was given to the patient by 
the Thrombosis Specialist Nurse responsible for their care. If interested in 
principle, the patient was asked to provide a contact telephone number and 
convenient contact time. The chief investigator then contacted the potential 
participant by telephone after 24-48 hours to ask them if they wished to 
participate in the study and to answer any questions they may have. If they 
agreed, a first follow-up appointment was scheduled for seven days post 
diagnosis.  
 
For those persons who did not adequately understand verbal explanations or 
written information given in English, an overview of the research project was 
given to any person accompanying them to their diagnostic appointment and 
acting as their interpreter. The patient information leaflet in English was 
provided to the patient as standard so that they had the opportunity to receive 
assistance in reading the information from a friend or family member or whoever 
had accompanied them to their appointment to act as their interpreter. 
 
If a patient required an official interpreter to be present during their appointment 
then this was arranged at the time of scheduling the diagnostic appointment as 
standard clinical practice. The interpreter then assisted with the taking of 
consent and communicating any questions/answers between the patient and 
the examiner (as per standard clinical practice). If an interpreter was available 
for follow-up appointments and a relative or friend was able to translate the 
patient information leaflet for the participant then they were included in the 
study. No funds were available to translate the patient information leaflet or 
provide a hospital interpreter for each visit. A person of any nationality may be 
referred for a DVT ultrasound and therefore the number of languages the 
patient information leaflet would have needed to be translated into could not be 
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known in advance. For these reasons it was not possible to include all patients 
that might not adequately understand verbal explanations or written information 
given in English. 
 
Figure 4.4 Study recruitment process flow diagram. 
 
171 
 
4.2.4 Subject compliance and withdrawal of participants 
Written consent to participate in the study was obtained from each participant at 
the first follow-up visit by the chief investigator in accordance with Good Clinical 
Practice (Department of Health, 2005). Each participant was asked to remain in 
the study for two years post diagnosis. If any participant wished to leave the 
study at any point during the two year follow-up period then they were free to do 
so without explanation and without this affecting their clinical care. Attempts 
were made to establish the reason for withdrawal for learning purposes 
although patients were not required to provide this information if they did not 
wish to do so. For participants that withdrew from the study without having 
completed the full two year follow-up, data were included up to the last follow-up 
at which point they were considered to have withdrawn from the study. 
 
If a patient did not attend a scheduled appointment, attempts were made to 
contact them by telephone to establish the reason for their lack of attendance 
and to confirm their intention to remain in the study. If they wished to continue in 
the study then a new appointment was scheduled for them. If they subsequently 
did not attend the second appointment without prior notice the process was 
repeated and one further appointment was scheduled. If they did not attend the 
third appointment without prior notice, no further appointment was scheduled for 
that follow-up interval. These participants were then re-contacted at the next 
follow-up interval and given one further appointment. If they failed to attend this 
appointment without prior notice then they were not offered a further 
appointment. Patients were therefore withdrawn from the study if they missed 
two full consecutive follow-up intervals. The withdrawal process is detailed in 
Figure 4.5. 
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Figure 4.5 Study withdrawal process flow diagram. 
 
 
 
 
4.2.5 Sample size 
The sample size calculation was based on the work of Peduzzi et al (1996) and 
reported by van Belle (2008) as a guideline for the minimum number of 
participants required to quantify regression coefficients with reasonable 
precision in an epidemiological study of this kind. Based on a calculation where 
p is the smallest of the proportions of negative or positive cases of PTS in the 
population and k the number of covariates, the minimum number of participants 
proposed is N = 10 k / p. Using research evidence that suggested that at least 
20% of patients with symptomatic DVT will develop PTS within two years 
despite `adequate' treatment of DVT (Bernardi and Prandoni, 2000; Saarinen et 
al, 2000; Kahn and Ginsberg, 2002) the minimum number of patients required 
for a 10 covariate model was 500 or for a three covariate model was 150. It was 
not known in advance how many covariates would significantly and 
independently predict PTS, nor their coefficients. However, within the time 
constraints of the study for recruitment and follow-up, a sample size of at least 
150 patients was likely to be highly informative. 
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4.3 Data management 
4.3.1 Data collection 
The following details were recorded at the initial diagnostic scan as per local 
protocol: thrombosis location and extent, if the thrombosis was occlusive or 
partially occlusive and if adherence to the vessel wall was complete or partial. 
Any relevant clinical history was recorded at initial presentation: the nature and 
duration of any clinical symptoms, history of previous ipsilateral and 
contralateral DVT or PE, pregnancy, intra-venous drug use (historic or current), 
details of any current anticoagulation regime, recent surgery, periods of 
immobility and cancer history. All of this information is routinely collected as part 
of the patient’s standard clinical care and was obtained from clinical history 
section of the diagnostic ultrasound report after the patient had consented to 
participate in the study at their first research follow-up visit. Where gaps in this 
information existed, the information was sought through direct questioning at 
the first research follow-up visit. In the event that the patient could not recall the 
information, it was gathered retrospectively from the patient’s medical records 
following their consent. 
 
The presence of any pre-existing medical conditions was recorded at each 
participant’s first follow-up visit after consenting to participate in the study, as 
well as the baseline details for sex, age and BMI. Details were recorded of all 
prescription medications being taken by each participant and of any regular 
non-prescription medications/vitamins/supplements. Any changes in medical 
history, prescription medicines and BMI were recorded at each study visit. 
 
The follow-up schedule comprised six visits at the following intervals: 1 week, 1 
month, 3 months, 6 months, 1 year and 2 years.  
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4.3.2 Ultrasound assessment 
At each visit participants underwent full compression ultrasound assessment of 
the complete lower limb venous tree of the affected leg from the level of the 
inguinal ligament to the ankle (common femoral vein, popliteal vein, peroneal 
veins, posterior tibial veins, anterior tibial veins, soleal veins, gastrocnemius 
veins, greater saphenous vein and short saphenous vein) to identify the 
presence or absence of residual or new DVT or superficial thrombophlebitis in 
each venous segment. The ultrasound assessment was undertaken using a GE 
Logic 9 by the Chief Investigator who is a Health and Care Professions Council 
registered CVS and is professionally accredited by the SVT.  
 
The presence of thrombus was recorded as occlusive or non-occlusive and 
details of recanalisation patterns were recorded in each segment. If the original 
diagnostic scan identified the presence of thrombus in the iliac veins then the 
abdominal venous system was also scanned in full at each follow-up visit. In all 
cases, if flow in the common femoral vein on spectral Doppler ultrasound was 
not phasic with respiration, a full assessment of the external iliac vein, common 
iliac vein and inferior vena cava was undertaken using colour and spectral 
Doppler ultrasound. 
 
4.3.3 Determining the thrombus load 
Fifteen venous segments were assigned a thrombus score at each visit: inferior 
vena cava, common iliac vein, external iliac vein, common femoral vein, 
profunda femoris vein, proximal femoral vein, distal femoral vein, popliteal vein, 
peroneal veins, posterior tibial veins, anterior tibial veins, soleal veins, 
gastrocnemius veins, greater saphenous vein and short saphenous vein. The 
thrombus load score was adapted from the updated reporting standards in 
venous disease from the Ad Hoc Committee on Reporting Standards of the 
Joint Council of the Society for Vascular Surgery and the North American 
Chapter of the International Society for Cardiovascular Surgery (Porter et al, 
1995) and a modified version of Haenan’s clot score as used by van Rij et al 
(2013). 
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Each venous segment was scored as follows: 
0 = patent 
1 = subsegmental, non-occlusive thrombus 
2 = subsegmental, occlusive thrombus 
3 = occlusive thrombus throughout segment 
 
4.3.4 Assessing for venous incompetence 
A DUS assessment for the competency of the deep and superficial veins was 
undertaken by the chief investigator at each research visit. An assessment of 
venous competency is not undertaken as part of the routine clinical diagnostic 
imaging for DVT and was carried out here for research purposes alone. Pulsed 
and colour Doppler was utilised to assess flow characteristics within the veins 
including phasicity, spontaneity and direction of flow. Flow characteristics were 
assessed in a longitudinal scan plane. The patients were examined standing to 
assess the competency of the venous valves against gravity. Manual distal 
compression was applied to the calf to augment the flow and to assess for 
reflux. Venous incompetence was defined as a reflux time >0.5s (Coleridge-
Smith et al, 2006). 
 
4.3.5 Assessment of anti-coagulation regime & compression use 
Details of the anti-coagulation treatment received by each participant in the 
study were collected as it was recognised that there were several different anti-
coagulation therapies available and that variation in anti-coagulation regimes 
may have occurred depending on patient pathway, patient profile, patient choice 
and primary care follow-up. Information regarding the anticoagulation regime 
prescribed and the recommended duration of the treatment was obtained from 
the patients’ discharge summary from their diagnostic visit. The accuracy of this 
information was then verified with the patient verbally at their first research visit 
and details were recorded on the data collection form (Appendix A3.8). 
Adequacy of anticoagulation therapy was monitored through access to the 
participants’ medical records where relevant (vitamin K antagonists where INR 
was monitored) and compliance with taking direct oral anticoagulants was 
assessed by direct questioning at each visit. Participants’ compliance with 
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compression stocking use was also recorded at each visit as ‘no use’, 
‘occasional use’ or ‘routine use all day, every day’. 
 
4.3.6 Dealing with extension/recurrence 
In the first twelve months of follow-up, any participant identified as having a 
recurrent DVT or an existing DVT that had extended at any point was 
immediately reviewed by the rapid access thrombosis clinic whether the patient 
was symptomatic or not. A recurrent DVT was diagnosed as the presence of 
new thrombus either in the ipsilateral or contralateral leg or the presence of new 
thrombus on old thrombus in the same venous section as the original 
thrombosis, all of which were confirmed on DUS. In the 12 to 24 month period, if 
thrombus was identified in an asymptomatic patient in a venous segment that 
had previously been recorded as having no thrombus present yet was not 
consistent in appearance with acute thrombus, this was treated as an incidental 
finding of an asymptomatic recurrence of unknown age. These few cases were 
also reviewed by the thrombosis clinic who sought haematology advice 
regarding the need for further review. The details of all recurrences and patient 
outcomes were recorded. 
 
4.3.7 Assessment for PTS 
At each visit, a detailed clinical assessment was made of the leg in which the 
thrombosis was or had been present and the patients' symptoms, including 
pain, aching, heaviness, itching, cramp and paraesthesia were recorded using 
an interviewer-administered questionnaire. The Villalta Scale (Kahn, 2009) was 
used to quantify the symptoms of the burden of venous disease at the end of 
the two year follow-up period. The presence of oedema, teleangiectasias, 
reticular veins, varicose veins, hyperpigmentation, eczema, 
lipodermatosclerosis and ulceration were recorded.  
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4.3.8 Data handling and record keeping 
Data were collected and retained in accordance with the Data Protection Act 
1998. Anonymity and confidentiality were ensured throughout by anonymising 
patient identity when recording data by allocating each patient to a research ID 
number. Identifiable data such as patient details and the Project ID were stored 
separately to the clinical data collected. Only the Chief Investigator had access 
to participants' personal data during the study.  
 
The data generated by the study were processed and analysed by the Chief 
Investigator using the same NHS computer on which the data were stored. All 
data were stored in Microsoft Excel spreadsheets which were password 
protected and placed on personal computers that were also password protected 
and protected by a firewall.  The two spreadsheets containing identifiable data 
and clinical data were only linked by patient ID numbers so that participants 
could not be identified by persons outside of the study should they access the 
clinical data (Peat, 2002). All fields in the spreadsheet were clearly labelled and 
logical categorisation was used. Measures were taken to ensure that all data 
were entered in a consistent manner and data entry was undertaken by the 
single researcher to minimise errors. Limits on allowable data were incorporated 
in the spreadsheet to minimise data entry errors. The data were saved regularly 
and backed up. All analysis and data sorting were undertaken on a separate 
copy of the spreadsheet so that if mistakes were made it was possible to return 
to the original unaltered copy of the data (Peat, 2002). 
 
Study documents (paper and electronic) were retained in a secure location during 
and after study completion. All source documents will be retained for a period of 
five years following the end of the study. Where study related information was 
documented in the medical records – those records are identified by a ‘Do not 
destroy before dd/mm/yyyy’ label where the date is five years after the last 
patient’s last study clinic visit. 
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4.4 Research management 
4.4.1 Minimising bias 
Efforts were made to minimise follow-up bias by trying to minimise the number 
of people who left the study before the end of their follow-up schedule due to 
resolution of their symptoms (Peat, 2002). Multiple methods were used to 
maximise follow-up rates including regular contact with study participants, 
reminders to attend follow-up appointments, choice for appointment times and 
reimbursement of travel and parking expenses for attending appointments. 
Every effort was made to ensure that all participants were treated in an identical 
way with standardised procedures for data collection (Peat, 2002). 
Measurement bias was minimised by using a standardised method and a 
calibrated ultrasound machine operated by a single accredited vascular scientist 
for all observations and through the use of objective and clinically important 
outcome measurements. No interim analyses were undertaken to avoid 
analysis bias. 
 
4.4.2 Research governance, ethics, R & D approval and monitoring 
Ethical approval for the study was obtained from NRES South West - Central 
Bristol (REC Reference: 13/SW/0075) on 23rd May 2013, the UWE Research 
Ethics Sub-Committee of the School of Health and Life Sciences (Reference: 
HLS/13/05/73) on 13th June 2013 and the Research and Development office at 
UHBristol (SU/2013/4278) on 15th January 2014. Written and dated approvals 
were gained for the study protocol, participant recruitment procedures, written 
consent form and all written information provided to the participants including the 
invitation letter and patient information leaflet. The participant information leaflet 
encouraged the patient to discuss with the Chief Investigator any aspects of the 
study that they did not understand and provided a contact telephone number for 
this purpose. It also highlighted that refusal to participate would not affect any 
aspect of their ongoing medical care. Participant confidentiality was maintained 
at all times during the study and individuals were not identifiable in any reported 
findings. The study was accepted onto the National Institute for Health Research 
(NIHR) portfolio. Copies of all approvals are located in Appendices A3.1-A3.4. 
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The study was conducted in accordance with the Research Governance 
Framework for Health and Social Care and GCP (Department of Health, 2005). 
The chief investigator for the study undertook and maintained the relevant GCP 
training throughout the duration of the research period in order to ensure 
compliance throughout the study. The study was monitored and audited in 
accordance with UHBristol Trust policy. All study related documents were made 
available on request for monitoring and audit by UHBristol and the relevant 
LREC. 
 
4.4.3 Safety assessments 
Due to the nature of this study it was not expected that there would be any safety 
issues beyond those associated with a normal routine clinical assessment for 
DVT as was routinely performed in the Vascular Science Unit (VSU). Therefore 
the standard health and safety considerations that are applied during a clinical 
lower limb venous assessment were implemented during the research data 
collection. Possible adverse events identified included a patient slip, trip or fall 
when entering the examination room or a diabetic event. Any adverse events 
were recorded either in accordance with the standard UHBristol adverse event 
reporting structure or the UHBristol Research Related Adverse Event Reporting 
Policy. The ultrasound machine used in the study was subjected to the standard 
electrical safety testing and Medical Equipment Management Organisation 
(MEMO) testing that is routinely applied to all diagnostic equipment in VSU. The 
room, equipment and environment used for the study were subject to the routine 
quality assurance checks undertaken on a weekly and monthly basis in VSU as 
per local protocol. 
 
4.5 Data analysis 
Descriptive statistics were used to describe the completeness of the dataset in 
terms of initial recruitment, exclusion, participant refusal and losses to follow up. 
Missing data were reported descriptively for all independent and dependent 
variables to support the choice of data analysis technique. Adherence to the 
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follow-up schedule was described to support the quality and completeness of the 
data obtained and descriptive statistics were used to describe the recruited 
cohort in relation to the wider picture of the population from which the participants 
were recruited. All analyses were run using International Business Machines 
Corporation (IBM) Statistical Product and Service Solutions (SPSS) software 
Version 24 (IBM, Armonk, New York, USA). 
 
Outcome data for each of the four key outcomes after DVT that were examined 
during the two year follow-up period were initially analysed using graphical 
methods of analysis to understand the level of spread and where appropriate any 
change over time.   
 
In the case of participants recruited to the study with bilateral DVT, data for both 
limbs were reported in descriptive statistics but for inferential analyses one limb 
was selected at random using the RAND() function in Microsoft Excel. The limb 
DVT pairs were sorted by the size of the random number and the largest 
number in each pairing chosen for the inferential analyses. 
. 
For all inferential analyses, the data for all independent and dependent variables 
collected at baseline and during follow-up were first inspected for their 
distribution. For those variables with continuous data this was done by plotting 
normal Q-Q plots and inspecting them visually. If ambiguous, the Shapiro-Wilk 
test for normality was examined. All continuous data variables were judged to be 
not normally distributed and were subsequently categorised. Categorical data 
were inspected by examining frequencies by category to ensure all categories 
contained an adequate number of cases for any inferential statistical tests.  
 
Independent variables considered to potentially have a causative relationship 
with each of the dependent variables, were first cross tabulated against them and 
inspected for association and potential trends. Odds ratios for dichotomous 
variables were calculated where appropriate to describe the strength of any 
association suggested by the frequency data (Petrie and Sabin, 2009). 
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Significance of the odds ratio was assessed using confidence intervals at 95% 
(Morgan, 2003) and an alpha value of 0.05. 
A chi-square test of independence was then performed to highlight the variables 
with a potentially significant relationship with each dependent variable for 
inclusion in regression modelling. Validity of the chi-square statistic requires that 
20% of the expected frequencies for each cell in the contingency table is 
greater than five; if this was violated the Fisher’s exact probability test was used 
(Pallant, 2007). For the purposes of inclusion of the variables into a regression 
model, a p-value cut off of < 0.25 was used from the results of the chi-square 
analysis (Hosmer and Lemeshow, 2000) to ensure consideration of all 
potentially important independent variables when fitted to a multivariate model 
(Bursac et al, 2008). 
 
For each independent variable, the following null and alternative hypotheses 
were used: 
 
H0    There is no association between the independent variable and the 
dependent variable  
 
H1   There is an association between the independent variable and the 
dependent variable  
 
The second objective was to assess the combined possible effects of the 
independent variables as predictors of each dependent variable.  As all 
dependent (outcome) variables were binary, logistic regression analysis was 
used.  Those variables identified as having a potentially significant relationship 
with the dependent variable from the results of the chi-square analysis (using a 
p-value cut off of <0.25) were entered into the regression models in a 
backwards stepwise manner using simple contrast and with the reference 
category set as the first category in each variable. The entry level for the model 
was set as p = <0.25 and the removal level was set as p <0.10.  
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An odds ratio was calculated from the regression coefficient. Significance tests 
of the odds ratio were produced for the variables under examination to test the 
null hypothesis that the relevant logistic regression coefficient was 0, with an 
alpha value of 0.05. 
 
H0 = The confidence interval around the adjusted odds ratio includes 1, 
indicating a probable random association 
 
H1 = The confidence interval around the adjusted odds ratio excludes 1, 
indicating a probable non-random association  
 
The overall fit of the model was assessed using the Nagelkerke R square to 
give an indication of the amount of variation in the dependent variable explained 
by the model (Pallant, 2007) and the classification plot produced by SPSS was 
examined to give an impression of the overall fit of the model. 
 
The results of the analyses described are presented in the following chapter. 
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CHAPTER 5: RESULTS – DEMOGRAPHIC DATA  
 
This chapter is the first of six results chapters and presents the recruitment and 
retention data for the prospective observational study to provide context 
regarding the cohort from which the analyses of the primary outcomes of DVT 
resolution, recurrence, venous incompetence and the development of PTS were 
undertaken. The chapter will present the recruitment and retention data for the 
study participants, an overview of the completeness of the data obtained and 
the key demographic information of the cohort in relation to the population from 
which it was drawn. 
 
5.1 Recruitment 
Between 29th January 2014 and 4th January 2016 4580 DUS assessments for 
query lower limb DVT were performed on 3642 patients. The flow of patients 
through the study is detailed in Figure 5.1. Of these 1086 assessments (24%) in 
884 patients were positive for lower limb DVT. During the two year recruitment 
period, 884 people were therefore considered for inclusion to the research 
study. Of those, 626 patients (71%) failed to meet the inclusion criteria and 
were excluded from the study. Some participants met more than one of the 
exclusion criteria but the primary reasons for exclusion are detailed in Table 5.1. 
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Figure 5.1 Diagrammatic representation of the flow of patients through the 
study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 Reasons for exclusion from study participation.   
 
Reason for exclusion n % 
Immobility 171 27.3 
Intravenous drug user (IVDU) 157 25.1 
Active Cancer 147 23.5 
Previous ipsilateral DVT 63 10.0 
Non acute DVT 47 7.5 
Unable to give informed consent 24 3.8 
Her Majesty’s Prison (HMP) 8 1.3 
Pregnant 6 1.0 
Risk to lone worker 3 0.5 
Total 626 100.0 
66 
185 
 
 
In total, 258 patients with a first episode of lower limb DVT were approached to 
participate in the study. Of those, 87 (34%) declined participation. All patients 
that declined participation were asked the reason for declining. The reasons for 
declined participation are detailed in Table 5.2. 
 
Table 5.2 Reasons given by potential participants for declined participation. 
 
Reason given for decline n % 
Time commitment 30 34.5 
Did not want to give reason 25 28.7 
Too far to travel 12 13.8 
Did not want to come back to 
hospital 
11 12.6 
Did not feel well enough to come 
back 
8 9.2 
Scan was too painful 1 1.1 
Total 87 100.0 
 
 
One hundred and seventy one patients agreed to take part in the study, three of 
whom had bilateral DVT in which case both legs were monitored in the study. It 
should be noted that, as described in Section 4.5, data for both limbs were 
reported in descriptive statistics (as different limbs may have different 
outcomes) but for all inferential analyses one limb was selected at random. This 
accounts for the variations in sample sizes in different data reports. Table 5.3 
details the characteristics of the sample population from which the study cohort 
was recruited.  
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Table 5.3 Demographic characteristics of the recruited sample and the 
populations from which it was drawn. 
 
  
All scans 
n (%) 
All +ve scans 
n (%) 
Declined n  
(%) 
Recruited n 
(%) 
Total number of patients 3642 884 87 171 
Mean age 60.9 ±19.7 58.6 ±18.8 60.0 ±17.4 55.9 ±16.5 
Age range 15 - 101 20-97 22-85 21-85 
Men 1559 (43) 488 (55) 44 (51) 105 (61) 
Women 2083 (57) 396 (45) 43 (49) 66 (39) 
Outpatients 2773 (76) 670 (76) 87 (100) 171 (100) 
Inpatients 869 (24) 214 (24) 0 (0) 0 (0) 
Bilateral assessments 397 (9) 39 (6) 0 (0) 3 (2) 
Multiple visits  427 (12) 127 (14) N/A N/A 
2 visits 351 103 N/A N/A 
3 visits 52 19 N/A N/A 
4 visits 15 3 N/A N/A 
5 visits 7 1 N/A N/A 
6 visits 1 1 N/A N/A 
7 visits 1 0 N/A N/A 
 
More women presented for assessment for query DVT than men but more men 
tested positive for DVT upon assessment than women. There were no major 
differences in the basic demographics of the target population (all positive 
cases of DVT) and the recruited sample with both groups showing similar mean 
age, age range and sex distribution pattern. A similar number of men and 
women declined to participate in the study indicating that the larger percentage 
of male participants compared to female participants is a result of more men 
testing positive for DVT rather than any sex related reason for research 
engagement. A lower percentage of participants recruited to the study had 
bilateral DVT than the target population however and no inpatients were 
recruited to the study cohort. This reflects the fact that patients with bilateral 
disease and those requiring hospital admission were in generally poorer health 
and for this reason more likely to meet one or more of the exclusion criteria. The 
recruited sample therefore represented a generally healthier population as a 
result of this selection and this is considered in the discussion of the study 
findings. 
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5.2 Retention to the study 
 
5.2.1 Completeness of the data 
The retention rate over the two year follow-up period was 86% (Table 5.4). The 
majority of those lost to follow-up left the study between the final two follow-up 
intervals when the time frame between follow-up intervals was greatest.  
 
Table 5.4 Complete data sets at each follow-up interval by number of 
participants and percentage of cohort. 
 
Complete Data Sets  
(n = 171 participants) n % 
1 week 171 100 
1 month 165 97 
3 months 163 95 
6 months 160 94 
1 year 156 92 
2 years 147 86 
 
All of the 24 participants that did not complete the two full years of follow-up left 
the study permanently as none re-engaged with follow-up having missed an 
earlier appointment. In all cases the time point at which they last participated in 
the study was therefore the time point at which they left the study. Five 
participants were deceased during the follow-up period (three from cardio-
vascular disease related illness and two from cancer diagnosed during the 
study). The remaining participants were either lost to follow-up (10 participants) 
or informed the researcher that they did not wish to continue in the study for 
various reasons (one too unwell, two mental health reasons, six too busy). An 
examination of the baseline data collected for those participants that did not 
complete the full two years of follow up revealed no significant trends in terms of 
age, sex or TLS on diagnosis (Appendix A4.1).  
 
An analysis of missing data was conducted across the data set obtained from 
the recruited cohort. This demonstrated that 147 participants (150 limbs) 
completed the full two years of follow-up and had no gaps in their data set at 
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any of the data points for any variable. Thirty five of the 62 key variables for 
which data were collected had some missing data however overall only 5% of 
the 10,602 individual data values were missing (Appendix A4.2). The missing 
data were examined for the presence of any pattern. Gaps in the data were 
found during follow-up over the course of 24 months with the largest numbers of 
missing data items occurring in those variables for which there was a single 
assessment at the final 24 month follow-up point (Table 5.5). There were no 
missing data in the variables for which data were collected at baseline on entry 
into the study. 
Table 5.5 List of variables containing some missing data over the full 24 months 
of follow-up at 6 time points. 
Variable 
Missing Valid 
N N % 
Thrombus evolution pattern at 24 months 24 14.0% 147 
PTS category 24 14.0% 147 
PTS diagnosis 24 14.0% 147 
Villalta score 24 14.0% 147 
Free from any thrombus at 24 months  24 14.0% 147 
Index DVT resolution at 24 months 24 14.0% 147 
Thrombus load score at 24 months 24 14.0% 147 
Newly developed venous incompetence within 24 months 22 12.9% 149 
Location of new venous incompetence 22 12.9% 149 
Cancer diagnosis during 24 months follow-up 22 12.9% 149 
New phlebitic episode during 24 months follow-up 22 12.9% 149 
DVT recurrence within 24 months 21 12.3% 150 
DVT recurrence symptomatic 21 12.3% 150 
DVT recurrence location leg 21 12.3% 150 
DVT recurrence location site 21 12.3% 150 
Anticoagulation therapy ongoing at time of recurrence 21 12.3% 150 
Index DVT resolved at time of recurrence 21 12.3% 150 
Time of recurrence from index DVT (months) 21 12.3% 150 
Location of venous incompetence 18 10.5% 153 
Venous incompetence 18 10.5% 153 
Resolution at 12 months 15 8.8% 156 
Thrombus load score at 12 months 15 8.8% 156 
Index DVT resolved within 2 years 13 7.6% 158 
Resolution at 6 months 11 6.4% 160 
Thrombus load score at 6 months 11 6.4% 160 
Index DVT resolved on stopping anticoagulation 10 5.8% 161 
Thrombus evolution pattern at 3 months 8 4.7% 163 
Resolution at 3 months 7 4.1% 164 
Thrombus load score at 3 months 7 4.1% 164 
Resolution at 1 month 6 3.5% 165 
Thrombus load score at 1 month 6 3.5% 165 
Anticoagulation duration category 6 3.5% 165 
Stocking use duration category 5 2.9% 166 
Duration consistent stocking use (months) 5 2.9% 166 
Key:  
DVT: deep vein thrombosis 
PTS: post thrombotic syndrome 
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The pattern of missing data indicated that it should be considered to be not 
missing at random. Multiple imputation is generally considered as the most 
appropriate technique for dealing with data that are not missing at random in 
order to minimise its potential to undermine the validity of the results (Lodder, 
2013). Irrespective of the missing data categorisation, however, pairwise 
deletion would not pose a major threat to statistical power, as the overall 
percentage of missing data items was only 5% (Lodder, 2013). Therefore a 
‘pairwise’ deletion method was used to create the final data set on which the 
analyses were performed. This meant that the maximum number of available 
cases for each variable was used in the analyses and accounts for the small 
variation in sample sizes for different analyses reported in the results.   
 
5.2.2 Adherence to follow-up schedule  
An examination was undertaken to determine the proportion of scheduled 
research appointments met within the allowable limits. Overall 962 scheduled 
outpatient follow-up appointments were completed during the 46.5 month data 
collection period covering recruitment and follow-up. Seven hundred and 
seventy (80%) of these took place within the pre-determined acceptable 
timeframes for each follow-up interval as illustrated in Table 5.6. More than 50% 
of the appointments that fell outside of the acceptable window occurred at the 1 
week follow-up interval point where there was less flexibility for scheduling a 
mutually convenient appointment time for the participant and researcher. The 
mean time to follow up for the first appointment was 8 days ±2 days (range 7 to 
19 days).  
 
Table 5.6 Number and percentage of appointments that took place within the 
pre-determined acceptable time limits at each follow-up stage. 
Appointments within 
pre-determined time 
limits  n % 
1 week (± 3 days) 145/171 85 
1 month (± 7 days) 155/165 94 
3 months (± 2 weeks) 159/163 98 
6 months (± 3 weeks) 158/160 99 
1 year (± 1 month) 153/156 98 
2 years (± 2 months) 0/147 100 
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5.3 Cohort characteristics  
The characteristics of the study cohort at recruitment are presented in Table 5.7 
alongside those for the “complete cases” cohort (those who completed two 
years of complete follow-up with no gaps in data).  
 
Table 5.7 Study cohort baseline demographic data (recruited and complete 
cases cohorts). 
Baseline characteristics 
Recruited 
cohort n (%) 
Complete data cohort  
n (%) 
Number of participants 171 147 
Number of limbs 174 150 
Mean Age 56 ± 17 57 ± 16 
Age range 21-85 21-85 
Male sex 105 (61) 90 (61) 
Left limb 102 (59) 90 (61) 
Previous contralateral DVT 10 (6) 7 (5) 
Pre-existing venous incompetence 41 (24) 35 (23) 
Body Mass Index (BMI)    
     Underweight 3 (2) 3 (2) 
     Normal weight 36 (21) 32 (22) 
     Over weight 61 (36) 57 (39) 
     Obese 56 (33) 43 (29) 
     Very obese 15 (9) 12 (8) 
Smoking history    
     Never smoked 79 (46) 71 (48) 
     Previous smoker 61 (36) 53 (36) 
     Active smoker 31 (18) 23 (16) 
Diabetes Mellitus    
     Non-insulin dependent 9 (5) 8 (5) 
     Insulin dependent 4 (2) 3 (2) 
Hypertension 47 (27) 39 (27) 
Congestive heart failure 2 (1) 1 (1) 
Provocation    
     Unprovoked 110 (64) 98 (67) 
     Provoked 61 (36) 49 (33) 
Location of DVT    
     Ilio-femoral 10 (6) 9 (6) 
     Femoral-popliteal 74 (43) 67 (46) 
     Distal 87 (51) 71 (48) 
    Concurrent phlebitis 32 (18) 27 (18) 
Anticoagulation treatment   
    DOACs (Rivaroxaban) 147 (86) 128 (87) 
    LMWH & vitamin K antagonist 
(warfarin) 
23 (13) 18 (10) 
    Aspirin only 1 (1) 1 (1) 
Duration of anticoagulation (range) 
1 month to 
lifelong  
1 month to lifelong  
Mean number of days between 
symptoms onset and diagnosis 
(range) 
12.2 ± 16.8 SD 
(1-90) 
11.3 ± 13.9 SD 
(1-90) 
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The recruited cohort was made up of ambulatory patients with a tendency to be 
overweight. Only 21% of participants in the recruited cohort had a BMI in the 
normal range of between 18.5 and 24.9 with 77% of participants being 
overweight, obese or very obese. In terms of other cardio-vascular risk factors, 
almost half of the recruited cohort had never smoked, only 7% suffered from 
diabetes mellitus, 27% from hypertension and only 2 participants had a 
diagnosis of congestive heart failure. Thirty seven of the 174 limbs examined 
(21%) were found to have pre-existing venous incompetence in one or more 
location(s) (all in the superficial venous system and defined as the presence of 
venous reflux of >0.5 seconds on Doppler ultrasound examination). 
 
Ten (6%) of the recruited participants had previously been diagnosed with a 
contralateral DVT. The majority of DVTs were classified as unprovoked (64%) 
and affected the left leg (59%). In terms of DVT extent, in just over half the total 
cases (51%) the DVT was confined to the distal deep veins (calf vessels), 43% 
involved the femoral-popliteal vessels and only 8% of cases had iliac 
involvement. The presence of superficial thrombophlebitis was recorded in 32 of 
the 174 limbs recruited to the study (18%) at the time of DVT diagnosis. The 
majority of participants had sought medical advice for their query DVT in a 
timely manner with 67% having seven days or less between the onset of their 
symptoms and their confirmed diagnosis of DVT with ultrasound. The time 
between symptoms onset and diagnosis as reported in the clinical history 
ranged from one day to 90 days however with a mean duration of 12 days and a 
median duration of seven days. The majority of participants presented and were 
diagnosed with a DVT within one week of the onset of their symptoms as shown 
in Figure 5.2. 
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Figure 5.2 Duration of symptoms prior to DVT diagnosis by participant (n=171) 
 
 
 
 
Following diagnosis by the clinic where the research was undertaken the vast 
majority (86%) of participants were treated with DOACs (Rivaroxaban). One 
participant commenced treatment with Rivaroxaban but had their treatment 
changed after seven days due to extension of the DVT. All participants were 
discharged from the care of the Thrombosis Specialist Nurses to the care of 
their General Practitioner (GP) after three weeks. The discharge letter sent to 
the GP included a recommendation to continue the anticoagulation therapy for a 
minimum of six weeks if the DVT occurred following recent orthopaedic surgery 
or a minimum of three months in all other cases. The majority of participants 
(65%) received oral anticoagulation therapy for between three and six months 
but treatment duration ranged from one month to 12 months with 16% 
continuing oral anticoagulation therapy long term (beyond study duration and 
with medical advice to continue treatment until otherwise advised). Data for the 
duration of anticoagulation for six of the participants was unknown due to early 
withdrawal from the study prior to completing anticoagulation therapy (Table 
5.8).  
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Table 5.8 Duration of anticoagulation therapy for the recruited cohort to the 
nearest whole month (n = 171). * indicates anticoagulation for longer than 2 
years with a medical plan for continuation until contraindicated. 
 
Duration of anticoagulation therapy n  % 
< 2 months  20 12 
3 months 84 49 
4-12 months 34 20 
Long term* 27 16 
Unknown 6 3 
Total 171 100 
 
 
Seventy seven of the participants (45%) were reviewed by a haematologist in 
the two year period following their DVT however only six (4%) were found to 
have thrombophilia (three with Factor V Leiden, one with Protein S Deficiency, 
one with Polycythaemia vera and one with Anti-phospholipid Syndrome). One 
participant was found to have Idiopathic Thrombocytopenic Purpura during 
follow-up and their anti-coagulation treatment was stopped. Two of the 
participants were offered a haematology appointment which they did not attend 
and the remaining participants in the cohort (92, 54%) were not considered to 
require haematological review. 
 
Fifty two of the 171 participants (30%) presented for further ultrasound 
examination for a second query lower limb DVT through the standard diagnostic 
clinical pathway during the 24 months following diagnosis of their index DVT 
(Table 5.9). These visits were not part of the research follow-up but the date 
and outcome of any clinical visit was recorded as information for the purpose of 
informing the study. 
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Table 5.9 The number of additional clinical attendances by study participants 
during the 24 month period following the diagnosis of their index DVT. 
 
Number of extra 
clinical visits during 
follow-up in 
addition to those in 
the protocol for the 
index DVT 
n % 
0 119 70 
1 38 22 
2 10 6 
3 3 2 
4 0 0 
5 0 0 
6 1 1 
Total  171 100 
 
 
The majority of these clinical visits for ultrasound examination (71%) were for 
query DVT in the same leg in which the index DVT had occurred although a 
small percentage (4%) presented for assessment of both legs at some point 
during the 24 month period following diagnosis of their index DVT. Two thirds of 
the clinical ultrasound assessments for query DVT were negative for the 
condition and 34% of the clinical visits resulted in a positive diagnosis of a new 
DVT. 
 
Descriptive statistical analysis was performed on key elements of the baseline 
data for the recruited cohort (n = 171 participants, 174 limbs) to characterise it 
in terms of age, sex, BMI, provocation status and DVT extent. Age data were 
grouped into terciles as this provided three evenly populated categories and 
would demonstrate any trend. There was an even representation amongst age 
groups across the study cohort and the age of participants ranged from 21 
years to 85 years. The mean age was 56 years (± 17 years standard deviation) 
and there were more male (61% overall) than female participants in each of 
three defined cohort age groups (Figure 5.3).  
195 
 
Figure 5.3 Graph illustrating the distribution of sex by age group at recruitment 
(n = 171 participants). 
 
 
 
The distribution of BMI categories across the age groups was similar (Figure 
5.4). 
 
 
 
Figure 5.4 Graph illustrating the distribution of BMI categories by age group at 
recruitment (n = 171 participants). 
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Distal DVTs were slightly more numerous in the younger age group. The few 
cases of ilio-femoral DVT were evenly distributed across the age groups and 
generally there was no significant difference in the distribution of DVT extent 
between the age groups as illustrated in Figure 5.5. 
 
Figure 5.5 Graph illustrating the distribution of DVT extent by age group at 
recruitment (n = 171 participants, 174 limbs). 
 
 
 
The majority of DVT cases were considered unprovoked across all three age 
categories. There was a slightly increased frequency of provoked DVT cases in 
the older age category (Figure 5.6). 
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Figure 5.6 Graph illustrating DVT provocation status by age group at 
recruitment (n = 171 participants, 174 limbs). 
 
 
 
 
Previous studies have demonstrated that provoked DVT is usually associated 
with more distal disease (Eichinger et al, 2010; Kyrle et al, 2010) which is a 
trend that was also seen in this cohort. Although there was a much larger 
proportion of unprovoked compared to provoked DVT in this cohort, a slightly 
larger percentage of the provoked DVT group comprised distal rather than 
proximal disease as illustrated in Figure 5.7. 
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Figure 5.7 Graph illustrating DVT provocation status by index DVT extent at 
recruitment (n = 171 participants, 174 limbs). 
 
 
 
5.4 Summary  
The study had a recruitment rate of 66%, good adherence to the follow-up 
schedule and a high retention rate over two years of 86% which has resulted in 
a high level of completeness of the data collected. The exclusion criteria for the 
study were all carefully justified; however, the level of exclusion meant that the 
recruited sample represented a generally healthy population as a result of 
selection against those with active cancer and mobility issues who were likely to 
have multiple comorbidities. The impact of this pragmatic selection is 
considered further in Section 11.6.1 of the Discussion chapter.  
The following chapter will present an overview of the natural history of DVT in 
the cohort which subsequently informed the analyses for the primary outcomes 
for the study (DVT resolution, recurrence, venous incompetence and PTS). 
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CHAPTER 6: RESULTS – THROMBUS EVOLUTION   
 
This chapter describes the results of the data analysis relating to the natural 
history of the index DVT and changes in thrombus burden over time in this 
cohort of patients with a first episode of DVT who were followed prospectively 
over 24 months.  
 
6.1 Changes in Thrombus Load Score (TLS) 
 
6.1.1 Introduction 
Each of the fifteen venous segments assessed with ultrasound for the index 
DVT were assigned a thrombus score at each visit as follows: 
0 = patent 
1 = sub-segmental, non-occlusive thrombus 
2 = sub-segmental, occlusive thrombus 
3 = occlusive thrombus throughout segment 
 
6.1.2 Changes in TLS between follow-up visits 
The individual thrombus scores for each venous segment were tabulated at 
diagnosis and at each follow-up visit and the TLS for the whole DVT limb was 
calculated as the sum of the scores from each segment (see case example in 
Appendix A5.1). TLS was tabulated at the seven time points (diagnosis, 1 week, 
1 month, 3 months, 6 months, 12 months and 24 months) (Appendix A5.2) and 
examined for changes over time. The mean TLS and standard deviations at 
each time point are shown in Table 6.1 and demonstrate a decrease in TLS 
over time as would be expected. 
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Table 6.1 Mean thrombus load scores at diagnosis and each follow-up interval 
(n = 171 participants). 
 
TLS on 
diagnosis 
TLS 
at 7 
days 
TLS at 
1 
month 
TLS at 
3 
months 
TLS at 
6 
months 
TLS at 
12 
months 
TLS at 
24 
months 
N 
Valid 171 171 165 164 160 156 147 
Missing 0 0 6 7 11 15 24 
Mean 7.17 6.58 4.32 2.27 1.46 1.16 1.15 
Std. 
Deviation 
6.17 5.80 4.67 3.26 2.48 2.11 2.35 
 
 
The analysis of changes in TLS was undertaken on individual cases (DVT 
limbs) and reported as categorical data at cohort level as per the definitions in 
Table 6.2. 
 
Table 6.2 Grading method for thrombus load scores when converted to 
categorical data. 
Grading Definition 
Unchanged No change in TLS compared to TLS at reference point* 
Zero TLS = 0 
Reduced Reduction in TLS compared to TLS at reference point 
Increased Increase in TLS compared to TLS at reference point 
 
* note: ‘reference point’ is used here as a general term and varies for the 
analysis being undertaken (refers to either the time of diagnosis, study entry 
point or previous assessment as per analyses described below) 
 
 
The analysis was undertaken on the recruited cohort of 174 limbs and reports 
outcomes at each of the follow-up time points. Case level data were included up 
until the last follow-up time point attended and the missing data category 
indicates where the participant did not attend the follow-up appointment at that 
time point.  
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It was important to first determine if there was any significant difference 
between the thrombus load scores at DVT diagnosis and those at the point of 
entry into the research study at seven days post diagnosis. This analysis 
allowed the identification of any significant differences resulting from the fact 
that the diagnostic scan was undertaken by scientists other than the author. It 
also permitted further examination of any differences between scan results at 
diagnosis and those at the first research scan seven days post diagnosis that 
could not be attributable to treatment. Almost half of the individual cases (48%) 
saw no change in TLS in the first seven days between diagnosis and their first 
research follow-up visit (Table 6.3, Figure 6.1). For those in whom there was a 
change in TLS in this time period, 41% saw a reduction and 11% experienced 
an increase.  
 
Table 6.3 Changes in TLS between follow-up visits (n = 174 limbs). 
 
 
7 days n 
(%) 
1 month 
n (%) 
3 
months 
n (%) 
6 
months 
n (%) 
12 
months 
n (%) 
24 
months 
n (%) 
TLS Reduced  68 (39) 108 (62) 68 (39) 38 (22) 29 (17) 10 (5) 
TLS Zero  
(index DVT 
resolved) 
4 (2) 28 (16) 78 (45) 96 (55) 97 (56) 97 (56) 
TLS 
Unchanged  83 (48) 29 (17) 19 (11) 24 (14) 28 (16) 36 (21) 
TLS Increased  19 (11) 3 (2) 1 (1) 5 (3) 5 (3) 7 (4) 
Data Missing 0 (0) 6 (3) 8 (4) 11 (6) 15 (8) 24 (14) 
Total  174 (100) 
174 
(100) 
174 
(100) 
174 
(100) 
174 
(100) 
174 
(100) 
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Figure 6.1 Graph of changes in TLS between follow-up visits (n = 174 limbs). 
 
 
 
 
The expected thrombus evolution status following seven days of anticoagulation 
therapy was no change or a reduction in TLS and therefore the 19 cases in 
which the TLS increased between diagnosis and the first research scan 
underwent closer examination. The differences between the findings at the 
diagnostic scan and those from the first research scan are described in Table 
6.4 along with the potential influencing factors. 
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Table 6.4 Likely reasons for increase in TLS between diagnostic scan and first 
research scan at seven days post diagnosis. 
Number 
of cases 
Differences between diagnostic 
scan and study entry scan not 
attributable to 7 days treatment 
with anticoagulation therapy 
Potential influencing factors 
6 
Superficial thrombophlebitis 
reported on study entry scan but 
not on diagnostic scan. 
Superficial veins only assessed for 5cm section to 
main junction with deep vein or symptomatic 
segment in diagnostic scan but complete vein 
assessed during research scan. 
1 
Profunda vein DVT reported on 
study entry scan but not on 
diagnostic scan. 
Only proximal section of profunda vein examined 
as part of diagnostic scan so possible extension 
but also much newer ultrasound machine used for 
research scan so better visualisation of this 
deeper vein. 
5 
Extension from 
gastrocnemius/soleal veins to 
peroneal or posterior tibial veins 
reported in study entry scan 
compared to diagnostic scan. 
Possible extension from muscle sinuses to calf 
vessels but also much newer ultrasound machine 
used for research scan so better visualisation of 
small calf vessels and more time available for 
scan. 
2 
Extension to more proximal 
location as partial thrombus 
reported in study entry scan 
compared to diagnostic scan. 
Possible extension however partial thrombus 
potentially missed at diagnostic scan as much 
newer ultrasound machine used for research scan 
so better visualisation and more time available for 
scan. 
1 
Clear extension from distal to 
proximal (calf vein into popliteal 
vein) reported in study entry scan 
compared to diagnostic scan. 
Clear extension of DVT and patient treatment 
changed as a result. 
2 
Thrombus reported in new 
location in study entry scan that 
was not reported in diagnostic 
scan. 
Possible new thrombus in new location but more 
likely missed at diagnostic scan as much newer 
ultrasound machine used for research scan so 
better visualisation and more time available for 
scan. 
1 
Extension reported from partial 
thrombus in diagnostic scan to 
occlusive thrombus in study entry 
scan. 
Possible extension of partial thrombus to 
occlusive thrombus or level of occlusivity mis-
diagnosed at diagnostic scan as much newer 
ultrasound machine used for research scan so 
better visualisation and more time available for 
scan. 
1 
Extension of occlusive thrombus 
within single vein segment 
reported in study entry scan 
compared to diagnostic scan. 
Possible extension within femoral vein from distal 
vein to proximal vein however precise location in 
femoral vein also not well reported in diagnostic 
scan as this level of detail not required clinically. 
19 Total  
 
Key: DVT: deep vein thrombosis
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From the point of entry into the research study, the majority of the sample (78%) 
then experienced a reduction in TLS between the first research scan at the 
seven day follow-up time point and the one month follow-up interval with only 
17% seeing no change and only 2% seeing an increase between visits. From 
the one month follow-up time point to the final follow-up visit there was a 
reasonably consistent proportion of the sample (between 11% and 21%) for 
whom there was no change in TLS between each visit. There was also little 
change in the percentage of participants who experienced an increase in TLS 
between visits over this time period (between 2% and 4%) which reflects the 
small number of DVT recurrences.  
 
6.1.3 Changes in Thrombus Load Score from baseline  
Analysis was then undertaken to compare changes in TLS at each follow-up 
time point in relation to that at baseline (entry point to the research study at 
seven days post DVT diagnosis (Table 6.5, Figure 6.2). The majority of the 
sample (79%) had experienced a reduction in TLS by the one month follow-up 
interval with only 16% seeing no change and only 2% (3 cases) seeing an 
increase compared to their baseline scan. There was a large increase in the 
percentage of participants for whom the DVT then completely resolved between 
the one month and three month follow-up visits. The percentage of participants 
in whom the index DVT completely resolved changed little between the six 
month and 24 month time points. However the majority of those participants 
with residual thrombus at 3 months continued to have non-zero TLS at each 
follow-up visit up to the end of the project (24 months) suggesting that the 
status of the thrombus burden at three months could be indicative of the longer 
term resolution status. Analysis of this potential association is reported in 
Chapter 7. 
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Table 6.5 Changes in TLS between each follow-up visit and that at baseline (n 
= 174 limbs).   
 
1 month 
n (%) 
3 months n 
(%) 
6 months n 
(%) 
12 months n 
(%) 
24 months n 
(%) 
TLS Reduced  109 (63) 78 (45) 62 (36) 58 (33) 50 (28) 
TLS Zero  (index 
DVT resolved) 
28 (16) 78 (45) 96 (55) 97 (56) 97 (56) 
TLS Unchanged  28 (16) 8 (5) 5 (3) 3 (2) 2 (1) 
TLS Increased  3 (2) 2 (1) 0 (0) 1 (1) 1 (1) 
Data Missing 6 (3) 8 (4) 11 (6) 15 (8) 24 (14) 
Total sample 174 (100) 174 (100) 174 (100) 174 (100) 174 (100) 
 
 
 
Figure 6.2 Graph of changes in TLS between each follow-up visit and that at 
baseline (n = 174 limbs).   
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6.2 Percentage changes in thrombus burden  
 
6.2.1 Introduction 
The starting point for any DVT evolution in terms of the magnitude of its initial 
thrombus burden is not necessarily reflected in its categorisation to a proximal 
or distal DVT. A DVT is considered proximal if it involves the popliteal vein or 
more proximal vein. However, a partial thrombus in the common femoral vein, 
for example, would have a lower TLS than a distal DVT isolated to the calf but 
comprised of occlusive thrombus throughout the peroneal, posterior tibial, soleal 
and gastrocnemius veins. In order to capture changes in thrombus burden 
therefore, the TLS data were re-examined as percentage changes rather than 
numerical changes between follow-up intervals (Appendices A5.3 and A5.4). 
The analysis of percentage changes in thrombus burden was undertaken on 
individual cases (DVT limbs) and reported as categorical data at cohort level. 
Categorisation was undertaken at case level to classify each case into a 
thrombus evolution category at key time points in the follow-up schedule (3, 6, 
12 and 24 months). These data are presented in Appendix A5.5. 
 
6.2.2 Determining patterns of change 
The analysis of percentage change in thrombus load score over the 2 year 
follow-up period led to eight clear patterns of thrombus evolution being identified 
which are described in Table 6.6. Examples of each of the patterns are detailed 
in Appendix A5.5, Table A5.5.2. 
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Table 6.6 Definitions of the eight different thrombus evolution patterns identified 
from the percentage changes in TLS at key time points over the two year follow-
up period.  
* resolution defined as TLS = 0 
Following categorisation at case level, data were reported as categorical data at 
cohort level and are presented in Table 6.7 and Figure 6.3. The analysis was 
undertaken on the cohort of 174 limbs and case level data were included up 
until the last of the key follow-up time points attended. The missing data 
category indicates where the participant did not attend for follow-up at that time 
point.  
Table 6.7 Number of participants by DVT evolution category at four key time 
points over the two year follow-up period.  
DVT Evolution Category 
3 months 
n (%) 
6 months 
n (%) 
12 months 
n (%) 
24 months 
n (%) 
Static 14 (8) 20 (11) 27 (16) NR 
Reducing 70 (40) 42 (24) 28 (16)  NR 
Extending  4 (2)  NR NR NR 
Fast resolution 78 (45) 74 (43) 69 (40)* 67 (39)* 
Standard resolution NR 20 (11) 24 (14) 24 (14) 
Non-standard resolution NR 3 (2) 5 (3) 10 (6) 
Reducing recurrence NR 3 (2) 5 (3) NR 
Slow unresolved NR NR NR 48 (28) 
Incomplete Data 8 (5) 12 (7) 16 (9) 25 (14) 
Total 174 (100) 174 (100) 174 (100) 174 (100) 
Key: 
NR: Not relevant   * denotes recurrence as explained in the following section. 
DVT 
Evolution 
Category 
Definition 
Static No change in thrombus burden 
Reducing Continued decrease at each follow-up visit up to one year 
Extending  Increase in thrombus burden during first three months 
Fast 
resolution 
Resolution* within three months 
Standard 
resolution 
Continued decrease at each follow-up visit with resolution within 
one year 
Non-
standard 
resolution 
Not following standard resolution pattern but resolved by two 
years 
Reducing 
recurrence 
Recurrence of DVT after initial resolution but followed by 
subsequent ongoing resolution 
Slow 
unresolved 
Some reduction in thrombus burden over two years but 
incomplete resolution 
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Figure 6.3 Percentage of participants in each DVT evolution category at four 
key time points over the two year follow-up period.  
 
 
 
The largest percentage of participants fell in the fast resolution category 
(resolution within three months of diagnosis) as recorded at each of the four key 
time points analysed. The slight decrease in this percentage at each time point 
after 3 months represents the movement of a small number of participants from 
the fast resolution category that developed a recurrent ipsilateral DVT (site of 
recurrences analysed and presented separately) during follow-up and hence 
moved to a different category after the three month time point.  
 
There was a progressive decline in the percentage of participants falling into the 
reducing DVT evolution category at the different time points over the two year 
follow-up period. This reflects a number of these participants moving into the 
other categories over time as their DVT either resolved, extended or entered a 
static or slow unresolved status. With the exception of this category, there was 
generally little change in the percentages in the other categories over time with 
those classified as “static” or “fast resolving” at the three month time point 
generally remaining in that category for the duration of follow-up. 
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A further analysis was undertaken to compare the classification of the DVT 
evolution pattern after the final visit at two years post DVT diagnosis with the 
DVT evolution pattern after three months of follow-up post DVT diagnosis. As 
seen in Table 6.8, those participants whose DVT evolution pattern was 
classified as “fast resolution” at three months all retained this classification at 
the final two year visit if they remained in follow-up until this point. None of the 
participants in this group entered any of the non-resolution categories despite 
the fact that a small number of these cases experienced a recurrent DVT 
between three and 24 months. The reliability of the diagnosis of recurrent DVT 
is examined in Section 11.6.2 of the Discussion chapter. 
 
Of those whose DVT evolution was classified as static at three months, 50% 
remained unresolved at two years post DVT diagnosis. Similarly, of those with a 
DVT evolution pattern classified as reducing at three months, 57% remained 
unresolved at two years post DVT diagnosis. Unexpectedly however, three out 
of the four cases with an extending DVT at three months had eventual 
resolution by two years. 
 
Table 6.8 The final outcome DVT evolution pattern category at 2 years post 
diagnosis in relation to the DVT evolution pattern category at the three month 
follow-up point. 
Evolution pattern at 3 months 
post DVT 
Evolution pattern at 2 years 
post DVT 
Number of 
cases 
Static (n=14) 
Non-standard resolution 6 
Slow unresolved 7 
Missing 1 
Reducing (n=70) 
Standard resolution 22 
Non-standard resolution 3 
Slow unresolved 40 
Missing 5 
Extending (n=4) 
Standard resolution 2 
Non-standard resolution 1 
Slow unresolved 1 
Fast (n=78) 
Fast 67 
Missing 11 
Missing (n=8) Missing 8 
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6.3 Summary  
For the majority of participants TLS decreased over time as expected. There 
was either no change or a decrease in TLS noted for all but a few cases 
between the diagnostic scan and the study entry point. This suggested that the 
pattern of change in the first seven days met with expectations and that no 
unexpected key changes had been missed in the time period before the first 
study observation. Close examination of the individual cases provided logical 
explanations for all cases where TLS increased during this time frame.  
 
The majority of participants experienced a reduction in TLS in the first month 
and this was followed by a sharp increase in the number of DVT resolutions 
between the one month and three month follow-up points. There was then little 
change in the number of resolutions between the six month and 24 month time 
points. Examination of the percentage changes in thrombus burden over time 
identified eight different thrombus evolution patterns that describe the natural 
history of DVT under treatment. These patterns could then be used to 
categorise thrombus change for the examination of any possible associations 
with the primary endpoints of the study (resolution, recurrence, venous 
incompetence and PTS) which are reported in the following four chapters. In 
addition, both data from the examination of changes in absolute TLS and 
percentage changes in TLS suggested that the state of the thrombus at three 
months could be indicative of the longer term resolution status. Further analysis 
of this potential association is reported in the following chapter. 
 
211 
 
CHAPTER 7: RESULTS – DVT RESOLUTION   
 
7.1 Introduction 
 
This is the first of four chapters describing the results of the data analysis for the 
four primary endpoints for the observational study. This chapter reports the 
examination of the data obtained regarding the resolution status of the index 
DVT and associations between baseline characteristics or those that presented 
during follow-up and DVT resolution within 24 months. 
 
7.2 DVT resolution overview 
 
The number of DVT cases that had resolved at each follow-up time interval was 
analysed (Figure 7.1) and this showed that there was a sharp increase in the 
number of DVT resolutions between one month post diagnosis and three 
months post diagnosis. Thereafter there was only a small increase in the 
number of resolutions to six months and from six months to two years there was 
little change in the number of DVT resolutions. 
 
Figure 7.1 Number of cases (blue bars) and % (orange line) of index DVT 
resolution at each follow-up time interval over the two year follow-up period (n= 
174 limbs) 
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7.3 DVT resolution at the point of stopping anticoagulation 
treatment  
The data were then examined to determine the number of cases where the DVT 
had resolved at the time of stopping anticoagulation therapy (Figure 7.2). This 
analysis revealed that only 46% of cases of DVT had actually resolved at the 
time of discontinuing the clinically prescribed anticoagulation treatment and that 
34% of cases remained unresolved at the point when treatment was stopped.  
 
Figure 7.2 Resolution of index DVT at the point of stopping treatment with 
anticoagulation therapy (see Table 5.8 for details of anti-coagulation duration).  
 
 
 
7.4 Eventual resolution of the index DVT within 24 months 
The process of thrombus resolution did not necessarily end at the time 
anticoagulation therapy was discontinued however and thrombi continued to 
resolve in cases where treatment had stopped. At the end of the 24 month 
follow-up period, the majority of index DVT cases (at least 66%) had completely 
resolved with only at least 27% of index DVT cases remaining unresolved 
(Figure 7.3). 
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Figure 7.3 Resolution of index DVT within 24 months of DVT diagnosis (n = 
174 limbs). 
 
 
7.5 Selection of variables and data manipulation 
An examination of associations between the potentially important predictor 
variables on which data had been collected and index DVT resolution within 24 
months was conducted including only one randomly selected limb from bilateral 
cases (n = 158). Putative predictors of DVT resolution (Table 7.1) were selected 
through consideration of the findings from existing research evidence as 
described in Chapter 2 and existing knowledge of the disease processes 
relating to the outcome concerned.  
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Table 7.1 List of variables selected for examination for any relationship with 
index DVT resolution within 24 months. 
Variables selected for examination for 
relationship with DVT resolution  
Age 
Sex 
BMI 
Treatment type 
Treatment duration 
Smoking 
Diabetes 
Hypertension 
Congestive heart failure 
TLS at diagnosis 
DVT location 
Provocation status 
Presence of clotting disorder 
Previous contralateral DVT 
Pre-existing venous incompetence 
Stocking use 
Concurrent phlebitis at DVT diagnosis 
Duration of symptoms before treatment 
 
Key: 
BMI: body mass index 
DVT: deep vein thrombosis 
TLS: thrombus load score 
The continuous data collected for age, BMI, duration of symptoms before 
commencing treatment, duration of consistent stocking use, TLS at diagnosis 
and each of the follow-up interval time points and the Villalta score were first 
examined for normal distribution (Figure 7.4 and Table 7.2). 
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Figure 7.4 Normal Q-Q plots for variables originally with continuous data 
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Table 7.2 Results of Shapiro-Wilk test for normality for variables with 
continuous data. 
 
Variable 
Shapiro-Wilk test for 
normality 
Statistic df Sig 
Age at entry (years) 0.968 171 0.001 
BMI at entry 0.955 171 <0.001 
Duration of symptoms before commencing treatment 
(days) 0.6 171 <0.001 
Duration of consistent compression stocking use 
(months) 0.681 166 <0.001 
Thrombus load score at diagnosis of index DVT 0.843 171 <0.001 
Thrombus load score at 1 week 0.845 171 <0.001 
Thrombus load score at 1 month 0.823 165 <0.001 
Thrombus load score at 3 months 0.734 163 <0.001 
Thrombus load score at 6 months 0.656 160 <0.001 
Thrombus load score at 12 months 0.609 156 <0.001 
Thrombus load score at 24 months 0.557 147 <0.001 
Villalta Score 0.806 147 <0.001 
 
 
None of the variables with continuous data were normally distributed and data 
for these variables were subsequently categorised for analysis purposes. 
Categorisation was undertaken following careful examination of the data and 
with a view to creating an even distribution with sufficient numbers of cases in 
each category for analysis purposes.  
 
Age data were initially categorised into intervals of ten years to examine for 
trend as shown in Figure 7.5.  Categories for participants aged 45 years and 
younger had greater percentages of DVT resolution than those in the categories 
for those aged 46 years and older. Age was then transformed into a 
dichotomous variable combining the three age categories including and below 
the age of 45 and the four categories including and above the age of 46 years. 
The decision to dichotomise the data in this way was taken as the researcher 
felt there was a change in the pattern of the data at this age point and it 
provided similar sized groups for analysis. 
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Figure 7.5 Graph showing the distribution of index DVT resolution within 24 
months by age group. 
 
BMI data were initially grouped using the recognised categories from the NHS 
choices BMI calculator (underweight, normal weight, overweight, obese and 
very obese) but later dichotomised as overweight or normal weight to prevent 
small numbers in categories. The data for the duration of symptoms before 
diagnosis were arranged into four categories to best reflect short, medium, long 
and very long duration (≤ 3 days, 4-7 days, 8-30 days and ≥ 31 days 
respectively). Durations of longer than 1 month were few and for the other three 
categories the data was fairly evenly split.  
 
Similarly compression stocking use was categorised into four typical patterns of 
usage seen in the data distribution and consistent with the researcher’s 
experience in clinical practice. Compliance is determined partly by the ease of 
getting the stockings on and off. If patients are able to do this (elderly patients 
with less range of movement find this harder) this is apparent within the first few 
days following diagnosis. Other patterns of compression use relate to when the 
patient’s leg starts to feel better or when they consider the treatment period to 
have stopped (generally around the minimum anti-coagulation treatment period 
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of three months). Those that continued to use compression for 4 months or 
longer were generally split into those that used it for up to a year and decided to 
stop using it when the advice changed regarding their use and those that 
continued to use them long term as they found it helped their symptoms or 
because the original advice had been to wear them for 2 years. The data for 
TLS at diagnosis were categorised to represent those with very isolated 
thrombus (TLS 1-4), and those with more extensive thrombus (TLS ≥ 5).  
 
7.6 Factors not associated with index DVT resolution  
Cross tabulation revealed no statistically significant associations (at p<0.05) 
between the resolution of the index DVT within 24 months and sex, BMI, 
treatment type, smoking history, hypertension, whether the index DVT was 
provoked or unprovoked, the presence of concurrent superficial 
thrombophlebitis at the time of index DVT diagnosis, stocking use or the 
duration of symptoms prior to commencing anticoagulation therapy.  
 
Table 7.3 Cross tabulations for independent variables where no statisticaly 
significant association (at p<0.05) with index DVT resolution within 24 months 
was identified. 
Sex & index DVT resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
Sex 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
Male 67 (70) 29 (30) 96 (100) 
Female 44 (71) 18 (29) 62 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
 
BMI & index DVT resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
BMI 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
Not over weight 22 (63) 13 (37) 35 (100) 
Over weight 78 (70) 34 (30) 112 (100) 
Total 100 (68) 47 (32) 158 (100) 
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Treatment type & index DVT resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
Treatment type 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
LMWH & warfarin 14 (67) 7 (33) 21 (100) 
DOACS 96 (71) 40 (29) 136 (100) 
None 1 (100) 0 (0) 1 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
Smoking history & index DVT resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
Smoking history 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
Never smoked 51 (70) 22 (30%) 73 (100) 
Ex-smoker 42 (74) 15 (26) 57 (100) 
Current smoker 18 (64) 10 (36%) 28 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
 Hypertension & index DVT resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
Hypertension 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
No hypertension 80 (69) 36 (31) 116 (100) 
Hypertension 31 (74) 11 (26) 42 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
 Provocation status & index DVT resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
Provocation status 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
Unprovoked 71 (68) 33 (32) 104 (100) 
Provoked 40 (74) 14 (26) 54 (100) 
Total 111 (70) 47 (30) 158 (100)   
 
Phlebitis on DVT diagnosis & index DVT resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
Phlebitis 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
None 90 (69) 40 (31) 130 (100) 
Phlebitis 21 (75) 7 (25) 28 (100) 
Total 111 (70) 47 (30) 158 (100) 
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Duration of stocking use & index DVT resolution within 24 months 
Missing predictor variable = 5, Missing outcome variable = 13 
Duration of stocking use 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
Not used 47 (71) 19 (29) 66 (100) 
3 weeks – 3 months 32 (73) 12 (27) 44 (100) 
4-12 months 21 (64) 12 (36) 33 (100) 
≥ 13 months 11 (73) 4 (27) 15 (100) 
Total 111 (70) 47 (30) 158 (100) 
  
Duration of symptoms before diagnosis & index DVT resolution within 24 
months 
Missing predictor variable = 0, Missing outcome variable = 13 
Duration of symptoms 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
≤ 3 days 33 (80) 8 (20) 41 (100) 
4-7 days 40 (66) 21 (34) 61 (100) 
8-30 days 30 (67) 15 (33) 45 (100) 
≥ 31 days 8 (73) 3 (27) 11 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
Case numbers of diabetes mellitus, congestive heart failure, any blood 
coagulation disorder or a history of previous contralateral DVT were too small 
for any reliable analysis (Table 7.4) and were therefore not included any further 
in the analyses for any of the dependent variables discussed in Chapters 8, 9 
and 10.  
 
Table 7.4 Cross tabulations for independent variables where case numbers 
were identified as being too small to provide reliable analyses. 
Diabetes & index DVT resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
Diabetes 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
No diabetes 103 (71) 43 (29) 146 (100) 
Diabetes 8 (67) 4 (33) 12 (100) 
Total 111 (70) 47 (30) 158 (100) 
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Congestive heart failure & index DVT resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
Congestive heart failure 
(CHF) 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
No CHF 109 (70) 47 (30) 156 (100) 
CHF 2 (100) 0 (0) 2 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
Presence of clotting disorder & index DVT resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
Clotting disorder 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
None 106 (70) 46 (30) 152 (100) 
Clotting disorder 5 (83) 1 (17) 6 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
Previous contralateral DVT & index DVT resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
Previous contralateral DVT  
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
None 106 (71) 44 (29) 150 (100) 
Yes 5 (63) 3 (38) 8 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
7.7 Factors associated with index DVT resolution  
Cross tabulation of frequencies did however reveal substantive associations 
between DVT resolution by 24 months and DVT location, TLS at diagnosis, 
treatment duration, the presence of pre-existing superficial venous 
incompetence, and age.   
 
A strong association existed between the location of the index DVT and its 
resolution within 24 months of diagnosis (Table 7.5). The index DVT was more 
likely to resolve in those participants with a distal DVT that did not extend into 
the popliteal vein compared to those with a proximal DVT which involved the 
popliteal vein, femoral vein or iliac veins (OR=36.2;95% CI 10.5 – 125.1, 
p<0.001)). 
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Table 7.5 Cross tabulation of frequency data for index DVT resolution within 24 
months by DVT location (distal or proximal). 
DVT location & index DVT resolution within & index DVT 
resolution within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
DVT location 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
Distal 79 (96) 3 (4) 82 (100) 
Proximal 32 (42) 44 (58) 76 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
 
As expected, a further strong association was seen between the thrombus 
burden of the index DVT at diagnosis (indicated by TLS) and its resolution 
within 24 months (Table 7.6). The index DVT was more likely to resolve in those 
participants with a smaller thrombus burden (and therefore less extensive DVT) 
compared to those with larger thrombus burden (and therefore more extensive) 
DVT (OR =24.3 (95% CI 8.09 – 73.23, p = <0.001)). 
 
Table 7.6 Cross tabulation of frequency data for index DVT resolution within 24 
months by thrombus burden (thrombus load score at diagnosis). 
Thrombus load score at diagnosis & index DVT resolution  
Missing predictor variable = 0, Missing outcome variable = 13 
Thrombus load 
score at diagnosis 
Index DVT 
resolved n 
(%) 
Index DVT 
not resolved 
n (%) 
Total n (%) 
1-4 77 (95) 4 (5) 81 (100) 
≥ 5 34 (44) 43 (56) 77 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
An association was also seen between treatment duration and resolution of the 
index DVT. Those participants that received extended anticoagulation therapy, 
beyond the minimum of three months recommended by the Thrombosis 
Specialist Nurses on discharge were less likely to have complete resolution of 
the index DVT within 24 months (Table 7.7). The odds ratio indicated that the 
index DVT was three times more likely to resolve in those participants treated 
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with anticoagulation for ≤ three months compared to those who were treated for 
longer than three months (OR = 3.06 (95% CI 1.51 – 6.20, p = 0.002)). Those 
participants prescribed extended anticoagulation by their GP may have had 
other comorbidities that led to the clinical decision to treat them for longer and 
that therefore the potential for confounding was important in this case. Data for 
all possible comorbidities was not captured and therefore more detailed 
analysis of this was not possible.  
 
Table 7.7 Cross tabulation of frequency data for index DVT resolution within 24 
months by treatment duration. 
Treatment duration & index DVT resolution 
Missing predictor variable = 0, Missing outcome variable = 13 
Treatment duration 
Index DVT 
resolved n 
(%) 
Index DVT 
not resolved 
n (%) 
Total  
n (%) 
≤ 3 months 79 (79) 21 (21) 100 (100) 
> 3 months 32 (55) 26 (45) 58 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
 
A further association was seen between the presence of pre-existing superficial 
venous incompetence and DVT resolution within 24 months (Table 7.8). On 
examination of the frequency data and by calculating an odds ratio, pre-existing 
superficial venous incompetence appeared to be associated with a greater 
likelihood of index DVT resolution within 24 months (OR = 2.42, (95% CI 0.93-
6.28, p = 0.07)). Although the 95% confidence interval crossed one and was not 
statistically significant, as the numbers in one cell were small, it warranted 
further investigation. 
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Table 7.8 Cross tabulation of frequency data for index DVT resolution within 24 
months by the presence of pre-existing superficial venous incompetence. 
Pre-existing superficial venous incompetence & index DVT resolution 
within 24 months 
Missing predictor variable = 0, Missing outcome variable = 13 
Pre-existing superficial 
venous incompetence 
Index DVT 
resolved n (%) 
Index DVT not 
resolved n (%) 
Total  
n (%) 
No 82 (67) 41 (33) 123 (100) 
Yes 29 (83) 6 (17) 35 (100) 
Total 111 (70) 47 (30) 158 (100) 
 
As previously described, a potential weak association had also been noted 
between age and index DVT resolution within 24 months with the frequency 
data showing a general trend towards DVT resolution decreasing with age when 
categorised into approximate 10 year intervals (Figure 7.5). Following cross 
tabulation with age as a dichotomous variable (Table 7.9), an odds ratio 
indicated that the index DVT was twice as likely to resolve in those participants 
aged 45 years or younger at the time of diagnosis than those aged 46 years or 
older. (OR = 2.38, 95% CI 1.04 – 5.42, p = 0.06). Although this was not 
statistically significant at the p = <0.05 level, it was close to approaching 
significance and therefore warranted further investigation. 
 
 
Table 7.9 Cross tabulation of frequency data for index DVT resolution within 24 
months by age category.  
Age category & index DVT resolution 
Missing predictor variable = 0, Missing outcome variable = 13 
Age category 
Index DVT 
resolved n 
(%) 
Index DVT 
not resolved 
n (%) 
Total  
n (%) 
≤45 40 (82) 9 (18) 49 (100) 
≥46 71 (65) 38 (35) 109 (100) 
Total 111 (70) 47 (30) 158 (100) 
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Results of chi-square tests for all of the variables examined and their 
relationship with index DVT resolution within 24 months are shown in Table 
7.10.  The Chi-square analysis confirmed no significant (p<0.05) association 
between resolution of the index DVT and sex, BMI, smoking history, 
hypertension, whether the index DVT was provoked or unprovoked, treatment 
type, the duration of consistent use of compression stockings, the presence of 
concurrent superficial thrombophlebitis at the time of index DVT diagnosis or 
the duration of symptoms prior to commencing anticoagulation therapy. A p-
value cut off of < 0.25 instead of the standard p value of 0.05 was used to 
identify those variables for further examination through inclusion in the 
regression model as described in Section 4.5 of the methods chapter. 
 
Table 7.10 Results of chi-square tests of associations with DVT resolution with 
* indicating those variables selected for inclusion in the regression model 
(based on p <0.25). 
Independent variable n Chi-square df 
Asymptotic 
sig (2-
sided) 
DVT location (proximal or distal)* 158 55.52 1 <0.001 
TLS at DVT diagnosis* 158 48.95 1 <0.001 
Treatment duration category* 158 9.97 1 <0.01 
Age ≤45 or ≥46 at study entry* 158 4.40 1 0.04 
Pre-existing superficial venous incompetence* 158 3.42 1 0.07 
Duration of symptoms before starting treatment 158 3.00 3 0.39 
Congestive heart failure 158 0.86 1 0.35 
Provocation status 158 0.57 1 0.45 
Presence of clotting disorder 158 0.51 1 0.48 
BMI category at study entry 158 3.38 4 0.50 
Concurrent superficial thrombophlebitis 158 0.37 1 0.55 
Hypertension 158 0.35 1 0.56 
Previous contralateral DVT 158 0.24 1 0.62 
Smoking 158 0.80 2 0.67 
Treatment type 158 0.56 2 0.76 
Diabetes mellitus 158 0.08 1 0.78 
Duration of consistent use of compression 158 0.92 3 0.82 
Sex 158 0.03 1 0.88 
 
Key: 
BMI: body mass index 
DVT: deep vein thrombosis 
TLS: thrombus load score 
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7.8 Results of the regression analysis  
Some of the five independent variables identified as having a potentially 
important association with index DVT resolution within 24 months (DVT 
location, TLS at diagnosis, treatment duration, the presence of pre-existing 
superficial venous incompetence and age) might have been confounding each 
other and so multiple regression analysis was required to determine the degree 
of independent association which could be related to causation. The 
independent variables were therefore entered into the regression model as 
described in Section 4.5 of the methods chapter and the full model output is 
presented in Appendix A6.  
 
The variable for anticoagulation duration category was removed from the model 
at step 2, the variable for age category was removed at step 3 and the variable 
for pre-existing superficial venous incompetence was removed at step 4. The 
model explained 57.0 % (Nagelkerke R2) of the variance in index DVT 
resolution within 24 months. The results of the regression analysis 
demonstrated that, of the five independent variables examined in the model, 
only two maintained a significant relationship with index DVT resolution within 
24 months when adjusted for possible confounding by other variables in the 
regression model (Table 7.11). 
  
Table 7.11 Results from the final backwards stepwise regression model 
examining adjusted relationships between DVT location and TLS at diagnosis 
on index DVT resolution within 24 months.  
 
Regression 
Coefficient 
S.E. df Sig. 
Adjusted 
OR 
95% C.I.for 
Adjusted OR 
Lower Upper 
Step 
4
a
 
DVT location:  
Proximal (reference) 
or Distal 2.81 .663 1 .000 
1 
16.7 4.56 61.1 
TLS at diagnosis : 
>4 (reference)  
or ≤ 4 2.30 .607 1 .000 
1 
9.95 3.02 32.7 
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The regression analysis was then re-run with the final model variables entered 
in a single step in order to avoid the program only using cases that were not 
missing on all tested independent variables as the complete cases sample size 
was the same for each of the variables. This did not change any of the values 
for the two variables. 
 
Therefore, as shown in Table 7.11, when adjusted for confounding, cases of 
distal DVT remained significantly more likely to resolve than proximal DVT with 
an adjusted OR = 16.7 (95% CI 4.55 – 61.1, p = <0.001). The index DVT was 
also significantly more likely to resolve within 24 months in those participants 
with a lower thrombus burden compared to a higher thrombus burden with an 
adjusted OR = 9.95 (95% CI 3.02 – 32.7, p = <0.001).  
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CHAPTER 8: RESULTS – DVT RECURRENCE   
 
8.1 Introduction 
This is the second of four chapters describing the results of the data analysis for 
the four primary endpoints for the study. This chapter reports the examination of 
the data obtained regarding DVT recurrence and the results of the examination 
for any associations between baseline characteristics, or those that presented 
during follow-up, and DVT recurrence within the 24 month follow-up period. 
 
8.2 DVT recurrence overview 
Twenty five of the 171 participants (15%) were known to have a confirmed DVT 
recurrence diagnosed on ultrasound during the two year follow-up period after 
the initial diagnosis of their index DVT (Figure 8.1). A recurrence was defined as 
the presence of new thrombus either in the ipsilateral or contralateral leg or the 
presence of new thrombus on old thrombus in the same venous section as the 
original thrombosis, all of which were confirmed on DUS. This includes 
symptomatic recurrences identified during clinical assessment outside of the 
research study and incidental findings of asymptomatic recurrence of unknown 
age detected during research follow-up.  
 
Figure 8.1 DVT recurrence status of participants from the cohort (n = 171) 
during the two year follow-up period after the diagnosis of their index DVT. 
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Twenty four of the cases of recurrence were diagnosed with ultrasound at the 
investigator’s Trust and one case was diagnosed with ultrasound at a different 
Trust in Bristol (the patient brought their results from the other Trust with them 
to their next research scan). One hundred and twenty five of the participants 
were known to not have been diagnosed with a recurrent DVT during the two 
year follow-up period post index DVT diagnosis but data were missing for 21 
participants for whom it was not possible to establish whether a recurrence had 
occurred or not as a positive diagnosis of DVT recurrence at any other hospital 
or primary care setting could not be discounted. The total sample for which data 
for DVT recurrence within 24 months were available was therefore 150 
participants. The majority of DVT recurrences were symptomatic (18/25, 72%) 
and identified by clinicians, however seven of the 25 cases (28%) were 
asymptomatic and the DVT recurrence was diagnosed during one of the follow-
up visits for the research study. On questioning, none of the seven participants 
with asymptomatic DVT recurrence were aware of any symptoms and would not 
have sought medical advice for symptoms suggestive of DVT recurrence. More 
than half of the cases of DVT recurrence (14/25, 56%) occurred during the 
seven to 12 month time period after the index DVT diagnosis (Figure 8.2) and 
the majority of recurrent cases (19/25, 76%) involved the same leg in which the 
index DVT had occurred (Figure 8.3).  
 
Figure 8.2 Time point in months at which the DVT recurrence occurred in 
relation to index DVT diagnosis (n = 25 participants with DVT recurrence within 
24 months). 
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Figure 8.3 Limb location of the recurrent DVT in relation to that of the index 
DVT (n = 25 participants with DVT recurrence within 24 months). 
 
 
 
Of those cases in which the recurrent DVT occurred in the same leg as the 
index DVT, more than half (11/19, 58%) involved the same site as the index 
DVT whilst 42% (8/19) of the cases involved a different site to the index DVT 
(Figure 8.4).  
 
Figure 8.4 Site location of ipsilateral recurrent DVT in relation to that of the 
index DVT (n = 19 participants with ipsilateral DVT recurrence within 24 
months). 
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The index DVT had resolved completely at the time of the recurrence in 15 of 
the 25 cases (60%) and some thrombus from the index DVT remained in 10 of 
the cases (40%). In seven of these 10 cases, the DVT recurrence involved the 
same site as the index DVT where residual thrombus was present but involved 
a different site in three of the cases. 
 
8.3 Selection of variables and data manipulation 
Putative predictors of recurrence (Table 8.1) were selected and the data for the 
continuous variables age, BMI, symptoms duration, compression stocking use 
and TLS at diagnosis were categorised as previously described in Section 7.5. 
As described in Section 7.6, case numbers of diabetes mellitus, congestive 
heart failure, any blood coagulation disorder or a history of previous 
contralateral DVT were too small for any reliable analysis and were therefore 
excluded. 
 
Table 8.1 List of variables selected for examination for any relationship with 
DVT recurrence within 24 months. 
Variables selected for examination for any 
relationship with DVT recurrence within 24 
months  
Age 
Sex 
BMI 
Treatment type 
Treatment duration 
Smoking 
Thrombus burden 
DVT location 
Provoked or unprovoked DVT 
Pre-existing venous incompetence 
Stocking use 
Index DVT resolved at time of recurrence 
Index DVT resolved at end of treatment 
Phlebitis on DVT diagnosis 
New phlebitis during follow-up 
Duration of symptoms before treatment 
 
 Key:  
BMI: body mass index 
DVT: deep vein thrombosis 
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8.4 Factors not associated with DVT recurrence 
An examination of associations between the potentially important independent 
variables listed in Table 8.1 and the dependent variable of DVT recurrence 
within 24 months was conducted as described previously in Section 7.6 for DVT 
resolution. Cross tabulation of frequencies revealed no substantive associations 
between the DVT recurrence within 24 months and sex, BMI, smoking history, 
DVT location, TLS of index DVT at diagnosis, whether the index DVT was 
provoked or unprovoked, pre-existing venous incompetence, treatment 
duration, stocking use, the duration of symptoms prior to commencing 
anticoagulation therapy or whether the index DVT had resolved by the time 
treatment with anticoagulation therapy was ceased (Table 8.2). 
 
Table 8.2 Cross tabulations for independent variables where no statistically 
significant association (at p<0.05) with DVT Recurrence within 24 months was 
identified. 
Sex & DVT recurrence 
Missing predictor variable = 0, Missing outcome variable = 21 
Sex 
No DVT 
recurrence n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
Male 76 (83) 16 (17) 92 (100) 
Female 49 (84) 9 (16) 58 (100) 
Total 125 (83) 25 (17) 150 (100) 
 
BMI & DVT recurrence 
Missing predictor variable = 0, Missing outcome variable = 21 
BMI 
No DVT 
recurrence n (%) 
DVT recurrence n 
(%) 
Total  
n (%) 
Not over weight 30 (86) 5 (14) 35 (100) 
Over weight 95 (85) 17 (15) 112 (100) 
Total 125 (85) 22 (15) 150 (100) 
 
Smoking history & DVT recurrence 
Missing predictor variable = 0, Missing outcome variable = 21 
Smoking history 
No DVT 
recurrence n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
Never smoked 60 (85) 11 (15) 71 (100) 
Ex-smoker 47 (85) 8 (15) 55 (100) 
Current smoker 18 (75) 6 (25) 24 (100) 
Total 125 (83) 25 (17) 150 (100) 
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DVT location & DVT recurrence 
Missing predictor variable = 0, Missing outcome variable = 21 
DVT location 
No DVT 
recurrence n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
Distal 61 (82) 13 (18) 74 (100) 
Proximal 64 (84) 12 (16) 76 (100) 
Total 125 (83) 25 (17) 150 (100) 
 
TLS of index DVT at diagnosis & DVT recurrence 
Missing predictor variable = 0, Missing outcome variable = 21 
Thrombus load score at 
diagnosis 
No DVT 
recurrence n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
1-2 32 (76) 5 (24) 37 (100) 
3-4 30 (77) 7 (23) 37 (100) 
5-10 30 (79) 6 (21) 36 (100) 
≥ 11 33(85) 7 (15) 40 (100) 
Total 125 (83) 25 (17) 150 (100) 
 
Provocation status & DVT recurrence 
Missing predictor variable = 0, Missing outcome variable = 21 
Provocation status 
No DVT 
recurrence n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
Unprovoked 81 (83) 17 (17) 98 (100) 
Provoked 44 (85) 8 (15) 52 (100) 
Total 125 (83) 25 (17) 150 (100) 
 
Pre-existing venous incompetence & DVT recurrence 
Missing predictor variable = 0, Missing outcome variable = 21 
Venous incompetence 
No DVT 
recurrence n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
None 98 (84) 19 (16) 117 (100) 
Yes 27 (82) 6 (18) 33 (100) 
Total 125 (83) 25 (17) 150 (100) 
 
Treatment duration & DVT recurrence 
Missing predictor variable = 0, Missing outcome variable = 13 
Treatment duration 
No DVT 
recurrence n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
≤ 3 months 82 (85) 14 (15) 96 (100) 
> 3 months 43 (77) 11 (23) 56 (100) 
Total 125 (83) 25 (17) 150 (100) 
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Duration of consistent use of compression & DVT recurrence 
Missing predictor variable = 5, Missing outcome variable = 21 
Duration of stocking use 
No DVT 
recurrence n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
Not used 50 (85) 9 (15) 59 (100) 
3 weeks - 3 months 36 (80) 9 (20) 45 (100) 
4-12 months 26 (84) 5 (16) 31 (100) 
≥ 13 months 13 (87) 2 (13) 15 (100) 
Total 125 (83) 25 (17) 150 (100) 
 
Duration of symptoms before diagnosis & DVT recurrence 
Missing predictor variable = 0, Missing outcome variable = 21 
Duration of symptoms 
No DVT 
recurrence n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
≤ 3 days 33 (85) 6 (15) 39 (100) 
4-7 days 47 (81) 11 (19) 58 (100) 
8-30 days 38 (84) 7 (16) 45 (100) 
≥ 31 days 7 (88) 1 (13) 8 (100) 
Total 125 (83) 25 (17) 150 (100) 
 
Index DVT resolved at end of treatment & DVT recurrence 
Missing predictor variable = 10, Missing outcome variable = 21 
Index DVT resolution at 
end of treatment 
No DVT 
recurrence n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
Resolved 60 (85) 11 (15) 71 (100) 
Not resolved 46 (79) 12 (21) 58 (100) 
Lifelong anticoagulation 19 (90) 2 (10) 21 (100) 
Total 125 (83) 25 (17) 150 (100) 
 
 
8.5 Factors associated with DVT recurrence 
Substantive associations were revealed however between DVT recurrence 
within 24 months and age, treatment type, and the presence of a new episode 
of superficial thrombophlebitis during this period.   
 
Examination of the distribution of DVT recurrence by age group (Figure 8.5) 
showed that DVT recurrence was greatest between the ages of 26-35 and 56-
65. It should be considered however that exclusion from the study of 
participants with a previous ipsilateral DVT may have contributed to lower 
recurrences in the older age groups as some of those with an increased risk of 
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recurrence had already been excluded due to previous recurrent episodes. The 
increase in DVT recurrence in the older age group may be related to the 
increased risk of other co-morbidities such as cancer, immobility and 
orthopaedic surgery as well as age. 
 
Figure 8.5 Frequency data for DVT recurrence within 24 months by age group. 
 
 
 
 
However, examining the data for any association between age as a 
dichotomous variable and DVT recurrence within 24 months (Table 8.3) 
indicated that recurrence was more likely in those aged ≤ 35 years compared to 
those aged >35 years with an odds ratio of 4.05 (95% CI 1.46 – 11.23, p = 
0.007)). This possible relationship was investigated further through inclusion in 
the regression model. 
 
Table 8.3 Cross tabulation of frequency data for DVT recurrence within 24 
months by age group. 
Age category & DVT recurrence 
Missing predictor variable = 0, Missing outcome variable = 21 
Age category 
No DVT recurrence 
n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
18-35 years 13 (62) 8 (38) 21 (100) 
36-85 years 112 (87) 17 (13) 129 (100) 
Total 125 (83) 25 (17) 150 (100) 
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An association was also seen between DVT recurrence within 24 months and 
the type of anticoagulation therapy received for the index DVT (Table 8.4). 
Frequency data demonstrated that participants treated with DOACs were more 
than three times less likely to experience a DVT recurrence during the follow-up 
period than those treated with LMWH and warfarin (OR = 3.63 (95% CI 1.26 – 
10.44, p = 0.017)).  
 
Table 8.4 Cross tabulation of frequency data for DVT recurrence within 24 
months by treatment type. 
Treatment type & DVT recurrence 
Missing predictor variable = 1, Missing outcome variable = 21 
Treatment Type 
No DVT recurrence 
n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
LMWH & warfarin 12 (63) 7 (37) 19 (100) 
DOACS 112 (86) 18 (14) 130 (100) 
Total 124 (83) 25 (17) 149 (100) 
 
A further potentially important association was noted between DVT recurrence 
within 24 months and the occurrence of a new episode of superficial 
thrombophlebitis within the same time period (Table 8.5). An odds ratio 
demonstrated that those participants that experienced a new episode of 
superficial thrombophlebitis during follow-up had an increased risk of 
developing a recurrent DVT (OR = 2.85 (95% CI 0.89 – 9.18, p = 0.08)). The 
odds ratio crossed one however and was not significant at the 0.05 probability 
level but warranted further examination. 
 
Table 8.5 Cross tabulation of frequency data for participants with a new episode 
of superficial thrombophlebitis and DVT recurrence within 24 months. 
New phlebitis during follow-up & DVT recurrence 
Missing predictor variable = 22, Missing outcome variable = 21 
New phlebitis 
during follow-up 
No DVT recurrence 
n (%) 
DVT recurrence 
n (%) 
Total  
n (%) 
None 113 (86) 18 (14) 131 (100) 
New phlebitis 11 (69) 5 (31) 16 (100) 
Total 124 (84) 23 (16) 147 (100) 
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Results of the chi-square analysis for all variables examined and their 
relationship with DVT recurrence within 24 months of the index DVT event are 
shown in Table 8.6.  The Chi-square analysis confirmed no significant 
association between recurrent DVT and sex, BMI, smoking history, DVT 
location, TLS of index DVT at diagnosis, whether the index DVT was provoked 
or unprovoked, pre-existing venous incompetence, treatment duration, stocking 
use, the duration of symptoms prior to commencing anticoagulation therapy or 
whether the index DVT had resolved by the time its treatment with 
anticoagulation therapy was ceased. A p-value cut off of < 0.25 was used to 
identify those variables for further examination through inclusion in the 
regression model instead of the standard p value of 0.05 due to its potential 
failure to specify all important independent variables when fitted to a 
multivariate model (Bursac et al 2008). 
 
Table 8.6 Results of chi-square tests of independence by independent variable 
with * indicating those variables selected for inclusion in the regression model 
(based on p = <0.25 as previously described in Section 4.5). 
Independent variable n 
Chi-
square 
df 
Asymptotic 
sig (2-sided) 
Age ≤35 or ≥36 at study entry* 150 8.07 1 <0.01 
Treatment type* 149 6.28 1 0.01 
New episode superficial thrombophlebitis during 
follow-up* 147 3.12 1 0.07 
Index DVT resolution within 3 months post diagnosis 150 0.91 1 0.34 
Treatment duration category 150 0.83 1 0.36 
Index DVT resolved at point of stopping 
anticoagulation treatment 150 1.52 2 0.47 
Smoking 150 1.45 2 0.49 
Sex 150 0.09 1 0.76 
Provocation status 150 0.09 1 0.76 
DVT location (proximal or distal) 150 0.09 1 0.77 
Concurrent superficial thrombophlebitis at DVT 
diagnosis 150 0.08 1 0.78 
Pre-existing venous incompetence 150 0.07 1 0.79 
BMI category at study entry 150 1.54 4 0.82 
Duration of consistent use of compression 150 0.57 3 0.90 
Duration of symptoms before starting treatment 150 0.41 3 0.94 
TLS of index DVT at diagnosis (TLS) 150 0.42 3 0.94 
Key: 
BMI: body mass index DVT: deep vein thrombosis TLS: thrombus load score 
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8.6 Results of the regression analysis 
Some of the three independent variables identified as having a potentially 
important association with DVT recurrence within 24 months (age ≤35 or ≥36 at 
study entry, treatment type and new phlebitis during follow-up) might have been 
confounding each other and so multiple regression analysis was required to 
determine the degree of independent association which could be related to 
causation. The independent variables were entered into the regression model 
as described in Section 4.5 of the methods chapter and the full model output is 
presented in Appendix A6. The variable for new episode of superficial 
thrombophlebitis was removed from the model at step 2. The model explained 
10 % (Nagelkerke R2) of the variance in DVT recurrence within 24 months. The 
results of the regression analysis demonstrated that, of the three independent 
variables examined in the model, only age maintained a significant relationship 
with DVT recurrence within 24 months at the p = <0.05 level although treatment 
type was very close to reaching significance Table 8.7).  
 
Table 8.7 Results from the backwards stepwise regression analysis to examine 
adjusted relationships between age, treatment type and DVT recurrence within 
24 months.  
 
Regression 
Coefficient 
S.E. df Sig. 
Adjusted 
OR 
95% C.I.for 
Adjusted OR 
Lower Upper 
Step 
2
a
 
Age at study entry 
≥36 (reference) or 
≤35 1.25 .552 1 .024 
1 
3.48 1.18 10.3 
Treatment type 
DOACs (reference) 
or LMWH & warfarin 1.11 .582 1 .057 
1 
3.02 .965 9.44 
 
The regression analysis was then re-run with the final step variables (age and 
treatment type) entered in a single step in order to avoid the program only using 
cases that were not missing on all tested independent variables (Table 8.8).  
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Table 8.8 Results from the entry method regression analysis when final model 
variables were entered in a single step to examine the adjusted relationship 
between age and treatment type on DVT recurrence within 24 months.   
 
Regression 
Coefficient 
S.E. df Sig. 
Adjusted 
OR 
95% C.I.for 
Adjusted OR 
Lower Upper 
Step 
1
a
 
Age at study entry 
≥36 (reference) or 
≤35 1.276 .534 1 .017 
1 
3.58 1.26 10.2 
Treatment type 
DOACs (reference) 
or LMWH & warfarin 1.151 .560 1 .040 
1 
3.16 1.06 9.46 
 
Using a single step entry technique both age and treatment type demonstrated 
a significant relationship with DVT recurrence within 24 months. Participants 
aged ≤35 years at the time of the index DVT diagnosis were more likely to 
experience a DVT recurrence within 24 months than those aged ≥36 years with 
an adjusted OR = 3.58 (95% CI 1.26 – 10.2, p <0.05). Participants treated with 
LMWH and warfarin were also more likely to experience a DVT recurrence 
within 24 months than those treated with DOACs (Rivaroxaban) with an 
adjusted OR = 3.16 (95% CI 1.06 – 9.46, p <0.05).  
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CHAPTER 9: RESULTS – VENOUS INCOMPETENCE   
 
9.1 Introduction 
This is the third of four chapters describing the results of the data analysis for 
the four primary endpoints of the observational study. This chapter reports the 
examination of the data obtained regarding the development of venous 
incompetence within 24 months of the index DVT event and the results of the 
examination for any associations between baseline characteristics or those that 
presented during follow-up. 
 
9.2 Venous incompetence overview 
Venous incompetence was detected in at least one of either the deep or 
superficial veins in 76 of the 174 limbs studied (44%) at some point during the 
24 month follow-up period. 80/174 limbs (46%) had no evidence of venous 
incompetence in any of the deep or superficial veins of the leg in which the 
index DVT occurred at any of the follow-up time points (Figure 9.1). Data were 
missing for 18/174 cases (10%). 
 
Figure 9.1 Presence of any venous incompetence (defined as pre-existing 
and/or newly developed incompetence in any vein in either the deep or 
superficial venous system at any time during the 24 month follow-up period) (n 
= 174 limbs). 
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As illustrated in Figure 9.2, where the presence of any venous incompetence 
was detected, superficial venous incompetence was detected in 52 limbs (68% 
of the 76 cases where venous incompetence was detected). Deep venous 
incompetence was detected in 43/76 of the limbs with any venous 
incompetence (57% of cases) and incompetence was detected in both the deep 
and superficial venous systems concurrently in 19/76 cases (25% of cases).  
 
Figure 9.2 Location of any venous incompetence (defined above) (n = 174 
limbs). 
 
 
 
Pre-existing venous incompetence (defined here as venous incompetence 
detected at any site at the first research visit) was present in 37/174 of the limbs 
in the study (21%) and this was located in the superficial venous system in all 
cases. Pre-existing deep venous incompetence was not detected in any of the 
patent deep venous segments in any of the 174 limbs at the first follow-up visit 
but it cannot be excluded that pre-existing deep venous incompetence may 
have been present in the segments where the DVT was present (and therefore 
could not be assessed for competence at that time).  
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Confirmed new venous incompetence (defined here as venous incompetence at 
a site where no venous incompetence had been detected during the first 
research visit) developed in at least one vein in 49/174 (28%) studied over 24 
months. As illustrated in Figure 9.3, for 8/49 (16%) of the cases of new venous 
incompetence this occurred in the superficial venous system alone, for 36/49 
(74%) of the limbs new venous incompetence was detected in the deep venous 
system alone and in 5/49 limbs (10%) new venous incompetence was detected 
in both the deep and superficial venous systems. The presence of pre-existing 
superficial venous incompetence had been detected at the first research visit in 
a third of the limbs (12/36, 33%) that later developed venous incompetence in 
the deep venous system during the 24 month follow-up period.  
 
Figure 9.3 Location of venous incompetence newly developed within 24 months 
of index DVT diagnosis (n = 49 limbs). 
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9.3 Selection of variables and data manipulation  
Putative predictors of venous incompetence (Table 9.1) were selected and the 
data for the continuous variables age, BMI, symptoms duration, compression 
stocking use and TLS at diagnosis were categorised as previously described in 
Section 7.5. The data for compression stocking use was then further 
categorised into two categories where compression stockings were not used 
and where they were used (i.e. for any duration longer than 3 weeks).  
 
Table 9.1 List of variables selected for examination for any relationship with 
venous incompetence. 
Variables selected for examination for any 
relationship with venous incompetence  
Age 
Sex 
BMI 
Hypertension 
Treatment type 
Treatment duration 
Smoking 
Thrombus burden (TLS) at diagnosis 
DVT location 
Provoked or unprovoked DVT 
Pre-existing venous incompetence 
Stocking use 
Index DVT resolved within 24 months 
Thrombus evolution pattern at 3 months 
Phlebitis on DVT diagnosis 
New phlebitis during follow-up 
Duration of symptoms before diagnosis 
DVT recurrence within 24 months 
 
Key: 
BMI: body mass index 
DVT: deep vein thrombosis 
TLS: thrombus load score 
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9.4 Factors not associated with venous incompetence 
An examination of associations between the potentially important independent 
variables (listed in Table 9.1) for which data had been collected and the 
dependent variable of the development of new venous incompetence within 24 
months was conducted, as described previously in Section 7.6 for DVT 
resolution. Cross tabulation of frequencies revealed no substantive associations 
between the development of new venous incompetence within 24 months and 
age, sex, smoking history, hypertension, BMI, the presence of pre-existing 
venous incompetence, the duration of symptoms prior to commencing 
anticoagulation therapy or the occurrence of a new episode of superficial 
thrombophlebitis during follow-up (Table 9.2). 
 
Table 9.2 Cross tabulations for independent variables where no statistically 
significant association (at p<0.05) with new venous incompetence within 24 
months was identified. 
Age category & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
Age category 
No new venous 
incompetence n (%) 
New venous 
incompetence n (%) 
Total  
n (%) 
18-45 27 (63) 16 (37) 43 (100) 
46-65 34 (69) 15 (31) 49 (100) 
66-85 39 (68) 18 (32) 57 (100) 
Total 100 (67) 49 (33) 149 (100) 
 
Sex & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
Sex 
No new venous 
incompetence n (%) 
New venous 
incompetence n (%) 
Total  
n (%) 
Male 60 (65) 32 (35) 92 (100) 
Female 40 (70) 17 (30) 57 (100) 
Total 100 (67) 49 (33) 149 (100) 
 
Smoking history & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
Smoking history 
No new venous 
incompetence n (%) 
New venous 
incompetence n (%) 
Total  
n (%) 
Never smoked 49 (69) 22 (31) 71 (100) 
Ex-smoker 35 (64) 20 (36) 55 (100) 
Current smoker 16 (70) 7 (30) 23 (100) 
Total 100 (67) 49 (33) 149 (100) 
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Hypertension & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
Hypertension 
No new venous 
incompetence n (%) 
New venous 
incompetence n (%) 
Total  
n (%) 
No hypertension 70 (65) 38 (35) 108 (100) 
Hypertension 30 (73) 11 (27) 41 (100) 
Total 100 (67) 49 (33) 149 (100) 
 
BMI & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
BMI 
No new venous 
incompetence n (%) 
New venous 
incompetence n (%) 
Total  
n (%) 
Not over weight 27 (77) 8 (23) 35 (100) 
Over weight 85 (76) 27 (24) 112 (100) 
Total 112 (76) 35 (24) 149 (100) 
 
Pre-existing venous incompetence & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
Pre-existing 
superficial venous 
incompetence 
No new venous 
incompetence n (%) 
New venous 
incompetence n (%) 
Total  
n (%) 
None 79 (68) 37 (32) 116 (100) 
Yes 21 (64) 12 (36) 33 (100) 
Total 100 (67) 49 (33) 149 (100) 
 
Duration of symptoms before diagnosis & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
Duration of 
symptoms 
No new venous 
incompetence n (%) 
New venous 
incompetence n (%) 
Total  
n (%) 
≤ 3 days 29 (76) 9 (24) 38 (100) 
4-7 days 38 (66) 20 (34) 58 (100) 
8-30 days 26 (59) 18 (41) 44 (100) 
≥ 31 days 7 (78) 2 (22) 9 (100) 
Total 100 (67) 49 (33) 149 (100) 
 
New phlebitis during follow-up & new venous incompetence 
Missing predictor variable = 22, Missing outcome variable = 22 
Phlebitis in follow-up 
No new venous 
incompetence n 
(%) 
New venous 
incompetence n (%) 
Total  
n (%) 
None 90 (68) 42 (32) 132 (100) 
New phlebitis 10 (67) 5 (33) 15 (100) 
Total 100 (68) 47 (32) 147 (100) 
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9.5 Factors associated with venous incompetence 
Cross tabulation of frequencies did however reveal strong associations between 
new venous incompetence within 24 months and several of the variables tested. 
Examination of the distribution of cases where new venous incompetence 
developed by DVT location (Table 9.3) indicated that those with a proximal DVT 
were more than four times more likely to develop new venous incompetence 
within 24 months of the diagnosis of their index DVT than those with a distal 
DVT (OR = 4.82 (95% CI 2.24 – 10.37, p <0.001)). 
 
Table 9.3 Cross tabulation of frequency data for the development of new 
venous incompetence within 24 months by DVT location. 
DVT location & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
DVT location 
No new 
incompetence 
n (%) 
New 
incompetence 
n (%) 
Total  
n (%) 
Distal 61 (84) 12 (16) 73 (100) 
Proximal 39 (51) 37 (49) 76 (100) 
Total 100 (67) 49 (33) 149 (100) 
 
 
A potential significant relationship was also seen between the thrombus 
evolution pattern of the index DVT at 3 months post diagnosis and the 
development of new venous incompetence within 24 months (Table 9.4) with 
fast resolution potentially associated with not developing venous incompetence. 
The percentage of participants that developed new venous incompetence in 24 
months of DVT diagnosis was less in participants for whom the DVT resolved 
within three months and were therefore categorised in the fast resolution 
category. When the thrombus evolution categories were grouped into two 
categories of fast resolution and non-fast resolution, those participants whose 
DVT did not resolve within three months of diagnosis were more likely to 
develop new venous incompetence than in the fast resolution evolution 
category (OR = 4.22 (95% CI 1.94 – 9.19, p = <0.001)). It must be considered 
however that any venous incompetence considered new may have been pre-
existing in any venous segments where DVT was present at the first research 
visit but could not be detected until the thrombus resolved.  
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Table 9.4 Cross tabulation of frequency data for the development of new 
venous incompetence within 24 months by index DVT thrombus evolution 
pattern at 3 months. 
Thrombus evolution pattern at 3 months & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
Thrombus evolution pattern 
at 3 months  
No new 
incompetence 
n (%) 
New 
incompetence 
n (%) 
Total  
n (%) 
Fast resolution (< 3 months) 55 (83) 11 (17) 66 (100) 
All other categories (static, 
reducing, extending) 
45 (54) 38 (46) 83 (100) 
Total 100 (67) 49 (33) 149 (100) 
 
A relationship was discovered between the presence of residual thrombus at 24 
months post DVT diagnosis and the development of new venous incompetence 
within the same period (Table 9.5). Those participants for whom the index DVT 
had not resolved within 24 months were more than three times more likely to 
develop new venous incompetence within the same time period (OR = 3.69 
(95% CI 1.77 – 7.69, p = <0.001)). 
 
Table 9.5 Cross tabulation of frequency data for the development of new 
venous incompetence within 24 months by complete index DVT resolution 
within the same time period. 
Index DVT resolved within 24 months & new venous incompetence 
Missing predictor variable = 13, Missing outcome variable = 22 
Index DVT resolution 
No new 
incompetence 
n (%) 
New 
incompetence 
n (%) 
Total  
n (%) 
Resolved 78 (78) 22 (22) 100 (100) 
Not resolved 24 (49) 25 (51) 49 (100) 
Total 100 (67) 49 (33) 149 (100) 
 
 
 
249 
 
A further relationship was seen between the thrombus load score of the index 
DVT at diagnosis and the development of new venous incompetence within 24 
months (Table 9.6) with a TLS of ≥ 5 associated with an increased likelihood of 
developing new venous incompetence (OR = 3.13 (95% CI 1.51 – 6.47, p = 
<0.01)). 
 
Table 9.6 Cross tabulation of frequency data for the development of new 
venous incompetence within 24 months by TLS of the index DVT at diagnosis. 
TLS at index DVT diagnosis & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
Thrombus load score at 
diagnosis 
No new 
incompetence 
n (%) 
New 
incompetence 
n (%) 
Total  
n (%) 
1-4 58 (79) 15 (21) 73 (100) 
≥ 5 42 (55) 34 (45) 76 (100) 
Total 100 (67) 49 (33) 149 (100) 
 
 
As shown in Table 9.7, the duration of anticoagulation therapy for the index 
DVT appeared to be associated with the development of new venous 
incompetence within 24 months with those prescribed extended anticoagulation 
more likely to develop incompetence (OR = 2.35 (95% CI 1.16 – 4.77, p = 
<0.05)). The type of anticoagulation therapy prescribed also appeared to be 
important (Table 9.8) with those prescribed LMWH and warfarin almost three 
times more likely to develop new incompetence than those prescribed DOACs 
(Rivaroxaban) (OR = 2.92 (95% CI 1.07 – 7.95, p = <0.05)).  
 
Table 9.7 Cross tabulation of frequency data for the development of new 
venous incompetence within 24 months by treatment duration. 
Treatment duration  & new venous incompetence 
Missing predictor variable = 6, Missing outcome variable = 22 
Treatment duration 
No new 
incompetence 
n (%) 
New 
incompetence 
n (%) 
Total  
n (%) 
≤ 3 months 71 (74) 25 (26) 96 (100) 
> 3 months 29 (55) 24 (45) 53 (100) 
Total 100 (67) 49 (33) 149 (100) 
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Table 9.8 Cross tabulation of frequency data for the development of new 
venous incompetence within 24 months by treatment type. 
Treatment Type  & new venous incompetence 
Missing predictor variable = 1, Missing outcome variable = 22 
Treatment type 
No new 
incompetence 
n (%) 
New 
incompetence 
n (%) 
Total  
n (%) 
LMWH & warfarin 8 (44) 10 (56) 18 (100) 
DOACS 91 (70) 39 (30) 130 (100) 
Total 99 (67) 49 (33) 148 (100) 
 
 
Table 9.9 shows that consistent use of compression stockings for longer than 3 
weeks also appeared to be associated with the development of new venous 
incompetence (OR = 2.18 (95% CI 1.03 – 4.59, p = <0.05)). This is however 
likely a result of multi-collinearity caused by the fact that those suffering from 
the symptoms caused by venous incompetence were more likely to have 
increased compliance with stocking use as they reduce the symptoms of pain 
and swelling.  In addition, the advice concerning stocking use changed during 
the course of the study as a result of evidence from the SOX Trial (Kahn et al, 
2014a). Initially participants were advised to wear the stockings for two years 
post DVT diagnosis; however, from 2014 onwards participants were advised to 
continue to wear the stockings if they found them beneficial. 
 
Table 9.9 Cross tabulation of frequency data for the development of new 
venous incompetence within 24 months by consistent use of compression 
stockings. 
Compression stocking use & new venous incompetence 
Missing predictor variable = 5, Missing outcome variable = 22 
Compression stocking use 
No new 
incompetence 
n (%) 
New 
incompetence 
n (%) 
Total  
n (%) 
Not used 44 (77) 13 (23) 57 (100) 
Used >3 weeks 56 (61) 36 (39) 92 (100) 
Total 100 (67) 49 (33) 149 (100) 
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On examination of the frequency data and by calculating an odds ratio, three 
further independent variables examined showed potential associations with a 
slightly greater likelihood of developing new venous incompetence within 24 
months but did not reach a probability value of less than 0.05 to reject the null 
hypothesis. Although the 95% confidence intervals crossed one, these variables 
warranted further investigation through inclusion in the regression model.  
 
The frequency data in Table 9.10 indicated that the presence of concurrent 
phlebitis on DVT diagnosis appeared to be associated with an increased 
likelihood of developing new venous incompetence (OR = 2.27 (95% CI 0.99 – 
5.19, p = 0.08)).  
Table 9.10 Cross tabulation of frequency data for the development of new 
venous incompetence within 24 months by the presence of concurrent 
superficial thrombophlebitis at index DVT diagnosis. 
Phlebitis on DVT diagnosis & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
Phlebitis 
No new 
incompetence n (%) 
New incompetence 
n (%) 
Total  
n (%) 
None 85 (71) 35 (29) 120 (100) 
Phlebitis 15 (52) 14 (48) 29 (100) 
Total 100 (67) 49 (33) 149 (100) 
 
Unprovoked DVT also appeared to have a potential association with the 
development of new incompetence as shown in Table 9.11 (OR = 1.81 (95% CI 
0.84 – 3.90, p = 0.13)) as did DVT recurrence (Table 9.12) (OR = 1.98 (95% CI 
0.79 – 4.99, p = 0.14)).  
 
Table 9.11 Cross tabulation of frequency data for the development of new 
venous incompetence within 24 months by index DVT provocation status. 
Provocation status & new venous incompetence 
Missing predictor variable = 0, Missing outcome variable = 22 
Provocation 
status 
No new 
incompetence n (%) 
New incompetence 
n (%) 
Total  
n (%) 
Unprovoked 63 (63) 37 (37) 100 (100) 
Provoked 37 (76) 12 (24) 49 (100) 
Total 100 (67) 49 (33) 149 (100) 
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Table 9.12 Cross tabulation of frequency data for the development of new 
venous incompetence within 24 months by DVT recurrence. 
DVT recurrence within 24 months & new venous incompetence 
Missing predictor variable = 22, Missing outcome variable = 22 
DVT recurrence 
within 24 months 
No new 
incompetence n 
(%) 
New 
incompetence n 
(%) 
Total  
n (%) 
No recurrence 88 (70) 37 (30) 125 (100) 
Recurrence 12 (55) 10 (45) 22 (100) 
Total 100 (68) 47 (32) 147 (100) 
 
 
Results of the chi-square analysis for all variables examined and their 
relationship with the development of new venous incompetence within 24 
months of the index DVT event are shown in Table 9.13.  The Chi-square 
analysis confirmed no significant (p<0.05) association between the 
development of venous incompetence and age, sex, BMI, smoking history, 
hypertension, pre-existing venous incompetence, the duration of symptoms 
prior to commencing anticoagulation therapy or the occurrence of a new 
episode of superficial thrombophlebitis during follow-up. Again, a p-value cut off 
of < 0.25 instead of the standard p value of 0.05 was used to identify those 
variables for further examination through inclusion in the regression model as 
described in Section 4.5 of the methods chapter. 
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Table 9.13 Results of chi-square tests of independence by independent 
variable with * indicating those variables selected for inclusion in the regression 
analysis for relationship with the development of new venous incompetence 
within 24 months of index (based on p = <0.25 as previously described in 
Section 4.5). 
Independent variable n 
Chi-
square 
Df 
Asymptotic 
sig (2-
sided) 
DVT location* 149 17.54 1 <0.001 
Thrombus evolution pattern at 3 months 
post DVT diagnosis* 149 14.12 1 <0.001 
Index DVT resolved within 24 months* 149 13.54 1 <0.001 
TLS index DVT at diagnosis* 149 9.87 1 <0.01 
Treatment duration category* 149 5.73 1 <0.05 
Treatment type* 149 4.66 1 <0.05 
Consistent use of compression stockings 
for > 3 weeks* 149 4.25 1 <0.05 
Concurrent superficial thrombophlebitis at 
DVT diagnosis* 149 3.86 1 <0.05 
Provocation status* 149 2.33 1 0.13 
DVT recurrence within 24 months* 147 2.16 1 0.14 
Hypertension 149 0.94 1 0.33 
Duration of symptoms before starting 
treatment 149 3.27 3 0.35 
Sex 149 0.39 1 0.53 
Pre-existing venous incompetence 149 0.23 1 0.63 
BMI category at study entry 149 2.51 4 0.64 
Age category at study entry 149 0.52 2 0.77 
Smoking 149 0.48 2 0.79 
New episode superficial thrombophlebitis 
during follow-up 147 0.01 1 0.91 
 
Key: 
BMI: body mass index 
DVT: deep vein thrombosis 
TLS: thrombus load score 
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9.6 Results of the regression analysis 
 
Because some of the ten variables identified as having a potentially important 
association with the development of new venous incompetence within 24 
months might have been confounding each other multiple regression analysis 
was required to determine their degree of independent association.  
 
A two-stage logistic regression modelling procedure was used to account for the 
limitations of the sample size and the number of variables asspociated with this 
outcome and the full model outputs are presented in Appendix A6. The 
variables were grouped together chronologically according to whether they were 
baseline characteristics (Group 1: DVT location, TLS at diagnosis, treatment 
type, concurrent superficial thrombophlebitis at DVT diagnosis and DVT 
provocation status) or characteristics associated with follow-up (Group 2: 
thrombus evolution pattern at three months post DVT diagnosis, resolution of 
the index DVT within 24 months, anticoagulation treatment duration, consistent 
use of compression stockings and DVT recurrence during follow-up).  
 
 
In the Group 1 model, the variable for TLS on index DVT diagnosis was 
removed from the model at step 2 and the variable for provocation status was 
removed at step 3. The model explained 22.0% (Nagelkerke R2) of the variance 
in the development of new venous incompetence within 24 months. Of the five 
independent variables examined in the model, only three (DVT location, 
treatment type and concurrent superficial thrombophlebitis at the time of index 
DVT diagnosis) maintained a significant relationship with new venous 
incompetence within 24 months at the 0.1 probability level for inclusion in the 
combined model when adjusted for possible confounding (Table 9.14).  
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Table 9.14 Results from the Group 1 model of the backwards stepwise 
regression analysis to examine adjusted relationships between DVT location, 
treatment type and concurrent superficial thrombophlebitis at index DVT 
diagnosis on the development of new venous incompetence within 24 months.  
 
Regression 
Coefficient S.E. 
d
f Sig. 
Adjusted 
OR 
95% C.I.for 
Adjusted OR 
Lower Upper 
Step 
3
a
 
DVT location              
distal (reference) or            
proximal 1.57 .404 1 <0.001 
1 
4.81 2.18 10.6 
Treatment type DOACs 
(reference)  or           
LMWH & warfarin 1.28 .570 1 .025 
1 
3.59 1.18 11.0 
Concurrent superficial 
thrombophlebitis at DVT 
diagnosis                 
absent (reference) or 
present .888 .466 1 .057 
 
1 
2.43 .975 6.06 
 
 
In the second Group 2 model, the variable for anticoagulation duration category 
was removed from the model at step 2 and the variable for DVT recurrence 
within 24 months was removed at step 3. The model explained 20.3% 
(Nagelkerke R2) of the variance. Of the five independent variables examined in 
the model, again only three (thrombus evolution pattern at 3 months, index DVT 
resolution status and compression stocking use) maintained a significant 
relationship with new venous incompetence within 24 months for inclusion in the 
combined model when adjusted for confounding.  
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Table 9.15 Results from the final Group 2 model of the backwards stepwise 
regression analysis to examine adjusted relationships between index DVT 
thrombus evolution pattern, index DVT resolution within 24 months and the 
consistent use of compression stockings on the development of new venous 
incompetence within 24 months. 
 
Regression 
Coefficient S.E. df Sig. 
Adjusted 
OR 
95% C.I.for 
Adjusted OR 
Lower Upper 
Step 
3
a
 
Thrombus evolution pattern 
at 3 months 
Fast (reference) or 
Other 1.07 .502 1 .033 
1 
2.92 1.09 7.82 
Index DVT resolution status  
Resolved (reference) or  
Not resolved .839 .472 1 .075 
1 
2.31 .918 5.83 
Compression stocking use 
not used (reference) or  
used  for > 3 weeks  .854 .413 1 .038 
1 
2.35 1.05 5.27 
 
 
The six variables that maintained a significant relationship with the development 
of new venous incompetence within 24 months at the 0.1 probability level (DVT 
location, treatment type, the presence of concurrent superficial thrombophlebitis 
on index DVT diagnosis, thrombus evolution pattern at three months, index DVT 
resolution within two years and the consistent use of compression stockings) 
were then entered into a combined model. The model explained 25.9% 
(Nagelkerke R2) of the variance in the development of new venous 
incompetence within 24 months. Thrombus evolution pattern at 3 months was 
removed at step two. The results of the final regression analysis demonstrated 
that, of the six independent variables examined in the model, only three (DVT 
location, the use of compression stockings and treatment type) maintained a 
significant relationship with new venous incompetence within 24 months at the 
0.05 probability level when adjusted for possible confounding by other variables 
(Table 9.16) although the presence of concurrent superficial phlebitis at index 
DVT diagnosis and the resolution of the index DVT within 24 months were close 
to reaching significance at the 0.05 probability level.  
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Table 9.16 Results from the final combined Group 1 and Group 2 backwards 
stepwise regression model for new venous incompetence within 24 months 
 
 
Regression 
Coefficient 
S.E. df Sig. 
Adjusted 
OR 
95% C.I.for 
Adjusted OR 
Lower Upper 
Step 
2
a
 
DVT location                                 
distal (reference) or                              
proximal 1.08 .488 1 .028 
1 
2.93 1.13 7.63 
Concurrent superficial 
thrombophlebitis at DVT 
diagnosis                
absent (reference) or                
present .947 .494 1 .055 
1 
2.58 0.979 6.80 
Compression stockings 
not used (reference) or  
used  for > 3 weeks 1.02 .450 1 .024 
1 
2.77 1.15 6.71 
Treatment type     
DOACs (reference) or          
LMWH & warfarin 1.58 .611 1 .010 
1 
4.85 1.46 16.1 
Index DVT resolution 
status  
Resolved (reference) or  
Not resolved .957 .492 1 .052 
1 
2.60 0.99 6.85 
 
 
The regression analysis was then re-run with the final model variables entered 
in a single step in order to avoid the program only using cases that were not 
missing on all tested independent variables. As shown in Table 9.17, when 
adjusted for confounding, DVT location, treatment type and the consistent use 
of compression stockings for > 3 weeks all maintained a significant relationship 
with the development of new venous incompetence within 24 months.  
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Table 9.17 Results from the final model of the entry method regression analysis 
to examine adjusted relationships between DVT location, treatment type and 
the consistent use of compression stockings on the development of new venous 
incompetence within 24 months when entered in a single step.   
 
Regression 
Coefficient 
S.E. df Sig. 
Adjusted 
OR 
95% C.I.for 
Adjusted OR 
Lower Upper 
Step 
1
a
 
DVT location                                 
distal (reference) or                              
proximal 1.08 .488 1 .028 
1 
2.93 1.13 7.63 
Concurrent superficial 
thrombophlebitis at DVT diagnosis 
absent (reference) or                
present .947 .494 1 .055 
1 
2.58 0.979 6.80 
Compression stockings              not 
used (reference) or  
used  for > 3 weeks 1.02 .450 1 .024 
1 
2.77 1.15 6.71 
Treatment type DOACs (ref) or 
LMWH & warfarin 1.58 .611 1 .010 
1 
4.85 1.46 16.1 
Index DVT resolution status  
Resolved (reference) or  
Not resolved .957 .492 1 .052 
1 
2.60 0.992 6.85 
 
Therefore, those participants prescribed LMWH and warfarin were more than 
four times more likely to develop new venous incompetence within 24 months 
than those prescribed DOACs (Rivaroxaban) (OR = 4.85 (95% CI 1.46 – 16.1, p 
= <0.05)). In addition, those with a proximal DVT were more likely to develop 
new venous incompetence within 24 months of the diagnosis of their index DVT 
than those with a distal DVT (OR = 2.58 (95% CI 1.13 – 7.63, p = <0.05)). 
Finally, those participants that consistently used compression stockings for 
longer than 3 weeks were more likely to develop new venous incompetence 
than those not using stockings (OR = 2.77 (95% CI 1.15 – 6.71, p = <0.05)). 
This relationship is however likely to reflect the increased use of, and 
compliance with, compression therapy for the management of the symptoms of 
venous incompetence rather than a causative relationship and is discussed 
further in Chapter 11, Section 11.4. 
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CHAPTER 10: RESULTS - PTS  
 
10.1 Introduction 
This is the final chapter of the four chapters describing the results of the data 
analysis for the four primary endpoints for the study. This chapter reports the 
examination of the data obtained regarding the development of PTS at 24 
months post the index DVT event and the results of the examination for any 
associations between baseline characteristics or those that presented during 
follow-up. 
 
10.2 PTS overview 
The 171 study participants were assessed at each follow-up visit for the 
presence of pain and/or swelling in the leg in which the index DVT was 
diagnosed prior to the formal PTS assessment at 24 months post DVT. The 
number of participants describing pain and/or with visible swelling to the leg at 
each follow-up time point is described in Figure 10.1. All participants remained 
symptomatic for pain and/or swelling at one week post diagnosis of the index 
DVT but from the one month to the 12 month follow-up time points the number 
of participants remaining symptomatic for pain and/or swelling steadily reduced. 
There was however a small increase in the number of participants reporting 
pain and/or swelling at the 24 month follow-up time point which may be 
indicative of the development of PTS occurring between 12 and 24 months post 
diagnosis of the index DVT. It must also be considered however that there may 
be an element of confounding from other sources such as DVT recurrences and 
patient reporting of symptoms being different at the final visit.  
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Figure 10.1 Number of participants symptomatic for pain and/or swelling at 
each of the six follow-up time intervals post diagnosis of the index DVT (n = 171 
participants, 174 limbs).  
 
 
 
Formal assessment for the presence of PTS was undertaken on 150 limbs in 
147 participants at 24 months post the diagnosis of the index DVT using the 
Villalta Scale as the measurement tool. As illustrated in Figure 10.2, PTS was 
considered absent (defined as Villalta score <5) in 98/171 cases (56% of the 
whole cohort) and considered to be present to some degree (indicated by a 
Villalta score ≥ 5) in 52/171 cases (30% of the cohort) as defined in Section 
1.6.2 of the introduction chapter (Villalta et al, 1994). It was not possible to 
determine the presence of absence of PTS in those participants who did not 
attend for the final follow-up visit at 24 months when the assessment for PTS 
was made (24/171 cases, 14% of the cohort).  
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Figure 10.2 Number of participants with PTS (Villalta Score ≥5) at 24 months 
post index DVT diagnosis (n = 171 participants, 174 limbs).  
 
 
 
As illustrated in Figure 10.3, the majority of the cases where PTS was 
considered present, the disease was classified as mild (Villalta score 5-9) 
(40/52, 77%) with only small percentages classified as moderate (4/52, 8%) and 
severe (8/52, 15%). 
 
Figure 10.3 PTS severity across the cohort at 24 months post index DVT 
diagnosis where Villalta Score ≤4 = no PTS, 5-9 mild PTS, 10-14 moderate PTS 
and ≥15 or the presence of a venous ulcer = severe PTS (n = 171 participants, 
174 limbs).  
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An examination of the individual elements of the Villalta Scale scoring system 
(see Fig. 10.4) was undertaken to establish if there was any trend present in the 
scoring of the individual elements or the frequency with which they were cited. 
As shown in Figures 10.4 and 10.5, there was consistency between the scoring 
and frequency of the individual elements of the scoring system. Of the patient 
reported symptoms, cramp was the highest scoring and most frequently cited 
symptom, followed by pain, heaviness and pruritus which each had similar 
scores and frequency. Of the clinician rated indications, pre-tibial oedema was 
both the most frequently observed and the highest scoring element with 
frequency and scores fairly evenly distributed amongst the other clinician rated 
elements of the scale. 
 
 
Figure 10.4 Graphical representation of the combined individual patient scores 
of the 11 elements of the Villalta Scale (6 clinician rated and 5 patient reported) 
for the 150 limbs in 147 participants who were assessed for the presence of 
PTS using the Villalta Scale at 24 months post index DVT diagnosis. 
 
 
 
 
263 
 
Figure 10.5 Graphical representation of the combined citation frequency of the 
11 elements of the Villalta Scale (6 clinician rated and 5 patient reported) for the 
150 limbs in 147 participants who were assessed for the presence of PTS using 
the Villalta Scale at 24 months post index DVT diagnosis. 
 
 
 
10.3 Selection of variables and data manipulation 
Putative predictors of PTS development (Table 10.1) were selected and the 
data for the continuous variables age, BMI, symptoms duration, compression 
stocking use and TLS at diagnosis were categorised as previously described in 
Section 7.5. The data for compression stocking use was then further 
categorised into two categories where compression stockings were not used 
and where they were used (i.e. for any duration longer than 3 weeks). The 
Villalta score data was categorised into those with and without the condition 
(PTS positive defined as Villalta Score ≥5). Categorising the data into the 
smaller categories that quantify the degree of PTS would have resulted in 
groups that were too small for analysis purposes. 
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Table 10.1 List of variables selected for examination for any relationship with 
the development of PTS. 
Variables selected for examination for any 
relationship with the development of PTS  
Age 
Sex 
BMI 
Hypertension 
Treatment type 
Treatment duration 
Smoking 
Thrombus burden (TLS) at diagnosis 
DVT location 
Provoked or unprovoked DVT 
Pre-existing venous incompetence 
Stocking use 
Index DVT resolved within 24 months 
Index DVT resolved at end of treatment 
Thrombus evolution pattern at 3 months 
Phlebitis on DVT diagnosis 
New phlebitis during follow-up 
Duration of symptoms before diagnosis 
DVT recurrence within 24 months 
 
Key: 
BMI: body mass index 
DVT: deep vein thrombosis 
TLS: thrombus load score 
10.4 Factors not associated with PTS 
An examination of associations between the potentially important independent 
variables (listed in Table 10.1) for which data had been collected and the 
dependent variable of the development of PTS at 24 months post index DVT 
was conducted, as described previously in Section 7.6 for DVT resolution. 
Cross tabulation of frequencies revealed no substantive associations between 
PTS development within 24 months and age, treatment type, smoking history, 
hypertension, TLS of index DVT at diagnosis, whether the index DVT was 
provoked or unprovoked, pre-existing venous incompetence, the duration of 
symptoms prior to commencing anticoagulation therapy, whether the index DVT 
had resolved by the time its treatment with anticoagulation therapy was ceased 
or DVT recurrence within 24 months (Table 10.2). 
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Table 10.2 Cross tabulations for independent variables where no statistically 
significant association (at p<0.05) with development of PTS at 24 months was 
identified. 
Age category & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
Age category No PTS n (%) PTS n (%) Total n (%) 
18-45 30 (70) 13 (30) 43 (100) 
46-65 29 (59) 20 (41) 49 (100) 
66-85 37 (67) 18 (33) 55 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
Treatment type & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
Treatment type No PTS n (%) PTS n (%) Total n (%) 
LMWH & warfarin 9 (50) 9 (50) 18 (100) 
DOACS 86 (67) 42 (33) 128 (100) 
None 1 (100) 0 (0) 1 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
Smoking history & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
Smoking history No PTS n (%) PTS n (%) Total n (%) 
Never smoked 47 (66) 24 (34) 71 (100) 
Ex-smoker 34 (64) 19 (36) 53 (100) 
Current smoker 15 (65) 8 (35) 23 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
Hypertension & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
Hypertension No PTS n (%) PTS n (%) Total n (%) 
No hypertension 71 (66) 37 (34) 108 (100) 
Hypertension 25 (64) 14 (36) 39 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
TLS at DVT diagnosis  & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
Thrombus load score at diagnosis No PTS n (%) PTS n (%) Total n (%) 
1-2 25 (69) 11 (31) 36 (100) 
3-4 25 (68) 12 (32) 37 (100) 
5-10 25 (71) 10 (29) 35 (100) 
≥ 11 21 (54) 18 (46) 39 (100) 
Total 96 (65) 51 (35) 147 (100) 
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Provocation status & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
Provocation status No PTS n (%) PTS n (%) Total n (%) 
Unprovoked 62 (63) 36 (37) 98 (100) 
Provoked 34 (69) 15 (31) 49 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
Duration of symptoms before DVT diagnosis & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
Duration of symptoms No PTS n (%) PTS n (%) Total n (%) 
≤ 3 days 26 (68) 12 (32) 38 (100) 
4-7 days 39 (68) 18 (32) 57 (100) 
8-30 days 27 (61) 17 (39) 44 (100) 
≥ 31 days 4 (50) 4 (50) 8 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
Index DVT resolved at end of treatment & PTS 
Missing predictor variable = 10, Missing outcome variable = 24 
Index DVT resolution by 
treatment end 
No PTS n (%) PTS n (%) Total n (%) 
Resolved 49 (71) 20 (29) 69 (100) 
Not resolved 34 (60) 23 (40) 57 (100) 
Lifelong treatment 13 (62) 8 (38)   21 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
DVT recurrence within 24 months & PTS 
Missing predictor variable = 21, Missing outcome variable = 24 
DVT recurrence within 24 months No PTS n (%) PTS n (%) Total n (%) 
No DVT recurrence 83 (66) 42 (34) 125 (100) 
DVT recurrence 13 (59) 9 (41%) 22 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
10.5 Factors associated with PTS 
Cross tabulation of frequencies did however reveal substantive associations 
between the development of PTS and several of the variables tested. A 
potentially significant relationship was seen between the development of PTS at 
24 months and sex (Table 10.3) with women more than twice as likely to 
develop PTS at 24 months post diagnosis of their index DVT than men (OR = 
2.48 (95% CI 1.23 – 4.98, p = <0.05)). 
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Table 10.3 Cross tabulation of frequency data for the development of PTS at 24 
months by sex. 
Sex & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
Sex 
No PTS 
n (%) 
PTS n 
(%) 
Total  
n (%) 
Male 66 (73) 24 (27) 90 (100) 
Female 30 (53) 27 (47) 57 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
 
A strong relationship was also noted between the development of PTS at 24 
months and BMI (Table 10.4) with those participants categorised as overweight 
at the time of their index DVT diagnosis more than four times more likely to 
develop PTS within 24 months than those who were not overweight (OR = 4.18 
(95% CI 1.51 – 11.58, p = <0.01)). 
 
Table 10.4 Cross tabulation of frequency data for the development of PTS at 24 
months by BMI. 
BMI  & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
BMI 
No PTS 
n (%) 
PTS n 
(%) 
Total  
n (%) 
Not overweight 30 (86) 5 (14) 35 (100) 
Overweight 66 (59) 46 (41) 112 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
 
 
As shown in Table 10.5, examination of the distribution of cases with the 
development of PTS at 24 months by DVT location indicated that those with a 
proximal DVT were more than twice as likely to develop PTS than those with a 
distal DVT (OR = 2.68 (95% CI 1.32 – 5.45, p = <0.01)). 
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Table 10.5 Cross tabulation of frequency data for the development of PTS at 24 
months by index DVT location. 
Index DVT location & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
DVT location 
No PTS 
n (%) 
PTS n 
(%) 
Total  
n (%) 
Distal 55 (76) 17 (24) 72 (100) 
Proximal 41 (55) 34 (45) 75 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
 
A potential significant relationship was also seen between the thrombus 
evolution pattern of the index DVT at three months post diagnosis and the 
development of PTS (Table 10.6) with fast resolution potentially associated with 
not developing PTS. The percentage of participants that developed PTS at 24 
months of DVT diagnosis was less in participants for whom the DVT resolved 
within three months and were therefore categorised in the fast resolution 
category. When the thrombus evolution categories were grouped into two 
categories of fast resolution and non-fast resolution, those participants whose 
DVT did not resolve within three months of diagnosis were more likely to 
develop PTS than those who were in the fast resolution category (OR = 2.61 
(95% CI 1.27 – 5.38, p = <0.01)). 
 
Table 10.6 Cross tabulation of frequency data for the development of PTS at 24 
months by index DVT thrombus evolution pattern at three months. 
Thrombus evolution pattern at 3 months  & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
Thrombus evolution pattern at 3 months  
No PTS 
n (%) 
PTS n 
(%) 
Total  
n (%) 
Fast resolution (within 3 months) 50 (77) 15 (23) 65 (100) 
All other categories (static, reducing, 
extending) 
46 (56) 36 (44) 82 (100) 
Total 96 (65) 51 (35) 147 (100) 
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A relationship was also noted between whether the index DVT had resolved 
within 24 months following diagnosis and the development of PTS (Table 10.7). 
Those participants for whom the index DVT had not resolved and where 
residual thrombus remained from the index DVT event were more likely to 
develop PTS at 24 months than those whose index DVT had resolved by this 
time point (OR = 2.46 (95% CI 1.20 – 5.16, p = <0.05)). 
 
Table 10.7 Cross tabulation of frequency data for the development of PTS by 
resolution of the index DVT within 24 months. 
Index DVT resolved within 24 months & PTS 
Missing predictor variable = 13, Missing outcome variable = 24 
Index DVT resolution within 24 months of 
diagnosis 
No PTS 
n (%) 
PTS n 
(%) 
Total  
n (%) 
Resolved 72 (72) 28 (28) 100 (100) 
Not resolved 24 (51) 23 (49) 47 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
 
A potential relationship was also noted between the development of PTS at 24 
months and the presence of venous incompetence. Only a small percentage 
(17/79, 22%) of those with no venous incompetence developed PTS within 24 
months of index DVT diagnosis compared to approximately half of those in each 
of the categories where venous incompetence was present (Table 10.8 and 
Figure 10.6). This was regardless of whether the incompetence was in the deep 
venous system, superficial venous system or both systems. 
 
Table 10.8 Cross tabulation of frequency data for the development of PTS 
within 24 months by the presence and location of venous incompetence. 
Venous incompetence & PTS 
Missing predictor variable = 21, Missing outcome variable = 24 
Deep venous incompetence 
No PTS 
 n (%) 
PTS  
n (%) 
Total  
n (%) 
Superficial only 14 (50) 14 (50) 28 (100) 
Deep only 13 (54) 11 (46) 24 (100) 
Both 7 (44) 9 (56) 16 (100 
None 62 (78) 17 (22) 79 (100 
Total 96 (65) 51 (35) 147 (100) 
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Figure 10.6 Frequency data for the development of PTS at 24 months by the 
presence and location of venous incompetence. 
 
 
 
When the venous incompetence categories were grouped into two categories of 
those with venous incompetence (at any location) and those without, those 
participants with venous incompetence were more than three times more likely 
to develop PTS than those without (OR = 3.65 (95% CI 1.78 – 7.47, p = 
<0.001)). 
 
The frequency data in Table 10.9 indicated that not using compression 
stockings appeared to increase the likelihood of developing PTS (OR = 1.92 
(95% CI 0.96 – 3.85, p = 0.06)). Although the 95% confidence interval crossed 
one, it was close to reaching significance and warranted further investigation. 
 
Table 10.9 Cross tabulation of frequency data for the development of PTS at 24 
months by the use of compression stockings. 
Consistent compression stocking use & PTS 
Missing predictor variable = 5, Missing outcome variable = 24 
Compression stocking use 
No PTS 
n (%) 
PTS n 
(%) 
Total  
n (%) 
Not used 32 (56) 25 (44) 57 (100) 
Used > 3 weeks 64 (71) 26 (29) 90 (100) 
Total 96 (65) 51 (35) 147 (100) 
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Treatment duration (Table 10.10) also appeared to have a potential association 
with the development of PTS with those treated with anticoagulation therapy for 
longer than 3 months being more likely to develop PTS at 24 months of the 
diagnosis of their index DVT than those who were treated for three months or 
less (OR = 1.90 (95% CI 0.94 – 3.83, p = 0.07)).  
 
Table 10.10 Cross tabulation of frequency data for the development of PTS at 
24 months by treatment duration. 
Treatment duration  & PTS 
Missing predictor variable = 6, Missing outcome variable = 24 
Treatment duration 
No PTS 
n (%) 
PTS n 
(%) 
Total  
n (%) 
≤ 3 months 67 (71) 28 (29) 95 (100) 
>3 months 29 (56) 23 (44) 52 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
 
Superficial thrombophlebitis was also a potentially important factor in the 
development of PTS with those who had concurrent phlebitis at the time of their 
index DVT diagnosis (Table 10.11) more likely to develop PTS (OR = 2.00 (95% 
CI 0.86 – 4.68, p = 0.10)) as were those who developed a new episode of 
phlebitis during the 24 month follow-up period (OR = 2.34 (95% CI 0.80 – 6.87, 
p = 0.11)) as shown in Table 10.12. Again, although the 95% confidence 
interval crossed one these variables, they warranted further investigation. 
 
Table 10.11 Cross tabulation of frequency data for the development of PTS at 
24 months by the presence of concurrent superficial thrombophlebitis at index 
DVT diagnosis. 
Phlebitis on DVT diagnosis &  & PTS 
Missing predictor variable = 0, Missing outcome variable = 24 
Phlebitis 
No PTS 
n (%) 
PTS n 
(%) 
Total  
n (%) 
None 82 (68) 38 (32) 120 (100) 
Phlebitis 14 (52) 13 (48) 27 (100) 
Total 96 (65) 51 (35) 147 (100) 
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Table 10.12 Cross tabulation of frequency data for the development of PTS at 
24 months by the occurrence of a new episode of superficial thrombophlebitis 
during follow-up. 
New phlebitis during follow-up & PTS 
Missing predictor variable = 22, Missing outcome variable = 24 
Phlebitis in follow-up 
No PTS 
n (%) 
PTS n 
(%) 
Total  
n (%) 
None 88 (67) 43 (33) 131 (100) 
New phlebitis 7 (47) 8 (53) 15 (100) 
Total 96 (65) 51 (35) 147 (100) 
 
 
Results of the chi-square analysis for all variables examined and their 
relationship with the development of PTS at 24 months of the index DVT event 
are shown in Table 10.13.  The Chi-square analysis confirmed no significant 
(p<0.05) association between the development of PTS and age, treatment type, 
smoking, hypertension, thrombus burden of the index DVT at diagnosis, 
provocation status, the duration of symptoms prior to commencing 
anticoagulation therapy, whether the DVT had resolved at the time of stopping 
anticoagulation therapy or DVT recurrence within 24 months of the index DVT 
diagnosis.
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Table 10.13 Results of chi-square tests of independence by independent 
variable with * indicating those variables selected for inclusion in the regression 
analysis for the dependent variable of PTS development (based on p = <0.25 as 
previously described in Section 4.5). 
Independent variable n 
Chi-
square 
df 
Asymptotic 
sig (2-
sided) 
Venous incompetence* 147 13.54 4 <0.01 
Overweight Yes or No* 147 8.44 1 <0.01 
DVT location* 147 7.65 1 0.01 
Thrombus evolution pattern at 3 months* 147 6.94 1 0.01 
Sex* 147 6.60 1 0.01 
Index DVT resolved within 24 months* 147 6.19 1 0.01 
Duration of consistent use of compression 
stockings* 147 3.45 1 0.06 
Treatment duration category* 147 3.23 1 0.07 
Concurrent superficial thrombophlebitis at 
DVT diagnosis* 147 2.64 1 0.10 
New episode superficial thrombophlebitis 
during follow-up* 147 2.49 1 0.12 
Treatment type 147 2.59 2 0.27 
Thrombus burden of index DVT at 
diagnosis (TLS) 147 3.20 3 0.36 
Index DVT resolved at point of stopping 
anticoagulation treatment 147 1.91 2 0.39 
Provocation status 147 0.54 1 0.46 
DVT recurrence within 24 months 147 0.44 1 0.51 
Age category at study entry 147 1.28 2 0.53 
Duration of symptoms before starting 
treatment 147 1.54 3 0.67 
Hypertension 147 0.03 1 0.85 
Smoking 147 0.06 2 0.97 
 
Key: 
BMI: body mass index 
DVT: deep vein thrombosis 
TLS: thrombus load score 
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10.6 Results of the regression analysis 
A two-stage logistic regression modelling procedure was used (as described in 
Section 4.5 of the methods chapter) to determine the degree of independence 
of the associations found. The full model outputs are presented in Appendix A6. 
The variables were grouped together as described in Section 9.6. Group 1 
comprised the baseline characteristics (BMI, sex, DVT location and concurrent 
superficial thrombophlebitis at diagnosis) and Group 2 comprised 
characteristics associated with follow-up (venous incompetence, thrombus 
evolution pattern at three months post DVT diagnosis, resolution of the index 
DVT within 24 months, anticoagulation treatment duration, the consistent use of 
compression stockings and the occurrence of a new episode of superficial 
thrombophlebitis during follow-up). In the Group 1 model, the variable for 
concurrent superficial thrombophlebitis was removed at step 2 (Table 10.14). 
The model explained 21.7% (Nagelkerke R2) of the variance in the development 
of PTS within 24 months. Of the four independent variables examined in the 
model, three (sex, BMI and index DVT location) maintained a significant 
relationship with the development of PTS within 24 months at the at the 0.1 
probability level for inclusion in the combined model when adjusted for possible 
confounding.  
 
Table 10.14 Results from the Group 1 model of the backwards stepwise 
regression analysis to examine adjusted relationships between BMI, sex, DVT 
location and concurrent superficial thrombophlebitis at diagnosis on the 
development of PTS at 24 months. 
 
Regression 
Coefficient S.E. df Sig. 
Adjusted 
OR 
95% C.I.for 
Adjusted OR 
Lower Upper 
Step 
2
a
 
Sex male (reference) or 
female 1.15 .394 1 .004 
1 
3.15 1.46 6.82 
BMI                               
not overweight (ref) or 
overweight 1.53 .551 1 .006 
1 
4.61 1.57 13.57 
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DVT location             
distal (reference) or 
proximal 1.11 .393 1 .005 
1 
3.04 1.41 6.56 
In the Group 2 model, the variable for anticoagulation duration was removed 
from the model at step 2, the variable for thrombus evolution pattern at three 
months was removed at step 3 and the variable for new episode of superficial 
thrombophlebitis during follow-up was removed at step 4 (Table 10.15). The 
model explained 23.3% (Nagelkerke R2) of the variance in the development of 
PTS within 24 months. Of the six independent variables examined in the model, 
three (venous incompetence, index DVT resolution status at 24 months and 
compression stocking use) maintained a significant relationship with the 
development of PTS within 24 months at the 0.1 probability level for inclusion in 
the combined model when adjusted for possible confounding. 
 
Table 10.15 Results from the Group 2 model of the backwards stepwise 
regression analysis to examine adjusted relationships between venous 
incompetence, thrombus evolution pattern at three months post DVT diagnosis, 
resolution of the index DVT within 24 months, anticoagulation treatment 
duration, the consistent use of compression stockings and the occurrence of a 
new episode of superficial thrombophlebitis during follow-up on the 
development of PTS at 24 months. 
 
Reg. 
Coeff. 
S.E. df Sig. AOR 
95% C.I.for 
Adjusted OR 
Lower Upper 
Step 
4
a
 
No venous incompetence (ref)   3 .001 1   
Deep venous incompetence  .974 .570 1 .088 2.65 .866 8.10 
Superficial venous incompetence 1.81 .534 1 .001 6.12 2.15 17.42 
Both deep and superficial venous 
incompetence 1.92 .627 1 .002 6.83 2.00 23.33 
Index DVT resolution status  
resolved within 24 months (ref)              
not resolved 1.02 .451 1 .024 
1 
2.76 1.14 6.69 
Compression stockings                  
not used (reference) or                
used for > 3 weeks 1.14 .421 1 .007 
1 
3.12 1.37 7.10 
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The six independent variables that maintained a significant relationship with the 
development of PTS within 24 months were then entered into a combined 
model. The model explained 31.9% (Nagelkerke R2) of the variance in the 
development of PTS within 24 months. The variable for DVT location was 
removed from the model at step 2. The results of the final regression analysis 
demonstrated that only five variables maintained a significant relationship with 
the development of PTS at the 0.1 probability level when adjusted for possible 
confounding by other variables (Table 10.16).  
 
Table 10.16 Results from the combined backwards stepwise regression 
analysis to examine adjusted relationships between sex, BMI, DVT location, 
venous incompetence, whether the index DVT resolved within 24 months and 
the consistent use of compression stockings on the development of PTS within 
24 months.  
 
Regression 
Coefficient 
S.E. df Sig. 
Adjusted 
OR 
95% C.I.for 
Adjusted OR 
Lower Upper 
Step 
2
a
 
Sex male (reference) or 
female .830 .419 1 .048 2.29 1.01 5.21 
BMI not overweight 
(reference) or overweight 1.513 .589 1 .010 4.54 1.43 14.4 
No venous incompetence 
(reference)   3 .010    
Deep venous incompetence  1.120 .607 1 .065 3.06 .932 10.07 
Superficial venous 
incompetence 1.452 .555 1 .009 4.27 1.44 12.7 
Both deep and superficial 
venous incompetence 1.777 .648 1 .006 5.91 1.66 21.0 
Index DVT resolution status  
Resolved (reference) or Not 
resolved 1.104 .469 1 .019 3.02 1.20 7.57 
Compression stockings not 
used (reference) or used for 
> 3 weeks .973 .444 1 .028 2.65 1.11 6.31 
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The regression analysis was then re-run with the final model variables (sex, 
BMI, venous incompetence, whether the index DVT resolved within 24 months 
and the consistent use of compression stockings) entered in a single step in 
order to avoid the program only using cases that were not missing on all tested 
independent variables. This did not change any of the values. Therefore, as 
shown in Table 10.16, following adjustment for confounding, women remained 
more than twice as likely to develop PTS within 24 months of the diagnosis of 
their index DVT than men (OR = 2.29 (95% CI 1.01 – 5.21, p = <0.05)). 
Participants classified as overweight (BMI) were more than four times more 
likely to develop PTS than those who were not overweight (OR = 4.54 (95% CI 
1.43 – 14.40, p = <0.05)). An adjusted relationship was also maintained 
between the resolution status of the index DVT and the development of PTS 
with those whose DVT had not resolved within 24 months of diagnosis three 
times more likely to develop PTS than those whose DVT had resolved (OR = 
3.02 (95% CI 1.20 – 7.57, p = <0.05)). The relationship between the use of 
compression stockings was also significant following adjustment for 
confounding with those not using compression stockings more likely to develop 
PTS within 24 months than those who used the stockings consistently for more 
than three weeks (OR = 2.65 (95% CI 1.11 – 6.31, p = <0.05)). 
 
Venous incompetence also maintained an important relationship with the 
development of PTS but superficial venous incompetence appeared to be more 
important than deep venous incompetence. Those with superficial venous 
incompetence remained more than four times more likely to develop PTS than 
those with no venous incompetence (OR = 4.27 (95% CI 1.44 – 12.69, p = 
<0.01) and those with a combination of both superficial and deep venous 
incompetence more than five times more likely to develop PTS than those with 
no venous incompetence (OR = 5.91 (95% CI 1.66 – 21.05, p = <0.01). Deep 
venous incompetence alone however did not maintain a significant relationship 
with the development of PTS at the 0.05 probability level once adjusted for 
confounding. An examination of the number of cases in each location of venous 
incompetence was undertaken to consider if this result was likely due to small 
case numbers, however case numbers of deep venous incompetence alone 
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were greater than those with both deep and superficial venous incompetence 
combined. 
 
This analysis completes the final chapter presenting the results from the 
observational study. A summary of all findings described across the five results 
chapters, will now be presented in the following discussion chapter. The 
findings will then be discussed in relation to the existing knowledge in this field 
and in light of the strengths and limitations of the study. 
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CHAPTER 11: DISCUSSION 
 
11.1 Introduction 
This chapter summarises the main findings of the study, examines these 
findings in relation to the existing evidence, discusses what they might mean, 
and the implications for clinical practice. The strengths and limitations of the 
research are also evaluated and recommendations provided for future research.  
 
11.2 Summary of key findings 
This project successfully followed a cohort of 147 participants (from a cohort of 
171 initially recruited) with a first episode of acute DVT over a period of two 
years following diagnosis. These data provided important information regarding 
the natural history of DVT as well as outcome data for DVT resolution. The key 
findings relating to thrombus evolution were: 
 
 The majority of the cohort had a reduction in thrombus burden between 
the study entry point and one month post DVT diagnosis.  
 There was a large increase in the percentage of participants for whom 
the DVT resolved between the one month and three month follow-up.  
 There was an initial period of significant change in thrombus evolution in 
the first three months post DVT diagnosis but after this resolution leveled 
off.  
 Only approximately half of the cases had resolved by the time 
anticoagulation therapy ceased regardless of treatment duration. 
 About one third of cases remained unresolved at 2 years which may 
have a significant impact on symptom burden post DVT.  
 
As previously described in the results chapters, several associations were 
identified between both characteristics present at baseline and those presenting 
during follow-up and the four outcomes after DVT that were examined. Equally 
as important as the associations identified however are those characteristics 
that were not found to be associated with any of these outcomes. This 
information is summarised in Table 11.1.  
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Table 11.1 Summary of the regression analyses to examine significant adjusted 
relationships between the variables for which data was collected and the four 
outcomes 24 months post diagnosis: index DVT resolution, DVT recurrence, the 
development of venous incompetence and PTS in the sample of 147 
participants. 
 
Dependent Variable Resolution Recurrence Incompetence PTS 
Age (<35 years) X  X X 
Sex (Female) X X X 
BMI (Raised) X X X 
Treatment type (LMWH & Warfarin) X   X 
Treatment duration X X X X 
Smoking history X X X X 
Hypertension X   X X 
TLS at diagnosis (Lower)  X X X 
DVT location  (distal) X (proximal) X 
Provocation status X X X X 
Pre-existing venous incompetence X X X   
Stocking use (not using) X X  
Concurrent phlebitis at DVT diagnosis X X X X 
Duration of symptoms before treatment X X X X 
Index DVT resolved within 24 months   X X 
Thrombus evolution pattern at 3 months     X X 
DVT recurrence     X X 
New phlebitis during follow-up     X X 
Venous incompetence       
 
Key 
 Modifiable factor which could 
inform management 
 Association found 
X No association found 
 Not examined 
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11.3 How this relates to previous literature and expert opinion  
The findings from this study in terms of DVT evolution support the existing 
evidence that it is a dynamic process and the pre-existing belief that 
progression and resolution can proceed simultaneously at different sites of a 
thrombosis (Kearon, 2003). Resolution rates in the current study were similar to 
earlier smaller studies in which up to 50% of previously abnormal compression 
ultrasound assessments do not normalise within 1 year of follow-up and in 
which both isolated distal DVT and smaller thrombus burdens were associated 
with complete DVT resolution (Cronan & van Leen, 1989; Murphy & Cronan, 
1990; Mantoni, 1991; Heijboer et al, 1992; Prandoni et al, 1993; Franzeck et al, 
1997; Holmstrom et al, 1997; Piovella et al, 2002; Prandoni et al, 2002).  
 
Several previous studies found that compared with distal DVTs proximal DVT 
was associated with worse clinical and haemodynamic outcomes (Meissner et 
al, 1998; Asbeutah et al, 2004; Tick et al, 2010; Yamaki et al, 2010; Yamaki et 
al, 2016) and multi-level DVT was associated with PTS (van Romshort et al 
1994; Labropoulos et al, 2008). In the current study, although the location and 
extent of the DVT were associated with the resolution within 24 months, which 
itself was associated with PTS, following adjustment for confounding, these 
variables did not in themselves demonstrate an association with PTS 
development. This aligns with the findings from Prandoni et al (2005) which 
demonstrated no association between the extent of the initial DVT and the 
development of PTS. 
 
As found here most previous studies detected a modest or strong statistical 
association between residual occlusion and PTS (Meissner et al, 1998 
(specifically popliteal vein occlusion); Prandoni et al, 2005; Labropoulos et al, 
2008; Roumen-Klappe et al, 2009; Tick et al, 2010; Haig et al, 2013; Vedovetto 
et al, 2013). This was however found to be dependent on the simultaneous 
presence of venous incompetence in several of the studies in which it was 
assessed (Prandoni et al, 2005 (specifically in combination with popliteal vein 
reflux); Franzeck et al, 1997; Van Rij et al, 2013; Yamaki et al, 2016) whilst in 
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the current study lack of DVT resolution and superficial or combined superficial 
and deep venous incompetence were independently associated with PTS.  
 
There were significant differences in the methodology between studies however 
as detailed in the literature review in Chapter 2 which may have hidden the 
association found. For example the smaller final sample sizes used for the 
analysis in some studies (Prandoni et al, 2005 n = 64; Franzeck et al, 1997, n = 
39; Van Rij et al, 2013, n = 114; Yamaki et al, 2016, n = 116) may not have 
been sufficient to detect this association. Furthermore, Prandoni et al  (2005) 
only included participants with proximal DVT and there was significant 
information lacking from both Franzeck et al (1997) and Van Rij et al (2015) 
regarding the cohort selection hence the association with other important 
characteristics cannot be determined. All of these studies either lacked detail or 
were significantly flawed in at least one aspect of the method relating to the 
diagnostic measurements for residual thrombus, venous incompetence or PTS, 
all of which could have resulted in a masking of any association.  
 
The number of DVT recurrences within 24 months in the cohort (15%) was 
similar to that reported previously by Baglin et al (2003) (19%). They examined 
the same time period and confirmed that the majority of patients with a first 
episode of unprovoked DVT will not have a recurrent episode. Other previous 
studies with follow-up durations ranging from 2-25 years reported that the risk of 
recurrence is much lower in those with a post-operative DVT (Prandoni et al, 
1996) with one study reporting a 0% recurrence rate in those whose DVT 
occurred within 6 weeks of surgery (Baglin et al, 2003).  Provocation status was 
not however associated with recurrence in the current study. The associations 
between age and treatment type and DVT recurrence that were identified in the 
current study were not previously supported by the literature although no study 
in which the cohort was primarily treated with DOACs and where these 
variables were analysed was identified. Unlike previous studies (Prandoni et al, 
2005; Labropoulos et al, 2009; Jeraj et al, 2017), which all found an association 
between ipsilateral recurrent DVT and the development of PTS, no such 
association was found in the current study. 
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One of the key results from the current study suggested that the duration of 
anticoagulation was not associated with any of the outcomes after DVT, 
including recurrence. This supports evidence found in a previous well-designed 
randomised study which demonstrated that the duration of anticoagulation had 
little effect on VTE recurrence rates in patients with unprovoked initial events, 
with longer treatment duration merely delaying the recurrence until after 
anticoagulation is stopped (Agnelli et al, 2001; Agnelli et al, 2003). Similarly, 
findings from the current study identified no association between unresolved 
DVT and recurrence.  This is similar to the findings from a SLR and meta-
analysis which found that the presence of residual obstruction was not 
associated with an increased risk of VTE recurrence in patients with an 
unprovoked DVT that were not taking oral anti-coagulation at the time of 
assessment (Carrier et al, 2011).  
 
The same review did however find that when data from patients with any DVT, 
whether provoked or unprovoked, were combined residual obstruction was 
found to be significantly associated with VTE recurrence (Carrier et al, 2011).  
This differs to the findings from the current study in which both provoked and 
unprovoked cases were included in the analysis. Unlike the current study 
however, the SLR did not include data from studies where patients were treated 
with DOACs. The review also concluded however that there was no consensus 
on whether the residual vein obstruction increases the risk of recurrence with 
some studies demonstrating an association between residual obstruction and 
recurrent VTE and some demonstrating no association. No association between 
provocation status and any of the outcomes after DVT was identified in the 
current study.  
 
Findings relating to the role of venous incompetence in PTS development 
echoed the results of Haenen et al (2002) which showed superficial venous 
reflux to be the most important risk factor for the development of PTS and that 
deep reflux alone was not associated with PTS. Multiple previous studies 
demonstrated association between venous reflux in some form (deep or 
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superficial or a combination of both) and PTS (Meissner et al, 1998; Roumen-
Klappe et al, 2005; Roumen-Klappe et al, 2009; Latella et al, 2010; Tick et al, 
2010; Haig et al, 2013) but deep venous reflux in isolation was not associated 
with PTS. Several other studies only found an association between PTS and 
reflux when combined with residual obstruction but, in contrast to the current 
findings and those of Haenen (2002), reflux alone was not associated with PTS 
(Franzeck et al, 1997; Prandoni et al, 2005; Yamaki et al, 2016).  
 
There were both similarities and differences between the results from the 
current study and those previously reported regarding several key baseline 
characteristics and the development of PTS. Several previous studies 
demonstrated that age was positively associated with the likelihood of 
developing PTS after a DVT (van Dongen et al, 2005; Schulman et al, 2006; 
Kahn et al, 2008a, Tick et al, 2008) although this association was not seen in 
the current study. Conversely two studies found BMI not to be associated with 
the development of PTS (Tick et al, 2010; Yamaki et al, 2016) whereas the 
current study detected a significant association between PTS development and 
being overweight. This finding was also seen in several previous studies 
although  to a lesser degree (up to 1.5-fold in Tick et al, 2008 and up to 2-fold in  
van Dongen et al, 2005; Stain et al, 2005; Kahn et al, 2008a; Galanaud et al, 
2013).  
 
Sex was also identified as important in the current study with women more than 
twice as likely to develop PTS. This supports the findings from the MEGA study 
of 1916 patients which found that female participants were more likely to 
develop PTS than male participants (RR 1.5, 95% CI 1.3-1.8) (Tick et al, 2008) 
and contradicts the findings from the smaller study from Stain et al (2005) which 
found that being male had a weak association with PTS (OR 1.6, 95% CI 1.0-
2.8). 
 
The evidence base regarding the efficacy of stockings in the prevention of PTS 
remains equivocal.  The current study found that those participants that did not 
use stockings were more likely to develop PTS within two years. The advice 
285 
 
given to patients in the researcher’s Trust with regard to compression therapy 
following DVT changed during the course of the data collection period of this 
study as a result of the evidence from the SOX Trial (Kahn et al, 2014a). The 
advice changed from using stockings for two years post DVT as a primary 
recommendation for the prevention of PTS to not recommending their use (and 
therefore not prescribing them) unless the patient was already using them and 
experiencing a positive effect.  
 
Unlike previous randomised trials that found a positive association between 
using compression and the prevention of PTS, the SOX trial did not exclude 
patients with pre-existing CVI which may have masked the effect of 
compression therapy. The current study also did not exclude individuals with 
pre-existing CVI but, unlike the SOX trial, participants were assessed for pre-
existing venous incompetence and the associations detected were adjusted for 
confounding by this. Results from the present study suggested that using 
stockings even for just three weeks or more after DVT diagnosis reduced the 
likelihood of developing PTS. This is important information supporting the use of 
compression hosiery, even if only in the short term following DVT diagnosis. 
 
The peer group opinion study reported in Section 3.6 revealed that the Vascular 
Scientists only rated two variables as being unrelated to PTS, one of which was 
sex yet this study found female sex to be significantly related to the 
development of PTS. In the Vascular Scientists’ opinions the most important 
factors in the development of PTS related to the extent and location of the DVT, 
levels of DVT resolution after treatment and the presence of deep venous 
reflux, and insufficient anticoagulation therapy. Whilst the results from the 
observational study supported this belief in the importance of DVT resolution, 
which in itself was related to the location and extent of the index DVT, treatment 
duration and deep venous incompetence were not found to be associated with 
PTS development. The vascular scientists surveyed also believed BMI to be 
important along with poor compliance with compression therapy and superficial 
venous incompetence, all of which were found to be associated with PTS in the 
observational study.  In contrast they believed provocation status to be 
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important yet no association between this and any of the outcomes after DVT 
were observed.  
 
11.4 Implications of the study  
Firstly, this study has provided useful information regarding the natural history 
of DVT that could inform the appropriate management of patients diagnosed 
with DVT and enable those professionals involved in the care of this patient 
group to better inform patients of the potential outcomes after their thrombosis. 
Particularly as some of the findings are in contrast to the opinions of the 
Vascular Scientists (as identified in the peer group opinion study reported in 
Section 3.6), disseminating the information from this study amongst the 
researcher’s professional group is of significant value. Information gained from 
this study goes some way towards answering the patients’ questions that 
initially prompted the research: when will it go away and will my leg go back to 
normal? This information will help us better prepare patients for the period 
following diagnosis of their DVT and help them to manage their expectations 
with regard to anxiety about their DVT resolving and the improvement in their 
symptoms. 
 
The study was designed with a high level of internal validity and followed a 
reasonably sized cohort over a significant period of time.  Statistical analyses 
were used to determine the presence of any associations between a wide range 
of baseline and disease characteristics and four important outcomes after DVT: 
resolution, recurrence, venous incompetence and PTS. The findings from this 
study can therefore confidently be considered applicable to an ambulatory 
population with a first episode of DVT. 
 
As this is one of the earliest observational studies of DVT patients where a large 
number in the cohort were treated with DOACs (Rivaroxiban), a particularly 
significant finding from this study was that those treated with LMWH and 
warfarin had worse outcomes than those treated with Rivaroxiban with the 
former being associated with a threefold greater risk of DVT recurrence and a 
fourfold greater risk of developing venous incompetence. This provides 
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important information to support the national recommendation that the DOACs 
rivaroxaban, dabigatran, edoxaban and apixaban can be used as options for 
anticoagulation treatment for DVT and in secondary prevention (NICE 
Technology Appraisal Guidance, 2012; NICE Technology Appraisal Guidance, 
2014; NICE Technology Appraisal Guidance, 2015a; NICE Technology 
Appraisal Guidance, 2015b). 
 
From the researcher’s personal experience based on discussions with 
colleagues in other Trusts, DOACs are increasingly being used as a treatment 
option for DVT in many Trusts. This is supported by information from a 
retrospective cohort study that used prospectively collected data from patients 
enrolled in the RIETE registry (www.riete.org, 2001) which demonstrated that 
the use of direct oral anticoagulants increased from 0.5% in 2010 to 13.4% in 
2014 (Morillo et al, 2016) compared to 87% of the cohort in this study. Not only 
does the use of DOACs remove the need for INR monitoring, hence reducing 
both the financial burden associated with this and the patient burden (Obi and 
Wakefield, 2018), but this research indicates that the use of DOACs could also 
be improving patient outcomes after DVT.  
 
Current protocol in the researcher’s Trust leaves an element of patient choice to 
the treatment options with some patients preferring not to take DOACs.  
Anecdotally the reasons reported for rejecting DOACs include a lack of 
monitoring of INR and unwillingness to try newer treatments, preferring those 
that they had previously heard about and perhaps knew of others that had 
received them. This study has provided evidence to reassure patients in the 
local population that the use of DOACs may have significant benefits for longer 
term outcomes after DVT. 
 
In line with the findings from the peer group opinion study, the number with 
complete resolution of their DVT was significantly greater in distal DVT than 
proximal and those with a small thrombus burden were also more likely to 
completely resolve. Whilst thrombus extent and location was not found to be 
directly associated with the development of PTS, the presence of residual 
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thrombus at two years post DVT was associated with PTS. Therefore this 
information could be important for risk stratification of patients whose thrombus 
is less likely to resolve completely and are therefore at greater risk of 
developing PTS. As thrombus resolution levels were largely determined by 
three to six months post DVT diagnosis, a rescan at this time point to establish 
the degree of resolution could help identify both those at risk of non-resolving 
DVT and therefore more likely to develop PTS and those for whom treatment 
could be ceased with little concern for long term detriment.  
 
Currently, any rescan, at any time point post DVT, to inform the resolution 
status of the thrombus as part of routine clinical practice is not supported by the 
literature and there is currently no standard for ordering an ultrasound at the 
end of anticoagulation treatment periods (Needleman et al, 2018). From the 
researcher’s experience in current clinical practice, this does occur in a limited 
number of cases in the researcher’s hospital at the request of the 
haematologists when planning long term treatment for patients with an 
unprovoked DVT and few identified risk factors. However, a literature search 
revealed no existing evidence to support this strategy.  
 
Another important finding from this study was that those participants aged less 
than 35 years at the time of their presentation with a first episode of DVT were 
three times more likely to experience a recurrent DVT within 2 years. This 
suggests that age could be a useful indicator of risk of recurrence. The 
exclusion of individuals with a previous ipsilateral DVT from the study (n = 63) 
may have contributed to lower numbers of recurrences in the older age groups 
as some of those with an increased risk of recurrence would have already been 
excluded due to this not being their first presentation with DVT. Those excluded 
on this basis would most likely be those presenting with a second episode of 
DVT as following a first recurrence episode most patients are likely to be 
prescribed long term anticoagulation to manage their risk of further recurrences. 
Young participants presenting with a first episode DVT may therefore warrant 
enhanced screening for clotting disorders regardless of the provocation status 
of their DVT and careful examination for other potential risk factors for 
289 
 
recurrence. This patient group may also benefit from enhanced counselling 
regarding the signs and symptoms of recurrent DVT and encouragement to 
seek medical attention early should they experience any of these. 
 
DVT recurrence within two years was not found to be associated with the 
development of PTS in this study which goes against findings from three 
previous studies (Prandoni et al, 2005; Labropoulos et al, 2009; Jeraj et al, 
2017) which found an association between ipsilateral recurrent DVT and the 
development of PTS. The studies did however have longer follow-up durations 
of up to 5 years (Prandoni et al 2005; Labropoulos et al, 2009) and 3 years 
(Jeraj et al 2017).  There were also significant differences in the methodology 
between these studies (as described in Chapter 2, Table 2.5) and with the 
researchers study that should be considered. For example, unlike the current 
study, Prandoni et al (2015) and Labropoulos et al (2009) both excluded distal 
DVT and Jeraj et al (2017) lacked detail in the reporting of the initial DVT 
diagnosis, making it impossible to determine if this was objectively diagnosed, if 
all participants were classified using the same procedure and even if this was a 
first episode of DVT in all cases. Jeraj et al (2017) did report details of recurrent 
DVTs but it was not clear if this referred to the index DVT or recurrence that 
occurred during follow-up. Nevertheless, the findings from these previous 
studies indicate that there is a need to explore the longer term effects of 
recurrence beyond two years from the initial DVT diagnosis.  
 
The findings of the current study provide information that could inform more 
individualised counselling for patients with DVT regarding their risk of 
developing PTS. The significant association found between elevated BMI and 
PTS development in this study suggests that further research is warranted in 
order to demonstrate the sensitivity and specificity of using BMI as a predictor of 
PTS at different BMI cut offs. This could inform future risk stratifying of DVT 
patients at an early stage and selecting those for more aggressive treatments 
such as catheter directed thrombolysis or mechanical clot retrieval techniques 
which are more effective when employed soon after DVT diagnosis rather than 
in the chronic stages of DVT. This would require further investigation however, 
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as although there may be an association, its value for screening purposes may 
still be poor and possibly unsafe, especially as the more aggressive 
interventions have risks. Although this association has been observed in 
previous studies, as discussed in Section 11.3, other studies have previously 
reported no association between BMI and PTS and the role of high BMI in the 
development of PTS remains under debate. This study adds high quality 
evidence to this debate and raises an important question about the use of 
DOACs in patients with a high BMI. Unlike warfarin, DOACs are not dosed for 
weight and patients treated with DOACs do not undergo INR monitoring to 
determine if their blood is within the therapeutic range.  
 
Since the distribution volume of DOACs is related to body weight and its 
correlates (that is, surface area and BMI), extremes in body weight may affect 
their efficacy or safety (Scaglione, 2013). The International Society of 
Thrombosis and Haemostasis recommends avoiding DOACs in patients with a 
BMI >40 kg/m2 or weight >120 kg because of limited clinical data in this group 
of patients (Martin et al, 2016). However, the “dilutional effect” of high body 
weight on plasma concentration is of varying importance depending on the 
specific DOAC (De Catarina & Lip, 2017).  
 
Several studies have found that rivaroxaban can be used at a fixed dose 
irrespective of weight. Kubitza et al (2007) reported no differences in the safety, 
tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban due to body 
weight in the healthy volunteers studied when examining three weight 
categories (< or = 50 kg, 70-80 kg and >120 kg). Arachchillage et al (2016) 
evaluated the effect of extreme body weight on rivaroxaban levels and showed 
that patients with weight >120 kg had similar levels of rivaroxaban and 
prothrombin time and activated partial thromboplastin time compared with 
patients with standard body weight for VTE treatment. Additionally, the post hoc 
analyses of patients by weight or BMI in the rivaroxaban pivotal Phase 3 trial 
showed that efficacy and safety outcomes in BMI >35 kg/m2 (n = 972) or weight 
>90 kg (n = 2035) were consistent with the overall analysis in patients with BMI 
⩽35 kg/m2 (n = 6104) or weight ⩽90 kg (n = 5044), respectively (Upritchard, 
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2016). The current study has however suggested that weight might be an 
important consideration when determining DVT treatment for a patient with an 
elevated BMI and that there is potentially an issue with DOAC dosing in this 
patient group that warrants further research. 
 
Similarly, women were found to be more than twice as likely to develop PTS in 
the current study but previous studies have provided conflicting evidence 
regarding any association between sex and PTS. This may be due to issues 
with sample size and methodological quality in previous studies, as discussed in 
detail in the literature review in Chapter 2, which may have resulted in the 
masking of any significant association between sex and PTS. This study has 
provided evidence to suggest that female sex may be associated with the 
development of PTS and therefore this is an area that warrants further 
investigation before it could be employed in the early risk stratification of DVT 
patients for PTS. 
 
The results of this study also suggest further research is indicated in the 
duration of stocking use after DVT in the prevention of PTS which could lead to 
revised recommendations about using stockings for a shorter time period. 
Compression stockings have always presented issues with low compliance and 
many people report barriers to their use including difficulty in getting them on, 
wearing them during hot weather, remembering to re-order new prescriptions 
when they lose their elasticity and not finding them suitable with clothing 
choices (Tandler, 2016). Tolerance and a willingness to persevere with using 
them may be significantly improved if patients believed that they would make a 
difference and if they knew that difference could be obtained with using them for 
only a short duration of a few weeks post diagnosis.  
 
The role of venous reflux in the development of PTS has remained frequently 
debated with several prominent research groups having produced conflicting 
evidence (Kahn et al, 2014a). This study identified a significant relationship 
between venous incompetence and PTS but with the results of the regression 
analysis indicating that superficial venous incompetence was more important 
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than deep venous incompetence as deep venous incompetence only had a 
significant relationship with PTS in the presence of concurrent superficial 
incompetence. The presumption that valvular damage caused by valve leaflet 
paralysis in the presence of deep vein thrombosis is the mechanism behind any 
involvement of venous incompetence in PTS (Roumen-Klappe et al, 2009; 
Vedantham, 2009) may therefore be inaccurate.   
 
This raises the question of whether clinicians need to routinely examine the 
possibility of treating superficial venous incompetence in cases of PTS in the 
absence of residual obstruction. A full venous ultrasound assessment for both 
residual obstruction and venous incompetence in PTS cases would identify 
patients that might benefit from intervention for superficial venous incompetence 
where residual obstruction or deep venous incompetence, which would usually 
contraindicate this, is absent. Unfortunately patients presenting with symptoms 
of PTS are often only assessed for recurrent acute DVT and in the absence of 
this are sent away with a diagnosis of PTS and the advice that little can be done 
for this other than symptom management with compression stockings. These 
results suggest that there may be more that could be done for this group of 
patients in terms of treatment options for superficial venous incompetence. 
 
This study has also raised a potentially important question regarding the 
efficacy of extended anticoagulation therapy for the prevention of DVT 
recurrence or PTS. The recommendation from the researcher’s Trust to general 
practitioners after DVT diagnosis is to continue anticoagulation therapy for a 
minimum of three months for patients with an unprovoked DVT and six weeks 
for a calf DVT provoked by orthopaedic surgery. This resulted in considerable 
variation in treatment duration within the cohort studied. The majority of 
participants (65%) received oral anticoagulation therapy for between three and 
six months but, excluding those that were prescribed long term anticoagulation 
therapy beyond the duration of the study (16%), treatment duration ranged from 
one month to 12 months. Treatment duration however was not found to be 
related to any of the outcomes in this study which suggests uncertainty 
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regarding the benefits of extended anticoagulation and whether it is warranted 
or justified. 
 
The current research was designed with one of the aims being to provide 
information that could permit the early identification of individuals with an 
increased risk of developing PTS. Those at risk could then be provided with the 
best available prevention strategy on an individual basis. There has been 
debate as to whether one of the possible beneficial treatment strategies could 
be prolonged anticoagulation therapy for certain patient groups (Verhovsek et 
al, 2008). The findings have however highlighted that extended anticoagulation 
may not be of benefit in terms of reducing the risk of developing PTS nor was it 
associated with the outcomes of DVT resolution, recurrence or the development 
of venous incompetence. 
 
11.5 Strengths of the research 
11.5.1 Relevance and novelty 
This is a topical area of research as demonstrated by the emergence of several 
new publications since conception of the study which were identified during the 
re-run of the SLR described in Chapter 2 Van Rij et al, 2013; Haig et al, 2013; 
Vedovetto et al, 2013; Yamaki et al, 2016; Jeraj et al, 2017). The evidence 
generated in this observational study supports the existing evidence described 
in the opening background chapter of this thesis, which suggested that there is 
variability in the response to treatment in terms of thrombosis resolution and 
residual venous function as well as patient outcomes in terms of on-going 
symptoms of pain and swelling, grouped under the umbrella term PTS. As 
described in Chapters 2 and 3, the existing evidence demonstrated that there 
remained considerable uncertainty regarding the underlying pathophysiology of 
PTS. Whilst it is acknowledged that the gaps and conflicts in the existing 
evidence are unlikely to be answered by a single centre research study, I 
believe that my experience in the clinical diagnosis of DVT using ultrasound has 
allowed me to bring a different perspective to the design and implementation of 
an observational study in this field which brings with it a focus on the data 
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collection process and addresses several key issues in terms of reliability of the 
data. This study has provided evidence to help build the bigger picture, has 
demonstrated that good research practice is possible in a study of this kind and 
has created a platform for future research.  
 
Only one previous study had reported results from a DVT cohort where a large 
percentage of participants (61%) were treated with DOACs rather than LMWH 
and warfarin (Jeraj et al, 2017). The study by Jeraj et al (2017) was however 
limited to an assessment of the relationship between recanalisation and the 
development of PTS in participants with a proximal DVT. They did not provide 
any information on the natural history of thrombus resolution and only carried 
out a single follow-up assessment for each participant, which occurred at any 
point between 12 and 36 months post DVT diagnosis. The thrombus burden of 
the initial DVT was also not described which could have significantly influenced 
any relationship with PTS development. The study by Jeraj et al (2017) also 
suffered from several key methodological limitations including a lack of detail 
regarding the initial DVT diagnosis making it impossible to determine if this was 
objectively diagnosed and if all participants were classified using the same 
procedure or even if this was a first episode of DVT in all cases. There is 
currently no published evidence providing data regarding the natural history in 
both proximal and distal DVT in participants that were treated with Rivaroxaban.  
 
Due to the nature of the study and the requirement to travel to hospital for 
multiple follow-up appointments over a period of two years, the resulting cohort 
was a somewhat selected population with reasonable mobility and therefore in 
generally good health. This could be seen as a limitation of the study, however, 
it also reflects the population for whom the more aggressive endovenous 
treatments such as catheter directed thrombolysis and venous stenting 
procedures may be considered.  Careful risk stratification is required prior to 
these treatments, due to their invasive and expensive nature, to ensure that 
they are directed only to those patients most at risk of short or long term 
complications from their DVT.  This risk stratification is currently focused 
predominantly on the risk of adverse events rather than consideration of those 
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most likely to benefit from the procedure as there is a lack of existing evidence 
on which to base such judgement. Existing evidence suggests (see Section 
1.3.7) that endovenous techniques are most effective in the treatment of acute 
rather than chronic thrombus which promotes early intervention rather than a 
‘wait and see’ strategy. The difficulty however lies in predicting at the acute 
stage of DVT whether a patient is likely to develop PTS in the longer term. This 
study provides useful data that represents a step towards a more evidential 
basis for treatment and patient selection. Future work to create a scoring 
system based on the weighted coefficients, tested in a new long term cohort 
would be required to move this forward clinically and this is discussed in Section 
11.7. 
 
11.5.2 Internal validity 
Substantial consideration was given to the design of this study in order to 
minimise threats to its internal validity. A strength of this research project was 
that it was led by and conducted by a vascular ultrasound specialist which 
provides confidence in the accuracy of the ultrasound data, especially for calf 
DVT which is known to be challenging to visualise on ultrasound (Bevis & Smith 
2016). The sensitivity and specificity for ultrasound compression technique for 
diagnosing proximal DVT in symptomatic patients is over 97% and 98%, 
respectively; however, these become markedly reduced to 71% and 94%, 
respectively, for calf vein thrombosis (Goodacre et al, 2005).  
 
The fact that the ultrasound data collection was undertaken by a single skilled 
researcher underpins confidence in the reproducibility of the results and 
removes any element of inter-operator variability. It is acknowledged that this 
also however represents a limitation to transferability. The researcher kept 
meticulous records of the extent of any residual thrombus in each individual 
participant between visits allowing for any changes in thrombus burden to be 
reliably detected. The ultrasound data collection was also undertaken on a 
single ultrasound machine (a GE Logic 9, less than 1 month old at the time data 
collection started) meaning that the latest ultrasound technology was used in 
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the study. The ultrasound machine also underwent weekly and monthly quality 
assurance testing as part of the department protocol to ensure that it was 
operating at a safe and effective level. The ability of both the operator and the 
equipment used to accurately detect changes in the extent of thrombus was of 
considerable importance in a study of this nature in which a large part of the 
analysis focused on changes in thrombus burden over time.  
 
The study design followed a pre-defined published protocol to ensure that all 
details of the methodology were transparent and accessible (Appendix A1.3). 
This was considered highly important following the results of the SLR detailed in 
Chapter 2 which identified that, for most of the studies, the limitations in 
methodological quality were likely due to inadequate reporting of methods which 
emphasised the need for detail and transparency when disseminating the 
research findings. The variables for examination in the study were determined 
following a systematic review of the existing evidence and a gathering of 
opinion from fellow professionals rather than the researcher’s personal opinion 
which substantiates the content of the research question. 
 
Unlike much of the previous research in this field, this study combined a large 
sample size with a good retention rate of 86% and a comprehensive follow-up 
schedule with both sufficient observations and duration of follow-up to capture 
change. The follow-up visits were also carefully scheduled in order to 
adequately observe the most likely time frame in which significant change would 
occur. Loss to follow-up was recorded and all attrition cases were carefully 
examined for any potential areas of bias. 
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11.6 Problems and Study Limitations 
11.6.1 Selection bias 
Although all participants were recruited appropriately in a hospital setting, there 
may be a significant number of people who have experienced a DVT but do not 
present to their GP or to hospital.  These people may have different 
characteristics and outcomes from the population that present to hospital 
outpatient settings. There are differences in the health of all individuals, 
including those recruited to this study, that arise from complex interactions 
linking environmental, economic, social, lifestyle and biological factors 
(Dahlgreen and Whitehead, 1991). Personal characteristics such as age, 
disability and sexual orientation often present barriers to a full integration in 
society, which includes the use of health services (Krieger, 1999). Moreover 
there are other people who are potentially vulnerable or socially excluded 
meaning that the participants in this research study were not necessarily 
representative of the DVT population as a whole.  
 
This could have relevance for two specific patient groups. Those with isolated 
calf vein DVT might not experience symptoms significant enough to provoke a 
hospital visit. In contrast, patients with very extensive proximal DVT might be 
highly symptomatic resulting in reduced mobility and therefore decreased 
likelihood of attending a hospital. These patient groups may have significant 
differences from the study population in terms of co-morbidities, lifestyle, and 
other potential risk factors for PTS as well as the obvious differences in terms of 
treatment received. In addition, amongst the population who do present at a 
hospital setting with a DVT, those patients that consent to participate in 
research may significantly differ in terms of co-morbidities, lifestyle and 
adherence to treatment regimen (for example, compliance with compression 
therapy) compared to those that do not consent to participate. Whilst these are 
factors that are difficult to control for in any research study, exclusions from the 
study do make it less generalizable to the wider target population.  
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The exclusion criteria were given careful consideration at the planning stage in 
order to balance the risk of including those patient groups that were at high risk 
of attrition. An analysis of recruitment patterns was also undertaken after one 
month and three months to determine if recruitment was progressing as 
planned and if any important groups were emerging from those that were not 
eligible or declined participation. In the first calendar month of the study being 
open to recruitment 88% of those diagnosed with a DVT were excluded from 
the study. A similar pattern was seen at three months with 86% excluded. This 
review identified several large and potentially important groups within the 
excluded patients: intra-venous drug users (21%), immobile patients (21%), 
those with active cancer (19%) and those with a previous episode of ipsilateral 
DVT (33%).  
 
Further consideration was given at this time point as to whether any of these 
groups could be included in the study.  Patients with a previous DVT had been 
excluded from the study due to the difficulty in determining differences in acute 
and non-acute thrombus.  This would make it difficult to establish the true extent 
of the baseline presentation of thrombus without knowledge of the resolution 
status of the previous episode (discussed further in Section 11.6.2). It was 
decided that patients with active cancer would remain excluded on 
consideration of several factors including possible drug interactions, the effect 
of hypercoagulability associated with malignancy and the burden to participants 
of attending follow-up appointments when already frequently undergoing 
hospital visits. Intra-venous drug users also remained excluded due to the 
nature of the DVT provocation being very specifically due to venous injury from 
needle use as previously reported.  
 
Patients with mobility issues were an important group, exclusion of whom 
results in a population sample biased towards a generally healthier cohort and 
therefore reduced generalisability of the study findings. There were however 
several challenges associated with including this group which were mainly of a 
practical nature including the necessity of hospital transport to attend outpatient 
appointments and the associated burden to the participant of unnecessary 
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hospital related travel. Considerations for patient safety in a lone worker 
environment were important where assistance for patient transfer to the 
examination couch or in the event of a clinical incident such as a fall would not 
be readily available in an isolated department with no emergency call button 
system. Furthermore, the significantly higher potential for poor quality 
ultrasound images in immobile patients as a result of limited ability to comply 
with positioning was a consideration in excluding this group.  These are all 
factors that will have affected other studies to varying degrees (although this is 
often not reported in publication and is therefore difficult to assess). It was 
therefore decided that this group should remain excluded from participation. 
 
These decisions resulted in a cohort that was predominately an ambulatory 
outpatient population that enjoyed relatively good health outside of their 
condition of having experienced a DVT. It must therefore be considered that the 
outcomes for inpatients and those that are immobile might be different and 
therefore the applicability of the findings to these groups should be considered 
with caution.  
 
Other than the potential bias as a result of the selection criteria there were no 
obvious differences between the final study cohort and those that presented for 
assessment, were diagnosed with a DVT or those that met the inclusion criteria 
but declined participation as described in Section 5.1, Table 5.3. The only 
notable difference between these groups was that more women presented for 
assessment for query DVT than men but more men tested positive for DVT 
upon assessment than women. This is broadly speaking reflective of the 
recognised pattern that women are more likely to access healthcare services 
than men (Bertakis et al, 2000; Department of Health, 2008). 
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11.6.2 Potential measurement errors 
There are several issues surrounding the various measurements undertaken in 
this study that must be considered when appraising the research quality.  
 
Establishing baseline 
Firstly, the study examined participants with a first episode of DVT. Establishing 
the true starting point for the subsequent observation of any changes in 
thrombus burden over time was of significant importance.  
 
Whilst previous contralateral DVT cases were recorded, it must be considered 
however that the status of ‘first episode of ipsilateral DVT’ can only be assumed 
rather than known. It cannot be completely excluded that study participants had 
experienced a previous ipsilateral DVT that had or had not completely resolved 
at the time of development of the index thrombosis. Several measures were 
implemented to ensure that the diagnosis of a first episode of DVT was as 
accurate as possible. The hospital electronic record for medical imaging for 
each potential participant was checked at the time of screening to ensure that 
no diagnostic ultrasound report indicating a previous ipsilateral DVT existed. 
Each potential participant was also questioned at the time of recruitment to the 
study to ensure that they had not been previously diagnosed with an ipsilateral 
DVT at a different hospital or that they could recall any time when they 
experienced the symptoms of a DVT for which they had not sought medical 
attention. 
 
Ultrasound quality 
The potential for measurement errors as a result of differences between the 
diagnostic scan and the first follow-up scan at 7 days was also considered. As 
detailed in the study methods, the original diagnostic scan for each research 
study participant was undertaken by a CVS from the Vascular Science Unit at 
UHBristol but not necessarily by the study chief investigator who undertook all 
of the surveillance ultrasound assessments. The diagnostic ultrasound was 
undertaken on an Antares Sonoline ultrasound machine (Siemens Healthcare 
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GmbH, Germany) whereas the surveillance ultrasound assessments were 
performed using a GE Logic 9. This raised potential issues regarding 
discrepancies between the quality of the ultrasound assessments due to 
different age and quality of the machines.  
 
All of the CVSs who undertook the diagnostic ultrasound assessments were 
trained locally under the standards of the National School of Healthcare Science 
NHS Scientist Training Program. Each assessment was undertaken following a 
defined protocol for diagnosing lower limb DVT as detailed in the methods 
(Section 4.3.2). The unit performs between 2000-2400 diagnostic ultrasound 
assessments for DVT annually. Each scientist is required to reach a level of 
competency that is measured and assessed locally against the standards of the 
national training program (NHS STP and professional body (SVT). These 
factors contribute to confidence in the results of the initial DVT diagnosis and 
the determination of the initial extent of the thrombus. 
 
Inter-operator quality assurance (QA) processes are routinely undertaken as 
part of routine clinical practice in the Vascular Science Unit. During the data 
collection period for the study, two such QA audits were carried out to assess 
the quality of the DVT diagnostic service and to ensure that all scientists met 
the agreed standards of diagnostic ultrasound for lower limb DVT. The QA audit 
takes place over at least a five day period during which each patient that has 
undergone diagnostic ultrasound for lower limb DVT (using the Antares 
Sonoline ultrasound machine) is asked if they will undergo a second ultrasound 
examination in which the assessment is repeated by a different scientist on a 
different ultrasound machine (GE Logic 9). The second examination is 
undertaken in a separate clinical room and the second scientist is blinded to the 
results of the initial diagnostic scan. The results of the two assessments are 
then compared by a third scientist who repeats the ultrasound assessment for a 
third time should there be any differences between the results from the first two 
assessments. These audits therefore mirror the process of the patient pathway 
ahead of their first research scan where the initial diagnostic scan was 
undertaken on a different machine and by a different operator and provide a 
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good indication of the quality consistency between the diagnostic assessment 
and the initial research assessment. 
 
The first QA audit took place between 9th and 13th March 2015 and involved 
three scientists. During this period, 43 patients underwent diagnostic ultrasound 
assessment for DVT. Ten patients were excluded from the QA process as they 
were either considered too unwell to undergo a second examination or did not 
consent to having the examination repeated for QA purposes. Therefore, 33 
patients underwent a repeat ultrasound assessment. At the diagnostic test 27 
patients tested negative and 6 tested positive for DVT. On repeat assessment, 
28 patients tested negative and 5 tested positive for DVT. This single 
discrepancy was assessed by a third scientist and the negative diagnosis for 
DVT was confirmed indicating one false positive result in the initial diagnostic 
assessments. This relates to a sensitivity of 100% and a specificity of 96% and 
a positive predictive value of 83% and a negative predictive value of 100%. The 
location and extent of the thrombus in positive cases was also compared for the 
diagnostic scan and the repeat scan. One posterior tibial vein thrombosis that 
was detected in the initial diagnostic scan was missed on the repeat scan 
(although the overall diagnostic outcome was not affected as the patient had 
thrombus elsewhere). There were four occasions where occlusive thrombus 
was incorrectly diagnosed as non-occlusive thrombus (once in the femoral vein, 
two in the soleal veins and one in the peroneal veins). One case was identified 
where insufficient information regarding the location and extent of superficial 
thrombophlebitis was provided in the diagnostic report.  
 
The second audit took place between 14th and 23rd November 2016 and 
followed the same format.  At the diagnostic test 36 patients tested negative 
and 6 tested positive for DVT. On repeat assessment, 34 patients tested 
negative and 8 tested positive for DVT. The two discrepancies were assessed 
by a third scientist and the two positive diagnoses for DVT were confirmed 
indicating two false negative results in the initial diagnostic assessments. This 
relates to a sensitivity of 75% and a specificity of 100% and a positive predictive 
value of 100% and a negative predictive value of 94%. Comparison of location 
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and extent of the thrombus for the diagnostic scan and the repeat scan in 
positive cases revealed three cases where there was disagreement in the 
extent of the DVT (concurrent superficial thrombophlebitis not identified in two 
diagnostic scans and the extension of a calf vessel DVT into the tibio-peroneal 
trunk not reported in one diagnostic scan). Both cases where the DVT diagnosis 
was missed involved isolated calf DVTs and the incorrect diagnostic scans were 
performed by the same junior scientist on all occasions. This identified the need 
for ongoing training for this scientist and an extension to their supervised 
scanning period before being deemed safe to practice without supervision. 
 
Whilst the two quality assurance audits revealed high levels of accuracy in the 
diagnostic ultrasound assessments for DVT and high levels of agreement 
between the different scientists and the two different ultrasound machines, the 
possibility of false positive or false negative diagnoses occurring and 
discrepancies in the extent of the initial DVT must be acknowledged. A false 
negative scan where the patient developed further symptoms or had a positive 
D-dimer test would have resulted in a rescan at seven days which would identify 
a small isolated calf DVT that may have originally been missed on ultrasound 
and then propagated. A false positive scan may have been identified if, at the 
first follow-up visit at one week post the original diagnosis, the patient presented 
with no evidence of DVT seen on ultrasound. This may however be normal in 
cases where the original DVT was reported as very isolated thrombus.  
 
Delay between diagnosis and study entry  
To account for differences between the extent of the DVT on diagnosis and the 
first research scan a detailed assessment of this data was conducted and 
reported in Section 6.1.2 of the results. This analysis allowed the identification 
of any significant differences resulting from the fact that the diagnostic scan was 
undertaken by scientists other than this researcher. It also permitted further 
examination of any unexpected differences between scan results at diagnosis 
and seven days that were not considered to be attributable to seven days of 
anticoagulation treatment. As reported, almost half of the individual cases (48%) 
saw no change in TLS in the first seven days between diagnosis and their first 
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research follow-up visit (Table 6.3, Figure 6.1). A reduction in TLS would be 
considered the expected direction of any change as a result of seven days of 
anticoagulation treatment and this was seen in 41% of patients at the first 
research scan.  
 
The small number of cases in which there was an increase in TLS (11%) was 
closely examined to determine the most probable cause. In 12 of the 19 cases 
possible extension had occurred although this was only supported by an 
increase in patient symptoms in one case. It must be acknowledged that the 
use of a newer ultrasound machine with better imaging resolution and more 
time available for the research scan compared to the diagnostic scan may have 
been influencing factors in some of these cases. In six cases superficial 
thrombophlebitis was reported on the study entry scan but not on the diagnostic 
scan which increased the TLS at the first study visit. The superficial veins are 
only assessed over a 5 cm section distal to the main junction with the deep vein 
or where symptoms are located in the diagnostic scan (due to time constraints) 
however the complete venous tree was assessed for the research scan when 
more time was available which may have influenced these results. There was 
one further case in which a profunda vein DVT was reported on the study entry 
scan but not on the diagnostic scan which may have been an omission in the 
diagnostic scan as only the proximal section of the profunda vein is examined 
as part of the diagnostic protocol. The potential for discrepancies between the 
diagnostic scan and the initial research scan must therefore be acknowledged. 
 
Diagnosis of PTS 
Another key area where measurement bias could affect the internal validity of 
the study is the assessment of the primary outcome of the development of PTS. 
Consideration must be given to the fact that, whilst the Villalta score is generally 
considered to be the most reliable of the available scoring systems, there is an 
element of subjectivity associated with PTS diagnosis. 
 
Villalta scores have been shown to correlate well with patient-reported quality of 
life in PTS. Correlation has also been demonstrated with clinical measurements 
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believed to be related to the underlying pathophysiology of the condition such 
as high AVP measurements (Kolbach et al, 2005). In that study of 124 patients 
with previous DVT a moderate correlation was demonstrated between both the 
CEAP system and Villalta Scale and the reference standard AVP (0.22 and 0.27 
respectively). It was however noted that a considerable degree of overlap 
occurred in AVP measurements in the different categories of clinical severity of 
PTS using the Villalta scale indicating a non-linear relationship between venous 
hypertension and PTS risk (Kolbach et al, 2005). This potential issue was 
addressed in this study by analysing PTS as a binary outcome measure rather 
than categorising the different levels of PTS to avoid small numbers in individual 
groups.  
 
The Villalta scale has also been shown to demonstrate high levels of inter-
observer reliability whether used by physicians (Villalta et al, 1994) or other 
health professionals trained in using the system. A recent study demonstrated a 
high level of inter-observer agreement of the presence of PTS in patients 
between two professionals at two different centres (Kappa 0.84, 95% CI 0.69-
0.95). The two assessors agreed on the presence of PTS in 32.3% of patients 
and the absence of PTS in 60.4% with disagreement in only 7.3%. Mean PTS 
scores obtained were also comparable between the two operators (3.79 ± 3.5 
SD versus 3.97 ± 3.83 SD, P = 0.74) and the inter-observer agreement was 
found to be good for mild and moderate PTS and excellent for severe PTS 
(Milan et al, 2016). It must however be considered that the number of 
participants with severe PTS was low and caution must therefore be applied in 
drawing conclusions from these data. It is noted, however, that these results are 
consistent with those from an earlier study with a similar design (Rodger et al, 
2008). In order to avoid any issues with inter-observer variability in the current 
study, all PTS assessments were undertaken by a single observer which is both 
a strength but also a potential weakness of the study design. 
 
The Villalta scale does lack specific criteria for grading the individual elements 
of the score which adds a level of subjectivity (Roumen-Klappe et al, 2009) to 
the diagnosis of PTS. As the PTS assessment was undertaken by a single 
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observer any bias caused by subjectivity was likely to be consistent throughout 
all PTS assessments. An examination of the individual elements of the Villalta 
Scale scoring system was undertaken to establish if there was any trend 
present in the scoring of the individual elements or the frequency with which 
they were cited as reported in Section 10.2, Figures 10.4 and 10.5. This 
analysis demonstrated that of the clinician-rated indications, pre-tibial oedema 
was both the most frequently observed and the highest scoring element with 
frequency and scores fairly evenly distributed amongst the other clinician-rated 
elements of the scale. There was also consistency between the scoring and 
frequency of the individual elements of the patient-reported aspects of the 
scoring system with cramp being the highest scoring and most frequently cited 
symptom, followed by pain, heaviness and pruritus, each with similar scores 
and frequency.  
 
The severity and frequency of these symptoms of PTS are consistent with those 
cited in the literature (Kahn et al, 2016), however, the way patients may 
perceive the presence or severity of the symptoms of PTS is subjective, with 
one person’s pain or cramp being potentially very different from the next. 
Without a gold standard test for PTS, measuring and reporting outcomes has 
historically been complex (Roumen-Klappe et al, 2009). Whilst the 
pathophysiological mechanisms underlying the development of PTS remain 
uncertain, scoring and classification systems for the condition can only provide 
indicators of the syndrome such as clinical features and patient reported 
symptoms. In the absence of a clearly defined measurement that correlates with 
the condition, it can be argued that no PTS scoring system can claim to be truly 
valid (Soosainathan et al, 2013), however, it could also be argued that having a 
subjective symptom element to the score is an advantage as it makes the study 
stronger and more clinically meaningful.  
 
An ideal scoring system for diagnosing PTS should be specific, validated, offer 
high levels of inter-observer reliability, demonstrate good correlation with the 
underlying pathophysiology, be able to delineate the range in severity of the 
syndrome and detect change (both positive and negative) and finally, must be 
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easy to use. Only the Villalta scale is widely considered as addressing all of 
these requirements to a satisfactory level as reflected in its widespread use in 
PTS research (Soosainathan et al, 2013) Indeed, the Villalta scale was 
recommended as the standard definition of PTS and the scoring system of 
choice to be used in clinical trials by the Scientific and Standardisation 
committee of the International Society on Thrombosis and Haemostasis (Kahn 
et al, 2009b)  
 
11.6.3 Attrition 
As reported in Section 5.2.1, the retention rate over the two year follow-up 
period was 86%. This was likely due to a proactive approach through 
engagement with all participants and ensuring that they knew how valuable their 
contribution was and how much their time was appreciated. Practical 
considerations such as offering patient choice for appointment days and times, 
including out of hours appointments and re-imbursement of travel expenses 
were among the measures taken to try and maximise retention based on 
feedback from the patient partners that had participated in the design of the 
study and the funding application. The majority of those lost to follow-up left the 
study between the final two follow-up intervals when the time frame between 
follow-up intervals was greatest. The main challenge during this 12 month gap 
between follow-up visits was that participants may have moved house or 
changed contact details. To minimise the chances of this, contact details were 
verified at each visit and all patients were asked at each contact to kindly inform 
the researcher if their contact details changed between visits. All cases where 
patients did not attend their appointment were followed up to try to establish if 
they had received the appointment details, the reason for any non-attendance 
and patient choice for appointment rescheduling to try to maximise the 
likelihood of retention to the study. In the event of being unable to contact a 
participant, their GP (who had been informed of their participation in the study at 
the point of recruitment) was contacted to check for any changes in their contact 
details and to confirm that the patient was not deceased. 
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Whilst good participant retention to the study resulted in a high quality data set, 
consideration was nonetheless given as to how best to deal with the data that 
was missing from an analysis point of view. Ideally a multiple imputation 
technique could have been used to impute the incomplete records however due 
to the small percentage of missing data items it was considered acceptable to 
use pairwise deletion. This meant that the maximum number of available cases 
for each variable was used in the analyses and accounted for the small 
variation in sample sizes for different analyses reported in the results.  
 
All lost cases were examined across several characteristics which showed they 
did not differ significantly from those used in the analysis and did not result in 
any substantive bias.  
 
11.7 Further research  
Several key future research themes have been identified and are grouped for 
discussion in this section. 
 
Larger study with longer term follow-up 
The findings from this study have confirmed the need for further large scale 
research in this field to build further upon both the existing evidence and the 
new evidence provided by the current study. It is clear that many of the 
questions that remain in terms of the pathophysiology of PTS will not be 
answered through small scale research. In particular, the roles of venous 
incompetence, sex, BMI and recurrent DVT in the development of PTS warrant 
further investigation. In addition, the role of compression stockings in preventing 
DVT and recommendations for the duration of their use warrants further 
research with a high quality randomised controlled trial specifically addressing 
stocking usage with allocation to varying durations of stocking use.  
 
The comprehensive scrutiny of the methodology of previous research studies of 
this kind provided a significant learning opportunity in designing the 
methodology for this observational study. The current study has demonstrated 
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that these are acceptable methods for a larger, study of short, medium and 
longer term outcomes after DVT which could provide further evidence relating to 
individualised risk stratification for PTS which could in turn influence the 
treatment strategy on a personalised level. 
 
 
Prediction models and clinical risk scoring tool for PTS 
This research study has generated a comprehensive data set that has provided 
useful information regarding the natural history of DVT under treatment and has 
identified several important associations between characteristics present at 
baseline and/or occurring during follow-up and the possible outcomes after 
DVT. As described in the background chapter of this thesis (Section 1.10) and 
the motivation for undertaking this study (Section 1.12), in the absence of 
effective therapies for PTS, preventative measures are warranted and the ability 
to identify those patients at increased risk at an early stage could determine 
more personalised treatment for the DVT (as discussed in Section 11.6). 
Further research steps are needed before these results could be used clinically 
in a safe and useful manner. These include the creation of a scoring system 
and its subsequent validation on a separate cohort. To this end further work is 
warranted to develop and validate a prediction model for PTS and to create and 
validate a clinical risk scoring system or tool that could be used to identify those 
individuals at increased risk of developing the condition.  
 
The ability of the model to generate predicted probabilities compared to 
observed outcome frequencies would require assessment and the regression 
coefficients of the models would need to be examined in order to derive a 
practical clinical score which would then require further external validation. The 
clinical risk assessment tool for the development of PTS should be easy to use, 
preferably with variables that are readily available at baseline and should not 
involve the use of any expensive diagnostic measurements. This would allow a 
risk assessment to be undertaken in the early stages after DVT diagnosis to 
identify those that would benefit most from catheter-directed thrombolysis. A 
further risk assessment tool could be designed using characteristics that 
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present during the sub-acute phase of DVT (three to six months post diagnosis) 
to identify patients that may either stop therapy or those that require continued 
or enhanced therapy.  
 
Further research using decision analytical modelling techniques would then be 
required to determine the acceptable threshold from both a medical perspective 
in terms of identifying those patients most at risk and from an economic 
perspective in terms of the efficient identification of those patients that can be 
excluded from requiring further or enhanced treatment. Validation of any risk 
scoring tools would then need to be undertaken using a new large cohort with 
DVT that would be followed prospectively. The development of such tools would 
have the potential to both improve patient care and reduce costs as the 
appropriate therapy or intervention could then be allocated to those likely to 
benefit most. It must however be considered that, with the high degree 
variability regarding factors associated with PTS and the relatively low 
prognostic value, at the moment a simple scoring system may not be very 
useful and there is much more work to be done first to clarify the underlying 
physiological processes involved in the development of PTS. 
 
 
Psychological impact of DVT 
Although the psychological impact of DVT was not investigated formally as part 
of this study, it was a recurrent theme in discussions with patients during their 
follow-up over the two year period. Many patients frequently referred to their 
“gratitude” at receiving follow-up and the “peace of mind” knowing that someone 
was “checking their leg”. The onset of a VTE can be life-threatening and 
traumatic with the potential to cause long-term health anxiety (Ozer et al, 2003). 
In addition to this, patients may have to live with ongoing symptoms, the risk of 
recurrence and the risk of bleeding associated with anticoagulation treatment. 
Studies into the impact of VTE to date however have largely focussed on 
health-related quality of life and only a few studies have examined the impact of 
DVT and PE on patient wellbeing in terms of distress, depression and ongoing 
anxiety after diagnosis (Bucholz et al, 2014; Bennett et al, 2016; Hunter et al, 
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2017). The limited evidence that does exist highlights some important themes 
relating to patients’ perceptions of VTE that were affirmed through discussions 
with patients during follow-up for this study. This warrants further investigation 
to inform the wider understanding of how people process and cope with the 
acute onset of what may become a long-term condition. 
 
A recent qualitative study used inductive thematic analysis of semi-structured 
interviews to explore the patient experience of VTE. A sample of 12 consecutive 
adult patients who had experienced a first time DVT or PE in the preceding 6 
months was recruited from an outpatient haematology clinic in a UK hospital 
(Hunter et al, 2017). One of the key themes to emerge from this study was that 
of hypervigilance associated with living with uncertainty and the fear of 
recurrence. The concept of an unprovoked event with its lack of medical 
explanation served to reinforce the anxiety and uncertainty which often 
manifested as hypervigilance to symptoms. Combined with the reported lack of 
information from health care professionals, especially at the time of hospital 
discharge which participants considered a critical time for information and 
support, this led to an increased use of primary health care resources to seek 
information and/or reassurance (Hunter et al, 2017).  
 
Participants described feeling that they had been given inadequate information 
regarding when to return to occupational activites and acceptable limits of 
physical exertion which contributed to feelings of ‘lack of control’ around their 
condition and ‘abandonment’ by the health care professionals involved in their 
diagnosis and treatment. Participants reported further anxiety around their 
treatment with anticoagulation therapy in particular regarding uncertainty of the 
treatment duration and bleeding risk. This lack of information led to many 
seeking alternative and less regulated sources of information via the internet 
which provided answers and a source of support for some but all participants 
reported that this also raised new anxieties (Hunter et al, 2017).  
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The majority of participants in the study by Hunter et al (2017) also reported 
anxiety regarding the uncertainty of whether the clots were still present.  This 
was often a focus of participant initiated conversation during follow-up in the 
current study with many repeatedly expressing their appreciation that they 
would “know how their DVT was doing” by participating in the study. The theme 
of uncertainty surrounding the treatment duration was also echoed by 
participants in the current study who frequently mentioned this as a concern.  
 
Interestingly, there appeared to be little difference in the level of distress 
experienced between patients that had experienced a DVT compared to a PE 
despite the fact that from an objective point of view a DVT is less immediately 
life-threatening and by association therefore may be considered less traumatic. 
Similar findings were however also reported in a study of people accessing a 
VTE internet support website (Bennett et al, 2016). Hunter et al (2017) identified 
that younger people reported a greater impact on their life than older 
participants which is possibly a reflection of the fact that younger individuals are 
more likely to experience disruption to routine life events such as pregnancy, 
occupation and engagement in physical activity, may have more limited life 
experience on which to draw and have a lack of peer support (Bucholz et al, 
2014).  
 
Of course research of this kind only offers a snap shot in time of patient 
experience of VTE and is at risk of participation bias making it difficult to know if 
the uptake of the study reflected generally higher levels of anxiety in this cohort. 
This may also be reflected in the uptake of the patient cohort in the current 
observational study. It does however raise important discussion points which 
would benefit from future research to assess the need for identifying and better 
supporting individuals at risk of significant psychological distress as a result of a 
diagnosis of DVT or PE. Further research in this area could lead to the 
development of support materials or mechanisms. 
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11.8 Summary  
This chapter has presented the key research findings from this work, examined 
them in the context of the existing evidence and professional opinion and 
interpreted their meaning for clinical practice. The chapter has further appraised 
the quality of the studies undertaken and presented clear plans for future. The 
following conclusions chapter revisits the aims and objectives of the current 
research and evaluateshow they have been met. 
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CHAPTER 12: CONCLUSIONS 
 
12.1 Introduction 
This final chapter re-examines the original aims, objectives and research 
question considering the degree to which they have been achieved. It then 
concludes with implications of the findings for future research and the 
contribution to new knowledge the research has made. 
 
12.2 Review of the research aims  
This thesis has sought to address the following aims 
 
To determine expert opinion regarding risk factors for the development of 
PTS.  
This aim was achieved by successfully performing a SLR which summarised 
and critically appraised the existing published and unpublished evidence 
regarding factors associated with the development of PTS. This information was 
then assimilated in order to construct a questionnaire which gathered 
professional opinion from the membership of the SVT and led to the creation of 
a list of the perceived risk factors for the development of PTS they considered 
to be the most important. The list played an integral role in determining the 
variables for which data would be collected in the observational study 
conducted to meet the second aim of the study as detailed in the following 
section. 
 
To identify the level of variation in response to oral anticoagulation 
treatment including DOACs and provide more precise and quantitative 
disease characterisation. 
This aim was achieved by designing and conducting a prospective cohort study 
using ultrasound to systematically examine and record changes in thrombus 
burden and resolution over time in patients with a first episode of acute 
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ipsilateral DVT.  This information permitted analysis of these changes which 
resulted in the description of eight clear patterns of thrombus evolution. Having 
satisfactorily assimilated information from the critical appraisal of the individual 
studies in the SLR, the study was effectively designed to record data from which 
to determine patient outcomes following anticoagulation treatment. These data 
permitted the analysis required to meet the third aim of the study as detailed in 
the following section.  
 
To statistically assess associations between characteristics present at 
baseline and those that present during follow-up and four main outcomes 
after DVT: resolution, recurrence, the development of venous 
incompetence and the development of PTS. 
Sufficient data were collected to enable statistical analysis of the relationships 
between 13 characteristics present at baseline and 6 characteristics that 
presented during follow-up and the four outcomes after DVT of resolution, 
recurrence, the development of venous incompetence and the development of 
PTS. This has enabled identification of characteristics associated with 
outcomes and the strengths of any associations identified.  
 
12.3 Final conclusions 
This study has been provided new evidence in a topical area of research where 
significant unknowns remain regarding risk factors for PTS. This study has 
demonstrated a contribution to new knowledge in this area by providing 
evidence regarding the clinical course of first episode DVT and how this, as well 
as the presence or absence of certain baseline characteristics might be related 
to important positive and negative outcomes after DVT.  
 
Appraisal of the research methods of the existing evidence and identification of 
pitfalls promoted internal validity. This is the first study of its kind which provides 
data regarding both the natural history of proximal and distal DVT and patient 
outcomes in a cohort where participants were treated with the new class of 
anticoagulant medications used for DVT. 
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The key messages from this study can be summarised as follows: 
• The study has provided information with which clinicians can better 
prepare patients for potential outcomes after DVT in order to better 
manage their expectations or anxiety.  
• The results indicate positive longer term outcomes after DOAC use 
which could enable clinicians to reassure patients about their use 
however they may not be suitable in those patients who are overweight. 
• The study has provided useful information for potential risk stratification 
for PTS patients and suggests that those with residual thrombus, women, 
those who are overweight and those that are not able to use 
compression stockings are more at risk of developing the condition. 
• Lifestyle advice regarding weight management and stocking use (even if 
only short term) may be beneficial in preventing PTS development. 
• Valvular damage as a result of DVT may not be linked to the 
development of PTS but the role of superficial venous incompetence 
might be important and warrants further research. 
• Extended anticoagulation may not be beneficial in the prevention of PTS. 
 
The information provided by this research is therefore important on two levels:  
 
1) It provides new knowledge that helps answer the key patient questions 
regarding outcomes after DVT that initially prompted the research and 
which will enable those involved in their diagnosis and care to advise 
them better and enable them to make informed choices regarding both 
treatment and lifestyle that may positively influence their outcomes after 
DVT.  
2) It provides useful information for the clinicians who are frequently faced 
with difficult decisions regarding appropriate individualised treatment for 
DVT in order to mitigate longer-term risks.  
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Finally, whilst it is acknowledged that the gaps and conflict in the existing 
evidence are unlikely to be answered by a single centre research study; this 
study has provided evidence to help build the bigger picture. It has established 
that good research practice is possible in a study of this kind and has created a 
platform for future research. This study has demonstrated that these are 
acceptable methods for a larger study of short, medium and longer term 
outcomes after DVT, designed to answer specific questions and which could 
provide further evidence relating to individualised risk stratification for PTS. This 
in turn could influence the treatment strategy on a personalised level following 
the development and testing of a clinical risk prediction model for PTS. 
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APPENDICES 
 
APPENDIX A1 LITERATURE REVIEW 
A1.1 Systematic Literature Review Search strategy 
The following search strategy was used for this review, using MeSH headings 
where applicable, and keyword searches {Higgins 2011} 
1: deep vein thrombosis OR DVT OR venous thrombosis OR proximal vein 
thrombosis OR calf vein thrombosis 
2: risk OR prognos* OR predict* 
3: postthrombotic syndrome OR post-thrombotic syndrome OR post thrombotic 
syndrome OR PTS OR postphlebitic syndrome OR post-phlebitic syndrome OR 
post phlebitic syndrome OR chronic venous disease OR chronic venous 
insufficiency OR venous stasis OR venous reflux 
4: Combine 1 AND 3 
5: Combine 2 AND 4 
 
MeSH headings used:  
Postphlebitic Syndrome [C14.907.952.760]    
Postthrombotic Syndrome [C14.907.952.880]  
Venous Thrombosis [C14.907.355.830.925] 
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A1.2 Example of data extraction form and quality assessment. 
Reviewer Name: Michelle Bonfield 
Date of extraction/review: 14/08/2013 
Study Authors: Franzeck et al 
Year of Publication: 1997 
Study Title: On the relationship between changes in the 
deep veins evaluated by duplex sonography 
and the post-thrombotic syndrome 12 years 
after deep vein thrombosis. 
Type of Study: Prospective cohort study 
Study Setting: Division of Vascular Medicine, University 
Hospital Zurich. 
Patient characteristics (age, 
sex, etc): 
Consecutive patients with first episode acute 
DVT. 
44 men and 14 women. 
Mean age 50.5 ±14.4 years (range 25-78) 
Sample size: 58 
Complete follow up of 12 years in 39 
patients 
Length of follow-up: 12 years (3, 6 and 12 months then yearly to 
5 years and final visit at 12 years). 
Treatment Intervention (type, 
dosage, duration): 
Initial bolus followed by continuous heparin 
infusion for 5 days then oral anticoagulants 
started on day 2 for 12 months (proximal 
DVT) or 6 months (distal DVT) plus Class III 
compression stockings. 
Method of DVT diagnosis:  Ascending phlebography 
Method of Reflux diagnosis: Colour duplex and Doppler with reflux > 2 
secs on proximal manual compression and 
or Valsalva manoeuvre. 
Method of PTS diagnosis: International Consensus Committee on 
Chronic Venous Disease (Classes 0, 1-3, 4, 
5 and 6). 
Risk factors for PTS identified: Combination of reflux and obstruction in 
partial re-canalised segments 50% limbs. 
Odds/Risk ratios: Not analysed. 
No associations found: Reflux alone with no obstruction. 
Obstruction of SFV and popliteal vein. 
Other relevant information:  
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1. Did the study address a clearly 
focused issue? 
Yes No Not Clear 
Consider:  
Were risk factors for PTS specifically 
studied? 
 
Notes:  
Only thrombosis resolution and 
reflux were assessed in relation to 
risk of developing PTS. 
2. Was the cohort recruited in an 
acceptable way? 
Yes No Not Clear 
Was the cohort representative of a 
defined population? 
 
 
 
 
 
 
Were all participants at a similar stage 
post diagnosis on assessment? 
 
Was the sample size sufficient to 
demonstrate an association? 
Consecutive patients with acute 
DVT – consecutive recruiting 
reduces bias. Exclusion criteria 
defined but number excluded not 
given. Lack of demographic 
information for participants. Large 
percentage of male participants.  
 
Yes, defined interval follow-up. 
 
 
No, only 39 patients with complete 
follow-up of 12 years. No sample 
size calculation performed. 
3. Was the exposure accurately 
measured to minimise bias? 
Yes No Not Clear 
Was the original DVT objectively 
diagnosed? 
 
 
 
 
 
Were all the subjects classified using the 
same procedure? 
Diagnosis with ascending 
phlebography but no information 
given regarding protocol or who 
made the diagnosis. Measurement 
and classification bias possible. 
 
All with same modality but cannot 
tell as protocol not given. 
 
4. Was the outcome accurately 
measured to minimise bias? 
Yes No Not Clear 
Was the presence/absence of venous 
reflux objectively diagnosed? 
 
 
 
 
 
 
 
 
Was the presence/absence of PTS 
objectively diagnosed using a validated 
system? 
Diagnosis with colour duplex 
ultrasound and reflux > 2 secs on 
Doppler. Why > 2 secs – widely 
accepted that 0.5 secs indicates 
reflux. No justification given with 
supporting evidence for this 
selection. 
Valsalva or manual compression 
used – not specified which used 
where and why. 
CEAP system used but has been 
revised since study was 
conducted. 
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Were the outcome measurement 
methods the same for all participants? 
 
Were the outcome assessors blinded? 
Valsalva or manual compression 
issue – not clear if this was the 
same for all patients. 
Not stated if physician blinded but 
sonographer could not be blinded. 
5. Have the authors identified all 
important confounding factors? 
Yes No Not Clear 
List the important confounding factors in 
the study. 
 
Identify any confounding factors not 
considered by the authors. 
 
 
 
 
 
 
 
 
Have they taken account of confounding 
factors in the analysis? 
Not listed in the study methods. 
 
 
Patient positioning for reflux 
assessment.  
Manual compression and/or 
Valsalva used for reflux 
assessment. 
Compliance with compression 
therapy Room temperature for 
reflux assessment not considered. 
Age, sex, previous DVT, genetic 
disorders, malignancy. 
 
No 
6. Was the follow up of subjects 
complete enough? 
Yes No Not Clear 
Was the duration of follow up long 
enough? 
 
 
Were the outcomes of participants that 
withdrew described and included in the 
analysis? 
 
 
Yes, 12 years but no justification 
for this F/U period given. 
 
Mortality 8/58 patients (5 vascular 
and 3 non-vascular deaths 
between 21 and 89 months post 
enrolment). 7/58 participants lost 
to follow-up due to migration or 
unwillingness to continue in study. 
Were participants that remained in 
the study different in any way – 
more compliant with compression 
therapy? 
7. What are the results of this study?  
What risk factors for PTS were identified? 
 
 
 
 
 
 
 
 
 
 
64% of 39 participants had normal 
clinical findings at 12 years. 
Mild PTS (class 1-3) in 28%. 
Moderate PTS (class 4) in 5%. 
Severe PTS (class 6) in 3%. 
 
Isolated calf DVT Mild PTS in 2/13 
patients. 
 
Proximal DVT 34% no PTS, 34% 
class 3, 8% class 4, 1 patient 
class 5. 
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How strong is the association between 
exposure and outcome? 
 
What factors were identified as not 
significant risk factors? 
 
Was appropriate statistical analysis 
used? 
 
Most frequent cause of PTS 
development was combination of 
reflux and obstruction in partial re-
canalised segments 50% off 
limbs). 
Reflux but no obstruction PTS in 
33%. 
Obstruction but no reflux PTS in 
8.5%. 
 
 
No odds ratios calculated. 
 
 
Reflux alone and obstruction 
alone. 
 
 
Basic descriptive statistical 
analysis, no odds ratios. Only 1 
Chi squared analysis for 
compression compliance. 
8. How precise are the results?   
Confidence intervals? No confidence intervals reported. 
9. Do you believe in the results? Yes No Not Clear 
Consider: 
 
Are the design and methods of the study 
sufficiently flawed to make the results 
unreliable? 
 
Are the results likely to be due to bias, 
chance or confounding? 
Notes: 
 
 
Yes, sample size too small. 
 
 
Highly possible with such a small 
sample size. 
10. Can the results of the study be 
applied to the local population? 
Yes No Not Clear 
Was a cohort study the appropriate 
method to answer this question? 
 
Are the subjects in the study sufficiently 
different to a local population? 
Yes 
 
 
Possibly. 
11. Do the results fit with other 
available evidence? 
Yes No Not Clear 
 Most frequent cause of PTS 
development was combination of 
reflux and obstruction also found 
by Prandoni et al, 2005 but 
conflicting with evidence in study 
by Yamaki et al, 2007. 
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12. What are the implications of this 
study for practice? 
 
 
 
 
 
This study in isolation has no 
implications for practice due to 
methodological limitations and 
small sample size.  
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A1.3 Publication of shared knowledge resource for performing SLRs  
Journal of Allied Health 2018 Fall; 47(3):167-171. 
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Appendix A2 PEER GROUP OPINION STUDY 
A2.1 UWE Faculty Research Ethics Committee approval 
 
 
Faculty of Health & 
Applied  
Sciences  
Glenside Campus 
Blackberry Hill 
Stapleton 
Bristol   BS16 1DD 
 
         Tel: 0117 328 1170 
UWE REC REF No:  HAS/13/10/135  
Date: 4th November 2013 
 
Michelle Bonfield 
Vascular Studies Unit 
Level 2 Queens Building 
Bristol Royal Infirmary 
Marlborough Street 
Bristol BS2 8HW 
 
Dear Michelle 
Application title:  A consensus study of the potential risk factors for the 
development of post-thrombotic syndrome 
Your ethics application was considered by the Faculty Research Ethics Committee and, based 
on the information provided, has been given ethical approval to proceed with the following 
conditions: 
 
1. We would advise that you alter the first line of the e-mail introduction to 
“undertaking a PhD” as it sounds more professional than “doing” but 
otherwise a very thought out and explained study. 
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If these conditions include providing further information please do not proceed 
with your research until you have full approval from the committee.  You must 
notify the committee in advance if you wish to make any significant 
amendments to the original application using the amendment form at 
http://www1.uwe.ac.uk/hls/research/researchethicsandgovernance.aspx. 
Please note that any information sheets and consent forms should have the 
UWE logo.  Further guidance is available on the web: 
http://www1.uwe.ac.uk/aboutus/departmentsandservices/professionalservices/
marketingandcommunications/resources.aspx 
The following standards conditions also apply to all research given ethical 
approval by a UWE Research Ethics Committee:   
1. You must notify the relevant UWE Research Ethics Committee in advance if 
you wish to make significant amendments to the original application: these 
include any changes to the study protocol which have an ethical dimension. 
Please note that any changes approved by an external research ethics 
committee must also be communicated to the relevant UWE committee.  
2. You must notify the University  Research Ethics Committee if you terminate 
your research before completion; 
3. You must notify the University Research Ethics Committee if there are any 
serious events or developments in the research that have an ethical 
dimension. 
 
Please note: The UREC is required to monitor and audit the ethical conduct of 
research involving human participants, data and tissue conducted by academic 
staff, students and researchers. Your project may be selected for audit from the 
research projects submitted to and approved by the UREC and its committees. 
We wish you well with your research. 
Yours sincerely 
 
 
Dr Julie Woodley 
Chair 
Faculty Research Ethics Committee 
c.c  Fiona Cramp
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A2.2 Risk Assessment 
 
 
Describe the activity being assessed:   
 
Completing electronic questionnaire. 
Assessed by: 
 
Michelle Bonfield 
Endorsed by: 
 
Fiona Cramp 
Who might be harmed: Vascular Scientists who are members of the Society for Vascular 
Technology of GB & Ireland 
 
How many exposed to risk:  
Date of Assessment:  
30/09/2013 
 
Review date(s):  
 
 
 
 
Ref: 
400 
400400 
GENERAL RISK ASSESSMENT FORM 
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Hazards Identified 
(state the potential harm) 
Existing Control Measures S L Risk 
Level 
Additional Control Measures S L 
 
Risk 
Level 
By whom 
and by 
when 
Date 
completed 
 
Repetitive strain injury 
 
 
The majority of potential participants are 
likely to be NHS employees who will have 
undertaken a work station safety 
assessment to minimise injuries whilst 
sitting at desk (RSI, eye strain etc) 
3 1 4  
No additional control measures. 
   Michelle 
Bonfield 
30/09/2013 
 
Eye strain 
The majority of potential participants are 
likely to be NHS employees who will have 
undertaken a work station safety 
assessment to minimise injuries whilst 
sitting at desk (RSI, eye strain etc) 
3 1 4  
No additional control measures. 
 
 
 
   Michelle 
Bonfield 
30/09/2013 
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RISK MATRIX: (To generate the risk level). 
Very likely 
5 
5 10 15 20 25 
Likely 
4 
4 8 12 16 20 
Possible 
3 
3 6 9 12 15 
Unlikely 
2 
2 4 6 8 10 
Extremely unlikely 
1 
1 2 3 4 5 
Likelihood (L) 
 
   Severity (S) 
Minor injury – No first aid 
treatment required 
1 
Minor injury – Requires First 
Aid Treatment 
2 
Injury - requires GP treatment 
or Hospital attendance  
3 
Major Injury 
 
4 
Fatality 
 
5 
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ACTION LEVEL: (To identify what action needs to be taken). 
 
POINTS: 
 
RISK LEVEL: ACTION: 
1 – 2 NEGLIGIBLE No further action is necessary. 
 
3 – 5 TOLERABLE Where possible, reduce the risk further 
6 - 12 MODERATE Additional control measures are required 
15 – 16 HIGH Immediate action is necessary 
20 - 25 INTOLERABLE Stop the activity/ do not start the activity 
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A2.3 E-mail sent to the membership of the Society of Vascular 
Technology (SVT) for the peer group opinion study. 
 
Dear Vascular Scientist,  
 
I am currently undertaking a PhD at the University of the West of England and 
my research project is a prospective observational study of patients with a first 
episode of lower limb DVT. As part of my research I am examining risk factors 
for the development of post-thrombotic syndrome (PTS). To identify the most 
important parameters to examine I am seeking the opinion of my clinical 
profession. 
 
The Director of Studies for the research project is Dr. Fiona Cramp and she can 
be contacted at the following address: 
 
Faculty of Health & Applied Sciences 
University of the West of England 
Glenside Campus 
Blackberry Hill 
Bristol BS16 1DD 
 
Tel: +44 (0)117 3288501 
 
I would be really grateful if you would complete the attached questionnaire for 
this consensus study.  
 
Ethical approval for the study has been obtained from the Research Ethics 
Committee of the University of the West of England (HAS/13/10/135). By 
completing this questionnaire your consent to participate in this study will be 
implied.  
 
Data will be collected and retained in accordance with the Data Protection Act 
1998. The questionnaire can be completed electronically and returned to me by 
e-mail or can be printed and returned to me by fax or post if you wish to 
complete it anonymously. Where participants return their responses by email 
the information will immediately be anonymised so that their responses cannot 
be attributed to them personally. The data from the returned questionnaires will 
be extracted and entered into an excel spreadsheet for data management. Your 
name will not be recorded but details of your accreditation status and clinical 
practice service will be recorded. It will not be possible to identify you from this 
information. The findings from the study will be reported in the PhD thesis and 
potentially in a conference presentation and/or peer reviewed journal. 
 
The deadline for returning the completed questionnaires is 27th November 2013. 
 
Thank you very much in advance for your help. 
Very best wishes, 
Michelle 
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A2.4 Information sheet sent to the membership of the Society of 
Vascular Technology (SVT) for the peer group opinion study. 
Consensus study of potential influencing factors in the development of post-thrombotic 
syndrome to be examined in prospective cohort study of patients with first episode of 
DVT. 
 
Introduction: 
Deep vein thrombosis (DVT) is known to have a number of well-recognised, potentially life-
threatening complications as well as chronic long-term sequelae known as post thrombotic 
syndrome (PTS). Not every patient that has a DVT will develop PTS but there is a lack of 
research evidence to indicate which patients will. There is conflicting research evidence 
regarding the impact of risk factors such as DVT location, resolution extent at treatment 
completion, or patient characteristics such as age, sex or body mass index on the risk of 
developing PTS. 
 
Purpose of the study: 
This consensus study is the second phase of a three phase study to examine the natural history 
of DVT in response to anticoagulation treatment and predictive risk factors for the development 
of recurrent DVT and PTS. This study is being undertaken as part of a PhD at the University of 
the West of England and is funded via an NIHR/CSO Healthcare Science Doctoral Research 
Fellowship. Phase 1 of the study comprised a systematic literature review of the current 
research evidence for risk factors for the development of PTS.  
 
This second phase of the research study comprises a consensus study of the opinion of the 
membership of the Society for Vascular Technology of Great Britain and Ireland regarding 
which potential risk factors for the development of PTS they consider to be important. The first 
two phases of the project will be used to identify and refine those risk factors predictive of PTS 
that will be subsequently examined in the prospective observational study which forms the third 
phase of this research.  
 
How to complete the survey: 
Page 2 contains a list of potential risk factors for PTS. You are asked to please place a cross in 
the box to indicate your opinion regarding the relationship of the parameters in the left hand 
column to the development of PTS. You are also invited to add any parameters that you think 
are missing in the empty boxes and grade them accordingly. By completing this questionnaire 
your consent to participate in this study is implied. Should you decide that you wish to withdraw 
your data from this study at any stage, please contact the researcher to request this (see 
contact details below). 
 
Please return the completed form before 27
th
 November 2013 to: Michelle Bonfield at:  
michelle.bonfield@uhbristol.nhs.uk  
 
Following receipt of the questionnaire all potential identifiers will be removed to ensure that 
responses cannot be attributed to any individual.  If you would prefer to return the questionnaire 
anonymously you can send it by Fax: 0117 342 2443 or by post to the following address: 
 
Michelle Bonfield 
Clinical Vascular Scientist 
Vascular Studies Unit 
Queens Building 
Bristol Royal Infirmary 
Marlborough Street 
Bristol BS2 8HW 
 
Thank you very much for your participation. 
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A2.5 Questionnaire sent to the membership of the Society of 
Vascular Technology (SVT) for the peer group opinion study. 
Please place a cross in the box to state your opinion regarding the relationship of the 
parameters in the left hand column to the development of post-thrombotic syndrome: 
 
Potential Risk Factors 
Not 
related 
Possibly 
related 
Related 
Related 
& very 
important 
Don’t 
Know 
Age      
Sex      
BMI      
Previous ipsilateral DVT      
Previous contralateral DVT      
D-dimer at presentation      
Extent of original DVT      
Iliac involvement in original DVT      
Residual thrombus      
Presence of deep venous reflux      
Combination of residual obstruction 
and reflux 
     
Pre-existing perforator incompetence      
Pre-existing superficial venous reflux      
Thrombophilic status      
Physical activity levels      
Inflammatory markers      
Venous outflow resistance      
Original DVT during pregnancy      
Calf muscle pump function      
Bilateral DVT at presentation      
Type of anticoagulation treatment      
Insufficient quality of anticoagulation      
Poor compliance with compression 
hosiery 
     
Original DVT provoked or 
unprovoked 
     
Location of original DVT      
Malignancy      
Transient v permanent risk factors      
Peak reflux velocity      
Reflux duration      
Smoking      
Diabetes      
Hypertension      
Congestive heart failure      
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You are invited to add any parameters that you think are missing in the empty boxes below and 
grade them accordingly: 
 
Risk factors not listed above: 
Not 
related 
Possibly 
related 
Related 
Related & 
very 
important 
Don’t 
Know 
      
      
      
      
 
Please provide the following information regarding your clinical experience: 
 
 Yes No 
AVS   
Currently in clinical practice    
Length of clinical practice  
 
Many thanks for your time. Your participation is very much appreciated. 
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A2.6 Results for the individual variables examined in the peer group 
opinion study. 
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Age
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Sex
% respondents  
 
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
BMI
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Previous ipsilateral DVT
% respondents  
  
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Previous contralateral DVT
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
D-dimer at presentation
% respondents  
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Extent of original DVT
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Iliac involvement of DVT
% respondents  
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Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Residual thrombus
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Presence of deep venous reflux
% respondents  
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Combination of residual obstruction and reflux
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Pre-existing perforator incompetence
% respondents  
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Pre-existing superficial venous reflux
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Physical activity levels
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Inflammatory markers
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Venous outflow resistance
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Original DVT during pregnancy
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Calf muscle pump function
% respondents
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Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Bilateral DVT at presentation
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Type of anticoagulation treatment
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Insufficient quality of anticoagulation
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Poor compliance with compression therapy
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Original DVT provoked or unprovoked
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Location of original DVT
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Malignancy
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Transient v permanent risk factors
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Peak reflux velocity
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Reflux duration
% respondents
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Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Smoking
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Diabetes mellitus
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Hypertension
% respondents
Not related
Possibly related
Related
Related & very important
Don't know
10 20 30 40 50 60 70 80 90 100
Congestive heart failure
% respondents  
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Appendix A3 OBSERVATIONAL STUDY METHODOLOGY  
A3.1 LREC provisional opinion 
 
 
391 
 
 
392 
 
 
 
393 
 
 
394 
 
A3.2 Response to LREC provisional opinion 
 
 
 
 
Vascular Studies Unit 
Level 2, Balloon Corridor 
Queens Building 
Bristol Royal Infirmary 
Marlborough Street 
Bristol, BS2 8HW 
 
Tel: 0117 342 2836 
Fax: 0117 342 2443 
 
13th May 2013 
 
Mrs. N. Nathoo 
Central Bristol REC 
Bristol Research Ethics Centre 
Level 3, Block B 
Whitefriars 
Lewins Mead 
Bristol BS1 2NT 
 
 
 
Dear Mrs Nathoo, 
 
Study Title:  The response of lower limb deep vein thrombosis to 
anticoagulation therapy: resolution, recurrence and post 
thrombotic syndrome. 
 
REC Ref:   13/SW/0075 
Protocol number: SU/2013/4278 
IRAS project ID:  123100 
 
Further to the letter detailing the outcome of the ethical review meeting held on 
26/04/2010 for the above study, please find enclosed the Participant Information 
Sheet and GP Letter which have been duly revised as requested by the REC. 
 
In view of the issues discussed during the ethical review meeting I can confirm 
the following: 
 
Whilst most patients will be receiving the standard anti-coagulation treatment 
following Trust protocol, details of the anti-coagulation treatment received by 
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each patient in the study will be collected as it is recognised that there are 
several different anti-coagulation therapies available and that variation from the 
standard protocol can occur depending on patient pathway and patient profile.  
 
Details of non-prescription medication being taken by participants will also be 
recorded as it is recognised that some non-prescription medication may react 
with anti-coagulants. 
 
Regarding the time required to undertake this study, I can confirm that 3 days 
per week over the next 5 years are dedicated to this research project which 
forms the basis of a PhD which is fully funded as part of an NIHR/CSO 
Healthcare Science Doctoral Research Fellowship held by myself. 
 
Height and weight measurements will be recorded for each patient at each 
follow-up visit in order to calculate body mass index. 
 
Patients diagnosed with a DVT whilst an inpatient may be included in the study 
providing they meet the inclusion criteria. For patients commencing anti-
coagulation therapy at ward level, details of their treatment would be available 
from their discharge summary which would be obtained so that the details as 
described above can be recorded. 
 
Potential participants will be asked if they are participating in other research 
studies and if the other research study has the potential to confound this study, 
they would not be recruited to this study. 
 
The statement that there is no direct benefit to patients taking part in the study, 
however, information from the study may help improve the treatment for future 
patients has been retained in the patient information leaflet on the advice of the 
committee.  
 
I hope that everything is in order and I look forward to hearing from you. 
 
Yours sincerely, 
 
 
 
 
Michelle Bonfield 
NIHR/CSO Doctoral Research Fellow & 
Clinical Vascular Scientist 
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A3.3 LREC favourable opinion 
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A3.4 University of the West of England ethical approval  
  
Faculty of Health & Life  
Sciences  
Glenside Campus 
         Blackberry Hill 
         Stapleton 
         Bristol    BS16 1DD 
 
         Tel: 0117 328 1170 
Our ref: JW/lt 
 
28 June 2019 
 
Mrs Michelle Bonfield 
NIHR/CSO Doctoral Research Fellow 
& Clinical Vascular Scientist 
Vascular Studies Unit 
Queens Building 
Bristol Royal Infirmary 
Marlborough Street 
Bristol    BS2 8HW 
 
Dear Michelle 
 
Application number: HLS/13/05/73 
Application title:  The response of lower limb deep vein thrombosis to anticoagulation 
therapy: resolution, recurrence and post thrombotic syndrome 
REC reference: 13/SW/0075 
 
Your NHS Ethics application and approval conditions have been considered by the Faculty 
Research Ethics Committee on behalf of the University.  It has been given ethical approval to 
proceed with the following conditions: 
 
You comply with the conditions of the NHS Ethics approval. 
You notify the Faculty Research Ethics Committee of any further correspondence with the NHS 
Ethics Committee. 
You must notify the Faculty Research Ethics Committee in advance if you wish to make any 
significant amendments to the original application. 
If you have to terminate your research before completion, please inform the Faculty Research 
Ethics Committee within 14 days, indicating the reasons. 
Please notify the Faculty Research Ethics Committee if there are any serious events or 
developments in the research that have an ethical dimension. 
Any changes to the study protocol, which have an ethical dimension, will need to be approved 
by the Faculty Research Ethics Committee. You should send details of any such amendments 
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to the committee with an explanation of the reason for the proposed changes.  Any changes 
approved by an external research ethics committee must also be communicated to the relevant 
UWE committee.  
 
Please note that all information sheets and consent forms should be on UWE headed paper. 
 
Please be advised that as principal investigator you are responsible for the secure storage and 
destruction of data at the end of the specified period.  Please note that the University Research 
Ethics Committee (UREC) is required to monitor and audit the ethical conduct of research 
involving human participants, data and tissue conducted by academic staff, students and 
researchers. Your project may be selected for audit from the research projects submitted to and 
approved by the UREC and its committees. 
 
Please note that your study should not commence at any NHS site until you have obtained final 
management approval from the R&D department for the relevant NHS care organisation.  A 
copy of the approval letter(s) must be forwarded to Leigh Taylor in line with Research 
Governance requirements. 
 
We wish you well with your research. 
 
Yours sincerely 
 
 
Dr Julie Woodley 
Chair 
Faculty Research Ethics Committee                      
 
c.c. Jon Pollock 
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A3.5 Study invitation letter 
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A3.6 Participant information leaflet  
 
 
 Vascular Studies Unit 
Level 2, Balloon Corridor 
Queens Building 
Bristol Royal Infirmary 
Marlborough Street 
Bristol, BS2 8HW 
 
Tel: 0117 342 2836 
Fax: 0117 342 2443 
 
 
 
PATIENT INFORMATION SHEET 
 
Study Title: The response of lower limb deep vein thrombosis to anticoagulation therapy: 
resolution, recurrence and post thrombotic syndrome. 
 
You are being invited to take part in a research study which is being undertaken as part of a 
PhD. First, it is important for you to know what the study is about. This information sheet is 
intended to provide details of the study being undertaken. 
 
What is the purpose of the study? 
 
This is a research study to see how a blood clot in the veins of the leg (deep vein thrombosis; 
DVT) changes over time and how much time it takes for it to disappear completely. The study 
will also explore reasons why one person’s clot might resolve more slowly than another 
person’s and if that affects how well their veins work or if they are likely to develop another 
thrombosis in the future.  
 
Why have I been chosen? 
 
You are being asked to participate in this study because you have been diagnosed with a deep 
vein thrombosis (DVT) in the veins in your leg.  
  
Do I have to take part? 
 
It is up to you to decide whether or not to take part. Your participation in this study is completely 
voluntary. If you do decide to take part you will be given this information sheet to keep and 
asked to sign a consent form. Only once you are satisfied that you have enough information will 
you be asked to do this. If you decide to take part you are still free to withdraw at any time 
and without giving a reason. A decision not to take part will not affect the standard of care you 
receive. Please note that your participation may be terminated by the investigator with or 
without your consent. 
 
What will happen to me if I take part? 
 
If you agree to take part in the research project you would be required to come into the hospital 
for further ultrasound scans of the veins in your leg so that we can monitor your blood clot and 
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check how your veins are working after your clot has gone. You will also undergo a physical 
examination of your leg and be asked questions about your general health and any symptoms 
you are experiencing. You would need to attend on 6 occasions for a follow-up ultrasound scan 
over a period of 2 years. The follow-up appointments will take place at 1 week, 1 month, 3 
months, 6 months, 1 year and 2 years after you have been told you have a DVT. 
How long does the examination last? 
 
Each ultrasound scan will last approximately 20 minutes and your travel expenses would be 
reimbursed each time you attend for a scan as part of the research project. 
 
 
What are the disadvantages or risks of taking part? 
 
There are no physical risks associated with taking part in the study as ultrasound is a safe and 
non-invasive imaging method. The disadvantage to taking part is that you will have to travel to 
the hospital for the extra ultrasound scans as part of the study which, although your expenses 
will be reimbursed, will result in time and effort on your part. 
 
What are the benefits to taking part? 
 
There is no direct individual benefit to taking part in this study however, the information we get 
from this study may help us improve the treatment for future patients with similar problems. 
 
What if I don’t want to take part, or change my mind once the study starts? 
 
You may withdraw from the study at any time, without giving a reason, and without affecting 
your medical care.  
 
What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. If you have a concern about any aspect of the study, you 
should ask to speak with the researcher who will do their best to answer your questions (see 
contact details below). If you remain unhappy and wish to complain formally, you can do this 
through the student’s Director of Studies at the University of the West of England as follows: 
 
Dr Fiona Cramp  
Associate Professor in Musculoskeletal Health & 
Director of Postgraduate Research Studies 
Faculty of Health & Life Sciences 
Glenside Campus 
University of the West of England 
Blackberry Hill 
Bristol, BS16 1DD Tel. 0117 3288501 
 
You may also complain formally using the NHS Complaints Procedure. Details can be obtained 
from the Patient Advice and Liaison Service (PALS) at the hospital. 
 
Will my taking part in the study be kept confidential? 
 
All information which is collected about you during the course of the study will be kept strictly 
confidential. Your identity will always remain confidential; you will be identified only by an 
individual subject number. Any information about you that leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. All data collected will be 
handled and kept confidential by the researcher in the Vascular Studies Unit of the Bristol Royal 
Infirmary who will abide by the Data Protection Act 1998 and the rights you have under this act.  
 
If you join the study, some of the data collected will be looked at by authorised persons at the 
University of the West of England. Data may also be looked at by representatives of regulatory 
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authorities and by authorised people from the NHS Trust to check that the study is being carried 
out correctly. All will have a duty of confidentiality to you as a research participant and nothing 
that could reveal your identity will be disclosed outside of the research site. 
 
What will happen to the results of the research study? 
 
Once all patients have completed their participation in the study (approximately 4 years), the 
information obtained will be analysed before the results are presented in the form of a PhD 
research thesis. The results of the study may also be presented at scientific meetings and 
published in scientific journals. On completion of the research, a summary sheet detailing the 
findings of the research and any publication details will be sent to each of the participants. 
Annual reports of the progress of the research and the financial management of the project will 
be made to the National Institute of Health Research Trainees Coordinating Centre as part of 
the terms of the fellowship contract. 
 
Who is organising and funding the research? 
 
This study is part of a PhD being undertaken by the Clinical Vascular Scientist that will be doing 
the scan of your leg veins. This person has planned and organised the research study and will 
be undertaking the research. The study is funded by the National Institute of Health Research 
and the Chief Scientific Officer as part of a Healthcare Science Doctoral Research Fellowship 
award. The researcher is employed as an Accredited Clinical Vascular Scientist in the Vascular 
Studies Unit of the Bristol Royal Infirmary.  
 
Who has reviewed this study? 
 
This study has been reviewed by the National Institute of Health Research, the University of the 
West of England, the South West 3 Research Ethics Committee and the University Hospitals 
Bristol Research and Development office. 
 
Who do I contact for further information? 
 
If you have any questions or want any addition information regarding the study, please contact: 
 
Michelle Bonfield BSc, MSc, AVS 
NIHR/CSO Doctoral Research Fellow & Clinical Vascular Scientist   
Tel.: 0117 3423562   E-mail: michelle.bonfield@uhbristol.nhs.uk 
 
Thank you for taking the time to read this information. 
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A3.7 Consent form   
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A3.8 Data collection form (Initial Visit) 
Patient Study ID No: 
Hospital number: 
D.O.B.: 
Age:  
Date of original DVT diagnosis: 
Date of visit: 
Follow-up stage: 
Height: 
Weight: 
BMI: 
Prescription medications: 
Non-prescription medications: 
Anti-coagulation therapy: 
D-dimer at presentation: 
Smoking history: 
Diabetes Mellitus: 
Hypertension: 
Congestive heart failure: 
Other medical conditions: 
Compliance with compression: 
Original DVT extent: 
Clot extension/regression: 
Superficial venous incompetence: 
Deep venous incompetence: 
Peak reflux velocities: 
Reflux duration: 
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A3.9 Data collection form (Visits 2-6) 
 
Study No:   Date:     F/U visit: 
Height: 
Weight: 
 
Stocking compliance details: 
 
 
Symptoms details: 
 
 
Medication details: 
 
 
Any changes to medical history? 
 
 
 
Thrombus details: 
 
 
 
Incompetence details: 
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A3.10 Letter to GP   
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A3.11 Publication of observational study protocol in BMC 
Haematology   
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412 
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Appendix A4 MISSING DATA 
A4.1 Cross tabulated data for key baseline characteristics and study 
completion 
 
Table A4.1.1 Cross tabulation of age category by study completion status 
Age & study completion 
Age category 
Completed 
study no gaps 
n (%) 
Did not 
complete study 
n (%) 
Total  
n (%) 
18-45 43 (81) 10 (19) 53 (100) 
46-65 49 (86) 8 (14) 57 (100) 
66-85 55 (90) 6 (10) 61 (100) 
Total 147 (86) 24 (14) 171 (100) 
 
Table A4.1.2 Cross tabulation of sex by study completion status 
Sex & study completion 
Sex 
Completed 
study no gaps 
n (%) 
Did not 
complete study 
n (%) 
Total  
n (%) 
Male 90 (86) 15 (14) 105 (100) 
Female 57 (86) 9 (14) 66 (100) 
Total 147 (86) 24 (14) 171 (100) 
 
Table A4.1.3 Cross tabulation of BMI category by study completion status 
BMI & study completion 
BMI category 
Completed 
study no gaps 
n (%) 
Did not 
complete study 
n (%) 
Total  
n (%) 
Not overweight 35 (90) 4 (10) 39 (100) 
Overweight 112 (85) 20 (15) 132 (100) 
Total 147 (86) 24 (14) 171 (100) 
 
Table A4.1.4 Cross tabulation of TLS at diagnosis by study completion status 
TLS & study completion 
TLS category on DVT 
diagnosis 
Completed 
study no gaps 
n (%) 
Did not 
complete study 
n (%) 
Total  
n (%) 
1-2 36 (78) 10 (22) 46 (100) 
3-4 37 (90) 4 (10) 41 (100) 
5-10 35 (85) 5 (12) 41 (100) 
Overweight ≥11 39 (89) 5 (11) 44 (100) 
Total 147 (86) 24 (14) 171 (100) 
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A4.2 Summary of missing values 
 
Figure A3.2.1 Summary of missing data values by variables, cases and values. 
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Appendix A5 THROMBUS EVOLUTION 
A5.1 Case level example raw TLS score data by segment, by visit 
 
Table A5.1.1 Example of individual thrombus scores for each venous segment 
at each follow-up visit for one participant (ID PTS0926). 
Study ID and Venous 
Segment 
Follow-up interval 
PTS0926 
0 
days 
7 
days 
1 
month 
3 
months 
6 
months 
12 
months 
24 
months 
Inferior Vena Cava 0 0 0 0 0 0 0 
Common Iliac Vein 0 0 0 0 0 0 0 
External Iliac Vein 0 0 0 0 0 0 0 
Common Femoral Vein 0 0 0 0 0 0 0 
Profunda Vein 0 0 0 0 0 0 0 
Proximal Femoral Vein 3 3 3 1 1 1 0 
Distal Femoral Vein 3 3 3 3 3 3 1 
Popliteal Vein 3 3 3 3 3 3 3 
Peroneal Veins 3 3 2 0 0 0 0 
Posterior Tibial Veins 3 3 2 0 0 0 0 
Anterior Tibual Veins 0 0 0 0 0 0 0 
Soleal Veins 2 2 0 0 0 0 0 
Gastrocnemius Veins 2 2 0 0 0 0 0 
Greater Saphenous Vein 0 0 0 0 0 0 0 
Short Saphenous Vein 0 0 0 0 0 0 0 
Total 19 19 13 7 7 7 4 
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A5.2 Case level data for TLS score totals by visit 
Table A5.2.1 Case level data of TLS at diagnosis and at each follow-up interval 
(n = 174 limbs) 
PTS No. 0 days 7 days 1 month 
3 
months 
6 
months 
12 
months 
24 
months 
10 3 3 2 4 1 5 0 
11 5 5 3 2 1 0 0 
33 9 7 6 3 0 0 0 
36 2 2 0 0 0 0 0 
40 18 18 14 10 4 3 1 
43 3 2 3 1 1 1 1 
53 12 12 7 3 1 0 0 
57 1 1 1 1 1 0 0 
59 7 7 3 1 0 0 0 
61 19 19 18 11 7 7 6 
73 8 11 9 2 1 Missing Missing 
76 6 6 4 1 0 0 0 
77 5 4 4 4 3 Missing Missing 
87 2 2 1 0 0 0 0 
92 2 2 1 0 0 0 0 
93 4 4 3 1 0 0 0 
126 5 4 3 1 0 0 0 
129 2 2 2 0 Missing Missing Missing 
154 11 8 8 7 7 7 13 
156 16 16 13 8 2 2 1 
161 4 4 2 2 0 0 0 
163 19 16 Missing Missing Missing Missing Missing 
164 2 3 0 0 0 3 Missing 
179 4 6 2 0 4 1 0 
186R 3 2 1 0 0 0 0 
186L 1 1 0 0 0 0 0 
195 4 2 3 1 0 0 0 
213 2 5 1 0 0 0 0 
220 1 1 1 0 0 0 0 
235 1 0 0 0 0 0 0 
249 12 9 7 3 3 2 2 
250 2 2 1 0 0 0 0 
267 4 4 2 0 4 1 0 
268 1 1 0 0 0 0 0 
276 4 6 5 2 0 0 0 
279 2 1 1 0 0 0 0 
284 8 8 7 3 0 0 0 
286 6 4 2 0 0 0 0 
297 8 8 5 1 1 1 4 
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301 6 4 2 0 0 0 Missing 
304 2 4 0 0 0 0 0 
306 6 3 1 1 0 0 0 
311 5 5 1 0 0 Missing Missing 
312 2 2 0 0 0 0 0 
320 5 5 2 0 0 0 Missing 
322 9 9 9 4 1 1 1 
333 5 5 1 0 0 0 0 
334 16 15 9 7 4 3 2 
345 4 1 0 0 0 0 0 
350 2 0 0 0 0 0 0 
351 4 2 0 0 0 0 0 
353 11 4 2 2 1 1 1 
367 4 3 0 0 0 0 0 
368 9 9 6 5 2 2 9 
370 3 2 2 0 0 0 0 
372 2 2 2 1 0 0 0 
375 3 3 2 0 0 0 0 
384 5 4 3 3 1 1 1 
388 4 1 2 2 0 0 0 
391 21 15 7 0 0 0 0 
396 22 18 13 8 8 6 Missing 
413 7 7 2 0 0 0 0 
421 1 1 0 0 0 0 Missing 
422 10 4 1 0 0 0 0 
424 4 4 4 0 0 0 0 
425 2 2 0 0 0 0 0 
432 4 4 2 1 0 0 0 
442 2 2 0 0 0 0 0 
443 7 4 1 0 0 0 0 
452 4 4 2 0 0 0 0 
455 4 2 2 0 0 0 0 
459 17 12 9 4 2 1 Missing 
463 5 4 3 1 1 0 2 
468 16 14 5 3 0 0 0 
469 1 14 9 8 3 2 2 
472 19 16 11 11 3 3 3 
474 1 0 0 0 0 0 0 
477 10 10 8 7 7 2 2 
482 2 1 0 0 0 0 0 
483 1 4 4 2 0 0 0 
486 15 10 10 5 4 2 2 
494 12 10 2 1 0 0 0 
496 2 1 0 0 0 0 0 
500 15 14 13 5 5 1 1 
505 2 2 1 0 0 0 0 
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508 1 1 1 1 0 0 0 
515 3 3 1 0 0 0 0 
527 24 24 12 9 6 5 5 
532 10 8 7 0 0 0 0 
539 2 2 0 0 0 Missing Missing 
543R 2 2 1 0 0 0 0 
543L 4 3 1 0 0 0 0 
546 10 8 4 0 0 0 0 
548 8 5 3 0 0 0 0 
561 11 11 2 2 1 1 1 
562 4 3 3 2 1 1 0 
563 6 6 0 0 0 0 0 
566 3 4 2 0 0 0 0 
568 24 20 18 9 5 5 5 
571 11 9 8 3 3 1 1 
574 11 11 8 4 1 1 1 
582 8 8 3 2 1 1 1 
584 17 17 9 6 3 2 Missing 
588 16 13 11 8 5 3 2 
590 4 4 4 Missing Missing Missing Missing 
595 15 15 3 0 0 2 2 
602 1 1 1 1 0 0 0 
611 2 1 0 0 0 0 Missing 
613 3 2 1 0 0 0 0 
622 10 10 6 3 1 0 0 
632 4 3 1 0 0 0 0 
644 1 1 Missing Missing Missing Missing Missing 
653 4 3 1 1 1 1 1 
657 2 4 1 0 Missing Missing Missing 
659 2 2 2 0 0 0 0 
704 8 6 3 1 0 1 1 
708 1 1 1 1 1 1 0 
712 17 19 11 6 4 3 1 
734 4 4 2 0 Missing Missing Missing 
737 2 4 Missing Missing Missing Missing Missing 
742 4 4 1 0 0 0 0 
749 3 3 2 Missing 0 0 Missing 
751 11 10 9 8 8 6 6 
753 11 11 7 7 7 6 6 
755 6 5 4 2 0 0 0 
758 8 7 1 0 0 0 0 
760 3 5 1 0 0 0 0 
765 15 12 11 3 1 1 1 
783 11 10 8 4 4 4 4 
786 3 3 1 0 0 0 0 
790 3 2 1 0 0 0 0 
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797 2 2 0 0 0 0 0 
809 13 13 6 2 2 1 0 
818 3 3 2 1 0 0 0 
825 4 4 2 1 0 0 1 
833 2 2 2 0 0 0 0 
844 19 19 11 11 9 7 6 
855 4 5 4 1 0 0 0 
862 4 3 3 0 0 0 0 
865 2 2 1 0 0 0 0 
870R 1 0 0 0 0 0 0 
870L 2 2 0 0 0 0 0 
877 5 1 0 0 0 0 0 
878 6 4 0 0 2 0 0 
879 13 12 10 1 1 1 1 
885 19 15 13 4 4 3 3 
892 25 26 26 13 12 9 9 
896 11 13 12 8 3 2 2 
898 3 3 2 0 0 0 0 
900 26 26 15 6 5 4 8 
903 2 2 0 0 0 0 0 
911 16 15 15 15 7 6 6 
919 2 3 Missing Missing Missing Missing Missing 
920 28 25 15 13 13 13 13 
921 13 11 8 8 4 3 2 
925 9 9 6 6 2 2 2 
926 19 19 13 7 7 7 4 
932 6 7 7 6 1 1 1 
943 4 2 2 2 2 0 0 
947 6 4 1 0 0 0 4 
956 7 7 7 2 4 2 2 
959 2 2 Missing Missing Missing Missing Missing 
969 3 2 1 0 0 0 0 
975 3 2 Missing Missing Missing Missing Missing 
976 18 18 11 2 8 7 7 
990 4 4 4 3 3 3 3 
993 2 2 2 2 2 1 0 
997 2 2 0 0 0 2 0 
1000 13 11 11 2 1 1 1 
1014 2 2 1 0 0 0 0 
1028 10 10 6 4 2 2 1 
1030 2 2 0 0 0 0 0 
1076 10 10 7 3 3 1 1 
1084 11 13 13 11 Missing Missing Missing 
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A5.3 Case level data for % change in TLS score between visits 
Table A5.3.1 Case level data of percentage change in TLS at each follow-up 
interval from the previous scan (n = 174 limbs) 
% change from previous scan 
PTS 
No. 
1 week 1 month 3 months 6 months 1 year 2 years 
10 0 -33 Recurrence Recurrence Recurrence -100 
11 0 -40 -33 -50 -100 Resolved 
33 -22 -14 -50 -100 Resolved Resolved 
36 0 -100 Resolved Resolved Resolved Resolved 
40 0 -22 -29 -60 -25 -67 
43 -33 Recurrence -67 0 0 0 
53 0 -42 -57 -67 -100 Resolved 
57 0 0 0 0 -100 Resolved 
59 0 -57 -67 -100 Resolved Resolved 
61 0 -5 -39 -36 0 -14 
73 38 -18 -78 -50 Missing Missing 
76 0 -33 -75 -100 Resolved Resolved 
77 -20 0 0 -25 Missing Missing 
87 0 -50 -100 Resolved Resolved Resolved 
92 0 -50 -100 Resolved Resolved Resolved 
93 0 -25 -67 -100 Resolved Resolved 
126 -20 -25 -67 -100 Resolved Resolved 
129 0 0 -100 Missing Missing Missing 
154 -27 0 -13 0 0 86 
156 0 -19 -38 -75 0 -50 
161 0 -50 0 -100 Resolved Resolved 
163 -16 Missing Missing Missing Missing Missing 
164 50 -100 Resolved Resolved Recurrence Missing 
179 50 -67 -100 Recurrence Recurrence -100 
186R -33 -50 -100 Resolved Resolved Resolved 
186L 0 -100 Resolved Resolved Resolved Resolved 
195 -50 Recurrence -67 -100 Resolved Resolved 
213 150 -80 -100 Resolved Resolved Resolved 
220 0 0 -100 Resolved Resolved Resolved 
235 -100 Resolved Resolved Resolved Resolved Resolved 
249 -25 -22 -57 0 -33 0 
250 0 -50 -100 Resolved Resolved Resolved 
267 0 -50 -100 Recurrence Recurrence -100 
268 0 -100 Resolved Resolved Resolved Resolved 
276 50 -17 -60 -100 Resolved Resolved 
279 -50 0 -100 Resolved Resolved Resolved 
284 0 -13 -57 -100 Resolved Resolved 
286 -33 -50 -100 Resolved Resolved Resolved 
297 0 -38 -80 0 0 Recurrence 
301 -33 -50 -100 Resolved Resolved Missing 
304 100 -100 Resolved Resolved Resolved Resolved 
306 -50 -67 0 -100 Resolved Resolved 
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311 0 -80 -100 Resolved Missing Missing 
312 0 -100 Resolved Resolved Resolved Resolved 
320 0 -60 -100 Resolved Resolved Missing 
322 0 0 -56 -75 0 0 
333 0 -80 -100 Resolved Resolved Resolved 
334 -6 -40 -22 -43 -25 -33 
345 -75 -100 Resolved Resolved Resolved Resolved 
350 -100 Resolved Resolved Resolved Resolved Resolved 
351 -50 -100 Resolved Resolved Resolved Resolved 
353 -64 -50 0 -50 0 0 
367 -25 -100 Resolved Resolved Resolved Resolved 
368 0 -33 -17 -60 0 Recurrence 
370 -33 0 -100 Resolved Resolved Resolved 
372 0 0 -50 -100 Resolved Resolved 
375 0 -33 -100 Resolved Resolved Resolved 
384 -20 -25 0 -67 0 0 
388 -75 Recurrence 0 -100 Resolved Resolved 
391 -29 -53 -100 Resolved Resolved Resolved 
396 -18 -28 -38 0 -25 Missing 
413 0 -71 -100 Resolved Resolved Resolved 
421 0 -100 Resolved Resolved Resolved Missing 
422 -60 -75 -100 Resolved Resolved Resolved 
424 0 0 -100 Resolved Resolved Resolved 
425 0 -100 Resolved Resolved Resolved Resolved 
432 0 -50 -50 -100 Resolved Resolved 
442 0 -100 Resolved Resolved Resolved Resolved 
443 -43 -75 -100 Resolved Resolved Resolved 
452 0 -50 -100 Resolved Resolved Resolved 
455 -50 0 -100 Resolved Resolved Resolved 
459 -29 -25 -56 -50 -50 Missing 
463 -20 -25 -67 0 -100 Recurrence 
468 -13 -64 -40 -100 Resolved Resolved 
469 1300 -36 -11 -63 -33 0 
472 -16 -31 0 -73 0 0 
474 -100 Resolved Resolved Resolved Resolved Resolved 
477 0 -20 -13 0 -71 0 
482 -50 -100 Resolved Resolved Resolved Resolved 
483 300 0 -50 -100 Resolved Resolved 
486 -33 0 -50 -20 -50 0 
494 -17 -80 -50 -100 Resolved Resolved 
496 -50 -100 Resolved Resolved Resolved Resolved 
500 -7 -7 -62 0 -80 0 
505 0 -50 -100 Resolved Resolved Resolved 
508 0 0 0 -100 Resolved Resolved 
515 0 -67 -100 Resolved Resolved Resolved 
527 0 -50 -25 -33 -17 0 
532 -20 -13 -100 Resolved Resolved Resolved 
539 0 -100 Resolved Resolved Missing Missing 
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543R 0 -50 -100 Resolved Resolved Resolved 
543L -25 -67 -100 Resolved Resolved Resolved 
546 -20 -50 -100 Resolved Resolved Resolved 
548 -38 -40 -100 Resolved Resolved Resolved 
561 0 -82 0 -50 0 0 
562 -25 0 -33 -50 0 -100 
563 0 -100 Resolved Resolved Resolved Resolved 
566 33 -50 -100 Resolved Resolved Resolved 
568 -17 -10 -50 -44 0 0 
571 -18 -11 -63 0 -67 0 
574 0 -27 -50 -75 0 0 
582 0 -63 -33 -50 0 0 
584 0 -47 -33 -50 -33 Missing 
588 -19 -15 -27 -38 -40 -33 
590 0 0 Missing Missing Missing Missing 
595 0 -80 -100 Resolved Recurrence 0 
602 0 0 0 -100 Resolved Resolved 
611 -50 -100 Resolved Resolved Resolved Missing 
613 -33 -50 -100 Resolved Resolved Resolved 
622 0 -40 -50 -67 -100 Resolved 
632 -25 -67 -100 Resolved Resolved Resolved 
644 0 Missing Missing Missing Missing Missing 
653 -25 -67 0 0 0 0 
657 100 -75 -100 Missing Missing Missing 
659 0 0 -100 Resolved Resolved Resolved 
704 -25 -50 -67 -100 Recurrence 0 
708 0 0 0 0 0 -100 
712 12 -42 -45 -33 -25 -67 
734 0 -50 -100 Missing Missing Missing 
737 100 Missing Missing Missing Missing Missing 
742 0 -75 -100 Resolved Resolved Resolved 
749 0 -33 Missing Missing Missing Missing 
751 -9 -10 -11 0 -25 0 
753 0 -36 0 0 -14 0 
755 -17 -20 -50 -100 Resolved Resolved 
758 -13 -86 -100 Resolved Resolved Missing 
760 67 -80 -100 Resolved Resolved Resolved 
765 -20 -8 -73 -67 0 0 
783 -9 -20 -50 0 0 0 
786 0 -67 -100 Resolved Resolved Resolved 
790 -33 -50 -100 Resolved Resolved Resolved 
797 0 -100 Resolved Resolved Resolved Resolved 
809 0 -54 -67 0 -50 -100 
818 0 -33 -50 -100 Resolved Resolved 
825 0 -50 -50 -100 Resolved Recurrence 
833 0 0 -100 Resolved Resolved Resolved 
844 0 -42 0 -18 -22 -14 
855 25 -20 -75 -100 Resolved Resolved 
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862 -25 0 -100 Resolved Resolved Resolved 
865 0 -50 -100 Resolved Resolved Resolved 
870R -100 Resolved Resolved Resolved Resolved Resolved 
870L 0 -100 Resolved Resolved Resolved Resolved 
877 -80 -100 Resolved Resolved Resolved Resolved 
878 -33 -100 Resolved Recurrence -100 Resolved 
879 -8 -17 -90 0 0 0 
885 -21 -13 -69 0 -25 0 
892 4 0 -50 -8 -25 0 
896 18 -8 -33 -63 -33 0 
898 0 -33 -100 Resolved Resolved Resolved 
900 0 -42 -60 -17 -20 100 
903 0 -100 Resolved Resolved Resolved Resolved 
911 -6 0 0 -53 -14 0 
919 50 Missing Missing Missing Missing Missing 
920 -11 -40 -13 0 0 0 
921 -15 -27 0 -50 -25 -33 
925 0 -33 0 -67 0 0 
926 0 -32 -46 0 0 -43 
932 17 0 -14 -83 0 0 
943 -50 0 0 0 -100 Resolved 
947 -33 -75 -100 Resolved Resolved 100 
956 0 0 -71 Recurrence 0 0 
959 0 Missing Missing Missing Missing Missing 
969 -33 -50 -100 Resolved Resolved Resolved 
975 -33 Missing Missing Missing Missing Missing 
976 0 -39 -82 Recurrence -13 0 
990 0 0 -25 0 0 0 
993 0 0 0 0 -50 -100 
997 0 -100 Resolved Resolved Recurrence Resolved 
1000 -15 0 -82 -50 0 0 
1014 0 -50 -100 Resolved Resolved Resolved 
1028 0 -40 -33 -50 0 -50 
1030 0 -100 Resolved Resolved Resolved Resolved 
1076 0 -30 -57 0 -67 -67 
1084 18 0 -15 Missing Missing Missing 
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A5.4 Case level data for % change in TLS score from baseline 
Table A5.4.1 Case level data of percentage change in TLS at each follow-up 
interval from the study entry scan at seven days post diagnosis (n = 174 limbs) 
% change from 1 week 
PTS No. 1 month 3 months 6 months 1 year 2 years 
10 -33 33 -67 67 -100 
11 -40 -60 -80 -100 Resolved 
33 -14 -57 -100 Resolved Resolved 
36 -100 Resolved Resolved Resolved Resolved 
40 -22 -44 -78 -83 -94 
43 Recurrence -50 -50 -50 -67 
53 -42 -75 -92 -100 Resolved 
57 0 0 0 -100 Resolved 
59 -57 -86 -100 Resolved Resolved 
61 -5 -42 -63 -63 -68 
73 -18 -82 -91 Missing Missing 
76 -33 -83 -100 Resolved Resolved 
77 0 0 -25 Missing Missing 
87 -50 -100 Resolved Resolved Resolved 
92 -50 -100 Resolved Resolved Resolved 
93 -25 -75 -100 Resolved Resolved 
126 -25 -75 -100 Resolved Resolved 
129 0 -100 Missing Missing Missing 
154 0 -13 -13 -13 Recurrence 
156 -19 -50 -88 -88 -94 
161 -50 -50 -100 Resolved Resolved 
163 Missing Missing Missing Missing Missing 
164 -100 Resolved Resolved Recurrence Missing 
179 -67 -100 Recurrence Recurrence -100 
186R -50 -100 Resolved Resolved Resolved 
186L -100 Resolved Resolved Resolved Resolved 
195 50 -50 -100 Resolved Resolved 
213 -80 -100 Resolved Resolved Resolved 
220 0 -100 Resolved Resolved Resolved 
235 0 0 0 0 -100 
249 -22 -67 -67 -78 -83 
250 -50 -100 Resolved Resolved Resolved 
267 -50 -100 Recurrence -75 -100 
268 -100 Resolved Resolved Resolved Resolved 
276 -17 -67 -100 Resolved Resolved 
279 0 -100 Resolved Resolved Resolved 
284 -13 -63 -100 Resolved Resolved 
286 -50 -100 Resolved Resolved Resolved 
297 -38 -88 -88 -88 Recurrence 
301 -50 -100 Resolved Resolved Missing 
304 -100 Resolved Resolved Resolved Resolved 
306 -67 -67 -100 Resolved Resolved 
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311 -80 -100 Resolved Missing Missing 
312 -100 Resolved Resolved Resolved Resolved 
320 -60 -100 Resolved Resolved Missing 
322 0 -56 -89 -89 -89 
333 -80 -100 -100 Resolved Resolved 
334 -40 -53 -73 -80 -88 
345 -100 Resolved Resolved Resolved Resolved 
350 0 0 0 0 -100 
351 -100 Resolved Resolved Resolved Resolved 
353 -50 -50 -75 -75 -91 
367 -100 Resolved Resolved Resolved Resolved 
368 -33 -44 -78 -78 Recurrence 
370 0 -100 Resolved Resolved Resolved 
372 0 -50 -100 Resolved Resolved 
375 -33 -100 Resolved Resolved Resolved 
384 -25 -25 -75 -75 -80 
388 100 100 -100 Resolved Resolved 
391 -53 -100 Resolved Resolved Resolved 
396 -28 -56 -56 -67 Missing 
413 -71 -100 Resolved Resolved Resolved 
421 -100 -100 Resolved Resolved Missing 
422 -75 -100 Resolved Resolved Resolved 
424 0 -100 Resolved Resolved Resolved 
425 -100 -100 Resolved Resolved Resolved 
432 -50 -75 -100 Resolved Resolved 
442 -100 -100 Resolved Resolved Resolved 
443 -75 -100 Resolved Resolved Resolved 
452 -50 -100 Resolved Resolved Resolved 
455 0 -100 Resolved Resolved Resolved 
459 -25 -67 -83 -92 Missing 
463 -25 -75 -75 -100 Recurrence 
468 -64 -79 -100 Resolved Resolved 
469 -36 -43 -79 -86 -86 
472 -31 -31 -81 -81 -84 
474 0 0 0 0 -100 
477 -20 -30 -30 -80 -80 
482 -100 Resolved Resolved Resolved Resolved 
483 0 -50 -100 Resolved Resolved 
486 0 -50 -60 -80 -87 
494 -80 -90 -100 Resolved Resolved 
496 -100 Resolved Resolved Resolved Resolved 
500 -7 -64 -64 -93 -93 
505 -50 -100 Resolved Resolved Resolved 
508 0 0 -100 Resolved Resolved 
515 -67 -100 Resolved Resolved Resolved 
527 -50 -63 -75 -79 -79 
532 -13 -100 -100 Resolved Resolved 
539 -100 Resolved Resolved Missing Missing 
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543R -50 -100 Resolved Resolved Resolved 
543L -67 -100 Resolved Resolved Resolved 
546 -50 -100 Resolved Resolved Resolved 
548 -40 -100 Resolved Resolved Resolved 
561 -82 -82 -91 -91 -91 
562 0 -33 -67 -67 -100 
563 -100 Resolved Resolved Resolved Resolved 
566 -50 -100 Resolved Resolved Resolved 
568 -10 -55 -75 -75 -79 
571 -11 -67 -67 -89 -91 
574 -27 -64 -91 -91 -91 
582 -63 -75 -88 -88 -88 
584 -47 -65 -82 -88 Missing 
588 -15 -38 -62 -77 -88 
590 0 Missing Missing Missing Missing 
595 -80 -100 Resolved Recurrence -87 
602 0 0 -100 Resolved Resolved 
611 -100 Resolved Resolved Resolved Missing 
613 -50 -100 Resolved Resolved Resolved 
622 -40 -70 -90 -100 Resolved 
632 -67 -100 Resolved Resolved Resolved 
644 Missing Missing Missing Missing Missing 
653 -67 -67 -67 -67 -75 
657 -75 -100 Missing Missing Missing 
659 0 -100 Resolved Resolved Resolved 
704 -50 -83 -100 Recurrence -88 
708 0 0 0 0 -100 
712 -42 -68 -79 -84 -94 
734 -50 -100 Missing Missing Missing 
737 Missing Missing Missing Missing Missing 
742 -75 -100 Resolved Resolved Resolved 
749 -33 Missing Missing Missing Missing 
751 -10 -20 -20 -40 -45 
753 -36 -36 -36 -45 -45 
755 -20 -60 -100 Resolved Resolved 
758 -86 -100 Resolved Resolved Missing 
760 -80 -100 Resolved Resolved Resolved 
765 -8 -75 -92 -92 -93 
783 -20 -60 -60 -60 -64 
786 -67 -100 Resolved Resolved Resolved 
790 -50 -100 Resolved Resolved Resolved 
797 -100 -100 Resolved Resolved Resolved 
809 -54 -85 -85 -92 -100 
818 -33 -67 -100 Resolved Resolved 
825 -50 -75 -100 Resolved Recurrence 
833 0 -100 Resolved Resolved Resolved 
844 -42 -42 -53 -63 -68 
855 -20 -80 -100 Resolved Resolved 
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862 0 -100 Resolved Resolved Resolved 
865 -50 -100 Resolved Resolved Resolved 
870R Resolved Resolved Resolved Resolved Resolved 
870L -100 Resolved Resolved Resolved Resolved 
877 -100 Resolved Resolved Resolved Resolved 
878 -100 Resolved Recurrence Resolved Resolved 
879 -17 -92 -92 -92 -92 
885 -13 -73 -73 -80 -84 
892 0 -50 -54 -65 -64 
896 -8 -38 -77 -85 -85 
898 -33 -100 Resolved Resolved Resolved 
900 -42 -77 -81 -85 -69 
903 -100 Resolved Resolved Resolved Resolved 
911 0 0 -53 -60 -63 
919 Missing Missing Missing Missing Missing 
920 -40 -48 -48 -48 -54 
921 -27 -27 -64 -73 -85 
925 -33 -33 -78 -78 -78 
926 -32 -63 -63 -63 -79 
932 0 -14 -86 -86 -86 
943 0 0 0 -100 Resolved 
947 -75 -100 Resolved Resolved Recurrence 
956 0 -71 -43 -43 -43 
959 Missing Missing Missing Missing Missing 
969 -50 -100 Resolved Resolved Resolved 
975 Missing Missing Missing Missing Missing 
976 -39 -89 -56 -61 -61 
990 0 -25 -25 -25 -25 
993 0 0 0 -50 -100 
997 -100 Resolved Resolved Recurrence Resolved 
1000 0 -82 -91 -91 -91 
1014 -50 -100 Resolved Resolved Resolved 
1028 -40 -60 -80 -80 -90 
1030 -100 Resolved Resolved Resolved Resolved 
1076 -30 -70 -70 -90 -90 
1084 0 -15 Missing Missing Missing 
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A5.5 Case level data for thrombus evolution pattern classification 
Table A5.5.1 Classification of thrombus evolution patterns for individual cases 
over the 2 year follow-up period based on % changes in TLS. 
PTS 
No. 
Thrombus Evolution Category 
3 months 6 months 12 months 24 months 
10 Early Recurrence Resolving Recurrence Resolving Recurrence Non-standard resolution  
11 Resolving Resolving Standard resolution Standard resolution 
33 Resolving Standard resolution Standard resolution Standard resolution 
36 Fast resolution Fast resolution Fast resolution Fast resolution 
40 Resolving Resolving Resolving Slow unresolved 
43 Early Recurrence Static Static Slow unresolved 
53 Resolving Resolving Standard resolution Standard resolution 
57 Static Static Non-standard resolution Non-standard resolution 
59 Resolving Standard resolution Standard resolution Standard resolution 
61 Resolving Resolving Static Slow unresolved 
73 Resolving Resolving Missing data Missing data 
76 Resolving Standard resolution Standard resolution Standard resolution 
77 Static Resolving Missing data Missing data 
87 Fast resolution Fast resolution Fast resolution Fast resolution 
92 Fast resolution Fast resolution Fast resolution Fast resolution 
93 Resolving Standard resolution Standard resolution Standard resolution 
126 Resolving Standard resolution Standard resolution Standard resolution 
129 Fast resolution Missing data Missing data Missing data 
154 Resolving Static Static Slow unresolved 
156 Resolving Resolving Static Slow unresolved 
161 Resolving Standard resolution Standard resolution Standard resolution 
163 Missing data Missing data Missing data Missing data 
164 Fast resolution Fast resolution Resolving Recurrence Missing data 
179 Fast resolution Fast resolution Resolving Recurrence Fast resolution 
186R Fast resolution Fast resolution Fast resolution Fast resolution 
186L Fast resolution Fast resolution Fast resolution Fast resolution 
195 Early Recurrence Standard resolution Standard resolution Standard resolution 
213 Fast resolution Fast resolution Fast resolution Fast resolution 
220 Fast resolution Fast resolution Fast resolution Fast resolution 
235 Fast resolution Fast resolution Fast resolution Fast resolution 
249 Resolving Static Resolving Slow unresolved 
250 Fast resolution Fast resolution Fast resolution Fast resolution 
267 Fast resolution Fast resolution Resolving Recurrence Fast resolution 
268 Fast resolution Fast resolution Fast resolution Fast resolution 
276 Resolving Standard resolution Standard resolution Standard resolution 
279 Fast resolution Fast resolution Fast resolution Fast resolution 
284 Resolving Standard resolution Standard resolution Standard resolution 
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286 Fast resolution Fast resolution Fast resolution Fast resolution 
297 Resolving Static Static Slow unresolved 
301 Fast resolution Fast resolution Fast resolution Missing data 
304 Fast resolution Fast resolution Fast resolution Fast resolution 
306 Resolving Standard resolution Standard resolution Standard resolution 
311 Fast resolution Fast resolution Missing data Missing data 
312 Fast resolution Fast resolution Fast resolution Fast resolution 
320 Fast resolution Fast resolution Fast resolution Missing data 
322 Resolving Resolving Static Slow unresolved 
333 Fast resolution Fast resolution Fast resolution Fast resolution 
334 Resolving Resolving Resolving Slow unresolved 
345 Fast resolution Fast resolution Fast resolution Fast resolution 
350 Fast resolution Fast resolution Fast resolution Fast resolution 
351 Fast resolution Fast resolution Fast resolution Fast resolution 
353 Static Resolving Static Slow unresolved 
367 Fast resolution Fast resolution Fast resolution Fast resolution 
368 Resolving Resolving Static Slow unresolved 
370 Fast resolution Fast resolution Fast resolution Fast resolution 
372 Resolving Non-standard resolution Non-standard resolution Non-standard resolution 
375 Fast resolution Fast resolution Fast resolution Fast resolution 
384 Resolving Resolving Resolving Slow unresolved 
388 Early Recurrence Standard resolution Standard resolution Standard resolution 
391 Fast resolution Fast resolution Fast resolution Fast resolution 
396 Resolving Resolving Resolving Missing data 
413 Fast resolution Fast resolution Fast resolution Fast resolution 
421 Fast resolution Fast resolution Fast resolution Missing data 
422 Fast resolution Fast resolution Fast resolution Fast resolution 
424 Fast resolution Fast resolution Fast resolution Fast resolution 
425 Fast resolution Fast resolution Fast resolution Fast resolution 
432 Resolving Standard resolution Standard resolution Standard resolution 
442 Fast resolution Fast resolution Fast resolution Fast resolution 
443 Fast resolution Fast resolution Fast resolution Fast resolution 
452 Fast resolution Fast resolution Fast resolution Fast resolution 
455 Fast resolution Fast resolution Fast resolution Fast resolution 
459 Resolving Resolving Resolving Missing data 
463 Resolving Resolving Standard resolution Standard resolution 
468 Resolving Standard resolution Standard resolution Standard resolution 
469 Resolving Resolving Resolving Slow unresolved 
472 Static Resolving Static Slow unresolved 
474 Fast resolution Fast resolution Fast resolution Fast resolution 
477 Resolving Static Resolving Slow unresolved 
482 Fast resolution Fast resolution Fast resolution Fast resolution 
483 Resolving Standard resolution Standard resolution Standard resolution 
486 Resolving Resolving Resolving Slow unresolved 
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494 Resolving Standard resolution Standard resolution Standard resolution 
496 Fast resolution Fast resolution Fast resolution Fast resolution 
500 Resolving Static Resolving Slow unresolved 
505 Fast resolution Fast resolution Fast resolution Fast resolution 
508 Static Non-standard resolution Non-standard resolution Non-standard resolution 
515 Fast resolution Fast resolution Fast resolution Fast resolution 
527 Resolving Resolving Resolving Slow unresolved 
532 Fast resolution Fast resolution Fast resolution Fast resolution 
539 Fast resolution Fast resolution Missing data Missing data 
543R Fast resolution Fast resolution Fast resolution Fast resolution 
543L Fast resolution Fast resolution Fast resolution Fast resolution 
546 Fast resolution Fast resolution Fast resolution Fast resolution 
548 Fast resolution Fast resolution Fast resolution Fast resolution 
561 Static Resolving Static Slow unresolved 
562 Resolving Resolving Static Non-standard resolution 
563 Fast resolution Fast resolution Fast resolution Fast resolution 
566 Fast resolution Fast resolution Fast resolution Fast resolution 
568 Resolving Resolving Static Slow unresolved 
571 Resolving Static Resolving Slow unresolved 
574 Resolving Resolving Static Slow unresolved 
582 Resolving Resolving Static Slow unresolved 
584 Resolving Resolving Resolving Missing data 
588 Resolving Resolving Resolving Slow unresolved 
590 Missing data Missing data Missing data Missing data 
595 Fast resolution Fast resolution Resolving Recurrence Fast resolution 
602 Static Non-standard resolution Non-standard resolution Non-standard resolution 
611 Fast resolution Fast resolution Fast resolution Missing data 
613 Fast resolution Fast resolution Fast resolution Fast resolution 
622 Resolving Resolving Standard resolution Standard resolution 
632 Fast resolution Fast resolution Fast resolution Fast resolution 
644 Missing data Missing data Missing data Missing data 
653 Resolving Static Static Slow unresolved 
657 Fast resolution Missing data Missing data Missing data 
659 Fast resolution Fast resolution Fast resolution Fast resolution 
704 Resolving Standard resolution Standard resolution Standard resolution 
708 Static Static Static Non-standard resolution 
712 Resolving Resolving Resolving Slow unresolved 
734 Fast resolution Missing data Missing data Missing data 
737 Missing data Missing data Missing data Missing data 
742 Fast resolution Fast resolution Fast resolution Fast resolution 
749 Missing data Missing data Missing data Missing data 
751 Resolving Resolving Resolving Slow unresolved 
753 Resolving Static Resolving Slow unresolved 
755 Resolving Standard resolution Standard resolution Standard resolution 
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758 Fast resolution Fast resolution Fast resolution Missing data 
760 Fast resolution Fast resolution Fast resolution Fast resolution 
765 Resolving Resolving Static Slow unresolved 
783 Resolving Resolving Static Slow unresolved 
786 Fast resolution Fast resolution Fast resolution Fast resolution 
790 Fast resolution Fast resolution Fast resolution Fast resolution 
797 Fast resolution Fast resolution Fast resolution Fast resolution 
809 Resolving Static Resolving Non-standard resolution 
818 Resolving Standard resolution Standard resolution Standard resolution 
825 Resolving Standard resolution Standard resolution Standard resolution 
833 Fast resolution Fast resolution Fast resolution Fast resolution 
844 Static Resolving Resolving Slow unresolved 
855 Resolving Standard resolution Standard resolution Standard resolution 
862 Fast resolution Fast resolution Fast resolution Fast resolution 
865 Fast resolution Fast resolution Fast resolution Fast resolution 
870R Fast resolution Fast resolution Fast resolution Fast resolution 
870L Fast resolution Fast resolution Fast resolution Fast resolution 
877 Fast resolution Fast resolution Fast resolution Fast resolution 
878 Fast resolution Resolving Recurrence Fast resolution Fast resolution 
879 Resolving Static Static Slow unresolved 
885 Resolving Static Resolving Slow unresolved 
892 Resolving Resolving Resolving Slow unresolved 
896 Resolving Resolving Resolving Slow unresolved 
898 Fast resolution Fast resolution Fast resolution Fast resolution 
900 Resolving Resolving Resolving Slow unresolved 
903 Fast resolution Fast resolution Fast resolution Fast resolution 
911 Static Resolving Resolving Slow unresolved 
919 Missing data Missing data Missing data Missing data 
920 Resolving Static Static Slow unresolved 
921 Static Resolving Resolving Slow unresolved 
925 Static Resolving Static Slow unresolved 
926 Resolving Static Static Slow unresolved 
932 Resolving Resolving Static Slow unresolved 
943 Static Static Non-standard resolution Non-standard resolution 
947 Fast resolution Fast resolution Fast resolution Fast resolution 
956 Resolving Resolving Recurrence Static Slow unresolved 
959 Missing data Missing data Missing data Missing data 
969 Fast resolution Fast resolution Fast resolution Fast resolution 
975 Missing data Missing data Missing data Missing data 
976 Resolving Resolving Resolving Slow unresolved 
990 Resolving Static Static Slow unresolved 
993 Static Static Resolving Non-standard resolution 
997 Fast resolution Fast resolution Fast resolution Fast resolution 
1000 Resolving Resolving Static Slow unresolved 
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1014 Fast resolution Fast resolution Fast resolution Fast resolution 
1028 Resolving Resolving Static Slow unresolved 
1030 Fast resolution Fast resolution Fast resolution Fast resolution 
1076 Resolving Static Resolving Slow unresolved 
1084 Resolving Missing data Missing data Missing data 
 
 
Table A5.5.2 Examples of each of the eight different thrombus evolution 
patterns identified from the percentage changes in TLS at key time points over 
the two year follow-up period. 
 
DVT 
Evolution 
Category 
Definition 
Static No change in thrombus burden 
Reducing Continued decrease at each follow-up visit up to one year 
Extending  Increase in thrombus burden during first three months 
Fast resolution Resolution within three months 
Standard 
resolution 
Continued decrease at each follow-up visit with resolution within 
one year 
Non-standard 
resolution 
Not following standard resolution pattern but resolved by two 
years 
Reducing 
recurrence 
Recurrence of DVT after initial resolution but followed by 
subsequent ongoing resolution 
Slow 
unresolved 
Some reduction in thrombus burden over two years but 
incomplete resolution 
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Appendix A6 REGRESSION ANALYSES 
 
Table A6.1 Results of regression analysis examining the combined effects of 
age, anticoagulation duration, DVT location, thrombus burden and pre-existing 
superficial venous incompetence on index DVT resolution within 24 months 
when entered into the model using a backwards stepwise method. 
 Variables in the Equation (Backwards LR) 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
DVT Location 
(Proximal or 
Distal)(1) 
2.667 .725 13.530 1 .000 14.398 3.476 59.631 
TLS on diagnosis 
Category(1) 
2.236 .619 13.048 1 .000 9.355 2.781 31.474 
Anticoagulation 
duration category(1) 
-.227 .511 .197 1 .657 .797 .293 2.171 
Age category (1) -.155 .578 .072 1 .788 .856 .276 2.660 
Pre-existing 
superficial venous 
incompetence(1) 
.776 .617 1.583 1 .208 2.172 .649 7.272 
Constant -2.148 .737 8.484 1 .004 .117   
Step 
2
a
 
DVT Location 
(Proximal or 
Distal)(1) 
2.712 .707 14.722 1 .000 15.058 3.768 60.174 
TLS on diagnosis 
Category(1) 
2.249 .617 13.286 1 .000 9.480 2.829 31.771 
Anticoagulation 
duration category(1) 
-.213 .508 .176 1 .675 .808 .299 2.187 
Pre-existing 
superficial venous 
incompetence(1) 
.769 .617 1.550 1 .213 2.157 .643 7.235 
Constant -2.206 .709 9.695 1 .002 .110   
Step 
3
a
 
DVT Location 
(Proximal or 
Distal)(1) 
2.812 .667 17.770 1 .000 16.644 4.502 61.528 
TLS on diagnosis 
Category(1) 
2.226 .613 13.201 1 .000 9.261 2.787 30.771 
Pre-existing 
superficial venous 
incompetence(1) 
.782 .615 1.617 1 .203 2.186 .655 7.293 
Constant -2.352 .620 14.389 1 .000 .095   
436 
 
Step 
4
a
 
DVT Location 
(Proximal or 
Distal)(1) 
2.814 .663 18.030 1 .000 16.677 4.550 61.125 
TLS on diagnosis 
Category(1) 
2.296 .607 14.296 1 .000 9.935 3.022 32.662 
Constant -1.743 .365 22.847 1 .000 .175   
 
 
Table A6.2 Results of regression analysis examining the combined effects of 
age, treatment type and the occurrence of a new episode of superficial 
thrombophlebitis during follow-up on DVT recurrence within 24 months when 
entered into the model using a backwards stepwise method. 
Variables in the Equation (Backwards LR) 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
Age category (1) -1.220 .562 4.703 1 .030 .295 .098 .889 
Treatment Type (1) 1.133 .593 3.643 1 .056 3.104 .970 9.934 
New Phlebitic 
Episode during F/U  
(1) 
-1.046 .631 2.751 1 .097 .351 .102 1.209 
Constant -.557 .396 1.982 1 .159 .573   
Step 
2
a
 
Age category (1) -1.248 .552 5.111 1 .024 .287 .097 .847 
Treatment Type (1) 1.105 .582 3.608 1 .057 3.018 .965 9.436 
Constant -.932 .322 8.374 1 .004 .394   
 
 
Table A6.3 Results of regression analysis examining the combined effects of 
age and treatment type on DVT recurrence within 24 months when entered into 
the model in a single step (Entry method). 
Variables in the Equation (Entry) 
 
B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
Age category 
(1) 
-1.276 .534 5.708 1 .017 .279 .098 .795 
Treatment Type 
(1) 
1.151 .560 4.228 1 .040 3.160 1.055 9.464 
Constant -.840 .307 7.510 1 .006 .432   
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Table A6.4 Results of regression analysis examining the combined effects of 
DVT location, TLS on diagnosis, treatment type, the presence of concurrent 
superficial thrombophlebitis on diagnosis and DVT provocation status on the 
development of new venous incompetence within 24 months when entered into 
the model using a backwards stepwise method. 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
DVT Location 
(Proximal or 
Distal)(1) 
1.254 .474 7.005 1 .008 3.505 1.385 8.872 
Treatment Type (1) 1.449 .577 6.316 1 .012 4.259 1.376 13.187 
Phlebitis present on 
DVT diagnosis (1) 
.822 .467 3.096 1 .078 2.276 .911 5.688 
Provocation 
Status(1) 
-.604 .449 1.807 1 .179 .547 .226 1.319 
TLS on diagnosis 
Category(1) 
.579 .471 1.512 1 .219 1.784 .709 4.486 
Constant -.213 .331 .414 1 .520 .808   
Step 
2
a
 
DVT Location 
(Proximal or 
Distal)(1) 
1.564 .408 14.733 1 .000 4.779 2.150 10.621 
Treatment Type (1) 1.362 .567 5.767 1 .016 3.903 1.284 11.860 
Phlebitis present on 
DVT diagnosis (1) 
.801 .467 2.941 1 .086 2.227 .892 5.561 
Provocation 
Status(1) 
-.604 .446 1.831 1 .176 .547 .228 1.311 
Constant -.235 .331 .503 1 .478 .791   
Step 
3
a
 
DVT Location 
(Proximal or 
Distal)(1) 
1.570 .404 15.136 1 .000 4.809 2.180 10.609 
Treatment Type (1) 1.278 .570 5.030 1 .025 3.588 1.175 10.956 
Phlebitis present on 
DVT diagnosis (1) 
.888 .466 3.632 1 .057 2.431 .975 6.063 
Constant -.109 .324 .114 1 .736 .897   
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Table A6.5 Results of regression analysis examining the combined effects of 
thrombus evolution pattern at three months, index DVT resolution within 24 
months, anticoagulation treatment duration, the consistent use of compression 
stockings and DVT recurrence within 24 months on the development of new 
venous incompetence when entered into the model using a backwards stepwise 
method. 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
TEP3(1) .930 .516 3.255 1 .071 2.535 .923 6.964 
Index DVT resolved 
within 2 years(1) 
.840 .483 3.029 1 .082 2.317 .899 5.969 
Anticoagulation 
duration category(1) 
.424 .407 1.081 1 .298 1.527 .687 3.394 
Stocking  Use (1) .862 .419 4.245 1 .039 2.369 1.043 5.382 
Recurrence (1) .603 .510 1.397 1 .237 1.827 .672 4.967 
Constant -.644 .303 4.510 1 .034 .525   
Step 
2
a
 
TEP3(1) 1.011 .507 3.970 1 .046 2.748 1.017 7.430 
Index DVT resolved 
within 2 years(1) 
.898 .478 3.527 1 .060 2.454 .962 6.264 
Stocking  Use (1) .847 .416 4.152 1 .042 2.333 1.033 5.270 
Recurrence (1) .615 .508 1.463 1 .226 1.849 .683 5.007 
Constant -.686 .299 5.252 1 .022 .504   
Step 
3
a
 
TEP3(1) 1.072 .502 4.557 1 .033 2.921 1.092 7.815 
Index DVT resolved 
within 2 years(1) 
.839 .472 3.161 1 .075 2.313 .918 5.832 
Stocking  Use (1) .854 .413 4.287 1 .038 2.350 1.047 5.274 
Constant -.906 .239 14.323 1 .000 .404   
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Table A6.6 Results of regression analysis examining the combined effects of 
thrombus evolution pattern at three months, the consistent use of compression 
stockings, DVT location and treatment type on the development of new venous 
incompetence when entered into the model using a backwards stepwise 
method. 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
TEP3(1) .810 .480 2.852 1 .091 2.248 .878 5.755 
Stocking  Use (1) 1.019 .436 5.451 1 .020 2.770 1.178 6.515 
DVT Location 
(Proximal or 
Distal)(1) 
1.194 .469 6.487 1 .011 3.300 1.317 8.270 
Treatment Type (1) 1.313 .584 5.048 1 .025 3.716 1.182 11.681 
Constant -.586 .296 3.922 1 .048 .556   
 
 
Table A6.7 Results of regression analysis examining the combined effects of 
consistent use of compression stockings, DVT location and treatment type on 
the development of new venous incompetence when entered into the model in a 
single step (Entry method). 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
Stocking  Use (1) .970 .430 5.091 1 .024 2.637 1.136 6.124 
DVT Location 
(Proximal or 
Distal)(1) 
1.606 .408 15.503 1 .000 4.983 2.240 11.085 
Treatment Type (1) 1.404 .576 5.936 1 .015 4.073 1.316 12.603 
Constant -.479 .284 2.849 1 .091 .619   
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Table A6.8 Results of regression analysis examining the combined effects of 
sex, BMI, DVT location and the presence of concurrent superficial 
thrombophlebitis on diagnosis on the development of PTS within 24 months 
when entered into the model using a backwards stepwise method. 
Variables in the Equation (Backwards LR) 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
Sex(1) 1.082 .400 7.306 1 .007 2.951 1.346 6.467 
Overweight(1) 1.541 .555 7.713 1 .005 4.670 1.574 13.856 
DVT Location 
(Proximal or 
Distal)(1) 
1.087 .394 7.599 1 .006 2.967 1.369 6.428 
Phlebitis present on 
DVT diagnosis (1) 
.429 .476 .812 1 .368 1.535 .604 3.901 
Constant -.955 .305 9.775 1 .002 .385   
Step 
2
a
 
Sex(1) 1.149 .394 8.520 1 .004 3.154 1.458 6.821 
Overweight(1) 1.528 .551 7.695 1 .006 4.609 1.566 13.567 
DVT Location 
(Proximal or 
Distal)(1) 
1.111 .393 7.986 1 .005 3.036 1.405 6.559 
Constant -1.075 .275 15.224 1 .000 .341   
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Table A6.9 Results of regression analysis examining the combined effects of 
venous incompetence, the thrombus evolution pattern at three months post 
DVT diagnosis, whether the index DVT resolved within 24 months, treatment 
duration, the consistent use of compression stockings and the occurrence of a 
new episode of superficial thrombophlebitis during follow-up on the 
development of PTS within 24 months when entered into the model using a 
backwards stepwise method. 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
Location of venous 
incompetence 
  
12.333 3 .006 
   
Location of venous 
incompetence(1) 
.969 .569 2.896 1 .089 2.635 .863 8.044 
Location of venous 
incompetence(2) 
1.686 .546 9.539 1 .002 5.400 1.852 15.747 
Location of venous 
incompetence(3) 
1.680 .654 6.600 1 .010 5.366 1.489 19.336 
TEP3(1) .402 .508 .626 1 .429 1.495 .552 4.049 
Index DVT resolved 
within 2 years(1) 
.733 .534 1.880 1 .170 2.081 .730 5.931 
Anticoagulation 
duration category(1) 
.258 .419 .379 1 .538 1.294 .569 2.941 
Stocking  Use (1) 1.123 .425 6.971 1 .008 3.074 1.336 7.074 
New Phlebitic Episode 
during F/U  (1) 
.639 .615 1.080 1 .299 1.894 .568 6.321 
Constant .158 .339 .218 1 .640 1.172   
Step 
2
a
 
Location of venous 
incompetence 
  
12.851 3 .005 
   
Location of venous 
incompetence(1) 
.963 .571 2.849 1 .091 2.621 .856 8.021 
Location of venous 
incompetence(2) 
1.706 .543 9.873 1 .002 5.507 1.900 15.963 
Location of venous 
incompetence(3) 
1.722 .648 7.059 1 .008 5.596 1.571 19.935 
TEP3(1) .461 .498 .858 1 .354 1.586 .598 4.208 
Index DVT resolved 
within 2 years(1) 
.770 .530 2.107 1 .147 2.159 .764 6.106 
Stocking  Use (1) 1.128 .425 7.066 1 .008 3.091 1.345 7.103 
New Phlebitic Episode 
during F/U  (1) 
.610 .611 .996 1 .318 1.840 .555 6.100 
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Constant .118 .332 .127 1 .722 1.126   
Step 
3
a
 
Location of venous 
incompetence 
  
13.907 3 .003 
   
Location of venous 
incompetence(1) 
1.008 .572 3.108 1 .078 2.741 .894 8.410 
Location of venous 
incompetence(2) 
1.750 .539 10.537 1 .001 5.756 2.001 16.562 
Location of venous 
incompetence(3) 
1.775 .643 7.632 1 .006 5.902 1.675 20.793 
Index DVT resolved 
within 2 years(1) 
1.040 .451 5.305 1 .021 2.828 1.168 6.852 
Stocking  Use (1) 1.123 .422 7.076 1 .008 3.074 1.344 7.033 
New Phlebitic Episode 
during F/U  (1) 
.607 .616 .971 1 .325 1.835 .549 6.135 
Constant .220 .316 .485 1 .486 1.246   
Step 
4
a
 
Location of venous 
incompetence 
  
15.771 3 .001 
   
Location of venous 
incompetence(1) 
.974 .570 2.915 1 .088 2.648 .866 8.098 
Location of venous 
incompetence(2) 
1.811 .534 11.497 1 .001 6.115 2.147 17.418 
Location of venous 
incompetence(3) 
1.921 .627 9.386 1 .002 6.827 1.998 23.332 
Index DVT resolved 
within 2 years(1) 
1.017 .451 5.077 1 .024 2.764 1.141 6.693 
Stocking  Use (1) 1.136 .421 7.297 1 .007 3.115 1.366 7.103 
Constant .004 .225 .000 1 .987 1.004   
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Table A6.10 Results of regression analysis examining the combined effects of 
sex, BMI, DVT location, venous incompetence, whether the index DVT resolved 
within 24 months and the consistent use of compression stockings on the 
development of PTS within 24 months when entered into the model using a 
backwards stepwise method. 
 
Variables in the Equation (Backwards LR) 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
Sex(1) .906 .428 4.480 1 .034 2.474 1.069 5.726 
Overweight(1) 1.457 .598 5.940 1 .015 4.292 1.330 13.848 
Location of venous 
incompetence 
  
10.349 3 .016 
   
Location of venous 
incompetence(1) 
1.041 .607 2.943 1 .086 2.832 .862 9.303 
Location of venous 
incompetence(2) 
1.415 .562 6.339 1 .012 4.118 1.368 12.392 
Location of venous 
incompetence(3) 
1.731 .650 7.085 1 .008 5.644 1.578 20.184 
Index DVT resolved 
within 2 years(1) 
.734 .548 1.794 1 .180 2.083 .712 6.100 
Stocking  Use (1) .996 .450 4.894 1 .027 2.707 1.120 6.541 
DVT Location 
(Proximal or 
Distal)(1) 
.646 .505 1.637 1 .201 1.907 .709 5.129 
Constant -.500 .318 2.465 1 .116 .607   
Step 
2
a
 
Sex(1) .830 .419 3.926 1 .048 2.292 1.009 5.208 
Overweight(1) 1.513 .589 6.602 1 .010 4.540 1.432 14.399 
Location of venous 
incompetence 
  
11.259 3 .010 
   
Location of venous 
incompetence(1) 
1.120 .607 3.401 1 .065 3.064 .932 10.073 
Location of venous 
incompetence(2) 
1.452 .555 6.840 1 .009 4.274 1.439 12.692 
Location of venous 
incompetence(3) 
1.777 .648 7.529 1 .006 5.914 1.662 21.047 
Index DVT resolved 
within 2 years(1) 
1.104 .469 5.530 1 .019 3.015 1.202 7.565 
Stocking  Use (1) .973 .444 4.806 1 .028 2.646 1.109 6.314 
Constant -.423 .309 1.879 1 .170 .655   
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Table A6.11 Results of regression analysis examining the combined effects of 
sex, BMI, venous incompetence, whether the index DVT resolved within 24 
months and the consistent use of compression stockings on the development of 
PTS within 24 months when entered into the model in a single step (Entry 
method). 
 
Variables in the Equation (Entry) 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Step 
1
a
 
Sex(1) .830 .419 3.926 1 .048 2.292 1.009 5.208 
Overweight(1) 1.513 .589 6.602 1 .010 4.540 1.432 14.399 
Location of venous 
incompetence 
  
11.259 3 .010 
   
Location of venous 
incompetence(1) 
1.120 .607 3.401 1 .065 3.064 .932 10.073 
Location of venous 
incompetence(2) 
1.452 .555 6.840 1 .009 4.274 1.439 12.692 
Location of venous 
incompetence(3) 
1.777 .648 7.529 1 .006 5.914 1.662 21.047 
Index DVT resolved 
within 2 years(1) 
1.104 .469 5.530 1 .019 3.015 1.202 7.565 
Stocking  Use (1) .973 .444 4.806 1 .028 2.646 1.109 6.314 
Constant -.423 .309 1.879 1 .170 .655   
 
 
 
